Content and Format of Substantial Equivalence Reports; Food and Drug Administration Actions on Substantial Equivalence Reports, 12740-12791 [2019-05787]
Download as PDF
12740
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 16 and 1107
[Docket No. FDA–2016–N–3818]
RIN 0910–AH89
Content and Format of Substantial
Equivalence Reports; Food and Drug
Administration Actions on Substantial
Equivalence Reports
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Proposed rule.
The Food and Drug
Administration (FDA) is issuing a
proposed rule to establish requirements
for the content and format of reports
intended to establish the substantial
equivalence of a tobacco product (SE
Reports). The proposed rule would
establish the information an SE Report
must include so that FDA may make a
substantial equivalence determination.
In addition, the proposed rule would
establish the general procedures FDA
intends to follow when evaluating SE
Reports, including procedures that
would address communications with
the applicant and the confidentiality of
data in an SE Report. The proposed rule
is intended to provide more clarity to
applicants and support efficient and
predictable reviews of SE Reports.
DATES: Submit either electronic or
written comments on the proposed rule
by June 17, 2019. Submit comments on
information collection issues under the
Paperwork Reduction Act of 1995 by
May 2, 2019.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before June 17, 2019.
The https://www.regulations.gov
electronic filing system will accept
comments until midnight Eastern Time
at the end of June 17, 2019. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
amozie on DSK9F9SC42PROD with PROPOSALS2
SUMMARY:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2016–N–3818 for ‘‘Content and Format
of Substantial Equivalence Reports;
Food and Drug Administration Actions
on Substantial Equivalence Reports.’’
Received comments will be placed in
the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
PO 00000
Frm 00002
Fmt 4701
Sfmt 4702
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
Submit comments on information
collection issues to the Office of
Management and Budget in the
following ways: Fax to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, Fax: 202–
395–7285, or email to oira_submission@
omb.eop.gov. All comments should be
identified with the title, ‘‘Substantial
Equivalence Reports for Tobacco
Products.’’
FOR FURTHER INFORMATION CONTACT:
Annette Marthaler or Daniel Gittleson,
Office of Regulations, Center for
Tobacco Products, Food and Drug
Administration, Document Control
Center, Bldg. 71, Rm. G335, 10903 New
Hampshire Ave., Silver Spring, MD
20993–0002, 877–287–1373, AskCTP@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
Table of Contents
Executive Summary
I. Background
II. Legal Authority
III. Description of Proposed Regulations
A. General (Proposed Subpart B)
B. Substantial Equivalence Reports
(Proposed Subpart C)
C. FDA Review (Proposed Subpart D)
D. Miscellaneous (Proposed Subpart E)
IV. Other Issues for Consideration
V. Paperwork Reduction Act of 1995
VI. Executive Order 13132: Federalism
VII. Consultation and Coordination with
Indian Tribal Governments
VIII. Analysis of Environmental Impact
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
IX. Economic Analysis of Impacts
X. References
XI. Effective Date
Executive Summary
amozie on DSK9F9SC42PROD with PROPOSALS2
Purpose of the Regulatory Action
This proposed rule would establish
requirements related to the content and
format of SE Reports, including the
information that SE Reports must
contain. FDA is basing this proposed
rule on the experience the Agency has
in reviewing thousands of SE Reports
since 2010. The SE Reports that FDA
has seen to date range widely in the
level of detail included. For example,
some have very little information on the
comparison of the new tobacco product
with a predicate tobacco product while
other SE Reports are much more
detailed in describing how the new
tobacco product compares to the
identified predicate tobacco product
and provide supporting information.
This wide variation in the depth of
content may be due, at least in part, to
confusion about what information FDA
needs from applicants to make a
substantial equivalence finding. FDA’s
experience reviewing this wide range of
SE Reports has been helpful in
developing this proposed rule, which
describes in detail the information that
an applicant would be required to
include in an SE Report.
The proposed rule also addresses
issues such as communications with the
applicant, the retention of records that
support the SE Report, confidentiality of
SE Report information, and electronic
submission of the SE Report and
amendments. The proposed rule is
intended to provide both applicants and
FDA with more certainty about the
content and format of SE Reports and
FDA’s review of the SE Reports. The
proposed rule is also intended to
provide more clarity to applicants and
help ensure that the SE pathway for
premarket review of a new tobacco
product is used when appropriate, e.g.,
when there is a valid predicate tobacco
product to which the new product can
be scientifically compared and support
efficient and predictable reviews.
Legal Authority
This proposed rule is being issued
based upon FDA’s authority to require
premarket review of new tobacco
products under sections 905(j) and
910(a) of the Federal Food, Drug, and
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
Cosmetic Act (FD&C Act) (21 U.S.C.
387e(j) and 387j(a)), FDA’s authority to
require reports under section 909(a) of
the FD&C Act (21 U.S.C. 387i(a)), FDA’s
authorities related to adulterated and
misbranded tobacco products under
sections 902 and 903 (21 U.S.C. 387b
and 387c), as well as FDA’s rulemaking
and inspection authorities under
sections 701(a) and 704 of the FD&C Act
(21 U.S.C. 371(a) and 374).
Summary of the Major Provisions
This proposed rule would establish
content and format requirements for SE
Reports. Under the proposed rule, an SE
Report must provide information
comparing the new tobacco product to
a predicate tobacco product, including
information that would enable FDA to
uniquely identify the new tobacco
product and the predicate tobacco
product. The proposed requirements
would help ensure that an SE Report
provides information necessary for FDA
to determine whether the new tobacco
product is substantially equivalent to a
tobacco product commercially marketed
in the United States as of February 15,
2007 (as required by section 910(a)(2)(A)
of the FD&C Act).
In addition, the proposed rule would
explain how an applicant can amend or
withdraw an SE Report, and explain
how an applicant may transfer
ownership of an SE Report to a new
applicant. The proposed rule also would
address FDA communications with
applicants on SE Reports, including
when FDA would issue deficiency
notifications; explain FDA review
cycles; and identify actions that FDA
may take on SE Reports. The proposed
rule would address when FDA may
rescind an SE order and explain how
long an applicant must maintain records
related to the SE Report. The proposed
rule also would explain FDA’s
disclosure provisions and provide for
electronic submission of SE Reports,
unless the applicant requests a waiver.
FDA is basing the proposed rule on our
experience reviewing SE Reports, and
the proposed rule is intended to provide
both applicants and FDA with more
certainty related to the information
needed to demonstrate substantial
equivalence and FDA’s review processes
with the goal of an efficient and
predictable review process for SE
Reports.
PO 00000
Frm 00003
Fmt 4701
Sfmt 4702
12741
Costs and Benefits
This proposed rule would impose
compliance costs on affected entities to
read and understand the rule, establish
or revise internal procedures, and fill
out a form for SE Reports. We estimate
that the present value of industry
compliance costs ranges from $0.60
million to $2.64 million, with a primary
estimate of $1.61 million at a 3 percent
discount rate, and from $0.56 million to
$2.32 million, with a primary estimate
of $1.43 million at a 7 percent discount
rate over 10 years. Annualized industry
compliance costs over 10 years range
from $0.07 million to $0.31 million,
with a primary estimate of $0.19 million
at a 3 percent discount rate and from
$0.08 million to $0.33 million, with a
primary estimate of $0.20 at a 7 percent
discount rate.
The benefits of this proposed rule are
potential time-savings to industry and
cost-savings to government. This
proposed rule clarifies when applicants
may certify that certain characteristics
are identical in the new tobacco product
and the predicate tobacco product.
Certifying may save applicants time in
preparing their SE Reports. In this
proposed rule, we intend to shorten
review times for SE Reports. In addition,
based on our experience with prior SE
Reports, we believe this proposed rule
would lead to better SE Reports, saving
us time in review and requiring fewer
staff to review SE Reports, which would
result in cost-savings. We estimate that
the present value of government costsavings ranges from $15 million to $198
million, with a primary estimate of $62
million at a 3 percent discount rate, and
from $12 million to $163 million, with
a primary estimate of $51 million at a
7 percent discount rate over 10 years.
Annualized government cost-savings
over 10 years range from $1.7 million to
$23.2 million, with a primary estimate
of $7.2 million at both 3 and 7 percent
discount rates.
The qualitative benefits of this
proposed rule include additional clarity
to industry about the requirements for
the content and format of SE Reports.
The proposed rule would also establish
the general procedures we intend to
follow in reviewing and communicating
with applicants. In addition, this
proposed rule would make the SE
pathway more predictable.
E:\FR\FM\02APP2.SGM
02APP2
12742
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
TABLE 1—SUMMARY OF ANNUALIZED COSTS AND BENEFITS OF THE PROPOSED RULE
[$2016 over 10 years]
Low
(3%)
amozie on DSK9F9SC42PROD with PROPOSALS2
Costs ........................................................
Benefits ....................................................
Net Benefits (rounded) .............................
$0.07
1.7
1.7
I. Background
The Family Smoking Prevention and
Tobacco Control Act (Tobacco Control
Act) (Pub. L. 111–31) was enacted June
22, 2009, and provided FDA the
authority to regulate tobacco products
under the FD&C Act. The FD&C Act, as
amended by the Tobacco Control Act,
requires that before a new tobacco
product may be introduced into
interstate commerce for commercial
distribution in the United States, the
new tobacco product must undergo
premarket review by FDA. Section
910(a)(1) of the FD&C Act defines a
‘‘new tobacco product’’ as: (1) Any
tobacco product (including those
products in test markets) that was not
commercially marketed in the United
States as of February 15, 2007, or (2) any
modification (including a change in
design, any component, any part, or any
constituent, including a smoke
constituent, or in the content, delivery
or form of nicotine, or any other
additive or ingredient) of a tobacco
product where the modified product
was commercially marketed in the
United States after February 15, 2007.
The FD&C Act establishes three
premarket review pathways for a new
tobacco product:
• Submission of a premarket tobacco
application under section 910(b);
• Submission of a report intended to
demonstrate that the new tobacco
product is substantially equivalent to a
predicate tobacco product under section
905(j)(1)(A) (‘‘SE Report’’); and
• Submission of a request for an
exemption under section 905(j)(3)
(implemented at § 1107.1 (21 CFR
1107.1)).
Under section 910(a)(2)(B) of the
FD&C Act, a manufacturer of a tobacco
product that was first introduced or
delivered for introduction into interstate
commerce for commercial distribution
after February 15, 2007, and prior to
March 22, 2011, that submitted an SE
Report 1 prior to March 23, 2011, may
continue to market the tobacco product
unless FDA issues an order that the
1 In this proposed rule, FDA refers to ‘‘SE
applications’’ as ‘‘SE Reports,’’ but the terms both
refer to a premarket submission under section
905(j)(1)(A) of the FD&C Act.
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
Medium
(3%)
High
(3%)
$0.19
7.2
7.1
$0.31
23.2
22.9
tobacco product is not substantially
equivalent. For any new tobacco
product introduced into commercial
distribution on or after March 22, 2011,
or for which a substantial equivalence
report was not submitted by March 23,
2011, a manufacturer must first submit
a premarket application under section
910 for the new tobacco product to FDA,
and FDA must issue an order
authorizing the commercial distribution
of the new tobacco product or find the
product exempt from the requirements
of substantial equivalence under section
910(a)(2)(A) of the FD&C Act, before the
product may be introduced into
commercial distribution. If a new
tobacco product is marketed without an
order or a finding of exemption from
substantial equivalence, it is adulterated
under section 902 of the FD&C Act and
misbranded under section 903 of the
FD&C Act and subject to enforcement
action.
Since 2010, FDA has received more
than 5,000 premarket applications.
Almost all of the premarket applications
have been SE Reports. To assist
manufacturers in preparing SE Reports,
FDA has issued guidance documents; 2
conducted Webinars; met with
manufacturers; posted technical project
lead reviews (which describe the
administrative, compliance, and
substantive scientific reviews completed
on a specific SE Report), general
information about not substantially
equivalent (NSE) determinations, and
orders (FDA posts the NSE orders for
provisional tobacco products,3 and SE
2 The guidance documents include: ‘‘Section
905(j) Reports: Demonstrating Substantial
Equivalence for Tobacco Products’’ (January 2011);
‘‘Establishing That a Tobacco Product Was
Commercially Marketed in the United States as of
February 15, 2007’’ (September 2014);
‘‘Demonstrating the Substantial Equivalence of a
New Tobacco Product: Responses to Frequently
Asked Questions’’ (December 2016); and ‘‘Meetings
with Industry and Investigators on the Research and
Development of Tobacco Products’’ (July 2016).
These guidance documents may be accessed at
https://www.fda.gov/TobaccoProducts/Labeling/
RulesRegulationsGuidance/default.htm.
3 ‘‘Provisional’’ tobacco products refer to those
tobacco products that were first introduced or
delivered for introduction into interstate commerce
for commercial distribution in the United States
after February 15, 2007, and prior to March 22,
2011, and for which a 905(j) (Substantial
PO 00000
Frm 00004
Fmt 4701
Sfmt 4702
Low
(7%)
Medium
(7%)
$0.08
1.7
1.7
$0.20
7.2
7.0
High
(7%)
$0.33
23.2
22.9
orders for all tobacco products); and
issued letters outlining deficiencies in
individual tobacco product SE Reports.
Manufacturers are now more informed
about what an SE Report should
contain, and FDA is more informed
about the range of tobacco products and
changes made to these products and the
data needed to demonstrate substantial
equivalence. The proposed rule is based
on this experience and would establish
requirements related to the substantial
equivalence premarket pathway and
provide both manufacturers and FDA
with more certainty related to the
information needed to demonstrate
substantial equivalence and FDA’s
review processes.
II. Legal Authority
As described in the following
paragraphs, FDA is proposing this rule
to prescribe the content, form, and
manner of reports intended to
demonstrate the substantial equivalence
of a new tobacco product to a predicate
tobacco product, as well as to establish
other requirements related to SE Reports
including requirements for keeping
records, making reports, and providing
information essential to FDA’s
implementation of the FD&C Act. In
accordance with section 5 of the
Tobacco Control Act, FDA intends that
the requirements that would be
established by this proposed rule be
severable and that the invalidation of
any provision of this proposed rule
would not affect the validity of any
other part of this rule.
Section 910(a)(2) of the FD&C Act
requires a new tobacco product to be the
subject of a premarket tobacco
application (PMTA) order unless FDA
has issued an SE order authorizing its
commercial distribution or the tobacco
product is exempt from substantial
equivalence. To satisfy the requirement
of premarket review, a manufacturer
may submit a report intended to
demonstrate the substantial equivalence
of a new tobacco product to a predicate
tobacco product under section 905(j) of
the FD&C Act. Section 905(j) provides
that FDA may prescribe the form and
Equivalence) Report was submitted no later than
March 22, 2011.
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
amozie on DSK9F9SC42PROD with PROPOSALS2
manner of the substantial equivalence
report, and section 910(a)(4) requires
that as part of the 905(j) report, the
manufacturer provide an adequate
summary of any health information
related to the new tobacco product or
state that such information will be made
available upon request.
Based on the information provided by
the applicant, section 910(a)(3)(A) of the
FD&C Act authorizes FDA to issue an
order finding substantial equivalence
when FDA finds that the new tobacco
product is in compliance with the
requirements of the FD&C Act and
either: (1) Has the same characteristics
as the predicate tobacco product or (2)
has different characteristics and the
information submitted contains
information, including clinical data if
deemed necessary by FDA, that
demonstrates that it is not appropriate
to regulate the product under (the
premarket tobacco application or
‘‘PMTA’’ provisions) because the
product does not raise different
questions of public health.
Section 909(a) of the FD&C Act
authorizes FDA to issue regulations
requiring tobacco product
manufacturers or importers to maintain
such records, make such reports, and
provide such information as may be
reasonably required to assure that their
tobacco products are not adulterated or
misbranded and to otherwise protect
public health.
Under section 902(6)(A) of the FD&C
Act, a tobacco product is adulterated if
it is required to have premarket review
and does not have an order in effect
under section 910(c)(1)(A)(i) of the
FD&C Act. Under section 903(a)(6) of
the FD&C Act, a tobacco product is
misbranded if a notice or other
information respecting it was not
provided as required by section 905(j) of
the FD&C Act. In addition, a tobacco
product is misbranded if there is a
failure or refusal to furnish any material
or information required under section
909 (section 903(a)(10)(B) of the FD&C
Act).
Section 701(a) of the FD&C Act gives
FDA general rulemaking authority to
issue regulations for the efficient
enforcement of the FD&C Act, and
section 704 of the FD&C Act provides
FDA with general inspection authority.
III. Description of Proposed Regulations
The proposed rule would add
subparts B through E to current part
1107 of Title 21. The requirements set
out in this proposed rule would not
apply to provisional SE Reports or to
any SE Report submitted before the
effective date of any final rule
associated with this proposed
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
rulemaking. FDA has published a final
rule extending the Agency’s ‘‘tobacco
product’’ authorities in the FD&C Act to
all categories of products that meet the
statutory definition of ‘‘tobacco
product’’ in the FD&C Act, except
accessories of such newly deemed
tobacco products (‘‘Deeming Tobacco
Products To Be Subject to the Federal
Food, Drug, and Cosmetic Act, as
Amended by the Family Smoking
Prevention and Tobacco Control Act;
Restrictions on the Sale and Distribution
of Tobacco Products and Required
Warning Statements for Tobacco
Products’’ (81 FR 28974, May 10, 2016)
(the Deeming final rule)). This proposed
rule would apply to SE Reports for all
tobacco products submitted after the
final rule is effective, including the
newly deemed tobacco products, that
FDA regulates under Chapter IX of the
FD&C Act. Proposed subparts D and E
set out FDA’s review processes and
would be applicable to FDA’s review of
SE Reports after the effective date of any
final rule. The proposed rule also would
amend § 16.1 (21 CFR 16.1) to add a
reference to proposed § 1107.50 (this
proposed section would address
rescission of an SE order).
A. General (Proposed Subpart B)
1. Scope (Proposed § 1107.10)
According to proposed § 1107.10,
subparts B through E would establish
the procedures and requirements for the
submission of an SE Report under
sections 905 and 910 of the FD&C Act,
the basic criteria for establishing
substantial equivalence, and the general
procedures FDA intends to follow when
evaluating SE Reports.
2. Definitions (Proposed § 1107.12)
Proposed § 1107.12 sets forth the
meaning of terms as they apply to
proposed subparts B through E of part
1107. Proposed § 1107.12 includes the
following definitions from the FD&C
Act:
• Additive. As defined in section
900(1) of the FD&C Act (21 U.S.C. 387),
‘‘additive’’ means any substance the
intended use of which results or may
reasonably be expected to result,
directly or indirectly, in its becoming a
component or otherwise affecting the
characteristic of any tobacco product
(including any substances intended for
use as a flavoring or coloring or in
producing, manufacturing, packing,
processing, preparing, treating,
packaging, transporting, or holding),
except that such term does not include
tobacco or a pesticide chemical residue
in or on raw tobacco or a pesticide
chemical.
PO 00000
Frm 00005
Fmt 4701
Sfmt 4702
12743
An additive can be a type of
ingredient in a tobacco product; an
example is methyl salicylate in
smokeless tobacco, which can serve as
an absorption enhancer and affect the
characteristics of the tobacco product by
changing the rate of absorption into the
body. Tobacco is not an additive.
• Brand. As defined in section 900(2)
of the FD&C Act, ‘‘brand’’ means a
variety of tobacco product distinguished
by the tobacco used, tar content,
nicotine content, flavoring used, size,
filtration, packaging, logo, registered
trademark, brand name, identifiable
pattern of colors, or any combination of
such attributes.
• Characteristic. As defined in
section 910(a)(3)(B) of the FD&C Act,
‘‘characteristic’’ means the materials,
ingredients, design, composition,
heating source, or other features of a
tobacco product. All of the terms used
in the definition of characteristic
(materials, ingredients, design, etc.) are
defined in proposed § 1107.12.
• Distributor. As defined in section
900(7) of the FD&C Act, ‘‘distributor’’
means any person who furthers the
distribution of a tobacco product,
whether domestic or imported, at any
point from the original place of
manufacture to the person who sells or
distributes the product to individuals
for personal consumption. Common
carriers are not considered distributors
for the purposes of this part.
• New tobacco product. As defined in
section 910(a)(1) of the FD&C Act, ‘‘new
tobacco product’’ means: (1) Any
tobacco product (including those
products in test markets) that was not
commercially marketed in the United
States as of February 15, 2007, or (2) any
modification (including a change in
design, any component, any part, or any
constituent, including a smoke
constituent, or in the content, delivery
or form of nicotine, or any other
additive or ingredient) of a tobacco
product where the modified product
was commercially marketed in the
United States after February 15, 2007.
Under the FD&C Act, and as reflected
in the proposed definition, new tobacco
products include those that are new
because they have been rendered new
through any modification (including a
change in design, any component, any
part, or any constituent, including a
smoke constituent, or in the content,
delivery or form of nicotine, or any
other additive or ingredient) of a
tobacco product where the modified
product was commercially marketed in
the United States after February 15,
2007 (21 U.S.C. 387j(a)(1)(B)). For
example, modifications to cigarette
paper, container closure systems (e.g.,
E:\FR\FM\02APP2.SGM
02APP2
amozie on DSK9F9SC42PROD with PROPOSALS2
12744
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
change from glass to plastic e-liquid
vials or from plastic to tin container
closures), product quantity,
specifications that change
characteristics (e.g., a modification to a
different tobacco cut size) would render
a tobacco product new.
Manufacturers sometimes co-package
tobacco products. Co-packaging two or
more legally marketed tobacco products,
where there are no changes, including
no change to the container closure
system(s), does not result in a new
tobacco product. Examples include a
carton of cigarette packs and a variety
pack of three smokeless tins shrinkwrapped together where the cigarette
packs and smokeless tins, respectively,
could be legally marketed separately.
However, if a manufacturer wishes to
co-package two or more tobacco
products (including their respective
container closure systems), premarket
review is required for any new tobacco
product that the manufacturer intends
to include in the co-package. An
example includes shrink-wrapping
grandfathered tobacco filler (in its
unmodified container closure system)
with new rolling papers; here premarket
authorization would be required for the
rolling papers. In addition, co-packaging
two or more tobacco products within
the same container closure system
results in a new tobacco product, unless
such co-packaged product is
grandfathered. Examples include an
RYO kit where rolling papers are placed
inside the tin of tobacco filler and
shrink-wrapping together two soft-packs
of cigarettes, neither of which had been
individually shrink-wrapped prior to
being co-packaged. FDA invites
comment on approaches to its review of
these types of SE Reports, including,
where relevant, how co-packaging
products impacts consumer use and
behavior.
In addition, for purposes of
determining whether a tobacco product
is new under section 910 of the FD&C
Act, and therefore requires premarket
authorization prior to marketing, a
‘‘tobacco product’’ can be considered to
encompass the whole product (e.g., a
pack of cigarettes or a tin of loose
tobacco), and is not limited to a single
unit or portion of the whole product
(e.g., a single cigarette or a single snus
pouch). See Philip Morris USA Inc. v.
U.S. Food & Drug Admin., 202 F. Supp.
3d 31, 55–57 (D.D.C. 2016).
Consequently, a change in product
quantity (e.g., decreasing the weight of
a smokeless package from 24 grams to
15 grams) results in a new tobacco
product subject to premarket review
since such a modification ‘‘necessarily
entails a change in the amount of the
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
constituent ingredients and additives
within the tobacco product, including
nicotine’’ (id. at 56).
FDA also considers a tobacco product
marketed exclusively in test markets on
February 15, 2007, to be a new tobacco
product that is subject to premarket
review by FDA. In addition, such test
marketed products cannot serve as valid
predicate products in an SE Report. A
tobacco product that the applicant
intends to test market after February 15,
2007, is also a new tobacco product
subject to premarket review under
section 910(a) of the FD&C Act because
it was not commercially marketed in the
United States as of February 15, 2007.
Because the terms ‘‘test marketing’’
and ‘‘commercially marketed’’ are not
interchangeable, FDA is considering
whether it would be useful to applicants
for the rule to further expand on or
define the terms ‘‘test marketing’’ and
‘‘commercially marketed.’’ Specifically,
FDA is considering whether to add the
following definition of test marketing:
‘‘test marketing’’ means distributing or
offering for sale (which may be shown
by advertisements, etc.) a tobacco
product in the United States for the
purpose of determining consumer
response or other consumer reaction to
the tobacco product, with or without the
user knowing it is a test product, in
which any of the following criteria
apply:
• Offered in a limited number of
regions;
• Offered for a limited time; or
• Offered to a chosen set of the
population or specific demographic
group.
FDA is considering whether to define
‘‘commercially marketed’’ as offering a
tobacco product for sale to consumers in
all or in parts of the United States.
Factors FDA may consider include
advertising or other means used to
communicate that the tobacco product
was available for purchase, including
dated advertisements, dated catalog
pages, dated promotional material,
dated trade publications, dated bills of
lading, dated freight bills, dated
waybills, dated invoices, dated purchase
orders, dated manufacturing documents,
inventory lists, or any other document
that demonstrates that the product was
commercially marketed (other than
exclusively in test markets) in the
United States as of February 15, 2007.
FDA invites comment on what evidence
would be sufficient to demonstrate that
a product was commercially marketed
(other than in test markets) as of
February 15, 2007.
FDA is inviting comments on: (1)
Whether the rule should further expand
on the interpretation or include
PO 00000
Frm 00006
Fmt 4701
Sfmt 4702
definitions of these terms, (2) the
substance of the definitions, if included,
and (3) whether or not the approach
described is adequate to protect the
public health.
• Package or packaging. As defined
in section 900(13) of the FD&C Act,
‘‘package’’ or ‘‘packaging’’ means a
pack, box, carton, or container of any
kind or, if no other container, any
wrapping (including cellophane) in
which a tobacco product is offered for
sale, sold, or otherwise distributed to
consumers. A subset of package is the
container closure system (also defined
in this proposed rule). For example, the
carton holding multiple soft packs of
cigarettes is considered the package, and
each soft pack with surrounding
cellophane is considered the container
closure system. Packaging that
constitutes the container closure system
is intended or reasonably expected to
affect or alter the performance,
composition, constituents, or
characteristics of the tobacco product
(e.g., leaching substances that are then
incorporated into a tobacco product),
but packaging that is not the container
closure system is not intended or
reasonably expected to affect or alter the
performance, composition, constituents,
or characteristics of the tobacco product.
• Substantial equivalence or
substantially equivalent. As defined in
section 910(a)(3)(A) of the FD&C Act,
the term ‘‘substantial equivalence’’ or
‘‘substantially equivalent’’ means, with
respect to the tobacco product being
compared to the predicate tobacco
product, that FDA, by order, has found
that the tobacco product:
Æ Has the same characteristics as the
predicate tobacco product or
Æ Has different characteristics and the
information submitted contains
information, including clinical data if
deemed necessary by FDA that
demonstrates that it is not appropriate
to require premarket review under
section 910(a), (b) and (c) of the FD&C
Act because the product does not raise
different questions of public health.
FDA notes that this proposed rule
does not include a proposed
interpretation of ‘‘same characteristics’’
and ‘‘different characteristics’’ under
section 910(a)(3)(A) of the FD&C Act.4
However, FDA recognizes that
stakeholders have requested additional
clarity on these terms. FDA continues to
consider the appropriate
implementation of these terms, as well
as public feedback the Agency has
received on the terms during workshops
4 FDA notes that products with identical
characteristics are not new products, and thus are
not required to undergo premarket review.
E:\FR\FM\02APP2.SGM
02APP2
amozie on DSK9F9SC42PROD with PROPOSALS2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
and in response to other Federal
Register notices (e.g., most recently, in
response to a notice related to the
Paperwork Reduction Act, 83 FR 45251,
September 6, 2018). For example, FDA
is considering whether the ‘‘same
characteristics’’ prong might be
appropriate for new tobacco products
that are so similar to the predicate
product that FDA would not need
scientific information to determine
whether the new product raises
different questions of public health.
Examples of changes between the new
and predicate products that might be
appropriate to proceed through ‘‘same
characteristics,’’ either individually or
in combination, include, nonexhaustively: (1) A change in product
quantity between the new and predicate
tobacco products; (2) a change in
container closure system for non-moist
tobacco products; (3) decreases in the
total amount of tobacco in the new
tobacco product without any
corresponding changes in other
ingredients or characteristics of the new
tobacco product; and (4) changes in the
non-combusted portion of a cigarette,
for example, a change in tipping paper
color from plain to cork, or a change in
adhesive, or the removal of a dye or ink.
Under this approach, a new product
would have ‘‘different characteristics’’ if
a product were dissimilar enough from
the predicate product that FDA could
not determine without scientific
information whether the new product
raised different questions of public
health. Examples of changes between
the new and predicate products that
might be appropriate to proceed through
‘‘different characteristics,’’ either
individually or in the aggregate,
include, non-exhaustively:
• A change in filter or ventilation of
a combusted tobacco product, because
such a change has the potential to affect
the public health analysis required to
assess substantial equivalence, such that
FDA would need scientific information
to determine whether the new product
raises different questions of public
health. For example, in some
circumstances, a change in filter could
result in an increase in ventilation and
a change in harmful or potentially
harmful constituent (HPHC) exposure
levels to the user, with effects on the
public health impact of the product. It
is possible that in some other
circumstances, a change in filter would
not have results that would affect the
public health impact of the product.
• A change in container closure
system for a moist smokeless tobacco
product, because FDA would need
scientific information to determine, for
example, whether or not such
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
differences could result in a change in
tobacco product stability that would
increase HPHC levels and exposures to
the user.
• A change in characterizing flavor in
the new product because FDA would
need scientific information to
determine, for example, whether or not
such differences could affect use
behaviors.
FDA notes that these examples are
illustrative only and are not intended to
convey that any differences specific to
an individual case would or would not
be appropriate to proceed through the
‘‘different characteristics’’ approach or
result in a determination of SE.
When a new product has different
characteristics, FDA would evaluate
whether the difference(s) in
characteristics, individually and in the
aggregate, do not cause the new product
to raise different questions of public
health. In determining if a new product
raises different questions of public
health, FDA may consider, among other
things, whether one or more of the
following is the case, as compared to the
predicate product, (1) the new product
has the potential to increase HPHC
yields, and, if so, the degree of such an
increase; (2) the new product has the
potential to increase toxicity; (3) the
new product has the potential to
increase initiation; (4) the new product
has the potential to increase abuse
liability; (5) the new product has the
potential to increase dependence; or (6)
the new product has the potential to
decrease cessation. Based on this
analysis, FDA will determine whether
the applicant has demonstrated that any
differences do not cause the new
product to raise different questions of
public health.
Please note that FDA is including
these examples based on the Agency’s
experience to date in reviewing SE
reports, and for purposes of soliciting
comments on this approach, and FDA
will continue to review each SE Report
and make an SE determination on the
basis of the information included in that
SE Report. FDA invites comment on the
terms ‘‘same characteristics’’ and
‘‘different characteristics,’’ the potential
approach discussed above, and any
alternative approaches to interpretation
of these terms, including examples of
new tobacco products that would have
the ‘‘same characteristics’’ as the
predicate, as well as new tobacco
products that would have ‘‘different
characteristics’’ from the predicate.
While the rule proposes that certain
information would be required for
reports submitted under either the same
characteristics or different
characteristics prong, we welcome
PO 00000
Frm 00007
Fmt 4701
Sfmt 4702
12745
comments on what information would
need to be included under either or both
prongs if the approach described above,
or an alternative approach, is
implemented. FDA also invites
comment on how we might evaluate
different questions of public health. In
your comment, please include your
reasoning for how you would
distinguish the scope of the same
characteristics prong from the different
characteristics prong, i.e., when an
applicant might claim that a proposed
new tobacco product is substantially
equivalent to a predicate tobacco
product because it has the ‘‘same’’
characteristics. FDA will consider all
comments and will seek to provide
additional clarity in the final rule, if
possible.
• Tobacco product. As defined in
section 201(rr) of the FD&C Act (21
U.S.C. 321(rr)), the term ‘‘tobacco
product’’ means any product that is
made or derived from tobacco that is
intended for human consumption,
including any component, part, or
accessory of a tobacco product (except
for raw materials other than tobacco
used in manufacturing a component,
part, or accessory of a tobacco product).
The term ‘‘tobacco product’’ does not
mean an article that is a drug under
section 201(g)(1), a device under section
201(h), or a combination product
described in section 503(g) of the FD&C
Act (21 U.S.C. 353(g)). As explained in
the definition of ‘‘new tobacco
product,’’ FDA ’s interpretation is that
the tobacco product encompasses the
whole product and is not limited to a
single unit or portion of the whole
product.
• Tobacco product manufacturer. As
defined in section 900(20) of the FD&C
Act, the term ‘‘tobacco product
manufacturer’’ means any person,
including a repacker or relabeler, who:
(1) Manufactures, fabricates, assembles,
processes, or labels a tobacco product or
(2) imports a finished tobacco product
for sale or distribution in the United
States. FDA interprets ‘‘manufactures,
fabricates, assembles, processes, or
labels’’ as including, but not being
limited to: (a) Repackaging or otherwise
changing the container, wrapper, or
labeling of any tobacco product package;
(b) reconstituting tobacco leaves; or (c)
applying any chemical, additive, or
substance to the tobacco leaf other than
potable water in the form of steam or
mist. Manufacturing activities typically
do not include the activities of destemming, drying, or packaging tobacco
leaves; mechanically removing foreign
material from tobacco leaves; and
humidifying tobacco leaves with
nothing other than potable water in the
E:\FR\FM\02APP2.SGM
02APP2
amozie on DSK9F9SC42PROD with PROPOSALS2
12746
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
form of steam or mist. A proposed
definition for the term ‘‘finished tobacco
product’’ is also included in the
proposed rule.
In addition, FDA proposes the
following definitions:
• Accessory. FDA proposes to define
‘‘accessory’’ as any product that is
intended or reasonably expected to be
used with or for the human
consumption of a tobacco product; does
not contain tobacco and is not made or
derived from tobacco; and meets either
of the following:
Æ Is not intended or reasonably
expected to affect or alter the
performance, composition, constituents,
or characteristics of a tobacco product;
or
Æ Is intended or reasonably expected
to affect or maintain the performance,
composition, constituents, or
characteristics of a tobacco product but
solely controls moisture and/or
temperature of a stored product; or
solely provides an external heat source
to initiate but not maintain combustion
of a tobacco product.
Examples of accessories are ashtrays
and spittoons because they do not
contain tobacco, are not derived from
tobacco, and do not affect or alter the
performance, composition, constituents,
or characteristics of a tobacco product.
Examples of accessories also include
humidors or refrigerators that solely
control the moisture and/or temperature
of a stored product and conventional
matches and lighters that solely provide
an external heat source to initiate but
not maintain combustion of a tobacco
product. This proposed definition is
also in accord with the definition
included in the Deeming final rule.
• Applicant. FDA proposes to define
‘‘applicant’’ as any manufacturer of
tobacco products who is subject to
chapter IX of the FD&C Act that submits
a premarket application to receive
marketing authorization for a new
tobacco product. For the purposes of
part 1107, a premarket application refers
to an SE Report or an exemption
request.
• Commercial distribution. FDA
proposes to define ‘‘commercial
distribution’’ as any distribution of a
tobacco product to consumers or to
another person through sale or
otherwise. This term does not include
transfers of a tobacco product between
registered establishments within the
same parent, subsidiary, and/or affiliate
company, nor does it include providing
a tobacco product for product testing
where such products are not made
available for consumption or resale.
This term would exclude the handing or
transfer of a tobacco product from one
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
consumer to another for personal
consumption. For foreign
establishments, the term ‘‘commercial
distribution’’ has the same meaning
except the term does not include
distribution of any tobacco products
that are neither imported nor offered for
import into the United States. This term
is intended to include a tobacco product
that is test marketed after February 15,
2007, and this term would encompass
distribution of free samples (e.g.,
smokeless products). FDA intends to
limit our enforcement of the
requirements of section 910 and 905(j)
to finished tobacco products (see the
Guidance for Industry and FDA Staff
entitled ‘‘Section 905(j) Reports:
Demonstrating Substantial Equivalence
for Tobacco Products’’ (76 FR 789,
January 6, 2011); see also Deeming final
rule, 81 FR at 29019).
• Component or part. FDA proposes
to define ‘‘component or part’’ as any
software or assembly of materials
intended or reasonably expected: (1) To
alter or affect the tobacco product’s
performance, composition, constituents,
or characteristics or (2) to be used with
or for the human consumption of a
tobacco product. Component or part
excludes anything that is an accessory
of a tobacco product. A container
closure system (which would also be
defined in this proposed section) is
considered a component or part. With
respect to these definitions, FDA notes
that ‘‘component’’ and ‘‘part’’ are
separate and distinct terms within
chapter IX of the FD&C Act. However,
for purposes of this proposed rule, FDA
is using the terms ‘‘component’’ and
‘‘part’’ interchangeably and without
emphasizing a distinction between the
terms. FDA may clarify the distinctions
between ‘‘component’’ and ‘‘part’’ in the
future. This proposed definition and
approach are in accord with the
Deeming final rule. FDA invites
comments on this approach.
• Composition. FDA proposes to
define ‘‘composition’’ as all of the
materials in a tobacco product,
including ingredients, additives, and
biological organisms. The term also
includes the manner in which these
ingredients, additives, biological
organisms, etc., are arranged and
integrated to produce a tobacco product.
Composition refers primarily to the
chemical and biological properties of a
tobacco product, whereas design refers
to the physical properties of a tobacco
product. A biological organism refers to
any living biological entity, such as an
animal, plant, fungus, or bacterium.
• Constituent. FDA proposes to
define ‘‘constituent’’ as any chemical or
chemical compound in a tobacco
PO 00000
Frm 00008
Fmt 4701
Sfmt 4702
product that is or potentially is inhaled,
ingested, or absorbed into the body, any
chemical or chemical compound in an
emission from a tobacco product, or any
chemical or chemical compound in
mainstream or sidestream tobacco
smoke that either transfers from any
component of the tobacco product to the
smoke or that is formed by the
combustion or heating of tobacco,
additives, or other component of the
tobacco product. Examples of
constituents include harmful or
potentially harmful constituents, total
particulate matter, nicotine-free dry
particulate matter, and water. A
constituent also could include any other
chemical or chemical compound
contained in or produced by a tobacco
product under conditions of use.
• Container closure system. FDA
proposes to define ‘‘container closure
system’’ as any packaging materials that
are a component or part of a tobacco
product.
Examples of a container closure
system include the blister pack around
a dissolvable tablet (in this example, if
there is a box around a blister pack, the
box is not considered a container
closure system if it is not intended or
reasonably expected to alter or affect the
dissolvable tablet), the can that contains
and protects a moist snuff product, and
the plastic-wrapped hard pack or soft
pack used to contain and protect
cigarettes. In the context of determining
whether a product is substantially
equivalent as defined in section
910(a)(3)(A) of the FD&C Act, a
container closure system is a component
or part of a tobacco product because of
its potential to alter or affect the
performance, composition, constituents,
or other physical characteristics of the
product. For example, if a change in the
container closure system could affect
the chemistry of the product, FDA could
require the applicant to demonstrate
that the change in the container closure
system does not cause the new tobacco
product to raise different questions of
public health. Although the FD&C Act
does not itself define ‘‘component’’ or
‘‘part,’’ FDA recently promulgated
definitions for these terms in the
Deeming final rule. According to 21 CFR
1100.3, ‘‘component or part’’ means any
software or assembly of materials
intended or reasonably expected: (1) To
alter or affect the tobacco product’s
performance, composition, constituents,
or characteristics or (2) to be used with
or for the human consumption of a
tobacco product. Component or part
excludes anything that is an accessory
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
amozie on DSK9F9SC42PROD with PROPOSALS2
of a tobacco product.5 The same
definitions are also reflected in this
rule’s proposed § 1107.12.
In addition, considering a distinct
subset of packaging (i.e., container
closure system) to be a component or
part is consistent with the FD&C Act.
For example, section 900(1) of the FD&C
Act defines an ‘‘additive’’ as any
substance the intended use of which
results or may reasonably be expected to
result, directly or indirectly, in its
becoming a component or otherwise
affecting the characteristic of any
tobacco product (including any
substance intended for use as a flavoring
or coloring or in producing,
manufacturing, packing, processing,
preparing, treating, packaging,
transporting, or holding), except that
such term does not include tobacco or
a pesticide chemical residue in or on
raw tobacco or a pesticide chemical.
This definition further evinces
Congress’s understanding that
packaging is not entirely separable from
the tobacco product. Finally, the
definition of ‘‘package’’ in section
900(13) of the FD&C Act does not
dictate a contrary result, and can be
reasonably interpreted to mean that a
distinct subset of packaging is also a
component or part of a tobacco product.
According to the proposed definition
above, packaging constitutes a container
closure system if it is intended or
reasonably expected to affect or alter the
performance, composition, constituents,
or characteristics of a tobacco product,
even if it is also used to protect or
contain the tobacco product. For
example, packaging materials constitute
a container closure system if substances
within that packaging are intended or
reasonably expected to affect product
moisture, e.g., when the manufacturer
changes the package of a moist snuff
from plastic to fiberboard, which can
affect microbial stability and TSNA
formation during storage. Another
example of this is when menthol or
other ingredients are applied to the
inner foil to become incorporated into
the consumed product (Ref. 1).
Packaging materials may also be
intended or reasonably expected to
5 ‘‘Accessory’’ is defined as any product that is
intended or reasonably expected to be used with or
for the human consumption of a tobacco product;
does not contain tobacco and is not made or derived
from tobacco; and meets either of the following: (1)
Is not intended or reasonably expected to affect or
alter the performance, composition, constituents, or
characteristics of a tobacco product or (2) is
intended or reasonably expected to affect or
maintain the performance, composition,
constituents, or characteristics of a tobacco product
but solely controls moisture and/or temperature of
a stored tobacco product or solely provides an
external heat source to initiate but not maintain
combustion of a tobacco product (§ 1100.3).
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
affect the characteristics of a tobacco
product by impacting the rate of
leaching into, and ultimately, the
amount of substances found in, the
consumable tobacco product. In fact, it
has been demonstrated that compounds
in packaging materials may also diffuse
into snuff and affect its characteristics
(Ref. 2). Thus, for example, packaging
material that affects the characteristics
of a tobacco product by impacting the
moisture level or shelf life of a tobacco
product is a container closure system
(e.g., a plastic versus a metal container
of smokeless tobacco). A difference in
tobacco moisture is reasonably expected
to affect microbial growth in the
product, extraction efficiency, and total
exposure to nicotine or the carcinogens
N-nitrosonornicotine (NNN) or 4(methylnitrosamino)-1-(3-pyridyl)-1butanone (NNK) (Ref. 26).
Treating a distinct subset of packaging
as a component or part thus furthers the
fundamental purpose of the Tobacco
Control Act to protect the public health.
This interpretation is also consistent
with the broad definition of ‘‘tobacco
product,’’ as well the definition of
‘‘additive,’’ which includes any
substance that may be reasonably
expected to result, directly or indirectly,
in its becoming a component or
otherwise affecting the characteristics of
any tobacco product—and not just
substances that do in fact have such
effects. This shows that Congress did
not intend for FDA to be required to
show that a container closure system
did in fact alter or affect the tobacco
product’s performance, composition,
constituents, or other characteristics.
Indeed, if FDA were to adopt a narrow
construction of ‘‘tobacco product’’ to
exclude these materials, the Agency’s
ability to evaluate whether the
differences between the new and
predicate tobacco product cause the
new tobacco product to raise different
questions of public health would be
impeded, thereby leaving the Agency
unable to fully execute its mission to
protect the public health.
• Design. FDA proposes to define
‘‘design’’ to mean the form and structure
concerning, and the manner in which,
components or parts, ingredients,
software, and materials are integrated to
produce a tobacco product. This term
refers to the physical properties of a
tobacco product. Examples of design
features include tip ventilation, paper
porosity, tobacco cut width, and filter
efficiency.
• Finished tobacco product. FDA
proposes to define ‘‘finished tobacco
product’’ to mean a tobacco product,
including all components and parts,
sealed in final packaging (e.g., filters or
PO 00000
Frm 00009
Fmt 4701
Sfmt 4702
12747
filter tubes sold separately to consumers
or as part of kits).
• Grandfathered tobacco product.
FDA proposes to define a
‘‘grandfathered tobacco product’’ to
mean a tobacco product that was
commercially marketed in the United
States on February 15, 2007. This term
does not include tobacco products
exclusively marketed in a test market as
of that date. FDA interprets the phrase
‘‘as of February 15, 2007,’’ as meaning
that the tobacco product was
commercially marketed in the United
States ‘‘on February 15, 2007,’’ and the
proposed definition reflects this
interpretation (see the final guidance
entitled ‘‘Establishing That a Tobacco
Product Was Commercially Marketed in
the United States as of February 15,
2007’’ (79 FR 58358, September 29,
2014)). A grandfathered tobacco product
is not subject to the premarket
requirements of section 910 of the FD&C
Act.
• Harmful or potentially harmful
constituent (HPHC). FDA proposes to
define ‘‘harmful or potentially harmful
constituent’’ as any chemical or
chemical compound in a tobacco
product or tobacco smoke or emission
that: (1) Is or that potentially could be
inhaled, ingested, or absorbed into the
body, including as an aerosol (vapor) or
any other emission and (2) causes or has
the potential to cause direct or indirect
harm to users or nonusers of tobacco
products.
FDA has previously discussed HPHCs
in FDA guidance documents (see the
final guidance entitled ‘‘Harmful and
Potentially Harmful Constituents’ in
Tobacco Products as Used in Section
904(e) of the Federal Food, Drug, and
Cosmetic Act’’ (76 FR 5387, January 31,
2011; revised guidance issued August
2016)). The current established list of
HPHCs can be found on FDA’s website
at https://www.fda.gov/
TobaccoProducts/Labeling/
RulesRegulationsGuidance/
ucm297786.htm (77 FR 20034, April 3,
2012). In addition, since the inception
of the SE program for tobacco products,
HPHCs have been considered ‘‘other
features,’’ and the proposed definition
of ‘‘other features’’ in this rule would
include HPHCs (see the final guidance
entitled ‘‘Section 905(j) Reports:
Demonstrating Substantial Equivalence
for Tobacco Products,’’ (January 5,
2011)).
• Health information summary. FDA
proposes to define ‘‘health information
summary’’ to mean a summary,
submitted by the applicant under
section 910(a)(4) of the FD&C Act, of
any health information related to the
new tobacco product. This would
E:\FR\FM\02APP2.SGM
02APP2
amozie on DSK9F9SC42PROD with PROPOSALS2
12748
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
include detailed information concerning
adverse health effects of the new
tobacco product. For example,
information concerning adverse health
effects includes specific adverse events
that have been reported to the applicant
and also includes any research or data
concerning adverse health effects of
which the applicant is aware.
• Health information statement. FDA
proposes to define ‘‘health information
statement’’ to mean a statement, made
under section 910(a)(4) of the FD&C Act
that health information related to the
new tobacco product would be made
available upon request by any person.
Like the health information summary,
the health information provided to a
person requesting it would be required
to include any health information
related to the new tobacco product,
including detailed information
regarding data concerning adverse
health effects of the new tobacco
product.
• Heating source. FDA proposes to
define ‘‘heating source’’ as the source of
energy that is used to burn or heat a
tobacco product. An example of a
heating source is a flame.
• Ingredient. FDA proposes to define
‘‘ingredient’’ as tobacco, substances,
compounds, or additives added to the
tobacco, paper, filter, or any other
component or part of a tobacco product,
including substances and compounds
reasonably expected to be formed
through a chemical reaction during
tobacco product manufacturing. For
example, an ingredient may be a single
chemical substance, leaf tobacco, or the
product of a reaction, such as a
chemical reaction, in manufacturing.
Examples of substances and compounds
(ingredients) reasonably expected to be
formed through a chemical reaction
during tobacco product manufacturing
include the following:
Æ The reaction of sugars with amines
to form families of compounds with
new carbon-nitrogen bonds, including
Maillard reaction products and Amadori
compounds.
Æ The reaction of sodium hydroxide
with citric acid to form sodium citrate.
Æ The production of ethyl alcohol, a
residual solvent, from ethyl acetate
during production of tipping paper
adhesive.
Æ Products of thermolytic reactions,
such as the production of carboxylic
acids from sugar esters.
Æ Products of enzymatically or
nonenzymatically catalyzed reactions,
such as the hydrolytic production of
flavor or aroma precursors from
nonvolatile glucosides.
Æ Products of acid-base reactions,
such as removal of a proton from
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
protonated nicotine to generate the basic
form of nicotine (‘‘free’’ nicotine).
• Material. FDA proposes to define
‘‘material’’ to mean an assembly of
ingredients. Materials are assembled to
form the tobacco product or components
or parts of tobacco products. For
example, material would include the
glue or paper pulp for a cigarette where
the paper pulp includes multiple
ingredients (e.g., multiple types of
tobacco, water, and flavors) assembled
into the paper (or pulp depending on
the water content).
• Other features. FDA proposes to
define ‘‘other features’’ to mean any
distinguishing qualities of a tobacco
product similar to those specifically
enumerated in section 910(a)(3)(B) of
the FD&C Act. The definition would
include: (1) HPHCs (note that the
definition of new tobacco product
includes any modification to any
constituents, including smoke
constituents, section 910(a)(1)(B) of the
FD&C Act) and (2) any other product
characteristics that relate to the
chemical, biological, and physical
properties of the tobacco product that
are necessary for SE Report review. As
described in the proposed definition of
HPHC, HPHC information is necessary
to provide a complete comparison
between the new and predicate tobacco
products: HPHCs are a subset of the
chemical and chemical compounds in a
tobacco product or tobacco smoke or
emission. As such, HPHC information
for the new and predicate tobacco
products is necessary for FDA to
determine whether the new tobacco
product raises different questions of
public health. Other features also would
encompass other product characteristics
that relate to the chemical, biological,
and physical properties that would not
be addressed as a material, ingredient,
design, composition, or heating source.
• Predicate tobacco product. FDA
proposes to define ‘‘predicate tobacco
product’’ to mean a tobacco product that
is a grandfathered tobacco product or a
tobacco product that FDA has
previously found to be substantially
equivalent under section 910(a)(2)(A)(i)
of the FD&C Act. This proposed
definition is also based on language in
section 905(j)(1)(A)(i) of the FD&C Act.
• Submission tracking number or
STN means the number that FDA
assigns to submissions that are received
from a manufacturer of tobacco
products, such as SE Reports and
requests for grandfather determinations.
• Substantial equivalence report or
SE Report. FDA proposes to define
‘‘substantial equivalence report’’ (also
known as a 905(j) report) or SE Report
to mean a submission under section
PO 00000
Frm 00010
Fmt 4701
Sfmt 4702
905(j)(1)(A)(i) of the FD&C Act that
includes the basis for the applicant’s
determination that a new tobacco
product is substantially equivalent to a
predicate tobacco product. This term
includes the initial SE Report and all
subsequent amendments (e.g.,
amendments include information an
applicant submits in response to a
deficiency letter).
B. Substantial Equivalence Reports
(Proposed Subpart C)
1. Submission of a Substantial
Equivalence Report (Proposed
§ 1107.16)
Proposed § 1107.16 explains the basic
timeframes that would be required for
submitting an SE Report to FDA before
commencing commercial distribution of
a new tobacco product. An applicant
may submit an SE Report to
demonstrate that a new tobacco product
is substantially equivalent to a predicate
tobacco product (an applicant could
also consider whether the exemption
under § 1107.1 or an application under
section 910(b) of the FD&C Act is a more
appropriate premarket pathway for the
applicant’s new tobacco product). If an
applicant chooses to submit an SE
Report for a new tobacco product, it
must do so at least 90 calendar days
before the date the applicant intends to
begin commercial distribution of the
product (see section 905(j)(1) of the
FD&C Act). The proposed rule also
provides that an applicant may not
begin commercial distribution of the
new tobacco product that is the subject
of the SE Report until FDA has issued
an order stating that the Agency has
determined that the new tobacco
product is substantially equivalent to a
predicate tobacco product (unless the
new tobacco product has received
authorization to be marketed through
another premarket pathway, i.e., PMTA
or exemption from substantial
equivalence). Otherwise, the new
tobacco product is both adulterated and
misbranded (sections 902(6)(A) and
903(a)(6) of the FD&C Act) and subject
to enforcement action.
2. Required Content and Format of an
SE Report (Proposed § 1107.18)
Since March 22, 2011 (the date that
SE Reports for provisional tobacco
products were required to be
submitted), FDA has gained
considerable experience in reviewing
more than 3,000 SE Reports submitted
under sections 905(j) and 910(a) of the
FD&C Act. As a result, FDA has
identified information essential to the
review of SE Reports, which is reflected
E:\FR\FM\02APP2.SGM
02APP2
amozie on DSK9F9SC42PROD with PROPOSALS2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
in the content and format requirements
of proposed § 1107.18.
a. Overview. Proposed § 1107.18(a)
provides an overview of the
requirements for the content and format
of an SE Report. Proposed § 1107.18(a)
would provide that the SE Report
include information that would enable
FDA to uniquely identify the new
tobacco product and the predicate
tobacco product and compare the new
tobacco product to a predicate tobacco
product. This information is necessary
for FDA both in reviewing the SE Report
so that we can understand the
comparison and also to issue an order
that appropriately identifies the tobacco
product that is subject to the order.
Providing sufficient information as
described in proposed § 1107.18 would
help enable FDA to determine whether
the new tobacco product is substantially
equivalent to a tobacco product
commercially marketed in the United
States as of February 15, 2007 (as
required by section 910(a)(2)(A) of the
FD&C Act).
The proposed provision would
require that the SE Report contain the
following elements:
• General information (described in
proposed § 1107.18(c));
• Summary (described in proposed
§ 1107.18(d));
• New tobacco product description
(described in proposed § 1107.18(e));
• Predicate tobacco product
description (described in proposed
§ 1107.18(f)). This would include a
statement that the predicate tobacco
product has not been removed from the
market at the initiative of FDA and has
not been determined by judicial order to
be adulterated or misbranded, and the
STN of the SE order finding the
predicate tobacco product SE, or the
STN of, or specific information
sufficient to support, a grandfathered
determination of the predicate tobacco
product. If the SE Report includes
information on the grandfathered status
of the predicate tobacco product (but
FDA has not yet made a grandfathered
determination 6), FDA would make the
grandfathered determination before
beginning substantive scientific review
of the SE Report to ensure that the
predicate tobacco product is valid;
• Comparison information (described
in proposed § 1107.18(g));
• Comparative testing information
(described in proposed § 1107.18(h))
6 FDA discusses the information the Agency will
consider, along with Agency’s general thinking on
grandfathered determinations, in the guidance
document, ‘‘Establishing That a Tobacco Product
Was Commercially Marketed in the United States as
of February 15, 2007’’ (79 FR 58358, September 29,
2014).
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
• Statement of compliance with
applicable tobacco product standards
under section 907 of the FD&C Act (21
U.S.C. 387g) (described in proposed
§ 1107.18(i));
• Health summary or statement
regarding the availability of such
information as required by section
910(a)(4) of the FD&C Act (described in
proposed § 1107.18(j));
• Compliance with part 25 (21 CFR
part 25) (environmental impact
considerations) (described in proposed
§ 1107.18(k)); and
• Certification statement (described
in proposed § 1107.18(l)).
If the SE Report were missing any of
these items, the Agency would, under
proposed § 1107.44(a), refuse to accept
the SE Report for review.
b. General Format. Proposed
§ 1107.18(b) provides the general
requirements for the format of the SE
Report and would require the applicant
to submit the SE Report with the
appropriate FDA form (Refs. 3 and 4).
Proposed § 1107.18(b) would require the
SE Report and any amendments to
contain a comprehensive index and
table of contents and be well organized,
legible, and written in the English
language. For any foreign language
documents, the original foreign
language document must be
accompanied by the English translation
and a certification by the applicant or
responsible official authorized to
represent the applicant that the
translation into English is accurate. The
comprehensive index would include the
listing of files and data associated with
those files (e.g., for an SE Report that is
electronically submitted, the
comprehensive index would include the
listing of files and associated metadata).
As described in proposed § 1107.62,
FDA is proposing that, for an SE Report
and supporting documents to be
accepted by FDA, the SE Report and
documents must be submitted to FDA in
an electronic format that the Agency can
process, read, review, and archive,
unless the Agency has previously
granted a waiver from these
requirements. FDA will not act on an SE
Report until the Center for Tobacco
Product’s (CTP’s) Document Control
Center has received an SE Report that
the Agency can process, read, review,
and archive. Applicants that are unable
to submit their reports in electronic
format would be advised to consult
proposed § 1107.62, which explains
how the applicant may obtain a waiver
from the electronic filing requirement.
FDA intends to provide information on
our website about technical
specifications related to submission,
including the electronic formats, which
PO 00000
Frm 00011
Fmt 4701
Sfmt 4702
12749
would allow FDA to process, read,
review, and archive the SE Report.
Providing technical specifications
information on our website enables FDA
to periodically update the electronic
formats that we are capable of accepting
so that we can accommodate quickly
evolving technology.
The requirements in proposed
§ 1107.18(b) and 1107.62 are intended to
address some of the problems we have
seen with SE Reports. For example,
some SE Reports have been submitted to
FDA in a proprietary format or
password protected without providing
FDA access or password information.
Following up with an applicant to
obtain access or password information
takes time and contributes to delays. In
addition, some electronic submissions
have not been in a static format, and
thus, the pages reformat, renumber, rebullet, or re-date each time the
document is accessed. Receiving SE
Reports with these issues affects our
ability to cross-reference, share, and
efficiently evaluate information. Lastly,
because FDA is required under
regulations governing Federal records to
maintain many files long term, and in a
‘‘sustainable’’ format (for more
information on sustainable formats,
please refer to National Archives and
Record Administration Bulletin 2014–
04, https://www.archives.gov/recordsmgmt/bulletins/2014/2014-04.html),
proposed § 1107.18(b) would ensure
that these files can be managed, opened,
and read by the Agency for the duration
of the retention period.
c. General information. Proposed
§ 1107.18(c) lists the information that
the SE Report would be required to
include. This information includes
general administrative information that
must specify the type of submission
(e.g., SE Report); the new tobacco
product with unique identification and
the predicate tobacco product with
unique identification (to enable us to
identify the new tobacco product as
well as identify the predicate product),
as well as contact information. The SE
Report must include the following
information using the FDA-provided
forms, as appropriate:
• The date the SE Report is submitted
(using the applicant-generated submittal
date, i.e., the date the applicant assigns
to it, which for a paper submission is
the date typically located at the top of
a cover letter, and for an electronic
submission is the date when the
document is uploaded to FDA’s
electronic submission system);
• Type of submission (e.g., SE Report
or amendment to an SE Report);
• Previously assigned FDA STN,
where applicable (e.g., in cases where
E:\FR\FM\02APP2.SGM
02APP2
12750
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
the applicant is submitting an
amendment to an SE Report, the Agency
has assigned a number in advance, or
the applicant is referencing a previously
denied SE Report);
• Any other relevant FDA STN, such
as a request for a grandfathered
determination, and cross-references to
meetings regarding the new tobacco
product (e.g., if FDA issues an order
denying marketing authorization for a
tobacco product and meets with the
applicant about it before the applicant
submits a new SE Report, the meeting
should be referenced in the new SE
Report);
• The name, address, and contact
information for the applicant and the
authorized representative or authorized
U.S. agent (for a foreign applicant). FDA
would require identification of an
authorized representative or, for foreign
applicants, authorized U.S. agent to
help FDA ensure adequate notice is
provided to applicants of official
Agency communications. In particular,
FDA may be unable to confirm that
adequate notice of Agency action or
correspondence concerning premarket
submissions is provided to foreign
applicants as FDA cannot necessarily
confirm receipt of correspondence sent
internationally. Accordingly, the
designation of a U.S. agent provides an
official contact to the Agency who can
receive the information or
documentation on behalf of the
applicant. Providing notice regarding
that SE Report to the U.S. agent would
constitute notice to the foreign
applicant. FDA requires identification of
a U.S. agent to assist FDA in
communicating with the foreign
applicant and help permit the Agency to
efficiently process SE Reports and avoid
delays. In many instances during the SE
Report review process, FDA has reached
out numerous times to a foreign
applicant and has either been unable to
speak with the applicant or was unable
to directly communicate questions and/
or concerns. This impediment has
resulted in delays or terminations in the
review of specific SE Reports and a
slowdown of the premarket application
process as a whole. A U.S. agent would
act as a communications link between
FDA and the applicant and would
facilitate timely correspondence
between FDA and foreign applicants,
including responding to questions
concerning pending applications and, if
needed, assisting FDA in scheduling
meetings with the foreign applicants to
resolve outstanding issues before agency
action is taken. In addition, the
authorized representative or U.S. agent
would be authorized to act on behalf of
the applicant for that specific SE Report.
• For both the new and predicate
tobacco product, information needed to
uniquely identify the products,
including:
Æ The manufacturer;
Æ Product name, including the brand
and sub brand;
Æ Product category; product
subcategory; and product properties, as
provided in table 2. The applicant
would select and provide for both the
new and predicate tobacco products the
appropriate category, subcategory, and
product properties (if the product does
not have a listed product property, e.g.,
ventilation or characterizing flavor, the
report must state ‘‘none’’ for that
property):
TABLE 2—TOBACCO PRODUCT CATEGORY, SUBCATEGORY, AND PRODUCT PROPERTIES INFORMATION
Tobacco product category
Tobacco product subcategory
Product properties
Cigarettes ........................................
Combusted, Filtered ......................
—Package type (e.g., hard pack, soft pack, clam shell).
—Product quantity (e.g., 20 cigarettes, 25 cigarettes).
—Length (e.g., 89 millimeter (mm), 100 mm).
—Diameter (e.g., 6 mm, 8.1 mm).
—Ventilation (e.g., none, 10%, 25%).
—Characterizing Flavor(s) 7 (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., hard pack, soft pack, clam shell).
—Product quantity (e.g., 20 cigarettes, 25 cigarettes).
—Length (e.g., 89 mm, 100 mm).
—Diameter (e.g., 6 mm, 8.1 mm).
—Characterizing Flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., hard pack, soft pack, clam shell).
—Product quantity (e.g., 20 cigarettes, 25 cigarettes).
—Length (e.g., 89 mm, 100 mm).
—Diameter (e.g., 6 mm, 8.1 mm).
—Ventilation (e.g., none, 10%, 25%).
—Characterizing Flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., hard pack, soft pack, clam shell).
Combusted, non-filtered ................
Combusted, Other .........................
amozie on DSK9F9SC42PROD with PROPOSALS2
Non-Combusted (e.g., a cigarette
where the tobacco is only heated not burned).
Cigarette, Co-Package ..................
Roll-Your-Own
Products.
VerDate Sep<11>2014
(RYO)
Tobacco
20:34 Apr 01, 2019
RYO Tobacco Filler .......................
Jkt 247001
PO 00000
Frm 00012
Fmt 4701
—Product quantity (e.g., 20 cigarettes, 25 cigarettes).
—Length (e.g., 89 mm, 100 mm).
—Diameter (e.g., 6 mm, 8.1 mm).
—Ventilation (e.g., none, 10%, 25%).
—Characterizing Flavor(s) (e.g., none, menthol).
—Source of energy (e.g., charcoal, electrical heater).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—For a new co-packaged tobacco product composed of multiple cigarette tobacco products, include, as applicable, all properties for
each individual tobacco product, as identified above.
—Package type (e.g., bag, pouch).
Sfmt 4702
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
12751
TABLE 2—TOBACCO PRODUCT CATEGORY, SUBCATEGORY, AND PRODUCT PROPERTIES INFORMATION—Continued
Tobacco product category
Tobacco product subcategory
Rolling Paper .................................
Filtered Cigarette Tube ..................
Non-Filtered Cigarette Tube ..........
Filter ...............................................
Paper Tip .......................................
RYO Co-Package ..........................
Other ..............................................
Smokeless Tobacco Products ........
Loose Moist Snuff ..........................
amozie on DSK9F9SC42PROD with PROPOSALS2
Portioned Moist Snuff ....................
Loose Snus ....................................
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
PO 00000
Frm 00013
Fmt 4701
Product properties
—Product quantity (e.g., 20 g, 40 g).
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, box, booklet).
—Product quantity (e.g., 50 sheets, 200 papers).
—Length (e.g., 79 mm, 100 mm, 110 mm).
—Width (e.g., 28 mm, 33 mm, 45 mm).
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, box).
—Product quantity (e.g., 100 tubes, 200 tubes).
—Length (e.g., 89 mm, 100 mm).
—Diameter (e.g., 6 mm, 8.1 mm).
—Ventilation (e.g., none, 10%, 25%).
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, box).
—Product quantity (e.g., 100 tubes, 200 tubes).
—Length (e.g., 89 mm, 100 mm).
—Diameter (e.g., 6 mm, 8.1 mm).
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, box).
—Product quantity (e.g., 100 filters, 200 filters).
—Length (e.g., 8 mm, 12 mm).
—Diameter (e.g., 6 mm, 8.1 mm).
—Ventilation (e.g., none, 10%, 25%).
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, box).
—Product quantity (e.g., 200 tips, 275 tips).
—Length (e.g., 12 mm, 15 mm).
—Width (e.g., 27 mm).
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—For a new co-packaged tobacco product composed of multiple
RYO tobacco products, include, as applicable, all properties for
each individual tobacco product (e.g., RYO tobacco, rolling paper,
filtered cigarette tube, non-filtered cigarette tube, filter, paper tip) as
identified above.
—Package type (e.g., bag, box).
—Product quantity.
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product.
—Package type (e.g., plastic can with metal lid, plastic can with plastic lid).
—Product quantity (e.g., 20 grams (g), 2 ounces).
—Tobacco cut size (e.g., 5 mm, 7 mm).
—Characterizing flavor(s) (e.g., none, menthol, cherry, wintergreen).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., plastic can with metal lid, plastic can with plastic lid).
——Product quantity (e.g., 22.5 g, 20 g).
—Portion count (e.g., 15 pouches, 20 pieces).
—Portion mass (e.g., 1.5 g/pouch, 2 g/piece).
—Portion length (e.g., 15 mm, 20 mm).
—Portion width (e.g., 10 mm, 15 mm).
—Portion thickness (e.g., 5 mm, 7 mm).
—Tobacco cut size (e.g., 5 mm, 7 mm).
—Characterizing flavor(s) (e.g., none, menthol, cherry, wintergreen).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., plastic can with metal lid, plastic can with plastic lid).
Sfmt 4702
E:\FR\FM\02APP2.SGM
02APP2
12752
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
TABLE 2—TOBACCO PRODUCT CATEGORY, SUBCATEGORY, AND PRODUCT PROPERTIES INFORMATION—Continued
Tobacco product category
Tobacco product subcategory
Portioned Snus ..............................
Loose Dry Snuff .............................
Dissolvable ....................................
Loose Chewing Tobacco ...............
Portioned Chewing Tobacco .........
Smokeless Co-Package ................
amozie on DSK9F9SC42PROD with PROPOSALS2
Other ..............................................
ENDS (Electronic Nicotine Delivery
System).
Open E-Liquid (e.g., an e-liquid in
a bottle with a removable cap).
Product properties
—Product quantity (e.g., 20 g, 2 ounces).
—Tobacco cut size (e.g., 5 mm, 7 mm).
—Characterizing flavor(s) (e.g., none, menthol, cherry, wintergreen).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., plastic can with metal lid, plastic can with plastic lid).
—Product quantity (e.g., 22.5 g, 20 g).
—Portion count (e.g., 15 pouches, 20 pieces).
—Portion mass (e.g., 1.5 g/pouch, 2 g/piece).
—Portion length (e.g., 15 mm, 20 mm).
—Portion width (e.g., 10 mm, 15 mm).
—Portion thickness (e.g., 5 mm, 7 mm).
—Tobacco cut size (e.g., 5 mm, 7 mm).
—Characterizing flavor(s) (e.g., none, menthol, cherry, wintergreen).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., plastic can with metal lid, plastic can with plastic lid).
—Product quantity (e.g., 20 g, 2 ounces).
—Tobacco cut size (e.g., 0.05 mm, 0.07 mm).
—Characterizing flavor(s) (e.g., none, menthol, cherry, wintergreen).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., plastic can with metal lid, plastic can with plastic lid).
—Product quantity (e.g., 22.5 g, 20 g).
—Portion count (e.g., 15 sticks, 20 tablets).
—Portion mass (e.g., 1.5 g/strip, 1.0 g/piece).
—Portion length (e.g., 10 mm, 15 mm).
—Portion width (e.g., 5 mm, 8 mm).
—Portion thickness (e.g., 3 mm, 4 mm).
—Tobacco cut size (e.g., 0.05 mm, 0.07 mm).
—Characterizing flavor(s) (e.g., none, menthol, cherry, wintergreen).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, pouch, wrapped).
—Product quantity (e.g., 20 g, 3 ounces).
—Tobacco cut size (e.g., 0.05 mm, 0.07 mm).
—Characterizing flavor(s) (e.g., none, menthol, cherry, wintergreen).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., plastic can with metal lid, plastic can with plastic lid).
—Product quantity (e.g., 20 g).
—Portion count (e.g., 10 bits).
—Portion mass (e.g., 2 g/bit).
—Portion length (e.g., 8 mm, 10 mm).
—Portion width (e.g., 6 mm, 8 mm).
—Portion thickness (e.g., 5 mm, 7 mm).
—Characterizing flavor(s) (e.g., none, menthol, cherry, wintergreen).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—For a new co-packaged tobacco product composed of multiple
smokeless tobacco products, include, as applicable, all properties
for each individual tobacco product as identified above.
—Package type (e.g., bag, box).
—Product quantity.
—Characterizing flavor(s) (e.g., none, tobacco, menthol).
—Additional properties needed to uniquely identify the tobacco product.
—Package type (e.g., bottle, box).
—Product quantity (e.g., 1 bottle, 5 bottles).
—Characterizing flavor(s) (e.g., none, tobacco, menthol, cherry, wintergreen).
—E-liquid volume (e.g., 10 ml).
—Nicotine concentration (e.g., 0, 0.2 mg/ml).
—PG/VG ratio (e.g., N/A, 0/100, 50/50).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
PO 00000
Frm 00014
Fmt 4701
Sfmt 4702
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
12753
TABLE 2—TOBACCO PRODUCT CATEGORY, SUBCATEGORY, AND PRODUCT PROPERTIES INFORMATION—Continued
Tobacco product category
Tobacco product subcategory
Product properties
Closed E-Liquid (e.g., a sealed
cartridge for use in an e-cigarette).
Closed
E-Cigarette
cigalike).
(e.g.,
a
Open E-Cigarette (e.g., a tank
system).
ENDS Component .........................
ENDS Co-Package ........................
ENDS Other ...................................
Cigars ..............................................
Filtered, Sheet-Wrapped Cigar ......
amozie on DSK9F9SC42PROD with PROPOSALS2
Unfiltered, Sheet-Wrapped Cigar ..
Leaf-Wrapped Cigar ......................
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
PO 00000
Frm 00015
Fmt 4701
—Package type (e.g., cartridge).
—Product quantity (e.g., 1 cartridge, 5 cartridges).
—Characterizing flavor(s) (e.g., none, tobacco, menthol, cherry, wintergreen).
—E-liquid volume (e.g., 10 ml).
—Nicotine concentration (e.g., 0, 0.2 mg/ml).
—PG/VG ratio (e.g., N/A, 0/100, 50/50).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., box, none, plastic clamshell).
—Product quantity (e.g., 1 e-cigarette, 5 e-cigarettes).
—Characterizing flavor(s) (e.g., none, tobacco, menthol, cherry, wintergreen).
—Length (e.g., 100 mm, 120 mm).
—Diameter (e.g., 6 mm, 8 mm).
—E-liquid volume (e.g., 2 ml, 5 ml).
—Nicotine concentration (e.g., 0, 0.2 mg/ml).
—PG/VG ratio (e.g., N/A, 0/100, 50/50).
—Wattage (e.g., 100 W, 200 W).
—Battery capacity (e.g., 100 mAh, 200 mAh).
—Additional properties needed to uniquely identify the tobacco product.
—Package type (e.g., box, none, plastic clamshell).
—Product quantity (e.g., 1 e-cigarette, 5 e-cigarettes).
—Characterizing flavor(s) (e.g., none, tobacco, menthol, cherry, wintergreen).
—Length (e.g., 100 mm, 120 mm).
—Diameter (e.g., 8 mm, 14 mm).
—E-liquid volume (e.g., 2 ml, 5 ml).
—Wattage (e.g., 100 W, 200 W).
—Battery capacity (e.g., 100 mAh, 200 mAh).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., box, none, plastic clamshell).
—Product quantity (e.g., 1 e-cigarette, 5 e-cigarettes).
—Characterizing flavor(s) (e.g., none, tobacco, menthol, cherry, wintergreen).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—For a new co-packaged tobacco product composed of multiple
ENDS tobacco products, include, as applicable, all properties for
each individual tobacco product as identified above.
—Package type (e.g., bag, box).
—Product quantity.
—Characterizing flavor(s) (e.g., none, tobacco, menthol, cherry).
—Additional properties needed to uniquely identify the tobacco product.
—Package type (e.g., hard pack, soft pack, clam shell).
—Product quantity (e.g., 20 filtered cigars, 25 filtered cigars).
—Characterizing flavor (e.g., none, menthol).
—Length (e.g., 89 mm, 100 mm).
—Diameter (e.g., 6 mm, 8.1 mm).
—Ventilation (e.g., none, 10%, 25%).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., box, film sleeve).
—Product quantity (e.g., 1 cigar, 5 cigarillos).
—Characterizing flavor (e.g., none, menthol).
—Length (e.g., 100 mm, 140 mm).
—Diameter (e.g., 8 mm, 10 mm).
—Tip (e.g., none, wood tips, plastic tips).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., box, film, sleeve, none).
—Product quantity (e.g., 1 cigar, 5 cigars).
—Characterizing flavor (e.g., none, whiskey).
—Length (e.g., 150 mm, 200 mm).
—Diameter (e.g., 8 mm, 10 mm).
Sfmt 4702
E:\FR\FM\02APP2.SGM
02APP2
12754
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
TABLE 2—TOBACCO PRODUCT CATEGORY, SUBCATEGORY, AND PRODUCT PROPERTIES INFORMATION—Continued
Tobacco product category
Tobacco product subcategory
Cigar Component ..........................
Cigar Tobacco Filler ......................
Cigar Co-Package .........................
Other ..............................................
Pipe Tobacco Products ...................
Pipe ................................................
Pipe Tobacco Filler ........................
Pipe Component ............................
Pipe Co-Package ...........................
Other ..............................................
Waterpipe Tobacco Products ..........
Waterpipe ......................................
Waterpipe Tobacco Filler ..............
amozie on DSK9F9SC42PROD with PROPOSALS2
Waterpipe Heat Source .................
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
PO 00000
Frm 00016
Fmt 4701
Product properties
—Wrapper material (e.g., burley tobacco leaf, Connecticut shade
grown tobacco leaf).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., box, booklet).
—Product quantity (e.g., 10 wrappers, 20 leaves).
—Characterizing flavor (e.g., none, menthol, cherry).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, pouch).
—Product quantity (e.g., 20 g, 16 ounces).
—Characterizing flavor (e.g., none, tobacco, menthol, cherry).
—Tobacco cut size (e.g., 5 mm, 10 mm).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—For a new co-packaged tobacco product composed of multiple
cigar tobacco products, include, as applicable, all properties for
each individual tobacco product as identified above.
—Package type (e.g., bag, box).
—Product quantity.
—Characterizing flavor(s) (e.g., none, tobacco, menthol).
—Additional properties needed to uniquely identify the tobacco product.
—Package type (e.g., box, none).
—Product quantity (e.g., 1 pipe).
—Length (e.g., 200 mm, 300 mm).
—Diameter (e.g., 25 mm).
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, pouch).
—Product quantity (e.g., 20 g, 16 ounces).
—Characterizing flavor(s) (e.g., none, menthol, Cavendish, cherry).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bowl, shank, stem, screen, filter).
—Product quantity (e.g., 1 bowl, 1 stem, 100 filters).
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—For a new co-packaged tobacco product composed of multiple pipe
tobacco products, include, as applicable, all properties for each individual tobacco product as identified above.
—Package type (e.g., bag, box).
—Product quantity.
—Characterizing flavor(s) (e.g., none, tobacco, menthol).
—Additional properties needed to uniquely identify the tobacco product.
—Package type (e.g., box, none).
—Product quantity (e.g., 1 waterpipe).
—Length (e.g., 200 mm, 500 mm).
—Width (e.g., 100 mm, 300 mm).
—Number of hoses (e.g., 1, 2, 4).
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, pouch).
—Product quantity (e.g., 20 g, 16 ounces).
—Characterizing flavor(s) (e.g., none, tobacco, menthol, apple).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., box, film sleeve, bag, none).
—Product quantity (e.g., 150 g, 680 g).
—Characterizing flavor(s) (e.g., none, menthol, apple).
—Portion count (e.g., 20 fingers, 10 discs, 1 base).
—Portion mass (e.g., 15 g/finger).
—Portion length (e.g., 40 mm, 100 mm).
—Portion width (e.g., 10 mm, 40 mm).
—Portion thickness (e.g., 10 mm, 40 mm).
—Source of energy (e.g., charcoal, battery, electrical).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
Sfmt 4702
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
12755
TABLE 2—TOBACCO PRODUCT CATEGORY, SUBCATEGORY, AND PRODUCT PROPERTIES INFORMATION—Continued
Tobacco product category
Tobacco product subcategory
Product properties
Waterpipe Component ...................
—Package type (e.g., bag, box, none).
—Product quantity (e.g., 1 base, 1 bowl, 1 hose, 10 mouthpieces).
—Characterizing flavor(s) (e.g., none, menthol, apple).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—For a new co-packaged tobacco product composed of multiple
waterpipe tobacco products, include, as applicable, all properties
for each individual tobacco product as identified above.
—Package type (e.g., bag, box).
—Product quantity.
—Characterizing flavor(s) (e.g., none, tobacco, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, box).
—Product quantity.
—Characterizing flavor(s) (e.g., none, tobacco, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
Waterpipe Co-Package .................
Waterpipe Other ............................
Other ...............................................
Other ..............................................
amozie on DSK9F9SC42PROD with PROPOSALS2
7 Characterizing flavors may include those added to certain components or parts (e.g., paper) of the tobacco product. If there is no characterizing flavor, the application must state ‘‘none.’’
The applicant would be required to
include any additional properties
needed to uniquely identify the tobacco
product, if applicable (e.g., use of
product descriptors such as ‘‘premium’’
would be required to be identified).
Proposed § 1107.18(c)(8) would also
require the address of the facilities
involved in the manufacture of the
tobacco products and any Facility
Establishment Identifier number. This
information would assist the Agency in
making environmental impact
considerations and determinations
under part 25 by helping FDA
understand the scale of products that
would be manufactured.
d. Summary. Proposed § 1107.18(d)
would require a summary at the
beginning of the SE Report. This
summary portion of the SE Report
would act as an abstract designed to
orient reviewers to the contents of the
SE Report. Under proposed
§ 1107.18(d), the summary would be
required to include three elements.
First, the summary would be required to
include a concise description of the
characteristics of the new tobacco
product. As stated in section
910(a)(3)(B) of the FD&C Act,
characteristics means ‘‘the materials,
ingredients, design, composition,
heating source, or other features of a
tobacco product,’’ all of which are
defined in proposed § 1107.12. Second,
the summary would also be required to
include the applicant’s basis for
whether the new tobacco product has
the same characteristics as the predicate
tobacco product or has different
characteristics from the predicate
tobacco product which the applicant
believes do not cause the new tobacco
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
product to raise different questions of
public health. Third, with respect to
those characteristics, the summary
would be required to include a
description of the similarities and
differences between the new tobacco
product and the predicate tobacco
product.
e. New tobacco product description.
Proposed § 1107.18(e) sets forth the
information that would be required in
the description of the new tobacco
product. Based on our experience
reviewing SE Reports, FDA has found
that, to have a meaningful scientific
comparison, a new tobacco product
should be compared to a single
predicate product (this is discussed in
more detail at proposed § 1107.18(f), the
section of this document describing the
predicate tobacco description).
Accordingly, proposed § 1107.18(e)
would require the applicant to identify
the new tobacco product in the SE
Report for comparison to one predicate
tobacco product. As is currently the
practice, applicants may continue to
bundle groups of SE Reports submitted
under proposed § 1107.18 that have the
same proposed modifications (e.g., a
change in ingredient supplier that
results in a new tobacco product). As
discussed previously, co-packaging two
or more tobacco products may result in
a new tobacco product.
Proposed § 1107.18(e) would require
that the SE Report describe the new
tobacco product in sufficient detail to
enable FDA to understand and evaluate
the characteristics of the new tobacco
product in comparison to the predicate.
Specifically, the Agency proposes that
this section of the SE Report include the
following information:
PO 00000
Frm 00017
Fmt 4701
Sfmt 4702
• A narrative description of the new
tobacco product, as well as detailed
drawings or schematics. The drawings
would be required to identify the
container closure system and illustrate
all of the product’s components. As
defined in proposed § 1107.12, a
‘‘component or part’’ of a tobacco
product is any software or assembly of
materials intended or reasonably
expected: (1) To alter or affect the
tobacco product’s performance,
composition, constituents, or
characteristics or (2) to be used with or
for the human consumption of a tobacco
product. The definition excludes
anything that is an accessory of a
tobacco product. For example, an
applicant submitting an SE Report for a
pouched snus product would illustrate
all the components and parts of the
product, including the pouch material
and tobacco filler. The narrative
description would identify all the
components, e.g., for a cigarette, the
applicant would identify the rod, and
the rod’s paper and filler, and so on.
• A description of and the function
for each component or part of the new
tobacco product as well as an
explanation of how each component or
part is integrated into the product
design.
• If the manufacturing process for the
new tobacco product could affect the
characteristics of the new product, an
applicant would be required to provide
an overview of the manufacturing
process. This overview would not need
to be an exhaustive discussion but
enough information to enable FDA to
fully understand and compare the
characteristics that can be affected by
the manufacturing process of the new
E:\FR\FM\02APP2.SGM
02APP2
amozie on DSK9F9SC42PROD with PROPOSALS2
12756
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
tobacco product and the predicate
tobacco product. FDA has found during
reviews of SE Reports that changes in
manufacturing, including fermentation,
may impact the characteristics of the
tobacco product, e.g., the quantities of
nicotine (total and free), as well as
HPHCs such as tobacco-specific Nnitrosamines (TSNAs). Such changes
could cause the new product to raise
different questions of public health, e.g.,
fermentation can increase the levels of
nicotine, which impacts dependence
and cessation (Refs. 36 and 37), and an
increase in TSNAs may increase the risk
for certain types of cancer (Ref. 38).
Thus, if fermentation is used in the
manufacturing process for the new
tobacco product, then the SE Report
would be required to describe the
process, including the type and quantity
of the microbial inoculum and/or
fermentation solutions (fermentation is
typically used in smokeless tobacco
products, and the hot and sticky
environment associated with
fermentation may contribute to bacteria
and growth of contaminants, which is a
major health and safety concern). If the
manufacturing process for the new
tobacco product does not affect the
characteristics of the new product
beyond what is described elsewhere in
the SE Report, an applicant would be
required to state that to satisfy this
provision.
f. Description of the predicate tobacco
product. Under proposed § 1107.18(f),
the SE Report would be required to
include a section describing the
predicate tobacco product. Under
proposed § 1107.18(f)(1), the applicant
would be required to identify one
predicate tobacco product that is either
a grandfathered tobacco product or a
tobacco product that FDA previously
found to be substantially equivalent to
a predicate tobacco product. The
applicant may reference the STN if FDA
has already made a grandfathered
determination, or provide specific
information sufficient to support a
grandfathered determination (see the
final guidance entitled ‘‘Establishing
That a Tobacco Product Was
Commercially Marketed in the United
States as of February 15, 2007’’ (79 FR
58358, September 29, 2014)). If the SE
Report includes information to
demonstrate the grandfathered status of
the predicate product, FDA intends to
make the grandfathered determination
on that predicate tobacco product before
beginning substantive scientific review
of the SE Report.
As with any new tobacco product,
applicants who wish to use the SE
pathway to obtain marketing
authorization for new co-packaged
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
products would have to identify a single
predicate tobacco product for each new
tobacco product. An applicant could use
a co-packaged product as a predicate so
long as it is a valid predicate; however,
an applicant would not be required to
use a co-packaged product as its
predicate tobacco product.
FDA invites comments on this
approach or any recommended
alternative approaches for co-packaged
products.
Proposed § 1107.18(f)(2)(i) would
require that the predicate tobacco
product chosen by the applicant be in
the same category (e.g., cigarette,
smokeless) and subcategory (e.g.,
filtered, non-filtered) as the new tobacco
product to provide a meaningful starting
point for our substantial equivalence
review. This proposed requirement
reflects FDA’s experience, which has
been that if the predicate and new
tobacco products differ on these points,
it is highly unlikely that we would be
able to find that the SE Report
demonstrates the substantial
equivalence of the new tobacco product
to the predicate tobacco product. For
example, when an SE Report includes a
predicate and new tobacco product that
are in different categories (e.g., a
comparison of a combusted tobacco
product to a smokeless product), the
considerable differences between the
products in almost every characteristic
will raise different questions of public
health (e.g., an applicant attempting to
compare a smokeless moist snuff
predicate to a new combusted filtered
cigarette would likely not be able to
demonstrate that the cigarette does not
raise different questions of public health
as compared to the smokeless moist
snuff, as the properties and
characteristics of the two products are
so vastly different. For example, an
applicant would not be able to show
that a ventilation of 25 percent would
not cause the cigarette to raise different
questions of public health given that the
smokeless moist snuff has no ventilation
characteristic with which to compare).
These drastic differences in
characteristics make it very hard for
applicants to provide the evidence
necessary to show that these differences
do not cause the new product to raise
different questions of public health
because addressing the uncertainty in
the influence on adverse health impact
on the user, product use, initiation, and
cessation would often require complex
clinical studies.
In addition, under proposed
§ 1107.18(f)(2)(ii), the predicate must
have been either commercially marketed
(not exclusively in a test market) in the
United States as of February 15, 2007 (a
PO 00000
Frm 00018
Fmt 4701
Sfmt 4702
grandfathered predicate tobacco
product), or have been previously
determined to be substantially
equivalent by FDA. If the SE Report is
using a grandfathered predicate tobacco
product, the SE Report must include a
statement that ‘‘I, (name of responsible
official), confirm that the predicate
tobacco product, (insert name of
predicate tobacco product), was
commercially marketed other than for
test marketing as of February 15, 2007’’
or reference the STN for a previous
determination by FDA that the predicate
tobacco product is grandfathered. The
statement would be a means of ensuring
that the applicant understands that the
product must have been commercially
marketed on February 15, 2007, to be
considered grandfathered, and supports
the information provided in proposed
§ 1107.18(f)(1).
Under proposed § 1107.18(f)(2)(iii),
the applicant would be required to
identify a predicate tobacco product that
is an individual product. As previously
discussed, an applicant could use a copackaged product as a predicate so long
as it is a valid predicate (e.g., on the
market as of February 15, 2007, or one
that was previously found SE).
However, a predicate could not be a
fictional product made up by combining
characteristics of two or more products
that are grandfathered or have been
found SE. In addition, under proposed
§ 1107.18(f)(2)(iv) and (v), the predicate
tobacco product could not be the subject
of a rescission order by FDA as
described in proposed § 1107.50 and
could not have been removed from the
market at the initiative of FDA or have
been determined by judicial order to be
adulterated or misbranded. These
proposed requirements are intended to
minimize some of the problems with
predicate tobacco products that FDA has
identified during SE Report reviews
which prevent us from proceeding with
an SE review.
g. Comparison information. Proposed
§ 1107.18(g) states that the SE Report
would be required to include a
comparison of the characteristics of the
new tobacco product and the predicate
tobacco product, as described in
proposed § 1107.19. FDA expects this
comparison to be a significant part of an
SE Report as it would be expected to
describe in detail how the product
characteristics of the new tobacco
product compare to the product
characteristics of the predicate tobacco
product.8 If the new tobacco product
8 FDA notes that some applications may use
surrogate tobacco products for discrete parts of an
SE application. A surrogate is a tobacco product for
which an applicant provides data it would like to
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
amozie on DSK9F9SC42PROD with PROPOSALS2
has some characteristics that are not
identical to the predicate, but some
characteristics that are identical, the
applicant must provide comparison
information related to the characteristics
that are not identical, but may certify
that the other characteristics are
identical under proposed
§ 1107.18(l)(2).
For example, if the modification
between the new and predicate product
is a change to fire standard compliant
(FSC) paper, the SE Report would state
and provide comparison information on
the difference of the non-FSC to FSC
paper, the change in filtration (e.g., if
there is a change in filtration due to the
change made to the paper), and the
change in tobacco blend (e.g., if there is
a change in blend made with the change
to the paper), but the SE Report could
then include a certification that all other
characteristics of the new and predicate
product, other than the modified paper,
filtration, and blend, are identical.
Another example is a change in product
quantity (e.g., an increase from 20 grams
to 35 grams of loose moist snuff). In this
scenario, if the per weight composition
has not changed, the applicant could
provide comparison information on
only the characteristics that differ
between the new and predicate product,
and include a certification under
proposed § 1107.18(l)(2) that all other
characteristics are identical. A third
example would be a container closure
system (CCS) substitution of a bag for a
box. In this case, the SE Report would
provide comparison information on the
change in CCS and the SE Report could
then include a certification under
proposed § 1107.18(l)(2) that the
characteristics of all non-CCS items
have not changed (e.g., rolling papers
are identical between the new and
predicate product). The applicant would
be required to maintain records
supporting the certification consistent
with proposed § 1107.58.
h. Comparative testing information.
Other than for characteristics that are
extrapolate to the new, predicate tobacco product
or both new and predicate tobacco products.
However, the surrogate tobacco product is neither
the new or predicate tobacco product (a
grandfathered determination is not necessary for
surrogate tobacco products as it is not a predicate
tobacco product). Data for a surrogate tobacco
product is provided in place of data or to provide
a bridge between data for the new or predicate
tobacco product. A surrogate tobacco product is
used when there is inadequate data available for the
new or predicate tobacco product; data for a
surrogate tobacco product supplement the data for
a new or predicate tobacco product. Unlike
predicate tobacco products, surrogate tobacco
product data may be in place at the start of
substantive scientific review or may be provided in
response to a deficiency letter. FDA invites
comments on the use of surrogate tobacco products.
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
identical (and for which the applicant
has certified that the characteristics are
identical under paragraph (l)(2)),
proposed § 1107.18(h) would require the
SE Report to include testing information
on the characteristics of the new and
predicate tobacco products as described
in section § 1107.19, except where the
applicant adequately justifies that such
comparative testing information is not
necessary to demonstrate that the new
product: (1) Has the same characteristics
as the predicate or (2) does not raise
different questions of public health. For
example, it may not always be necessary
to provide comparative testing
information on the heating source.
Comparative testing supports the SE
Report by showing the information
contained in the SE Report is
meaningful and accurate and, where
applicable, helps demonstrate that the
different characteristic(s) in a new
tobacco product does not raise different
questions of public health. FDA’s
experience has been that the summary
data provided in some SE Reports has
been miscalculated, and thus, a
substantial equivalence determination
was not supportable. To ensure the
accuracy of the data provided, FDA has
needed to review the experimental data.
Accordingly, proposed § 1107.18(h)(1)
would require that the SE Report
include test protocols, quantitative
acceptance criteria, and test results
(including means and variances, data
sets, and a summary of the results).
Under proposed § 1107.18(h)(2), the
testing would be required to be
conducted on a sufficient sample size
and on samples that reflect the final
tobacco product composition and
design. Proposed § 1107.18(h)(3) would
require the SE Report to state whether
the testing method for the new and
predicate products are the same and, if
they differ, to explain how the results of
the different test methods can be
compared. Under proposed
§ 1107.18(h)(4), the SE Report also must
identify any national and international
standards used to test the new and
predicate tobacco products and explain
any deviations.9 If no standards were
used for testing, the SE Report would be
required to state so. There are multiple
ways to satisfy this comparative testing
requirement that may not require
comparative testing on the specific
characteristic that is different between
the new and predicate tobacco product.
For example, if an applicant is
proposing to modify the container
9 In the guidance document entitled, ‘‘Section
905(j) Reports: Demonstrating Substantial
Equivalence for Tobacco Products’’ (January 2011),
FDA provided some examples of standards that
might be used to support an SE application.
PO 00000
Frm 00019
Fmt 4701
Sfmt 4702
12757
closure system of a smokeless tobacco
product for loose moist snuff, rather
than supply testing information on the
container closure system, the applicant
could demonstrate that the ingredients,
constituents, moisture, and stability of
the loose tobacco within the container
closure system are not affected by the
change in container closure system in a
way that would cause the new product
to raise different questions of public
health. As testing information on the
ingredients, constituents, moisture, and
stability information would already be
required for the smokeless tobacco
product, additional comparative testing
information on differences in the
container closure system would not be
required. Instead the applicant would
state that this information is already
covered by the submission of the
ingredients, constituents, moisture, and
stability information within the SE
Report.
i. Statement of compliance with
applicable tobacco product standards.
As required by section 905(j)(1)(B) of the
FD&C Act, under proposed § 1107.18(i),
the SE Report must list and describe the
action(s) that the applicant has taken to
comply with the requirements under
section 907 of the FD&C Act (tobacco
product standards) that are applicable to
the tobacco product. In the alternative,
the SE Report must state that there are
no requirements under section 907 that
are applicable to the new tobacco
product. For SE Reports that are
submitted after the finalization of this
rule, but still pending after issuance of
any future tobacco product standards,
FDA invites public comments on how
such pending SE Reports should be
considered or handled in relation to the
satisfaction of the requirement for a
statement of compliance with applicable
tobacco product standards.
j. Health information summary or
statement regarding availability of such
information. As required by section
910(a)(4) of the FD&C Act, the SE Report
must include either an adequate
summary of any health information
related to the new tobacco product or a
statement that such information would
be made available upon request by any
person. Proposed § 1107.18(j) would
codify this statutory requirement and
ensure that applicants provide adequate
information as required by section
910(a)(4). Under proposed
§ 1107.18(j)(1), if the applicant chooses
to provide a health information
summary, the applicant would be
required to provide a redacted version
of the full SE Report that excludes
research subject identifiers and trade
secret and confidential commercial
information as defined in §§ 20.61 and
E:\FR\FM\02APP2.SGM
02APP2
amozie on DSK9F9SC42PROD with PROPOSALS2
12758
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
20.63 (21 CFR 20.61 and 20.63). FDA
believes that an SE Report redacted in
the manner described would generally
provide an adequate summary of any
health information related to the new
tobacco product, as well as detailed
information regarding data concerning
adverse health effects of the new
tobacco product. The redacted SE
Report would be required to be
submitted with the original submission,
and a redacted copy of an amendment
would be required with the submission
of any amendment to the SE Report.
In addition, to the extent that there is
additional health information about the
new tobacco product, including any
information, research (e.g., published or
unpublished research, internal reports
or analyses), or data about adverse
health effects, that the applicant has or
knows about and that is not contained
in the SE Report, the applicant would be
required to provide such accurate and
complete, and not false or misleading,
information in the health information
summary. If there is no such additional
health information, the SE Report would
be required to include a statement that
the company does not have and does
not know of any such additional health
information. FDA would post the health
information summary, including the
redacted SE Report, and any additional
health information provided by the
applicant on FDA’s website.
Under proposed § 1107.18(j)(2), if the
applicant chooses to make the health
information available upon request, the
SE Report would be required to include
a certification statement made by an
authorized representative of the
applicant that an adequate summary of
any health information related to the
new tobacco product, including detailed
information regarding data concerning
adverse health effects of the new
tobacco product, would be made
available to a requestor within 30
calendar days of a request. The
certification is intended to ensure that
applicants understand that they are
responsible for providing this
information upon request.
Under proposed § 1107.18(j)(3), the
health information the applicant would
need to make available would be a copy
of the full SE Report (which includes
any amendments), excluding research
subject identifiers and trade secret and
confidential commercial information as
defined in §§ 20.61 and 20.63. To the
extent that the applicant has or knows
of any additional health information,
including any information, research, or
data regarding adverse health effects
that is not contained in the SE Report,
the applicant would also provide the
requester such accurate and complete,
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
and not false or misleading,
information. If there is no such
additional health information, the
applicant would provide the requester
with a statement that the company does
not have and does not know of any such
additional health information.
Proposed § 1107.18(j)(4) would
provide that requests for health
information be made to the authorized
representative of the applicant, whose
contact information the applicant would
provide to FDA. FDA intends to make
this contact information available on
FDA’s website. The applicant would be
required to update this contact
information with FDA whenever
necessary (e.g., the identified authorized
representative is no longer with the
company or the address or telephone
information changes). If an applicant
elects to include the statement in their
SE Report, the applicant would be
required to provide the information to
persons who request it. Applicants
would not be permitted to later amend
SE Reports on which FDA has issued a
marketing order to choose instead to
submit a health information summary.
Therefore, applicants that provide the
statement instead of providing the
summary to FDA as part of the SE
Report must be prepared to provide the
information required under section
910(a)(4) of the FD&C Act, as
implemented through proposed
§ 1107.18(j).
Under proposed § 1107.18(j)(5), to the
extent information is included in the
health information summary or the
health information provided upon
request under paragraphs (j)(1) and (2)
of this section that is not required by
section 910(a)(4) of the Federal Food,
Drug, and Cosmetic Act or paragraph (j)
of this section, that information cannot
contain a statement that would cause
the proposed new tobacco product to be
in violation of section 911 of the FD&C
Act (21 U.S.C. 387k) upon the
introduction or delivery for introduction
of the proposed new product into
interstate commerce. If an applicant
includes such a statement in its health
information summary or in the health
information the applicant provides
upon request, the review of the
applicant’s SE Report may be delayed.
FDA would generally not consider a
statement of relative risk to be required
by section 910(a)(4) of the FD&C Act or
paragraph (j) of this section if the risk
being conveyed is unrelated to the
applicant’s demonstration that the new
product is substantially equivalent and
FDA’s review of the SE Report. For
example, if an applicant submitted an
SE Report for a new smokeless tobacco
product and identified a smokeless
PO 00000
Frm 00020
Fmt 4701
Sfmt 4702
tobacco product as the predicate
product, a statement comparing the tar
in the new smokeless tobacco product to
the tar in a cigarette would generally be
unrelated to the applicant’s
demonstration that the new product is
substantially equivalent and FDA’s
review of the SE Report.
For the purposes of § 1107.18(j), any
statement an applicant is required to
include in a health information
summary or the health information
provided in response to a request—
including statements made in an SE
Report (e.g., comparisons of HPHCs
between the new and predicate tobacco
products)—typically would not cause
the proposed new tobacco product to be
in violation of section 911 of the FD&C
Act upon introduction or delivery for
introduction of the proposed new
product into interstate commerce.
Congress required applicants to submit
health information summaries with
their SE Reports or to provide such
information upon request. Nothing in
section 911 of the FD&C Act suggests
that Congress intended for that
provision to impede an applicant’s
ability to fulfill its obligations under
section 910(a)(4) of the FD&C Act.
k. Compliance with part 25. An
applicant must include an
environmental assessment (EA)
prepared in accordance with § 25.40 or
a valid claim of a categorical exclusion,
if applicable. (Under § 25.15(a), all
submissions requesting FDA action
require the submission of either a claim
of categorical exclusion or an EA.) In
accordance with § 25.40(a), an
environmental assessment must
include, at a minimum, brief
discussions of the need for the proposed
action, of alternatives as required by
section 102(2)(E) of the National
Environmental Policy Act (NEPA), of
the environmental impacts of the
proposed action and alternatives, a
listing of the agencies and persons
consulted, and the relevant
environmental issues relating to the use
and disposal from use. Although
applicants may wish to review the
categorical exclusions specific to
tobacco product applications at § 25.35,
the only categorical exclusion currently
available for an order authorizing the
marketing of a new tobacco product is
found at § 25.35(a), and applies only to
orders finding provisional products
substantially equivalent. If the applicant
believes the action would qualify for an
available categorical exclusion, the
applicant would be required to state
under § 25.15(a) and (d) that the action
qualifies for a categorical exclusion, cite
to the claimed exclusion, and state that
to the applicant’s knowledge no
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
extraordinary circumstances exist under
§ 25.21.
To evaluate the environmental impact
(as described in § 25.40(a)), information
that addresses the status of the new
tobacco product relative to the predicate
tobacco product would be required.
Accordingly, the environmental
assessment would be required to
include a statement indicating whether
the new tobacco product is intended to:
(1) Replace the predicate tobacco
product once the new tobacco product
receives market authorization and is
commercially marketed; (2) be a line
extension of the predicate tobacco
product; (3) be marketed along with the
predicate product by the same
manufacturer; and/or (4) be marketed
along with the predicate tobacco
product by a different manufacturer
(e.g., by a manufacturer other than the
manufacturer of the predicate tobacco
product). This statement would be
included in the section on the need for
the proposed action and would help
FDA understand the environmental
impact of an SE order by understanding
the marketing intention for the new and
predicate tobacco products. The
marketing authorization of a new
tobacco product may have a different
impact if the new tobacco product is
intended to be marketed along with the
predicate tobacco product than if the
new tobacco product is intended to
replace a predicate tobacco product.
l. Certification statement. Proposed
§ 1107.18(l)(1) would require that an
applicant include in the SE Report a
specific statement certifying that the
applicant would maintain all records to
substantiate the accuracy of the report
consistent with the record retention
requirements in proposed § 1107.58,
that, to the best of their knowledge, the
information and accompanying
submission are true and correct, no
material fact has been omitted, the
signer is authorized to submit the
information on the applicant’s behalf,
and that the signer understands that
anyone who knowingly and willfully
makes a materially false, fictitious, or
fraudulent statement or representation
in any matter within the jurisdiction of
the executive, legislative, or judicial
branch of the Government of the United
States is subject to criminal penalties
(under 18 U.S.C. 1001). The certification
is intended to provide FDA with
additional assurance that the applicant
has fully considered the SE Report and
its contents, that the applicant believes
there is a basis for making the findings
required by section 910(a)(2) of the
FD&C Act, and that the applicant
understands the potential consequences
of submitting false information to the
U.S. Government.
In addition, under proposed
§ 1107.18(l)(2), if an SE Report states
that the new tobacco product has certain
characteristics that are identical to the
predicate tobacco product (though not
all characteristics, such that the product
would not be ‘‘new’’), an applicant can
choose to submit a certification in lieu
of providing information for each
characteristic of the new and predicate
tobacco products. FDA would permit
the applicant to certify that the other
characteristics are identical as long as
the applicant maintains supporting
documentation, including the records
demonstrating the comparison
information detailed in proposed
§ 1107.19. The records would be
required to be maintained consistent
with proposed § 1107.58. The
certification must be signed by an
authorized representative of the
applicant.
12759
3. Comparison Information (Proposed
§ 1107.19)
This proposed section describes the
comparison information that would be
required in the SE Report. Comparative
testing supports the SE Report by
showing the information contained in
the SE Report is meaningful and
accurate; where applicable, the testing
also helps demonstrate that the different
characteristic(s) in a new tobacco
product does not raise different
questions of public health. FDA requests
public comments on the quantitative
and qualitative differences in each of
the design parameters for each of the
tobacco product categories identified
below as well as data to support such
values or characteristics.
a. Product design. Proposed
§ 1107.19(a) would require the SE
Report to include descriptions of the
product designs of the new and
predicate tobacco products and identify
any differences. This proposed section
would require that the information be in
a tabular format with a side-by-side
comparison of each design parameter of
the new and predicate tobacco products.
The SE report would also be required to
include for each design parameter a
target value and range of acceptable
values, actual measured value (if
applicable), and ranges of measured
values (if applicable) with units of
measure. The report would also be
required to include test data for each
applicable design parameter. Proposed
§ 1107.19(a)(1)-(6) would establish the
required design parameter information
for the tobacco product category, as
follows:
For cigarettes, the required design
parameter information to be provided
for each predicate and new tobacco
product would be:
amozie on DSK9F9SC42PROD with PROPOSALS2
TABLE 3—REQUIRED DESIGN PARAMETER INFORMATION FOR CIGARETTES
Provide target specification with upper and lower range limits for:
Provide test data (include test protocols, quantitative acceptance
criteria, data sets, and a summary of the results) for:
—Cigarette length (mm)
—Cigarette circumference (mm)
—Cigarette draw resistance (mm H2O)
—Tobacco filler mass (mg)
—Tobacco rod density (g/cubic centimeter (cm3))
—Tobacco moisture (%)
—Filter ventilation (%)
—Tipping paper length (mm)
—Cigarette paper base paper basis weight (g/meter squared(m2))
—Puff count.
—Cigarette draw resistance (mm H2O).
—Tobacco filler mass (mg).
—Tobacco moisture (%).
—Filter ventilation (%).
—Cigarette paper base paper basis weight (g/m2).
—Cigarette paper base paper porosity (CU).
—Cigarette paper band porosity (CU).
—Filter efficiency (%) [If no filter efficiency data is available for the
products, include information sufficient to show that the cigarette filter is unchanged (e.g., denier per filament, total denier, and filter
density)].
—Filter pressure drop (mm H2O).
—Cigarette
—Cigarette
—Cigarette
—Cigarette
paper
paper
paper
paper
VerDate Sep<11>2014
base paper porosity (CU)
band porosity (CU)
band width (mm)
band space (mm)
21:09 Apr 01, 2019
Jkt 247001
PO 00000
Frm 00021
Fmt 4701
Sfmt 4702
E:\FR\FM\02APP2.SGM
02APP2
12760
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
TABLE 3—REQUIRED DESIGN PARAMETER INFORMATION FOR CIGARETTES—Continued
Provide target specification with upper and lower range limits for:
Provide test data (include test protocols, quantitative acceptance
criteria, data sets, and a summary of the results) for:
—Filter efficiency (%) (If no filter efficiency data is available for the
products, include information sufficient to show that the cigarette filter
is unchanged (e.g., denier per filament, total denier, and filter density))
—Filter length (mm)
—Filter pressure drop (mm H2O)
FDA is proposing to require that these
parameters be included for cigarettes
because variations in these parameters
may cause the new tobacco product to
raise different questions of public
health, as described below:
• A difference in cigarette length may
alter tobacco biomarker levels (Ref. 5).
• A difference in cigarette
circumference may affect filter
efficiency and, in turn, smoke
constituent yields (Ref. 6).
• A difference in puff count can
directly affect smoke constituent yields
(Ref. 7).
• A difference in cigarette draw
resistance may result in differences in
the difficulty of pulling air through the
tobacco rod and, in turn, affect smoke
constituent yields (Ref. 8).
• A difference in tobacco filler mass
may affect smoke constituent yields
(Refs. 9 and 10).
• A difference in tobacco rod density
may modify burn properties and smoke
constituent yields (Refs. 11 and 12).
• A difference in tobacco moisture
may affect puff count (Refs. 13–15).
• A difference in cigarette paper base
paper basis weight may affect puff count
and smoke constituent yields (Ref. 16).
• A difference in cigarette paper base
paper porosity may affect smoke
constituent yields (Ref. 16).
• A difference in cigarette paper band
porosity may affect smoke constituent
yields since band porosity allows for the
overall assessment of the weighted
change in air flow through the cigarette
paper during active puffing (Refs. 18,
19, and 38).
• A difference in cigarette paper band
width may affect ventilation and, in
turn, smoke constituent yields (Ref. 20).
• A difference in cigarette paper band
space may affect ignition propensity
and, in turn, puff count (Ref. 21).
• A difference in filter efficiency may
affect smoke constituent yields (Refs. 18
and 20).
• A difference in denier per filament
may affect filter efficiency and, in turn,
smoke constituent yields (Ref. 22).
• A difference in total denier may
affect filter efficiency and, in turn,
smoke constituent yields (Ref. 22).
• A difference in filter density may
affect filter efficiency and, in turn,
smoke constituent yields (Ref. 22).
• A difference in filter pressure drop
may affect smoke constituent yields
(Ref. 23, slide 40).
• A difference in filter length may
affect filter efficiency and, in turn,
smoke constituent yields (Ref. 22).
• A difference in filter ventilation
may affect smoke constituent yields
(Ref. 6).
• A difference in tipping paper length
may affect smoke constituent yields
(Ref. 24).
For portioned and non-portioned
smokeless tobacco products, the
required design parameter information
to be provided for each predicate and
new tobacco product would be:
TABLE 4—REQUIRED DESIGN PARAMETER INFORMATION FOR PORTIONED AND NON-PORTIONED SMOKELESS TOBACCO
PRODUCTS
Provide target specification with upper and lower range limits for:
Provide test data (include test protocols, quantitative acceptance
criteria, data sets, and a summary of the results) for:
Portioned Smokeless Tobacco Products
—Tobacco cut size (mm)
—Tobacco moisture (%)
—Portion length (mm) (if applicable)
—Portion width (mm) (if applicable)
—Portion mass (mg) (if applicable)
—Portion thickness (mm) (if applicable).
—Pouch paper wicking.
—Pouch paper porosity (CU).
—Pouch paper basis weight (g/m2).
—Tobacco cut size (mm).
—Tobacco moisture (%).
—Portion mass (mg) (if applicable).
—Pouch paper porosity (CU).
—Pouch paper basis weight (g/m2).
Non-portioned Smokeless Tobacco Products
amozie on DSK9F9SC42PROD with PROPOSALS2
—Tobacco cut size (mm).
—Tobacco moisture (%).
—Tobacco cut size (mm).
—Tobacco moisture (%).
FDA is proposing to require that these
parameters be included for smokeless
tobacco products because variations in
these parameters may cause the new
tobacco product to raise different
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
questions of public health, as described
below:
• A difference in tobacco cut size may
alter the surface area and accessibility of
saliva to get to the surfaces of the
tobacco, thereby affecting the amount
PO 00000
Frm 00022
Fmt 4701
Sfmt 4702
and rate of constituents released from
the product (Ref. 25).
• A difference in tobacco moisture
may affect microbial growth in the
product, extraction efficiency, and total
exposure to nicotine, NNN, and NNK
(Ref. 26).
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
• A difference in portion mass may
affect user exposure to the tobacco
product and, in turn, exposure to the
HPHCs contained in each portion (Ref.
27).
• A difference in portion length as it
relates to portion size may affect the
amount of constituents in each portion
(Ref. 27).
• A difference in portion width may
result in a surface area difference, which
is proportional to the amount and rate
of constituents released from the
product (Ref. 28).
• A difference in portion thickness
may result in a surface area difference,
which is directly proportional to the
amount and rate of constituents released
from the product (Ref. 28).
• A difference in pouch paper basis
weight may alter the interactions
between the tobacco and oral cavity,
thereby affecting the amount and rate of
12761
constituents released from the product
(Ref. 29).
• A difference in pouch paper
porosity may alter the interactions
between the tobacco and oral cavity,
thereby affecting the amount and rate of
constituents released from the product
(Ref. 29).
For RYO tobacco rolling papers, the
required design parameter information
to be provided for each predicate and
new tobacco product would be:
TABLE 5—REQUIRED DESIGN PARAMETER INFORMATION FOR RYO TOBACCO ROLLING PAPERS
Provide target specification with upper and lower range limits for:
Provide test data (include test protocols, quantitative acceptance
criteria, data sets, and a summary of the results) for:
—Paper length (mm).
—Paper width (mm).
—Mass per paper (mg).
—Cigarette paper base paper basis weight (g/m)2.
—Cigarette paper base paper porosity (CU).
—Cigarette paper band porosity (CU) (if applicable).
—Cigarette paper band width (mm) (if applicable).
—Cigarette paper band space (mm) (applicable).
—Mass per paper (mg).
—Cigarette paper base paper basis weight (g/m2).
—Cigarette paper base paper porosity (CU).
—Cigarette paper band porosity (CU) (if applicable).
FDA is proposing to require that these
parameters be included for rolling
papers because variations in these
parameters may cause the new tobacco
product to raise different questions of
public health, as described below:
• A difference in overall length may
alter the surface area that is available for
tobacco packing, thereby affecting the
smoke constituent yields (Ref. 23, slide
46).
• A difference in overall width may
alter the surface area that is available for
tobacco packing, thereby affecting the
smoke constituent yields (Ref. 23, slide
46).
• A difference in total mass per pack
may be a result of a surface area or basis
weight difference and, in turn, may
affect puff count and smoke constituent
yields (Refs. 16 and 23 (slide 46)).
• A difference in RYO paper base
paper basis weight may affect puff count
and smoke constituent yields (Ref. 16).
• A difference in RYO paper base
paper porosity may affect smoke
constituent yields (Ref. 16).
• A difference in RYO paper band
porosity may affect smoke constituent
yields because band porosity allows for
the overall assessment of the weighted
change in air flow through the cigarette
paper during active puffing (Refs. 17
and 37).
• A difference in RYO paper band
width may affect ventilation and, in
turn, smoke constituent yields (Ref. 20).
• A difference in RYO paper band
space may affect ignition propensity
and, in turn, puff count (Ref. 21).
For RYO tobacco tubes, the required
design parameter information to be
provided for each predicate and new
tobacco product is as follows:
TABLE 6—REQUIRED DESIGN PARAMETER INFORMATION FOR RYO TOBACCO TUBES
Provide target specification with upper and lower range limits for:
Provide test data (include test protocols, quantitative acceptance
criteria, data sets, and a summary of the results) for:
—Tube length (mm).
—Tube circumference (mm).
—Total mass (mg).
—Cigarette paper base paper basis weight (g/m2).
—Cigarette paper base paper porosity (CU).
—Cigarette paper band porosity (CU).
—Cigarette paper band width (mm).
—Cigarette paper band space (mm).
—Total mass (mg).
—Cigarette paper base paper basis weight (g/m2).
—Cigarette paper base paper porosity (CU).
—Cigarette paper band porosity (CU).
amozie on DSK9F9SC42PROD with PROPOSALS2
For RYO tobacco filtered tubes, the
required design parameter information
to be provided for each new predicate
and new tobacco product would be:
TABLE 7—REQUIRED DESIGN PARAMETER INFORMATION FOR RYO TOBACCO FILTERED TUBES
Provide target specification with upper and lower range limits for:
Provide test data (include test protocols, quantitative acceptance
criteria, data sets, and a summary of the results) for:
—Tube length (mm).
—Tube circumference (mm).
—Total mass (mg).
—Tipping paper length (mm).
—Total mass (mg).
—Filter ventilation (%).
—Cigarette paper base paper basis weight (g/m2).
—Cigarette paper base paper porosity (CU).
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
PO 00000
Frm 00023
Fmt 4701
Sfmt 4702
E:\FR\FM\02APP2.SGM
02APP2
12762
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
TABLE 7—REQUIRED DESIGN PARAMETER INFORMATION FOR RYO TOBACCO FILTERED TUBES—Continued
Provide target specification with upper and lower range limits for:
Provide test data (include test protocols, quantitative acceptance
criteria, data sets, and a summary of the results) for:
—Filter ventilation (%).
—Cigarette paper base paper basis weight (g/m2).
—Cigarette paper base paper porosity (CU).
—Cigarette paper band porosity (CU).
—Cigarette paper band width (mm).
—Cigarette paper band space (mm).
—Filter length (mm).
—Filter denier per filament (DPF).
—Filter total denier (g/9000m).
—Filter density (g/cm3).
—Filter pressure drop (mm H2O).
—Cigarette paper band porosity (CU).
—Filter denier per filament (DPF).
—Filter total denier (g/9000m).
—Filter density (g/cm3).
—Filter pressure drop (mm H2O).
FDA is proposing to require that these
parameters be included for RYO tobacco
tubes because variations in these
parameters may cause the new tobacco
product to raise different questions of
public health, as described below:
• A difference in tube length may
alter tobacco biomarker levels (Ref. 5).
• A difference in tube circumference
may affect filter efficiency and, in turn,
smoke constituent yields (Ref. 6).
• A difference in total mass per pack
may be a result of a surface area or basis
weight difference and, in turn, may
affect puff count and smoke constituent
yields (Refs. 16 and 23 (slide 46)).
• A difference in tube paper base
paper basis weight may affect puff count
and smoke constituent yields (Ref. 16).
• A difference in tube paper base
paper porosity may affect smoke
constituent yields (Ref. 16).
• A difference in tube paper band
porosity may affect smoke constituent
yields since band porosity allows for the
overall assessment of the weighted
change in air flow through the cigarette
paper during active puffing (Refs. 17
and 37).
• A difference in tube paper band
width may affect ventilation and, in
turn, smoke constituent yields (Ref. 20).
• A difference in tube paper band
space may affect ignition propensity
and, in turn, puff count (Ref. 21).
• A difference in filter efficiency may
affect smoke constituent yields (Ref. 13).
• A difference in denier per filament
may affect filter efficiency and, in turn,
smoke constituent yields (Ref. 22).
• A difference in total denier may
affect filter efficiency and, in turn,
smoke constituent yields (Ref. 33).
• A difference in filter density may
affect filter efficiency and, in turn,
smoke constituent yields (Ref. 32).
• A difference in filter pressure drop
may affect smoke constituent yields
(Ref. 23, slide 40).
• A difference in filter length may
affect filter efficiency and, in turn,
smoke constituent yields (Ref. 32).
• A difference in ventilation may
affect smoke constituent yields (Ref. 24).
• A difference in tipping paper length
may affect smoke constituent yields
(Ref. 24).
For RYO tobacco, the required design
parameter information to be provided
for each predicate and new tobacco
product would be:
amozie on DSK9F9SC42PROD with PROPOSALS2
TABLE 8—REQUIRED DESIGN PARAMETER INFORMATION FOR RYO TOBACCO
Provide target specification with upper and lower range limits for:
Provide test data (include test protocols, quantitative acceptance
criteria, data sets, and a summary of the results) for:
—Tobacco filler mass (mg).
—Tobacco cut size (mm).
—Tobacco moisture (%).
—Tobacco filler mass (mg).
—Tobacco cut size (mm).
—Tobacco moisture (%).
FDA is proposing to require that these
RYO tobacco parameters be included for
RYO tobacco because variations in these
parameters may cause the new tobacco
products to raise different questions of
public health, as described below:
• A difference in tobacco filler mass
may affect smoke constituent yields
when used with rolling paper (Ref. 9).
• A difference in tobacco cut width
alters the size of the tobacco pieces,
which may result in more particulate
matter (Ref. 30).
• A difference in moisture may affect
smoke composition (Ref. 13).
For tobacco products not specifically
identified (e.g., ENDS, cigars) FDA
invites comments and information on
the parameters that may be needed to
support an SE Report.
VerDate Sep<11>2014
21:13 Apr 01, 2019
Jkt 247001
b. Heating source. Proposed
§ 1107.19(b) would require that the SE
Report include a description of any
heating source for both the new and
predicate tobacco products (e.g.,
burning coal, electric, chemical
reaction, carbon tip) and identify any
differences. If there is no heating source
for the new and predicate tobacco
products, the SE Report would be
required to state that.
c. Product composition. Proposed
§ 1107.19(c) would require that the SE
Report include descriptions of the
product composition of the new and
predicate tobacco products and identify
any differences. The information would
be required to be in tabular format with
a side-by-side comparison of the
materials and ingredients for each
PO 00000
Frm 00024
Fmt 4701
Sfmt 4702
component or part of the new and
predicate tobacco products. Under the
proposed rule, the SE Report would be
required to provide for each material
and ingredient the following
information: The quantity, the target
value and range of acceptable values,
actual measured value (where
applicable), and range of measured
values (where applicable) reported as
mass per component or part.
Proposed § 1107.19(c)(1) would
require that the SE Report include the
following information for each material
in the product:
• The material name and common
name (if applicable);
• The component or part where it is
located;
E:\FR\FM\02APP2.SGM
02APP2
amozie on DSK9F9SC42PROD with PROPOSALS2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
• The subcomponent or subpart
where it is located (if applicable);
• The function of the material;
• Quantities (including ranges or
means and acceptance limits) with
identification of any specification
variation between the new tobacco
product and predicate tobacco product;
• Specifications (including quality,
grades, and suppliers) used for the new
tobacco product and the predicate
(including any specification variations,
if applicable); and
• Any other material properties
necessary to characterize the new and
predicate tobacco products.
Proposed § 1107.19(c)(2) would
require that the SE Report include
information on ingredients other than
tobacco (information on tobacco
ingredients is addressed in proposed
§ 1107.19(c)(3)). Required information
would include:
• International Union of Pure and
Applied Chemistry chemical name and
common name (if applicable);
• Chemical Abstracts Service (CAS)
number(s) or FDA Unique Ingredients
Identifier;
• The function of the ingredient;
• The quantity with the unit of
measure (including ranges or means,
and acceptance limits) of the materials
in the new tobacco product and
predicate tobacco product (with any
specification variation, if applicable);
• The specifications (including purity
or grade and supplier);
• For complex purchased ingredients,
each single chemical substance reported
separately; and
• Any other ingredient information
necessary to characterize the new and
predicate tobacco products.
Proposed § 1107.19(c)(3) would
require information on tobacco
ingredients. This information would
include the following:
• The type of tobacco, including
grade and variety. This impacts the
characteristics of the products because
different grades have different
constituent profiles (the SE Report
would need to include information on
the applicant’s grading system so that
FDA understands the grade);
• The quantity, with the unit of
measure (including ranges or means,
and acceptance limits), of tobacco in the
new and predicate tobacco products
(with a specification variation, if
applicable);
• The specification of tobacco used
for the new tobacco product and
predicate tobacco product (with any
specific variation, if applicable);
• A description of any genetic
engineering that impacts characteristics,
because genetic engineering affects the
constituent profile; and
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
• Any other information about
tobacco ingredients necessary to
characterize the new and predicate
tobacco products.
If the new tobacco product does not
contain tobacco (e.g., rolling paper or
tipping paper), this section of the report
would be required to state that.
FDA is proposing that ingredient
quantities under proposed
§ 1107.19(c)(2) and (3) be reported as
mass per gram of tobacco for nonportioned tobacco products and as mass
per portion for portioned tobacco
products. These specific measurements
provide consistent, complete
information that would allow FDA to
understand the ingredient quantities. In
contrast, if ingredient quantities were
reported as percentages, FDA would
have to make assumptions about the
denominator used to calculate the
percentage. For example, if xylitol were
reported as 10 percent of a portioned
moist snuff, FDA would not able to
determine if xylitol was 10 percent of
the mass of the tobacco filler or of the
entire product (containing filler, paper,
etc.).
Proposed § 1107.19(c)(4) would
require that the SE Report include a
description of the container closure
system for the new and predicate
tobacco products, including a side-byside quantitative comparison of the
subcomponents or subparts and
materials and annotated illustrations.
d. Other features. Proposed
§ 1107.19(d) would require that the SE
Report include descriptions of any other
applicable features of the new and
predicate tobacco products and identify
any differences that exist. If a specific
feature described in proposed
§ 1107.19(d) is not applicable to the new
tobacco product, the SE Report would
be required to state as such. In response,
FDA may request a scientific
explanation for why a particular feature
is not applicable, and under proposed
§ 1107.19(d) the applicant would be
required to provide that information to
FDA. The SE Report must also address
any other product characteristics that
relate to the chemical, physical or
biological properties of the tobacco
product and are necessary for SE Report
review.
Specifically, proposed § 1107.19(d)(1)
would require that the SE Report
include HPHC and other constituent
information as appropriate to
demonstrate that: (1) The new tobacco
product has the same characteristics as
the predicate tobacco product or (2) any
differences in characteristics between
the new and predicate tobacco product
do not cause the new tobacco product
PO 00000
Frm 00025
Fmt 4701
Sfmt 4702
12763
to raise different questions of public
health, as follows:
• Constituent names in alphabetical
order,
• Common names,
• CAS number,
• Mean quantity and variance with
unit of measure,
• Number of samples and
measurement replicates for each sample,
• Analytical methods used,
description and associated reference(s),
• Testing laboratory(ies) and
accreditation information,
• Length of time between dates of
manufacture and dates of testing,
• Storage conditions of the tobacco
product before it was tested, and
• Full test data (including test
protocols, any deviations from the test
protocols, quantitative acceptance (pass/
fail) criteria, and complete data sets) for
all testing performed.
For combusted tobacco products,
constituent smoke yields from the new
and predicate products would need to
be determined using intense and nonintense smoking regimens.10 Two
smoking regimens are required in order
to understand the way that constituent
yields delivered by a tobacco product
can change over a range of different
smoking conditions. If constituent
yields were only reported from a single
smoking regimen, FDA would have
limited and potentially misleading
information about constituent yields
produced by a given tobacco product.
Many studies demonstrate that different
smoking regimens result in different
constituent yields from the same
product (Refs. 31 and 32). By requiring
both an intense and a non-intense
smoking regimen, FDA would have a
better understanding of quantities of
each constituent that may be produced
by the tobacco product when smoked
under different conditions. If an
alternative to these smoking regimens is
used, the applicant would be required to
provide an explanation of why the
alternative provides comparable results
to the intense and non-intense smoking
regimens.
FDA is proposing that the HPHC
information in an SE Report for a new
cigarette include, at a minimum, a
comparison of the quantities of nicotinedry particulate matter, total particulate
matter, carbon monoxide, and nicotine
(total) in the mainstream smoke of the
new tobacco product with that of the
predicate tobacco product, using both
intense and non-intense smoking
regimens. Further, additional HPHC
10 These refer to regimens by the International
Organization for Standardization and Health
Canada.
E:\FR\FM\02APP2.SGM
02APP2
amozie on DSK9F9SC42PROD with PROPOSALS2
12764
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
yields may need to be reported in order
to demonstrate that: (1) The new
tobacco product has the same
characteristics as the predicate tobacco
product or (2) any differences in
characteristics do not cause the new
tobacco product to raise different
questions of public health. For example,
blend differences may require reporting
of HPHC yields specific to the
differences in tobacco blends. Studies
show that the mainstream smoke of
burley and reconstituted tobaccos
contains much higher TSNA levels than
the mainstream smoke of bright and
oriental tobacco, whereas the
mainstream smoke of bright tobacco
contains higher benzo[a]pyrene levels
than other tobacco types (Refs. 33 and
34). Reconstituted tobacco can produce
high levels of carbon monoxide,
nitrogen oxides, and TSNAs during
combustion (Ref. 8). Smoke from
cigarettes made from expanded stems is
higher in carbon monoxide, nitrous
oxides, formaldehyde, tar,
benzo[a]anthracene, and benzo[a]pyrene
than smoke from cigarettes made of
puffed tobacco, expanded tobacco, or
freeze-dried tobacco (Ref. 30). Similarly,
addition of sugar or corn syrup to a
tobacco product may increase HPHCs
such as formaldehyde and may therefore
require additional HPHC measurements
(Ref. 35). Or, if the new tobacco product
contains significantly more guar gum (a
binder in rod paper and tobacco blends)
than the predicate product, additional
HPHC yields may be required to be
reported because pyrolysis of guar gum
may form formaldehyde, acetaldehyde,
acetone, benzene, cresol, and toluene
(Refs. 39–41).
Based on its experience reviewing
new tobacco products, FDA has found
significant increases in HPHCs (e.g.,
TSNAs and polycyclic aromatic
hydrocarbons (PAHs)) in cigarettes due
to changes in types of tobacco when
compared to a predicate tobacco
product. For all new cigarettes that have
a substantial increase in other types of
tobacco, to support a finding of SE the
applicant should include a comparison
of TSNAs and PAHs in the mainstream
smoke of the new tobacco product with
that of the predicate tobacco product
using both intense and non-intense
smoking regimens. Depending on the
specific differences between the new
and predicate products, quantities of
additional HPHCs in mainstream smoke
may be required to be reported.
For a smokeless tobacco product, the
HPHC information in an SE Report
would need to include a comparison of
the quantities of total and free nicotine,
total TSNAs, NNN, and NNK in the
tobacco of the products. Depending on
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
the specific differences between the new
and predicate products, the applicant
may be required to report quantities of
additional HPHCs in the product.
Proposed § 1107.19(d)(2) would
require that the SE Report include a
description and comparison of any other
features of the new and predicate
tobacco products.
Proposed § 1107.19(e) would require
stability information for smokeless
tobacco products and any tobacco
product that contains fermented
tobacco. As described in more detail in
the following paragraphs, stability
information is a particular concern with
smokeless tobacco products and other
tobacco products that contain fermented
tobacco because the characteristics of
these products can be affected by the
manufacturing process, storage
conditions, and length of time on a
shelf. Accordingly, proposed
§ 1107.19(e) would require stability
information for the new and predicate
tobacco products, including:
• A description of how stability is
indicated and whether stability testing
is identical for the predicate and new
tobacco products (proposed
§ 1107.19(e)(i));
• Any known or expected impacts on
product stability due to differences
between the new and predicate products
(if there are none, the SE Report would
state that) (proposed § 1107.19(e)(ii)).
For example, for products that contain
fermented tobacco, the SE Report would
be required to provide information on
the fermentation processing steps,
including the following:
Æ Composition of the inoculum
including species name(s) and
concentration(s)
Æ pH
Æ Temperature
Æ Moisture content
Æ Water activity
Æ Duration
Æ Ingredients added.
FDA is proposing to require that this
information be submitted in the SE
Report because these parameters of the
fermentation process can result in
different degrees of change in the
chemical constituents of the tobacco
(Refs. 42 and 43) and affect the type and
amount of microorganisms in the final
product (Ref. 44), thereby affecting the
stability of the product, which could
change the characteristics of the tobacco
product, which may cause the new
tobacco product to raise different
questions of public health. In addition,
the type and amount of the fermentation
inoculum can be used to control or
affect the fermentation process and thus,
can change the product as a result of
PO 00000
Frm 00026
Fmt 4701
Sfmt 4702
directed fermentation, which could
cause the new tobacco product to raise
different questions of public health (Ref.
45).
• Detailed stability testing
information, including test protocols,
quantitative acceptance criteria, data
sets, and a summary of the results for all
stability testing performed (proposed
§ 1107.19(e)(iii)). Stability testing would
be required to be performed at the
beginning (zero time), middle, and end
of the expected storage time for the
following chemical and microbial
endpoints:
Æ Microbial content data, including
total aerobic microbial count and total
yeast and mold count, along with
identification of detected
microbiological organisms by genus
and species names (if applicable)
Æ pH
Æ Moisture content
Æ Water activity
Æ Tobacco-specific nitrosamines
(TSNAs, including total, NNN, and
NNK)
Æ Nitrate and nitrite levels
Æ Preservatives and microbial metabolic
inhibitors, if any
Æ Method of heat treatment or
pasteurization used to reduce
microbial loads.
The proposed rule would require this
information because product stability is
affected by factors such as the
fermentation and stabilization processes
(if applicable), addition of chemical
additives to control microbial activity
(e.g., preservatives, metabolic inhibitors,
humectants), and water activity (aw) of
the product (Refs. 42, 46–48).
Additionally, factors such as nitrate/
nitrite concentrations, moisture content,
microbial content, storage temperature,
and pH are reported to influence the
microbial stability and TSNA formation
during storage of tobacco products (Refs.
49–53).
• Storage conditions for samples
retained for testing, identifying the test
methods used, along with testing of the
tobacco product in the same container
closure system as that in which the
tobacco product is intended to be
marketed, and testing supporting the
expiration date (proposed
§ 1107.19(e)(iv)). Accelerated studies,
combined with basic stability
information, could be used to support
tentative expiration dates provided full
shelf life studies are not yet available
but are being conducted. Where data
from accelerated studies are used to
project a tentative expiration date that is
beyond a date supported by actual shelflife studies, stability studies would need
to be conducted to support the SE
E:\FR\FM\02APP2.SGM
02APP2
amozie on DSK9F9SC42PROD with PROPOSALS2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
Report, including tobacco product
testing at appropriate intervals, until the
tentative expiration date could be
verified or the appropriate expiration
date could be determined.
Proposed § 1107.19(e)(v) and (vi)
would require information on the
stability testing laboratory and
identification of the microbiological
organisms by genus and species names,
where applicable, along with the culture
collection number either used during
the manufacturing process and/or
detected through stability testing.
Proposed § 1107.19(f) would require
applicants to state that the new tobacco
product has either: (1) The same
characteristics as the predicate tobacco
product and the basis for this
determination or (2) different
characteristics than the predicate
tobacco product. Where an applicant
states that its new tobacco product has
different characteristics than the
predicate tobacco product, the applicant
must also include an explanation as to
why a difference in any of the following
characteristics do not cause the new
product to raise different questions of
public health: Product design (see
§ 1107.19(a)); heating source (see
§ 1107.19(b)); materials and ingredients
(see § 1107.19(c)); and other features
(see § 1107.19(d)). In addition, in order
to demonstrate that a new tobacco
product with different characteristics is
substantially equivalent, an applicant
must also explain why any differences
in the manufacturing process that could
affect the characteristics of the new
product do not cause the new product
to raise different questions of public
health (see § 1107.18(e)). Similarly, for
smokeless tobacco products, an
applicant must explain why any
difference in stability between the new
tobacco product and the predicate
tobacco product does not raise different
questions of public health (see
§ 1107.19(e)).
Proposed § 1107.19(g) would explain
that, if the applicant is comparing the
new tobacco product to a predicate
product that FDA has previously found
to be substantially equivalent to another
product, FDA may request that the
applicant include information related to
the original grandfathered tobacco
product. Although an applicant can
support a showing of SE by comparing
the new tobacco product to a tobacco
product that is grandfathered or that
FDA has previously found SE, in order
to issue an SE order, FDA must find that
the new tobacco product is substantially
equivalent to a tobacco product
commercially marketed in the United
States as of February 15, 2007 (see
section 910(a)(2)(A)(i)(I) of the FD&C
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
Act). This statutory provision helps
FDA ensure that new tobacco products
using the substantial equivalence
pathway and relying on predicate
tobacco products previously found SE
do not vary so much from the original
grandfathered tobacco product that the
new product would actually raise
different questions of public health
compared to the originally
grandfathered tobacco product. New
products with differences that may
appear only incremental when a new
tobacco product is compared to a
predicate product previously found SE
may actually have had significant
changes when compared to the
grandfathered tobacco product.
Because the statute permits applicants
to compare to either a grandfathered
tobacco product or one that FDA has
previously found SE (section
905(j)(1)(A)(i)) but also requires FDA to
make an SE determination by comparing
the new tobacco product to the
grandfathered tobacco product (section
910(a)(2)(A)(i)(I)), FDA is proposing the
approach in § 1107.19(g). To meet its
statutory obligation, FDA may need to
look back to previously submitted SE
Reports in the SE chain that rely on the
original grandfathered product in order
to issue an SE order. Manufacturers
have been on notice since the passage of
the Tobacco Control Act that FDA must
make the comparison between the new
tobacco product and the original
grandfathered tobacco product, and in
doing so, may need to rely on
previously submitted SE Reports, even
if submitted by a different manufacturer
than the applicant at hand.
Accordingly, for SE Reports that
compare the new tobacco product to a
predicate tobacco product that FDA
previously found substantially
equivalent, proposed § 1107.19(g) states
that, if requested by FDA, the applicant
would be required to provide
information related to the original
grandfathered tobacco product, even if
the grandfathered tobacco product is
several tobacco products removed from
the predicate identified by the
applicant. FDA would request this
information when necessary to ensure
that any order issued by the Agency
complies with section 910(a)(2)(A)(i)(I)
of the FD&C Act. Before requesting this
information from the applicant, FDA
would review other relevant SE Reports
in the chain, for example, the first SE
Report that received an SE order using
the grandfathered product as a predicate
product to make this finding. If FDA is
unable to look back to data provided to
the Agency regarding the grandfathered
product and the applicant does not
provide the information, FDA would be
PO 00000
Frm 00027
Fmt 4701
Sfmt 4702
12765
unable to make the finding required by
section 910(a)(2)(A)(i)(I) of the FD&C
Act. FDA encourages applicants to
provide this information with the initial
SE Report to support an efficient review
of the SE Report, although FDA
acknowledges this may be more difficult
if the applicant is not the manufacturer
or owner of the predicate tobacco
product. FDA requests specific public
comment on this proposed provision
and any challenges it may present.
4. Amendments (Proposed § 1107.20)
Proposed § 1107.20(a) would permit
an applicant to submit an amendment to
an SE Report. Proposed § 1107.20(a)
would require any applicant who chose
to submit a health information summary
with its SE Report under proposed
§ 1107.18(j)(1) to submit with the
amendment a redacted copy of the
amendment that excludes research
subject identifiers and trade secret and
confidential and commercial
information as defined in §§ 20.61 and
20.63 (21 CFR 20.61 and 20.63).
An applicant may not amend an SE
Report to change the predicate tobacco
product (proposed § 1107.20(b)).
Because the comparison between the
new and predicate tobacco products is
the crux of the substantial equivalence
determination, changing the predicate
product changes the fundamental basis
of the analysis. An applicant that
determines that a predicate change is
necessary should withdraw the initial
SE Report and resubmit the SE Report
with the information related to the new
predicate tobacco product as described
in proposed § 1107.18.
In addition, under proposed
§ 1107.20(c), an applicant may not
amend a closed SE Report, e.g., one that
FDA has refused to accept, closed,
canceled, or issued an order for under
proposed § 1107.44, or one that has been
withdrawn under proposed § 1107.22.
Proposed § 1107.20(d) also explains that
FDA would review the additional
information in the next review cycle
(proposed § 1107.42 discusses review
cycles). As explained in proposed
§ 1107.62, SE Reports, including
amendments, would be submitted to
CTP’s Document Control Center. Phone
calls and emails to FDA staff would not
be considered amendments to an SE
Report.
5. Withdrawal by Applicant (Proposed
§ 1107.22)
Proposed § 1107.22 would permit an
applicant to make a request to withdraw
an SE Report unless FDA has closed the
SE Report through an action in
proposed § 1107.44 (all FDA actions in
proposed § 1107.44 would close the SE
E:\FR\FM\02APP2.SGM
02APP2
12766
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
amozie on DSK9F9SC42PROD with PROPOSALS2
Report except for a request for
additional information in proposed
§ 1107.44(b)). FDA has determined that
withdrawal of an SE Report would
benefit both the Agency and the
applicant by potentially saving time and
resources if the original SE Report might
otherwise be insufficient or marketing
authorization is no longer desired. The
withdrawal request would state: (1) If
the withdrawal is due to a health or
safety concern related to the tobacco
product; (2) the STN; and (3) the name
of the new tobacco product that is the
subject of the SE Report. This
information would assist FDA in
correctly identifying the SE Report to be
withdrawn and also help inform FDA as
to whether there were any concerns
under section 909 of the FD&C Act (e.g.,
relating to serious unexpected adverse
experiences). Under proposed
§ 1107.22(b), an SE Report would be
considered withdrawn when FDA issues
a notice stating the SE Report has been
withdrawn (see also proposed
§ 1107.40(e)).
The SE Report is an Agency record
even if withdrawn. Thus, under
proposed § 1107.22(c), FDA would
retain the withdrawn SE Report
consistent with Agency record retention
schedules and policies and, under the
Agency’s public information regulations
in part 20, would provide a copy to the
applicant upon request subject to
§ 20.45. If the withdrawal request is
made at the final review stage and FDA
has identified unresolved deficiencies
in the SE Report, FDA may provide a
list of deficiencies in the
communication that the Agency sends
to the applicant acknowledging
withdrawal. Under proposed
§ 1107.40(e), an SE Report would be
considered withdrawn when FDA issues
a notice stating that it is withdrawn.
6. Change in Ownership of an SE Report
(Proposed § 1107.24)
Proposed § 1107.24 would reflect that
transfers in ownership of SE Reports
occur. This proposed section is
intended to facilitate transfers of
ownership and help ensure that FDA
has current information regarding the
ownership of an SE Report. Proposed
§ 1107.24 applies to both pending SE
Reports and SE Reports that are the
subject of an SE order. Under proposed
§ 1107.24, at the time of the transfer, the
new and former applicants (or owners)
of the SE Report would be required to
submit certain information to the
Agency. First, the former applicant
would be required to submit a notice to
FDA identifying the new applicant and
stating that all of the former applicant’s
rights and responsibilities relating to the
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
SE Report have been transferred to the
new applicant. Second, the new
applicant would be required to submit
a signed notice to FDA containing the
following information:
• To the extent applicable, the new
applicant’s commitment to agreements,
promises, and conditions made by the
former applicant and contained in the
SE Report (e.g., this could be an
agreement by the new applicant to
conduct studies the former applicant
had agreed to conduct in support of a
request for an extension of time to
respond to a deficiency);
• The date that the change in
ownership is effective;
• Either a statement that the new
applicant has a complete copy of the SE
Report that FDA determined was
substantially equivalent (including any
amendments, or any records required to
be kept under proposed § 1107.58); or a
statement of intent to request a copy of
the SE Report under the Freedom of
Information Act (FDA’s implementing
regulations are in part 20); and
• A certification that no
modifications have been made to the
new tobacco product since the SE
Report was submitted to FDA.
Although FDA expects that the new
applicant would have a copy of the SE
Report from the former applicant, if the
new applicant requests a copy of the SE
Report from FDA, FDA would provide
a copy to the new applicant, subject to
the Freedom of Information Act
requirements as implemented by FDA at
part 20 and under the fee schedule in
§ 20.45.
The new applicant also would be
required to make available all required
records upon inspection by FDA
(proposed § 1107.58 would impose a
recordkeeping requirement). The
information required to be made
available for inspection would include
raw data and other information
necessary to substantiate the SE Report.
C. FDA Review (Proposed Subpart D)
1. Communications Between FDA and
Applicants (Proposed § 1107.40)
Proposed § 1107.40 would establish
general principles and provide clarity
regarding communications between
FDA and applicants during review of an
SE Report. Proposed § 1107.40(a)
explains that, during the course of
FDA’s review of an SE Report, FDA may
seek to communicate with applicants
about relevant matters, including
scientific and procedural issues that
arise during the review process.
Communications regarding medical
issues may arise if adverse events
reports exist for the tobacco product.
PO 00000
Frm 00028
Fmt 4701
Sfmt 4702
FDA may use a variety of methods to
communicate with applicants, such as
telephone conversations, letters, or
emails, depending on the circumstances
and issues. FDA would document any
communications regarding an SE Report
in accordance with 21 CFR 10.65.
Proposed § 1107.40(b) would provide
that applicants and representatives of
the Agency may have meetings to
discuss scientific and other issues.
Applicants interested in requesting
meetings would direct their requests to
the Office of Science through the
Document Control Center. For further
information, applicants may review the
guidance entitled ‘‘Meetings with
Industry and Investigators on the
Research and Development of Tobacco
Products’’ (May 25, 2012, 77 FR 31368;
revised guidance issued July 2016). As
discussed in this guidance, FDA does
not intend to grant meetings in most
circumstances to discuss an applicant’s
questions related to a pending SE Report
because the timing is frequently
inappropriate (e.g., premature or late,
depending on stage of review) and such
meetings are generally an inefficient or
duplicative use of resources. For
example, the applicant may be seeking
substantive information while FDA’s
review is underway but before FDA has
issued a deficiency letter or other
response. Please note that each SE
Report has a specific CTP contact to
whom an applicant may ask clarifying
questions, which helps ensure faster
and more direct responses. FDA
specifically requests public comment on
the proposed decision to not grant
meetings to discuss an applicant’s
questions related to a pending SE
Report. Specifically, FDA seeks to
understand if there are reasons why
such meetings may be necessary for an
applicant to respond to a deficiency
letter or if the absence of such meetings
present obstacles to the applicant in
responding to deficiency letters.
Proposed § 1107.40(c) would provide
that, upon receipt of an SE Report under
proposed § 1107.18, FDA would either
refuse to accept the SE Report or issue
an acknowledgement letter. FDA
requests comment on what a reasonable
period of time would be within which
such refusal to accept or
acknowledgement of receipt letters
should be issued.
Proposed § 1107.40(d) addresses
FDA’s notification of deficiencies in an
SE Report submitted under proposed
§ 1107.18. FDA reviewers would make
reasonable efforts to communicate to
applicants the procedural,
administrative, or scientific deficiencies
found in an SE Report and, if
appropriate, the data needed to enable
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
amozie on DSK9F9SC42PROD with PROPOSALS2
the Agency’s review. For example, a
reviewer might inform the applicant
that a signature is needed for a
certification, that provided test results
have last values cutoff or appear to have
a typographical error, or that the SE
Report is missing a reference for
support. This communication is
intended to give applicants an
opportunity to correct deficiencies in
the SE Report and to submit an
amendment if needed.
Proposed § 1107.40(e) explains that an
SE Report would be considered
withdrawn when FDA issues a notice
stating that it is withdrawn, which
would ensure that FDA has received the
withdrawal notification and that both
FDA and the applicant now consider the
SE Report as withdrawn.
FDA invites public comments on the
following topics related to reasonable
time periods to respond to a deficiency
letter:
• Appropriate timelines for
responding to a deficiency letter
identifying missing information that is
described in the final rule;
• Appropriate timelines for
responding to a deficiency letter
identifying missing information that
requests additional information not
described in the final rule;
• When requests for extensions of
time to respond to a deficiency letter
should be granted, and
• Whether or not deadlines to
respond to deficiency letters should be
tailored to the relative burden of the
request.
2. Review Cycles (Proposed § 1107.42)
Proposed § 1107.42(a) would set forth
the timeframe for FDA’s initial review
cycle. The ‘‘initial review cycle’’ would
consist of the 90 calendar days
following: (1) FDA’s receipt of the SE
Report and determination that a
predicate product is grandfathered (for
SE Reports that claim the predicate
product was commercially marketed in
the United States as of February 15,
2007, and FDA has not already
determined the tobacco product is
grandfathered) or (2) FDA’s receipt of an
SE Report (for SE Reports that contain
a predicate product that was previously
found substantially equivalent or for
which FDA has previously determined
that the predicate product is
grandfathered). As described in more
detail in proposed § 1107.44, FDA
intends to review the SE Report and
communicate with the applicant or take
an action on an SE Report during this
time period. At any time before FDA
issues an order on the SE Report, the
applicant would be allowed to
withdraw it under proposed § 1107.22.
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
Proposed § 1107.42(b) would provide
for the use of additional review cycles
to complete FDA’s review of an SE
Report. If FDA issues a deficiency letter
for an SE Report under proposed
§ 1107.40(d), FDA would stop reviewing
the SE Report until it received a
response to the notification of
deficiencies (or deficiency letter) or the
timeframe specified in the letter has
elapsed. If the applicant fails to provide
a response within the time period
provided, FDA would issue an order
denying marketing authorization for the
new tobacco product under the criteria
set forth in § 1107.48. If the applicant
provides a response within the allotted
timeframe, but FDA identifies the need
for additional information as a result of
this response, FDA could issue an
additional deficiency notification. Each
response would begin a new 90 calendar
day review cycle for FDA to review the
response.
FDA’s intent is to complete review of
an SE Report submitted under proposed
§ 1107.18 within a maximum of 270
review days (i.e., three 90-day review
cycles). Based on FDA’s review
experience, an SE Report should be
resolved within three review cycles. If
fewer review cycles are needed, FDA
intends to decide in a shorter time
period. Section 1107.40 would not
obligate FDA to notify applicants of
deficiencies in all circumstances before
taking an action on an SE Report per
proposed § 1107.44 or proposed
§ 1107.48. In any case where the SE
Report has significant deficiencies, FDA
might issue an order denying marketing
authorization without providing
additional opportunities to provide the
missing information. Examples of
significant deficiencies include when an
SE Report provides no scientific
evidence to substantiate a statement
from the applicant that the new tobacco
product does not raise different
questions of public health or when an
SE Report has multiple deficiencies but
the applicant does not provide
responses to all of the deficiencies. FDA
requests public comment on whether
FDA should provide specific timeframes
within which applicants would need to
respond to deficiency letters, along with
an explanation as to why the proposed
timeframes may be suitable for
addressing the concerns commonly
cited in the letters and why.
Proposed § 1107.42(c) states that, in
the event that an applicant’s response to
FDA’s deficiency notification(s) does
not provide adequate information or the
applicant provides information but the
SE Report remains deficient, FDA
intends to issue an order denying
market authorization under the criteria
PO 00000
Frm 00029
Fmt 4701
Sfmt 4702
12767
set forth in proposed § 1107.48. The
applicant also could make a written
request to withdraw the SE Report
under proposed § 1107.22 at any time
before FDA issues an order regarding
the SE Report.
3. FDA Action on an SE Report
(Proposed § 1107.44)
Proposed § 1107.44 lists six actions
FDA may take after completing review
of an SE Report:
• First, FDA could refuse to accept
the SE Report and not begin substantive
scientific review if the SE Report does
not comply with the requirements of
proposed § 1107.18 (this action would
stop the review clock and end the
review cycle). For example, FDA could
refuse to accept an SE Report that was
not written in English as required under
§ 1107.18(b), or did not provide the
information on product composition as
required under § 1107.19(c)(1). Or, FDA
could advise the applicant that the SE
Report is not appropriate under chapter
IX of the FD&C Act because the product
does not meet the definition of a tobacco
product under section 201(rr) of the
FD&C Act.
• Second, FDA could request
additional information as provided in
proposed § 1107.40(d).
• Third, FDA could issue a letter
closing the SE Report if it not possible
to make a determination on an SE
Report (sometimes referred to as an
administrative closure, for example,
which we might do when there is no
way to determine if a new product is SE
or NSE and additional information is
unavailable);
• Fourth, FDA could issue a letter
canceling the SE Report if FDA finds it
mistakenly acknowledged the SE
Report, e.g., the SE Report does not
pertain to a new tobacco product;
• Fifth, FDA could issue an order
finding the new tobacco product to be
substantially equivalent and in
compliance with the requirements of the
FD&C Act under proposed § 1107.46.
• Sixth, FDA could issue an order
denying marketing authorization under
proposed § 1107.48 (NSE order)
because:
Æ The applicant has failed to provide
the information needed for FDA to find
that the new tobacco product is
substantially equivalent to a tobacco
product that was commercially
marketed in the United States on
February 15, 2007;
Æ The new tobacco product is not
substantially equivalent to a tobacco
product that was commercially
marketed in the United States on
February 15, 2007; or
E:\FR\FM\02APP2.SGM
02APP2
12768
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
Æ The new tobacco product is not in
compliance with the requirements of the
FD&C Act. For example, a new tobacco
product is not in compliance with the
requirements of the FD&C Act if the
manufacturer of such product is in
arrears with respect to its user fees;
therefore, FDA would issue an NSE
order.
4. Issuance of an Order Finding a New
Tobacco Product Substantially
Equivalent (Proposed § 1107.46)
Proposed § 1107.46 would explain
that if, after review, FDA determines
that the new tobacco product is
substantially equivalent to a predicate
tobacco product that was commercially
marketed in the United States on
February 15, 2007, and in compliance
with the FD&C Act, the Agency would
send the applicant an order authorizing
the marketing of the product. The
marketing authorization would be
effective on the date the order is issued,
which would typically be noted on the
first page of the order.
amozie on DSK9F9SC42PROD with PROPOSALS2
5. Issuance of an Order Denying
Marketing Authorization (Proposed
§ 1107.48)
Proposed § 1107.48(a) would provide
that, in general, if FDA: (1) Is unable to
determine that the new tobacco product
is substantially equivalent to a predicate
tobacco product that was commercially
marketed in the United States on
February 15, 2007, or (2) determines
that the new tobacco product is not in
compliance with the FD&C Act, the
Agency would issue an NSE order
indicating that the manufacturer cannot
market the new tobacco product. FDA
would communicate this decision to the
applicant in writing. Proposed
§ 1107.48(b) provides that the NSE order
would describe the basis for denying
marketing authorization. FDA intends to
describe any deficiencies that FDA has
identified in an SE Report.
6. Rescission of Order (Proposed
§ 1107.50)
Proposed § 1107.50 would provide the
procedural mechanism for FDA to
rescind an SE order and describes the
grounds for when an SE order may be
rescinded. FDA intends to exercise this
authority in a judicious and timely way
in specific circumstances. FDA is
proposing this provision based on our
authority to issue an order only when it
can make the findings provided in
section 910(a)(2)(A)(i) of the FD&C Act
and our authority to promulgate
regulations for the efficient enforcement
of the FD&C Act (section 701 of the
FD&C Act). FDA’s inherent authority to
timely revisit and reconsider prior
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
decisions is also supported by case law,
with the inherent authority for timely
administrative reconsideration premised
on the notion that the ‘‘ ‘power to
reconsider is inherent in the power to
decide.’ ’’ See Ivy Sports Med. LLC, v.
Burwell, 767 F.3d 81, 86 (D.C. Cir. 2014)
(quoting Albertson v. FCC, 182 F.2d 397,
399 (D.C. Cir. 1950)). Where, as here,
nothing in the Tobacco Control Act
suggests that Congress intended to
displace this inherent authority in the
context of SE determinations, FDA may
rescind an SE order based on its
inherent authority. If, after issuing an SE
order, FDA later determines, for
example, that the order was based on
false information or there was an error
in information upon which the SE order
is based, FDA would rescind the SE
order. This proposed section would
provide that—
• First, FDA may rescind an SE order
if, after an order has issued, FDA
becomes aware that the tobacco product
for which the order has been issued:
Æ Does not have the same
characteristics as the predicate tobacco
product or
Æ has different characteristics and
there is insufficient information
demonstrating that it was not
appropriate to require a premarket
tobacco product application under
section 910(b) of the FD&C Act because
the product does not raise different
questions of public health.
• Second, FDA may rescind an SE
order if, after an order has issued, FDA
becomes aware that the SE Report
(including any submitted amendments)
contains an untrue statement of material
fact.
• Third, FDA may rescind an SE
order if the SE Report compared the
new tobacco product to a tobacco
product that FDA previously found
substantially equivalent, and the
predicate tobacco product relied on in
the SE Report has been found ineligible
because its SE Report (including any
submitted amendments) contains an
untrue statement of material fact, and/
or a predicate product on which any of
the previous substantial equivalence
determinations was based, going back to
the original grandfathered product, has
been found ineligible because its SE
Report (including any amendments)
contained an untrue statement of
material fact.
• Fourth, FDA may rescind an SE
order if FDA or the applicant has
removed from the market due to a
health or safety concern related to the
tobacco product:
Æ The predicate product on which the
substantial equivalence determination is
based and/or
PO 00000
Frm 00030
Fmt 4701
Sfmt 4702
Æ a predicate product on which any
of the previous substantial equivalence
determinations is based, going back to
the original grandfathered product, if
the SE Report compared the new
tobacco product to a tobacco product
that FDA previously found substantially
equivalent. FDA may rescind in this
scenario because the new tobacco
product is SE to, or is in the same
generational line as a predicate tobacco
product with safety issues, and,
therefore, may present similar safety
concerns.
Proposed § 1107.50(b) states that,
generally, FDA would rescind an SE
order only after it has provided notice
to the applicant and an opportunity for
a hearing under part 16. FDA is
proposing to amend § 16.1 to add a
reference § 1107.50. FDA encourages
applicants to bring errors to the
Agency’s attention that may necessitate
rescission, and FDA intends to work
with applicants in such scenarios.
In addition, FDA may need to rescind
an order without providing notice and
a prior opportunity for a hearing if FDA
finds that the continued marketing of
the tobacco product presents a serious
risk to public health, e.g., if the
applicant represented that the new
tobacco product conformed to a tobacco
product standard, but FDA later
determined that the new tobacco
product did not conform to a tobacco
product standard in a way that presents
a serious risk to public health. Another
example would be if FDA identifies data
integrity issues during an inspection
that would lead FDA to believe that the
tobacco product presents a serious risk
to public health. In these cases, FDA
would provide the applicant an
opportunity for a hearing as soon as
possible after the rescission.
D. Miscellaneous (Proposed Subpart E)
Subpart E describes other procedures
and requirements related to SE Reports,
including record retention, electronic
submission requirements, foreign data,
and confidentiality considerations.
1. Record Retention (Proposed
§ 1107.58)
Consistent with the authority to
require recordkeeping under section 909
of the FD&C Act, proposed § 1107.58,
would require applicants receiving an
order under proposed § 1107.46
authorizing the marketing of a new
tobacco product to maintain all records
supporting that SE Report for at least 4
years from the date of the order even if
such product is discontinued. FDA has
selected 4 years as a means to help
ensure that the records would be
available for at least one biennial FDA
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
amozie on DSK9F9SC42PROD with PROPOSALS2
inspection under section 704 and 905(g)
of the FD&C Act. The records would be
required to be legible, written in English
or an English translation provided, and
available for inspection and copying by
officers or employees designated by the
Secretary of Health and Human
Services. Applicants that have stopped
marketing a tobacco product may want
to retain the records for a longer period,
if the product might be reintroduced in
order to avoid the time and expense of
having to generate the information
again.
2. Confidentiality (Proposed § 1107.60)
Proposed § 1107.60(a) states that FDA
would determine the public availability
of any part of any SE Report and other
content related to an SE Report as
provided under this proposed section
and part 20 (Public Information). The
Freedom of Information Act (FOIA) (5
U.S.C. 552), as well as certain
provisions of the FD&C Act, e.g., section
301(j) (21 U.S.C. 331(j)) and section
906(c) (21 U.S.C. 387f(c)), govern the
disclosure of the existence of a pending
SE Report and the information
contained in such an SE Report. Under
FOIA, the public has broad access to
government documents. However, FOIA
provides certain exemptions from
mandatory public disclosure. One such
provision, 5 U.S.C. 552(b)(4), exempts
records that are ‘‘trade secrets and
commercial or financial information
obtained from a person and privileged
or confidential’’ from the requirement of
mandatory disclosure. Part 20 of FDA’s
regulations sets forth FDA’s general
regulations concerning public
availability of FDA records.
Like with drugs and devices, the
intent to market a tobacco product is
often considered confidential
commercial information, as premature
disclosure could result in a competitive
advantage to competitors. Therefore,
FDA is proposing § 1107.60(b)(1), which
would address the confidentiality of an
SE Report prior to the issuance of an
order under either proposed § 1107.46
or proposed § 1107.48. Under the
proposed regulation and consistent with
part 20, FDA would not publicly
disclose the existence of an SE Report
unless the applicant has publicly
disclosed or acknowledged the
existence (as such disclosure is defined
in § 20.81), or has authorized FDA in
writing to publicly disclose or
acknowledge, that the applicant has
submitted the SE Report to FDA.
Proposed § 1107.60(b)(2) provides that
FDA would not disclose the existence or
contents of an FDA communication
with an applicant regarding its SE
Report except to the extent that the
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
applicant has publicly disclosed or
acknowledged, or authorized FDA in
writing to publicly disclose or
acknowledge, the existence of or
contents of that particular FDA
communication. Proposed
§ 1107.60(b)(3) provides that FDA
would not disclose information
contained in an SE Report unless the
applicant has publicly disclosed or
acknowledged, or authorized FDA in
writing to publicly disclose or
acknowledge, that particular
information. If the applicant has
publicly disclosed or acknowledged, or
authorized FDA in writing to publicly
disclose or acknowledge, that particular
information contained in an SE Report,
FDA may disclose that particular
information.
Proposed § 1107.60(c) would address
the disclosure of data and information
after an order is issued under proposed
§ 1107.46. This proposed section would
provide that, after an order under
§ 1107.46 (finding a new tobacco
product substantially equivalent), FDA
would make the following information
related to the SE Report and order
available for public disclosure upon
request or at FDA’s own initiative,
including information from
amendments to the SE Report and
FDA’s reviews of the SE Report: (1) All
data previously disclosed to the public,
as such disclosure is defined in § 20.81;
(2) any protocol for a test or study,
except to the extent it is shown to fall
within the exemption established for
trade secrets and confidential
commercial information in § 20.61; (3)
information and data submitted to
demonstrate that the new tobacco
product does not raise different
questions of public health, except to the
extent it is shown to fall within the
exemptions established in § 20.61 for
trade secrets and confidential
commercial information, or in § 20.63
for personal privacy; (4) correspondence
between FDA and the applicant,
including any requests FDA made for
additional information and responses to
such requests, and all written
summaries of oral discussions between
FDA and the applicant, except to the
extent it is shown to fall within the
exemptions in § 20.61 for trade secrets
and confidential commercial
information, or in § 20.63 for personal
privacy; and (5) the environmental
assessment or, if applicable, the claim of
categorical exclusion from the
requirement to submit an environmental
assessment under part 25 of this
chapter.
Even after issuance of an order under
§ 1107.48 (Denying marketing
authorization), the applicant’s intent to
PO 00000
Frm 00031
Fmt 4701
Sfmt 4702
12769
market may still constitute confidential
commercial information, as the
applicant may still be planning to
market the new tobacco product that is
the subject of the SE Report (e.g., by
submitting a new SE Report, a PMTA,
or a request for exemption from
substantial equivalence, or by seeking
further review of the denial). Therefore,
proposed § 1107.60(d) addresses the
disclosure of data and information after
FDA issues an order under § 1107.48
(Denying marketing authorization).
Under this proposed subsection, FDA
may make certain information related to
the SE Report and the order available for
public disclosure upon request or at
FDA’s own initiative except to the
extent the information is otherwise
exempt from disclosure under part 20.
Information FDA may disclose includes
the tobacco product category (e.g.,
cigarette), tobacco product subcategory
(e.g., filtered), package size, and the
basis for the order denying marketing
authorization.
Proposed § 1107.60(e) addresses
disclosure of the health information
summary or statement and would
provide that health information required
by section 910(a)(4) of the FD&C Act, if
submitted as part of the SE Report
(which includes any amendments),
would be disclosed within 30 calendar
days of issuing a substantially
equivalent order. If the applicant has
instead submitted a 910(a)(4) statement
as provided in § 1107.18(j)(2), FDA
would make publicly available on
FDA’s website the responsible official to
whom a request for health information
may be made. FDA intends to include
this information on our website to
ensure that the information is easily
accessible to requestors.
3. Electronic Submission (Proposed
§ 1107.62)
Based on our authority in section 905
of the FD&C Act to prescribe the format
of SE Reports, proposed § 1107.62(a)
and (b) would require the applicant to
submit the SE Report and supporting
and other related documents in an
electronic format that FDA can process,
read, review, and archive unless a
waiver from this requirement is
requested by the applicant and FDA
grants the waiver. Reasons that an
applicant might request a waiver would
include that the applicant has no access
to email or a computer. Under proposed
§ 1107.62(c), an applicant that has a
waiver would submit a paper
submission to the address that FDA
provides in the letter granting the
waiver. FDA is proposing § 1107.62
based on FDA’s general experiences
with electronic submission, which FDA
E:\FR\FM\02APP2.SGM
02APP2
12770
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
has found helps facilitate premarket
reviews because electronic submission
typically has enabled FDA to receive,
open, and read a submission more
quickly than a submission submitted on
paper through postal mail. If this rule is
finalized, FDA intends to provide
information on submitting information
in an electronic format that FDA can
process, read, review and archive (e.g.,
method of transmission, media, file
formats, preparation, organization of
files, accompanying metadata) (https://
www.fda.gov/TobaccoProducts/
default.htm). FDA intends to update
this information as needed (e.g., to
accommodate changes in technology).
IV. Other Issues for Consideration
In addition to comments and
information on the proposed
requirements described in section III,
FDA is also seeking comments and
information on whether some
modifications to tobacco products that
result in a new tobacco product, beyond
those eligible for an exemption from
substantial equivalence, might be
handled through a ‘‘categorical’’
approach to substantial equivalence.
Under such an approach, FDA would
establish categories of modifications,
and if a modification is within a
category, the applicant could then
submit a streamlined SE Report that
identifies the modification and
demonstrates substantial equivalence.
FDA is soliciting concerns or benefits of
this type of approach, along with
information on the types of
modifications or categories that might
be handled in this way, or should not
be handled this way.
V. Paperwork Reduction Act of 1995
This proposed rule contains
information collection provisions that
are subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3520). A description of
these provisions is given in the
Description section of this document
with an estimate of the annual reporting
and recordkeeping. Included in the
estimate is the time for reviewing
instructions, searching existing data
sources, gathering and maintaining the
data needed, and completing and
reviewing each collection of
information.
FDA invites comments on these
topics: (1) Whether the proposed
collection of information is necessary
for the proper performance of FDA’s
functions, including whether the
information will have practical utility;
(2) the accuracy of FDA’s estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(3) ways to enhance the quality, utility,
and clarity of the information to be
collected; and (4) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques,
when appropriate, and other forms of
information technology.
Title: Substantial Equivalence Reports
for Tobacco Products.
Description: Tobacco Products,
Substantial Equivalence Reports,
Requirements for Submitting
Information Needed to Determine
Substantial Equivalence and
Maintaining Records to Support a
Substantial Equivalence Report.
This proposed rule would establish
requirements for the content and format
of substantial equivalence (SE) Reports
(proposed §§ 1107.18 and 1107.19).
Most of the proposed requirements
would mirror current practices and
recommendations related to the
submission of SE Reports, including
information related to part 25
(environmental considerations), but the
rule would provide both applicants and
FDA more certainty regarding the
content and format the SE Reports. A
health information summary or
statement would continue to be required
(section 910(a)(4) of the FD&C Act) and
the health summary or response to a
request would be required to be in the
format of a redacted SE Report, along
with any additional health information
about the new tobacco product,
including any information, research, or
data about adverse health effects, that
the applicant has or knows about and
that is not contained in the SE Report.
As is currently the practice, the
proposed rule would continue to permit
amendments for SE Reports submitted
under proposed § 1107.18, e.g., to
address deficiencies (proposed
§ 1107.20). Also in accordance with
current practice, the proposed rule
would continue to permit withdrawals
(proposed § 1107.22) of pending SE
Reports. The proposed rule would also
propose requirements for when the
ownership of an SE Report changes to
ensure that FDA has information related
to the current applicant (proposed
§ 1107.24).
The proposed rule would establish a
recordkeeping requirement, under
which applicants would be required to
maintain records supporting the SE
Report for an authorized new tobacco
product for 4 years from the date of an
order finding substantial equivalence,
even if such product is discontinued
(proposed § 1107.58).
The proposed rule would require that
respondents submit an SE Report in an
electronic format, unless a waiver from
this requirement is requested by the
applicant and granted by FDA
(proposed § 1107.62). FDA created two
new forms for submission; Form FDA
3964, Tobacco Amendment and General
Correspondence; and Form FDA 3965,
Tobacco Substantial Equivalence Report
Submission.
Description of Respondents:
Manufacturers of tobacco products who
submit SE Reports.
Existing Burden OMB Control Number
0910–0673
TABLE 9—ESTIMATED ANNUAL REPORTING BURDEN 1 2
amozie on DSK9F9SC42PROD with PROPOSALS2
Number of
responses per
respondent
Number of
respondents
Activity
Total annual
responses
Average
burden per
response
Total hours
Full SE 905(j)(1)(A)(i) and 910(a) .........................................................................
Full SE 905(j)(1)(A)(i) and 910(a) Bundled ...........................................................
Product Quantity Change SE Report ....................................................................
Product Quantity Change Bundled SE Report .....................................................
410
250
264
55
1
1
1
1
410
250
264
55
300
90
87
62
123,000
22,500
22,968
3,410
Totals .............................................................................................................
........................
........................
........................
........................
171,878
1 There
2 This
are no capital costs or operating and maintenance costs associated with this collection of information.
chart represents the currently OMB approved burden for the SE program.
Reporting Burden Updated Estimates
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
PO 00000
Frm 00032
Fmt 4701
Sfmt 4702
E:\FR\FM\02APP2.SGM
02APP2
12771
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
TABLE 10—ESTIMATED ANNUAL REPORTING BURDEN 1 2
Number of
respondents
Activity
Number of
responses per
respondent
Total annual
responses
Average
burden per
response
Total hours
Full SE 905(j)(1)(A)(i) and 910(a) ........................................
Full SE 905(j)(1)(A)(i) and 910(a) Bundled .........................
Product Quantity Change SE Report ..................................
Product Quantity Change Bundled SE Report ....................
683
456
239
192
1
1
1
1
683
456
239
192
300
90
87
62
204,900
41,040
20,793
11,904
Total ..............................................................................
........................
........................
........................
........................
278,637
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
2 Draft burden not yet OMB approved.
In the Federal Register of September
6, 2018 (83 FR 45251), FDA published
a notice soliciting comments on the
extension of the current SE program.
The numbers above in table 10 represent
the tentative revisions which have not
yet been approved by OMB. These
estimates revise the number of reports
under OMB control number 0910–0673
and take into account updated
registration and listing data. The
previous estimate for reports was 979
and total burden hours were 171,878.
This chart accounts for the tentative
increase in burden due to the expected
rise in submissions other than any
increases in burden due to the proposed
rule, if finalized.
New Reporting Per Rule
TABLE 11—ESTIMATED ANNUAL REPORTING BURDEN 1 2
Number of
respondents
21 CFR part
FDA 3965 Tobacco Substantial Equivalence Report Submission .............................................................................
FDA 3964 Tobacco Amendment and General Correspondence ..................................................................................
Waiver from Electronic submission 1107.62(b) ...................
Totals ............................................................................
Number of
responses per
respondent
Total annual
responses
Average
burden per
response
Total hours
1,570
1
1,570
.5
785
628
240
1
1
628
240
.083
.25
52
60
........................
........................
........................
........................
897
1 There
2 Draft
are no capital costs or operating and maintenance costs associated with this collection of information.
burden not yet OMB approved.
Final Combined Reporting Burden
(Tables 10 +11)
TABLE 12—ESTIMATED ANNUAL REPORTING BURDEN 1 2
Number of
respondents
21 CFR part
SE Report 1107.18 ..............................................................
Bundled SE 1107.18 ............................................................
SE Report where applicant provides certification for identical characteristics 1107.18(g) and 1107.18(1)(2) ..........
SE Report where applicant provides certification for some
identical characteristics (bundled) 1107.18(g) and
1107.18(1)(2) ....................................................................
FDA 3965 Tobacco Substantial Equivalence Report Submission .............................................................................
FDA 3964 Tobacco Amendment and General Correspondence Report ......................................................................
Waiver from Electronic submission 1107.62(b) ...................
amozie on DSK9F9SC42PROD with PROPOSALS2
Totals ............................................................................
Number of
responses per
respondent
Total annual
responses
1
1
683
456
300
90
204,900
41,040
239
1
239
87
20,793
192
1
192
62
11,904
1,570
1
1,570
.5
785
628
240
1
1
628
240
.083
.25
52
60
........................
........................
........................
........................
279,534
are no capital costs or operating and maintenance costs associated with this collection of information.
2 Draft burden not yet OMB approved.
New Final Recordkeeping Burden
20:34 Apr 01, 2019
Jkt 247001
PO 00000
Total hours
683
456
1 There
VerDate Sep<11>2014
Average
burden per
response
Frm 00033
Fmt 4701
Sfmt 4702
E:\FR\FM\02APP2.SGM
02APP2
12772
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
TABLE 13—ESTIMATED ANNUAL RECORDKEEPING BURDEN 1 2
Number of
recordkeepers
21 CFR part
Recordkeeping SE Report under 1107.18 1107.58 ....
Number of
records per
recordkeeper
471
Average
burden per
recordkeeping
Total annual
records
1
471
2.5
Total hours
1,178
1 There
amozie on DSK9F9SC42PROD with PROPOSALS2
are no capital costs or operating and maintenance costs associated with this collection of information.
2 Draft burden not yet OMB approved.
FDA’s estimates are based on
experience with SE Reports, registration
and listing data, interactions with the
industry, and information related to
other regulated products. As explained
above, taking into account the updated
registration and listing data for deemed
tobacco products, the estimated annual
number of SE Reports is expected to be
1,570. That estimate is not expected to
change as a result of the proposed rule,
if finalized.
When groups of full SE Reports or SE
Reports that each contain a certification
that some characteristics are identical
have identical content, they may be
bundled; when a group of similar
reports are bundled, the subsequent
bundled reports are expected to take
less time to prepare than the initial
report.
FDA has based these estimates on
information it now has available from
interactions with the industry,
information related to other regulated
products, and FDA expectations
regarding the tobacco industry’s use of
the substantial equivalence pathway to
market their products. Table 9 describes
the annual reporting burden for
compliance with the requirements to
demonstrate substantial equivalence
under the FD&C Act. We do not expect
a large burden increase for this program,
as, without the proposed rule,
manufacturers would routinely submit
SE Reports for new tobacco products,
and the Agency believes most
respondents are currently practicing
most of the proposed requirements. FDA
will revise this collection with the new
burden. FDA requests public comments
on the estimated burden associated with
the requirements associated with this
rule and whether there is any evidence,
information, or data to support alternate
burden estimates.
Table 11 describes the annual
reporting burden as a result of the
requirements proposed in §§ 1107.18
and 1107.19, implementing the
substantial equivalence requirements of
section 905(j)(1)(A)(i) and 910(a) of the
FD&C Act. This proposed rule would
require manufacturers to submit SE
Reports electronically (proposed
§ 1107.62). We estimate that it would
initially take about 30 minutes per
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
product to fill out the Form FDA 3965.
However, for amendments we estimate
that filling out the Form FDA 3964 will
take 5 minutes as applicants can copy
and paste from the first submission.
Proposed 1107.62(b) also allows for
waivers from the electronic format
requirement. FDA estimates that 240
respondents or 15 percent of SE Reports
(1,570) will submit a waiver.
Based on updated information, FDA
estimates that it will receive 683 full
initial SE Reports for a new tobacco
product each year under proposed
§ 1107.18 that take a manufacturer
approximately 300 hours to prepare.
Additionally, manufacturers may
bundle groups of SE Reports for their
new products in the same product
category and subcategory where the
proposed modifications are the same;
when a group of similar SE Reports are
bundled, the reporting burden for the
initial SE Report is expected to take the
same amount of time as a stand-alone
SE Report. However, the reporting
burden for subsequent bundled SE
Reports is expected to be lower than the
initial SE Report. We expect to receive
456 bundled SE Reports under proposed
§ 1107.18 (other than the initial SE
Report in the bundle) at approximately
90 hours per response for a total of
41,040 hours.
In the absence of more specific
information concerning SE Reports
where applicants provide a certification
for some identical characteristics under
proposed § 1107.18(g) and 1107.18(l)(2),
FDA estimates receiving 239 such SE
Reports at 87 hours per response for a
total of 20,973 hours. We also estimate
receiving 192 bundled SE Reports where
applicants provide a certification for
some identical characteristics under
proposed §§ 1107.18(g) and
1107.18(l)(2) (other than the initial SE
Report in the bundle) at 62 hours per
response for a total of 11,904 hours.
Although we believe that the number of
SE Reports that include a certification
will increase because the proposed rule
clarifies when applicants may certify
that certain characteristics are identical
in the new tobacco product and the
predicate tobacco product, in the
absence of specific information on how
many more applicants might choose to
PO 00000
Frm 00034
Fmt 4701
Sfmt 4702
certify, we are maintaining our previous
estimates at this time. We request
comment on these estimates.
FDA has based these estimates on the
full analysis of economic impacts and
experience with the recently-revised
existing information collection that
applies to tobacco products. In addition,
anyone submitting an SE Report is
required to submit an environmental
assessment prepared in accordance with
§ 25.40 under proposed § 1107.18(k).
The burden for environmental reports
has been included in the burden per
response for each type of SE Report.
Based on FDA’s experience with EAs
for currently regulated tobacco
products, we expect industry to spend
80 hours preparing an environmental
assessment for a full SE Report under
proposed § 1107.18.
Generally, an applicant may withdraw
its SE Report after submission (proposed
§ 1107.22), change the ownership of its
SE Report (proposed § 1107.24), and
amend its SE Report (proposed
§ 1107.20). The information required to
grant these requests is already being
collected, so we do not expect a change
in burden.
FDA estimates that 30 percent of SE
Reports or 471 respondents will
maintain required records related to
their SE Reports at 2.5 hours per record
for a total of 1,178 recordkeeping hours.
FDA estimates that the burden for
new requirements will increase this
collection by 108,834 (107,656 + 1,178
recordkeeping). The burden for the
submission of substantial equivalence
information is estimated to total 280,712
hours (279,534 reporting and 1,178
recordkeeping). This proposed rule also
refers to previously approved
collections of information found in FDA
regulations. Proposed § 1107.40
references meetings that may be held
with applicants who want to meet with
FDA to discuss scientific and other
issues. Additional information about
how to request meetings with FDA’s
CTP can be found in FDA’s guidance
entitled ‘‘Meetings with Industry and
Investigators on the Research and
Development of Tobacco Products.’’ The
collections of information in the
guidance referenced have been
approved under OMB control number
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
0910–0731. In addition to the premarket
application under section 910(b) and a
report under 905(j)(1)(A)(i), certain new
tobacco products may use the
exemption premarket pathway, see 21
CFR 1107.1. The collections of
information found in 21 CFR 1107.1
have been approved under OMB control
number 0910–0684.
To ensure that comments on
information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB (see ADDRESSES). All comments
should be identified with the title of the
information collection.
In compliance with the Paperwork
Reduction Act of 1995 (44 U.S.C.
3407(d)), the Agency has submitted the
information collection provisions of this
proposed rule to OMB for review. These
requirements will not be effective until
FDA obtains OMB approval. FDA will
publish a notice concerning OMB
approval of these requirements in the
Federal Register.
amozie on DSK9F9SC42PROD with PROPOSALS2
VI. Executive Order 13132: Federalism
We have analyzed this proposed rule
in accordance with the principles set
forth in Executive Order 13132. Section
4(a) of the Executive Order requires
Agencies to ‘‘construe . . . a Federal
statute to preempt State law only where
the statute contains an express
preemption provision or there is some
other clear evidence that the Congress
intended preemption of State law, or
where the exercise of State authority
conflicts with the exercise of Federal
authority under the Federal statute.’’
Section 916(a)(2) of the FD&C Act (21
U.S.C. 387p) is an express preemption
provision. Section 916(a)(2) provides
that ‘‘no State or political subdivision of
a State may establish or continue in
effect with respect to a tobacco product
any requirement which is different
from, or in addition to, any requirement
under the provisions of this chapter
relating to . . . premarket review.’’
Thus, if this proposed rule is made
final, the final rule would create
requirements that fall within the scope
of section 916(a)(2) of the FD&C Act.
VII. Consultation and Coordination
With Indian Tribal Governments
We have analyzed this proposed rule
in accordance with the principles set
forth in Executive Order 13175. We
have tentatively determined that the
rule does not contain policies that
would have a substantial direct effect on
one or more Indian Tribes, on the
relationship between the Federal
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
Government and Indian Tribes, or on
the distribution of power and
responsibilities between the Federal
Government and Indian Tribes. The
Agency solicits comments from tribal
officials on any potential impact on
Indian Tribes from this proposed action.
VIII. Analysis of Environmental Impact
The Agency has determined under 21
CFR 25.30(h) that this action is of a type
that does not individually or
cumulatively have a significant effect on
the human environment. No
extraordinary circumstances exist to
indicate that the specific proposed
action may significantly affect the
quality of the human environment.
Therefore, neither an environmental
assessment nor an environmental
impact statement is required.
IX. Economic Analysis of Impacts
We have examined the impacts of the
proposed rule under Executive Order
12866, Executive Order 13563,
Executive Order 13771, the Regulatory
Flexibility Act (5 U.S.C. 601–612), and
the Unfunded Mandates Reform Act of
1995 (Pub. L. 104–4). Executive Orders
12866 and 13563 direct us to assess all
costs and benefits of available regulatory
alternatives and, when regulation is
necessary, to select regulatory
approaches that maximize net benefits
(including potential economic,
environmental, public health and safety,
and other advantages; distributive
impacts; and equity). We believe that
this proposed rule is not an
economically significant regulatory
action as defined by Executive Order
12866.
The Regulatory Flexibility Act
requires us to analyze regulatory options
that would minimize any significant
impact of a rule on small entities.
Because we have determined that the
compliance costs are less than 0.1
percent of revenues, we propose to
certify that the rule would not have a
significant economic impact on a
substantial number of small entities.
The Unfunded Mandates Reform Act
of 1995 (section 202(a)) requires us to
prepare a written statement, which
includes an assessment of anticipated
costs and benefits, before proposing
‘‘any rule that includes any Federal
mandate that may result in the
expenditure by State, local, and tribal
governments, in the aggregate, or by the
private sector, of $100,000,000 or more
(adjusted annually for inflation) in any
one year.’’ The current threshold after
adjustment for inflation is $150 million,
using the most current (2017) Implicit
PO 00000
Frm 00035
Fmt 4701
Sfmt 4702
12773
Price Deflator for the Gross Domestic
Product. This proposed rule would not
result in an expenditure in any year that
meets or exceeds this amount.
This proposed rule would impose
compliance costs on affected entities to
read and understand the rule, establish
or revise internal procedures, and fill
out a form for SE Reports. We estimate
that the present value of industry
compliance costs ranges from $0.60
million to $2.64 million, with a primary
estimate of $1.61 million at a 3 percent
discount rate, and from $0.56 million to
$2.32 million, with a primary estimate
of $1.43 million at a 7 percent discount
rate over 10 years. Annualized industry
compliance costs over 10 years range
from $0.07 million to $0.31 million,
with a primary estimate of $0.19 million
at a 3 percent discount rate and from
$0.08 million to $0.33 million, with a
primary estimate of $0.20 million at a 7
percent discount rate.
The benefits of this proposed rule are
potential time-savings to industry and
cost-savings to government. This
proposed rule clarifies when applicants
may certify that certain characteristics
are identical in the new tobacco product
and the predicate tobacco product.
Certifying may save applicants time in
preparing their SE Reports. In this
proposed rule, we intend to shorten
review times for SE Reports. In addition,
based on our experience with prior SE
Reports, we believe this proposed rule
would lead to better SE Reports, saving
us time in review and requiring fewer
staff to review SE Reports, which would
result in cost-savings. We estimate that
the present value of government costsavings ranges from $15 million to $198
million at a 3 percent discount rate, and
from $12 million to $163 million at a 7
percent discount rate over 10 years.
Annualized government cost-savings
over 10 years range from $1.7 million to
$23.2 million at both 3 and 7 percent
discount rates.
The qualitative benefits of this
proposed rule include additional clarity
to industry about the requirements for
the content and format of SE Reports.
The proposed rule would also establish
the general procedures we intend to
follow in reviewing and communicating
with applicants. In addition, this
proposed rule would make the SE
pathway more predictable.
The proposed rule’s costs and benefits
are summarized in Table 14 entitled
‘‘Economic Data: Costs and Benefits
Statement.’’
E:\FR\FM\02APP2.SGM
02APP2
12774
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
TABLE 14—ECONOMIC DATA: COSTS AND BENEFITS STATEMENT
Units
Category
Low
estimate
Primary
estimate
High
estimate
Benefits:
Annualized Monetized
$millions/year.
Annualized .......................
Quantified .........................
Qualitative ........................
1.7
1.7
..................
..................
..................
7.2
7.2
..................
..................
..................
0.08
0.07
..................
..................
..................
Costs:
Annualized Monetized
$millions/year.
Annualized .......................
Quantified .........................
Qualitative.
Transfers:
Federal Annualized Monetized $millions/year.
Year
dollars
Discount
rate
(%)
Period
covered
(years)
23.2
23.2
..................
..................
..................
2016
2016
2016
2016
..................
7
3
7
3
..................
10
10
10
10
..................
0.20
0.19
..................
..................
0.33
0.31
..................
..................
2016
2016
2016
2016
7
3
7
3
10
10
10
10
..................
..................
2016
2016
7
3
10
10
2016
2016
7
3
10
10
From:
Other Annualized Monetized $millions/year.
Notes
Cost-savings to government.
Cost-savings to government.
Greater certainty for SE applicants.
To:
..................
..................
..................
From:
To:
Effects:
State, Local or Tribal Government: No effect
Small Business: No effect
Wages: No effect
Growth: No effect
In line with Executive Order 13771, in
Table 15 we estimate present and
annualized values of costs and costsavings over an infinite time horizon.
Our primary estimate of the present
value over an infinite time horizon of
net costs due to this proposed rule is
¥$101.4 million at a 7 percent discount
rate, and ¥$237.7 million at a 3 percent
discount rate. Our primary estimate of
the annualized net costs is ¥$7.1
million at a 7 percent discount rate and
¥$7.1 million at a 3 percent discount
rate. Table 15 summarizes the costs,
cost-savings and net costs of this
proposed rule. Based on these costsavings this proposed rule, if finalized,
would be considered a deregulatory
action under E.O. 13771.
TABLE 15—E.O. 13771 SUMMARY TABLE
[In $ Millions 2016 dollars, over infinite time horizon]
Primary
(7%)
Present Value of Costs ............................
Present Value of Cost Savings ................
Present Value of Net Costs .....................
Annualized Costs .....................................
Annualized Cost Savings .........................
Annualized Net Costs ..............................
Lower bound
(7%)
$2.05
103.49
(101.4)
0.14
7.24
(7.1)
Upper bound
(7%)
$0.57
24.84
(24.3)
0.04
1.74
(1.7)
Primary
(3%)
$3.56
331.18
(327.6)
0.25
23.18
(22.9)
$3.75
241.48
(237.7)
0.11
7.24
(7.1)
Lower bound
(3%)
$0.69
57.96
(57.3)
0.02
1.74
(1.7)
Upper bound
(3%)
$6.92
772.75
(765.8)
0.21
23.18
(23.0)
amozie on DSK9F9SC42PROD with PROPOSALS2
Note: Values in parentheses denote net negative costs (i.e., cost-savings).
We have developed a comprehensive
Economic Analysis of Impacts that
assesses the impacts of the proposed
rule. The full analysis of economic
impacts is available in the docket for
this proposed rule (Ref. 54) and at
https://www.fda.gov/AboutFDA/
ReportsManualsForms/Reports/
EconomicAnalyses/default.htm.
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
X. References
The following references are on
display in the Dockets Management
Staff (see ADDRESSES) and are available
for viewing by interested persons
between 9 a.m. and 4 p.m., Monday
through Friday; they are also available
electronically at https://
www.regulations.gov. FDA has verified
the website addresses, as of the date this
PO 00000
Frm 00036
Fmt 4701
Sfmt 4702
document publishes in the Federal
Register, but websites are subject to
change over time.
1. Wayne, G. F. and G. N. Connolly,
‘‘Application, Function, and Effects of
Menthol in Cigarettes: A Survey of
Tobacco Industry Documents,’’ Nicotine
& Tobacco Research, 6(Suppl. 1):S43–
S54, 2004.
2. Brunnemann, K. D., J. C. Scott, and D.
Hoffmann, ‘‘N-Nitrosomorpholine and
E:\FR\FM\02APP2.SGM
02APP2
amozie on DSK9F9SC42PROD with PROPOSALS2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
Other Volatile N-nitrosamines in Snuff
Tobacco,’’ Carcinogenesis, 3(6):693–696,
1982.
3. Draft Form FDA 3965 (Substantial
Equivalence Submission).
4. Draft Form FDA 3964 (Amendment).
5. Agaku, I. T., C. I. Vardavas, and G. N.
Connolly, ‘‘Cigarette Rod Length and Its
Impact on Serum Cotinine and Urinary
Total NNAL Levels, NHANES 2007–
2010,’’ Nicotine & Tobacco Research,
16(1):100–107, 2014.
6. Eaker, D. W., ‘‘Dynamic Behavior and
Filtration of Mainstream Smoke in the
Tobacco Column and Filter,’’ Recent
Advances in Tobacco Science, 16:103–
187, 1990.
7. Connolly, G. N., H. R. Alpert, G. F. Wayne,
et al., ‘‘Trends in Nicotine Yield in
Smoke and its Relationship with Design
Characteristics Among Popular US
Cigarette Brands, 1997–2005,’’ Tobacco
Control, 16(5):e5, 2007, doi: 10.1136/
tc.2006.019695.
8. American Tobacco, ‘‘Cigarette Pressure
Drop,’’ Bates Numbers 991508327–
991508331, 1990.
9. U.S. Department of Health and Human
Services, ‘‘The Health Consequences of
Smoking: The Changing Cigarette,’’ A
Report of the Surgeon General; 1981.
10. Torikaiu, K., Y. Uwano, T. Nakamore, et
al., ‘‘Study on Tobacco Components
Involved in Pyrolytic Generation of
Selected Smoke Constituents,’’ Food and
Chemical Toxicology, 43: 559–568, 2005.
11. Spears, A. W., ‘‘Effect of Manufacturing
Variables on Cigarette Smoke
Composition,’’ CORESTA Information
Bulletin, Special Issue: 65–78, 1974.
12. Geiss, O. and D. Kotzias, ‘‘Tobacco,
Cigarettes and Cigarette Smoke: An
Overview,’’ Institute for Health and
Consumer Protection, European
Commission, Directorate-General, Joint
Research Centre, 2007, available at
https://publications.jrc.ec.europa.eu/
repository/bitstream/111111111/8885/1/
7472%20-%20EUR22783EN_Geiss_
Kotzias.pdf.
13. DeBardeleben, M. Z., W. E. Claflin, and
W. F. Gannon, ‘‘Role of Cigarette
Physical Characteristics on Smoke
Composition,’’ Recent Advances in
Tobacco Science, 4:85–111, 1978.
14. Bourlas, M. C., D. F. Magin, R. A.,
Kornfeld, et al., ‘‘The Generation of
Water in the Tobacco Oven Volatile Test,
Beitra¨ge zur Tabakfoschung
International, 10(3), 149–154, 1980.
15. Coleman, W. M., ‘‘Tobacco Volatiles: Gas
Chromatography,’’ R. J. Reynolds
Tobacco Company, 4380–4388,
Academic Press, 2000.
16. Owens, W. F., ‘‘Effect of Cigarette Paper
on Smoke Yield and Composition,’’
Recent Advances in Tobacco Science,
4:3–24, 1978.
17. British American Tobacco, Research &
Development, ‘‘Lower Ignition
Propensity.’’
18. Adam, T., J. McAughey, C. Mocker, et al.,
‘‘Influence of Filter Ventilation on the
Chemical Composition of Cigarette
Mainstream Smoke,’’ Analytica Chimica
Acta, 657(1): 36–44, 2010.
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
19. Hammond, D., N. Collishaw, and C.
Callard, ‘‘Secret Science: Tobacco
Industry Research on Smoking
Behaviour and Cigarette Toxicity,’’ The
Lancet, 367 (9512) 781–787, 2006.
20. Browne, C. L., The Design of Cigarettes.
Charlotte, NC: Hoechst Celanese, 1990.
21. World Health Organization, ‘‘The
Scientific Basis of Tobacco Product
Regulation,’’ Second Report of a WHO
Study Group, WHO Technical Report
Series 951, 2008.
22. Taylor, M. J., Scientific Services Manager,
Filtrona Technology Centre, ‘‘The Role of
Filter Technology in Reduced Yield
Cigarettes,’’ Text of Presentation for
World Tobacco Symposium Kunming,
Nov. 17, 2004.
23. Podraza K., Director, Product Integrity,
Philip Morris USA, ‘‘Basic Principles of
Cigarette Design and Function,’’
Presentation to LSRO, Oct. 29–30, 2001
(Slides 40 & 46).
24. O’Connor, R. J., D. Hammond, A.
McNeill, et al., ‘‘How Do Different
Cigarette Design Features Influence the
Standard Tar Yields of Popular Cigarette
Brands Sold in Different Countries?,’’
Tobacco Control, 17(Suppl. 1):i1-i5,
2008, doi:10.1136/tc.2006.019166.
25. Dash, S., P. N. Murthy, L. Nath, et al.,
‘‘Kinetic Modeling on Drug Release from
Controlled Drug Delivery Systems,’’ Acta
Poloniae Pharmaceutica—Drug
Research, 67(3):217–223, 2010.
26. Gale, N., G. Errington, and K. McAdam,
Group Research & Development, British
American Tobacco, ‘‘Effects of Product
Format on Nicotine and TSNA
Extraction from Snus Pouches,’’
Presentation at the 67th Tobacco Science
Research Conference, Williamsburg, VA,
September 15–18, 2013.
27. Stepanov, I., J. Jensen, L. Biener, et al.,
‘‘Increased Pouch Sizes and Resulting
Changes in the Amounts of Nicotine and
Tobacco-Specific N-Nitrosamines in
Single Pouches of Camel Snus and
Marlboro Snus,’’ Nicotine & Tobacco
Research, 14(10):1241–1245, 2012.
28. Zhang, H., J. Zhang, and J. B. Streisand,
‘‘Oral Mucosal Drug Delivery: Clinical
Pharmacokinetics and Therapeutic
Applications,’’ Drug Delivery Systems,
41(9):661–680, 2002.
29. Lewis, S., G. Subramanian, S. Pandey, et
al., ‘‘Design, Evaluation and
Pharmacokinetic Study of Mucoadhesive
Buccal Tablets of Nicotine for Smoking
Cessation,’’ Indian Journal of
Pharmaceutical Sciences, 68:829–831,
2006.
30. Hoffmann, D. and I. Hoffmann, ‘‘The
Changing Cigarette: Chemical Studies
and Bioassays,’’ Chapter 5 in Risks
Associated with Smoking Cigarettes with
Low Machine-Measured Yields of Tar
and Nicotine, Smoking and Tobacco
Control Monograph No. 13:159–191,
Bethesda, MD: U.S. Department of
Health and Human Services, National
Institutes of Health, National Cancer
Institute, 2001, available at https://
cancercontrol.cancer.gov/brp/tcrb/
Monographs/13/m13_5.pdf.
31. Hammond, D., G. T. Fong, K. M.
Cummings, et al., ‘‘Cigarette Yields and
PO 00000
Frm 00037
Fmt 4701
Sfmt 4702
12775
Human Exposure: A Comparison of
Alternative Testing Regimens,’’ Cancer
Epidemiology, Biomarkers & Prevention,
15(8):1495–1501, 2006.
32. Rees, V. W., G. F. Wayne, B. F. Thomas,
et al., ‘‘Physical Design Analysis and
Mainstream Smoke Constituent Yields of
the New Potential Reduced Exposure
Product, Marlboro UltraSmooth,’’
Nicotine & Tobacco Research,
9(11):1197–1206, 2007.
33. Ding, Y. S., J. S. Trommel, X. J. Yan, et
al., ‘‘Determination of 14 Polycyclic
Aromatic Hydrocarbons in Mainstream
Smoke from Domestic Cigarettes,
Environmental Science & Technology,
39(2):471–478, 2005.
34. Ding, Y. S., L. Zhang, R. B. Jain, et al.,
‘‘Levels of Tobacco-Specific
Nitrosamines and Polycyclic Aromatic
Hydrocarbons in Mainstream Smoke
from Different Tobacco Varieties,’’
Cancer Epidemiology, Biomarkers &
Prevention, 17(12):3366–3371, 2008.
35. Baker, R. R., ‘‘The Generation of
Formaldehyde in Cigarettes—Overview
and Recent Experiments,’’ Food and
Chemical Toxicology, 44:1799–1822,
2006.
36. U.S. Department of Health and Human
Services, ‘‘Preventing Tobacco Use
Among Young People,’’ A Report of the
Surgeon General; 1994.
37. U.S. Department of Health and Human
Services, ‘‘How Tobacco Smoke Causes
Disease: The Biology and Behavioral
Basis for Smoking-Attributable Disease,’’
A Report of the Surgeon General; 2010,
available at https://
www.ncbi.nlm.nih.gov/books/NBK53017.
38. National Cancer Institute, Centers for
Disease Control and Prevention, U.S.
Department of Health and Human
Services, ‘‘Smokeless Tobacco and
Public Health: A Global Perspective, 91–
106, 2014, available at https://
cancercontrol.cancer.gov/brp/tcrb/
global-perspective/SmokelessTobacco
AndPublicHealth.pdf.
39. German Cancer Research Center (DKFZ),
‘‘Additives in Tobacco Products.
Contribution of Carob Bean Extract,
Cellulose Fibre, Guar Gum, Liquorice,
Menthol, Prune Juice Concentrate and
Vanillin to Attractiveness, Addictiveness
and Toxicity of Tobacco Smoking,’’
Report, 2012.
40. Naworal, J. D., ‘‘Pyrolysis GC/MS analysis
of Guar Gum and Hydroxypropyl Guar at
300 Degrees C and 600 Degrees C,’’
Philip Morris, Inter-Office
Correspondence, Mar. 26, 1990, available
at https://industrydocuments.
library.ucsf.edu/tobacco/docs/ptnn0108.
41. Baker, R. R. and L. J. Bishop, ‘‘The
Pyrolysis of Non-Volatile Tobacco
Ingredients Using a System that
Simulates Cigarette Combustion
Conditions,’’ Journal of Analytical and
Applied Pyrolysis, 74:145–170, 2005.
42. Smith, T. E., ‘‘A Literature Review of
Aging and Fermentation of Tobacco,’’
Brown and Williamson Tobacco
Corporation, 1964.
43. Cornell, A., W. F. Cartwright, and T. A.
Bertinuson, ‘‘Influence of
E:\FR\FM\02APP2.SGM
02APP2
12776
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
amozie on DSK9F9SC42PROD with PROPOSALS2
Microorganisms (Fermentation) on the
Chemistry of Tobacco,’’ Recent Advances
in Tobacco Science, 5:27–62, 1979.
44. Schulthess, D., Philip Morris
International, ‘‘Project Clover, MarlboroRoll Your Own, Report on the Microbial
Analysis,’’ January 26, 1984.
45. Geiss, V. L., Brown and Williamson
Tobacco Corporation, ‘‘Control and Use
of Microbes in Tobacco Product
Manufacturing,’’ 1989.
46. Andersen, R. A., P. D. Fleming, T. R.
Hamilton-Kemp, et al., ‘‘pH Changes in
Smokeless Tobaccos Undergoing
Nitrosation During Prolonged Storage:
Effects of Moisture, Temperature, and
Duration,’’ Journal of Agricultural and
Food Chemistry, 41:968–972, 1993.
47. Mutasa, E. S., K. J. Seal, and N. Magan,
‘‘The Water Content/Water Activity
Relationship of Cured Tobacco and
Water Relations of Associated Spoilage
Fungi,’’ International Biodeterioration,
26: 381–896, 1990.
48. St. Charles, F. K., ‘‘Reduction of the
Water Activity of Wet Snuff/259,’’ Brown
and Williamson Tobacco Corporation,
Research & Development, File Note,
December 20, 1989.
49. Andersen, R. A., H. R. Burton, P. D.
Fleming, et al., ‘‘Effect of Storage
Conditions on Nitrosated, Acylated, and
Oxidized Pyridine Alkaloid Derivatives
in Smokeless Tobacco Products,’’ Cancer
Research, 49:5895–5900, 1989.
50. Rutqvist, L.E., M. Curvall, T. Hassler, et
al., ‘‘Swedish Snus and the GothiaTek®
Standard,’’ Harm Reduction Journal,
8:11, 2011.
51. Brunnemann, K. D., B. Prokopczyk, M. V.
Djordjevic, et al., ‘‘Formation and
Analysis of Tobacco-Specific NNitrosamines,’’ Critical Reviews in
Toxicology 26(2):121–137, 1996.
52. Fisher, M. T., C. B. Bennett, A. Hayes, et
al., ‘‘Sources of and Technical
Approaches for the Abatement of
Tobacco Specific Nitrosamine Formation
in Moist Smokeless Tobacco Products,’’
Food and Chemical Toxicology, 50:942–
948, 2012.
53. Djordjevic, M. V., J. Fan, L. P. Bush, et
al., ‘‘Effects of Storage Conditions on
Levels of Tobacco-Specific NNitrosamines and N-Nitrosamino Acids
in U.S. Moist Snuff,’’ Journal of
Agricultural and Food Chemistry,
41:1790–1794, 1993.
54. Preliminary Regulatory Impact Analysis;
Initial Regulatory Flexibility Analysis;
Unfunded Mandates Reform Act
Analysis, Content and Format of
Substantial Equivalence Reports;
Proposed Rule.
XI. Effective Date
FDA proposes that any final rule that
issues based on this proposal become
effective 30 days after the final rule
publishes in the Federal Register.
List of Subjects
21 CFR Part 16
Administrative practice and
procedure.
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
21 CFR Part 1107
Administrative practice and
procedure, Smoke, Smoking, Tobacco,
Tobacco products.
Therefore, under the Federal Food,
Drug, and Cosmetic Act, and under
authority delegated to the Commissioner
of Food and Drugs, it is proposed that
chapter I of title 21 of the Code of
Federal Regulations be amended as
follows:
PART 16—REGULATORY HEARING
BEFORE THE FOOD AND DRUG
ADMINISTRATION
1. The authority citation for part 16
continues to read as follows:
■
Authority: 15 U.S.C. 1451–1461; 21 U.S.C.
141–149, 321–394, 467f, 679, 821, 1034; 28
U.S.C. 2112; 42 U.S.C. 201–262, 263b, 364.
2. In § 16.1(b)(2) add in numerical
sequence an entry for ‘‘§ 1107.50’’ to
read as follows:
■
§ 16.1
Scope.
*
*
*
*
*
(b) * * *
(2) * * *
§ 1107.50, relating to rescission of an
order finding a tobacco product
substantially equivalent.
*
*
*
*
*
PART 1107—EXEMPTIONS AND
SUBSTANTIAL EQUIVALENCE
REPORTS
3. The authority citation for part 1107
is revised to read as follows:
■
Authority: 21 U.S.C. 371, 374, 387b, 387c,
387e(j), 387i, and 387j.
4. The heading of part 1107 is revised
to read as set forth above.
■ 5. Add subparts B through E to read
as follows:
■
Subpart B—General
Sec.
1107.10 Scope.
1107.12 Definitions.
Subpart C—Substantial Equivalence
Reports
1107.16 Submission of a substantial
equivalence report.
1107.18 Required content and format of a
report.
1107.19 Comparison information.
1107.20 Amendments.
1107.22 Withdrawal by applicant.
1107.24 Change in ownership of an SE
report.
Subpart D—FDA Review
1107.40 Communications between FDA and
applicants.
1107.42 Review cycles.
1107.44 FDA action on an SE report.
1107.46 Issuance of an order finding a new
tobacco product substantially equivalent.
PO 00000
Frm 00038
Fmt 4701
Sfmt 4702
1107.48 Issuance of an order denying
marketing authorization.
1107.50 Rescission of order.
Subpart E—Miscellaneous
1107.58 Record retention.
1107.60 Confidentiality.
1107.62 Electronic submission.
Subpart B—General
§ 1107.10
Scope.
(a) Subparts B through E of this part
apply to a substantial equivalence report
(or SE Report) for a new tobacco product
that has:
(1) Characteristics different from a
predicate tobacco product and for which
information is submitted to demonstrate
it is not appropriate to regulate the
product under section 910(b) and (c) of
the Federal Food, Drug, and Cosmetic
Act because the new tobacco product
does not raise different questions of
public health; or
(2) The same characteristics as a
predicate tobacco product.
(b) These subparts set forth
procedures and requirements for the
submission to FDA of an SE Report
under sections 905 and 910 of the
Federal, Food, Drug, and Cosmetic Act;
the basic criteria for establishing
substantial equivalence; and the general
procedures FDA will follow when
evaluating submissions.
§ 1107.12
Definitions.
For purposes of this part:
Accessory means any product that is
intended or reasonably expected to be
used with or for the human
consumption of a tobacco product; does
not contain tobacco and is not made or
derived from tobacco; and meets either
of the following:
(1) Is not intended or reasonably
expected to affect or alter the
performance, composition, constituents,
or characteristics of a tobacco product;
or
(2) Is intended or reasonably expected
to affect or maintain the performance,
composition, constituents, or
characteristics of a tobacco product; but
(i) Solely controls moisture and/or
temperature of a stored product; or
(ii) Solely provides an external heat
source to initiate but not maintain
combustion of a tobacco product.
Additive means any substance the
intended use of which results or may
reasonably be expected to result,
directly or indirectly, in its becoming a
component or otherwise affecting the
characteristic of any tobacco product
(including any substances intended for
use as a flavoring or coloring or in
producing, manufacturing, packing,
processing, preparing, treating,
E:\FR\FM\02APP2.SGM
02APP2
amozie on DSK9F9SC42PROD with PROPOSALS2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
packaging, transporting, or holding),
except that the term does not include
tobacco or a pesticide chemical residue
in or on raw tobacco, or a pesticide
chemical.
Applicant means any manufacturer of
tobacco products who is subject to
chapter IX of the Federal Food, Drug,
and Cosmetic Act that submits a
premarket application to receive
marketing authorization for a new
tobacco product.
Brand means a variety of tobacco
product distinguished by the tobacco
used, tar content, nicotine content,
flavoring used, size, filtration,
packaging, logo, registered trademark,
brand name, identifiable pattern of
colors, or any combination of such
attributes.
Characteristic means the materials,
ingredients, design, composition,
heating source, or other features of a
tobacco product.
Commercial distribution means any
distribution of a tobacco product to
consumers or to another person through
sale or otherwise, but does not include
interplant transfers of a tobacco product
between registered establishments
within the same parent, subsidiary, and/
or affiliate company, nor does it include
providing a tobacco product for product
testing where such product is not made
available for consumption or resale.
‘‘Commercial distribution’’ does not
include the handing or transfer of a
tobacco product from one consumer to
another for personal consumption. For
foreign establishments, the term
‘‘commercial distribution’’ has the same
meaning, except that it does not include
distribution of a tobacco product that is
neither imported nor offered for import
into the United States.
Component or part means any
software or assembly of materials
intended or reasonably expected:
(1) To alter or affect the tobacco
product’s performance, composition,
constituents, or characteristics; or
(2) To be used with or for the human
consumption of a tobacco product.
Component or part excludes anything
that is an accessory of a tobacco
product.
Composition means the materials in a
tobacco product, including ingredients,
additives, and biological organisms. The
term includes the manner in which the
materials, for example, ingredients,
additives, and biological organisms, are
arranged and integrated to produce a
tobacco product.
Constituent means any chemical or
chemical compound in a tobacco
product that is or potentially is inhaled,
ingested, or absorbed into the body, any
chemical or chemical compound in an
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
emission from a tobacco product, or any
chemical or chemical compound in
mainstream or sidestream tobacco
smoke that either transfers from any
component of the tobacco product to the
smoke or that is formed by the
combustion or heating of tobacco,
additives, or other component of the
tobacco product.
Container closure system means any
packaging materials that are a
component or part of a tobacco product.
Design means the form and structure
concerning, and the manner in which,
components or parts, ingredients,
software, and materials are integrated to
produce a tobacco product.
Distributor means any person who
furthers the distribution of a tobacco
product, whether domestic or imported,
at any point from the original place of
manufacture to the person who sells or
distributes the product to individuals
for personal consumption. Common
carriers are not considered distributors
for the purposes of this part.
Finished tobacco product means a
tobacco product, including all
components and parts, sealed in final
packaging (e.g., filters or filter tubes sold
separately to consumers or as part of
kits).
Grandfathered tobacco product means
a tobacco product that was
commercially marketed in the United
States as of February 15, 2007, and does
not include a tobacco product
exclusively in test markets as of that
date. A grandfathered tobacco product is
not subject to the premarket
requirements of section 910 of the
Federal Food, Drug, and Cosmetic Act.
Harmful or potentially harmful
constituent (HPHC) means any chemical
or chemical compound in a tobacco
product or tobacco smoke or emission
that:
(1) Is or potentially is inhaled,
ingested, or absorbed into the body; and
(2) Causes or has the potential to
cause direct or indirect harm to users or
nonusers of tobacco products.
Health information statement means a
statement, made under section 910(a)(4)
of the Federal Food, Drug, and Cosmetic
Act, that the health information related
to a new tobacco product will be made
available upon request by any person.
Health information summary means a
summary, submitted under section
910(a)(4) of the Federal Food, Drug, and
Cosmetic Act, of any health information
related to a new tobacco product.
Heating source means the source of
energy used to burn or heat a tobacco
product.
Ingredient means tobacco, substances,
compounds, or additives contained
within or added to the tobacco, paper,
PO 00000
Frm 00039
Fmt 4701
Sfmt 4702
12777
filter, or any other component or part of
a tobacco product, including substances
and compounds reasonably expected to
be formed through a chemical reaction
during tobacco product manufacturing.
Material means an assembly of
ingredients. Materials are assembled to
form a tobacco product or components
or parts of tobacco products.
New tobacco product means:
(1) Any tobacco product (including
those products in test markets) that was
not commercially marketed in the
United States as of February 15, 2007;
or
(2) Any modification (including a
change in design, any component, any
part, or any constituent, including a
smoke constituent, or in the content,
delivery or form of nicotine, or any
other additive or ingredient) of a
tobacco product where the modified
product was commercially marketed in
the United States after February 15,
2007.
Other features means any
distinguishing qualities of a tobacco
product similar to those specifically
enumerated in section 910(a)(3)(B) of
the Federal Food, Drug, and Cosmetic
Act. Such other features include
harmful and potentially harmful
constituents and any other product
characteristics that relate to the
chemical, biological, and physical
properties of the tobacco product and
are necessary for review.
Package or packaging means a pack,
box, carton, or container of any kind or,
if no other container, any wrapping
(including cellophane), in which a
tobacco product is offered for sale, sold,
or otherwise distributed to consumers.
Predicate tobacco product means a
tobacco product that is a grandfathered
tobacco product or a tobacco product
that FDA has previously found
substantially equivalent under section
910(a)(2)(A)(i) of the Federal Food,
Drug, and Cosmetic Act.
Submission tracking number or STN
means the number that FDA assigns to
submissions that are received from a
manufacturer of tobacco products, such
as SE Reports and requests for
grandfather determinations.
Substantial equivalence or
substantially equivalent means, with
respect to a new tobacco product being
compared to a predicate tobacco
product, that FDA by order has found
that the new tobacco product:
(1) Has the same characteristics as the
predicate tobacco product; or
(2) Has different characteristics and
the information submitted contains
information, including clinical data if
deemed necessary by FDA, that
demonstrates that it is not appropriate
E:\FR\FM\02APP2.SGM
02APP2
12778
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
to require premarket review under
section 910(b) and (c) of the Federal
Food, Drug, and Cosmetic Act because
the new tobacco product does not raise
different questions of public health.
Substantial equivalence report or SE
Report means a submission under
section 905(j)(1)(A)(i) of the Federal
Food, Drug, and Cosmetic Act that
includes the basis for the applicant’s
determination that a new tobacco
product is substantially equivalent to a
predicate tobacco product. This term
includes the initial substantial
equivalence report and all subsequent
amendments.
Tobacco product means any product
made or derived from tobacco that is
intended for human consumption,
including any component, part, or
accessory of a tobacco product (except
for raw materials other than tobacco
used in manufacturing a component,
part, or accessory of a tobacco product).
The term ‘‘tobacco product’’ does not
mean an article that under the Federal
Food, Drug, and Cosmetic Act is a drug
(section 201(g)(1)), a device (section
201(h)), or a combination product
(section 503(g)).
Tobacco product manufacturer means
any person, including a repacker or
relabeler, who:
(1) Manufactures, fabricates,
assembles, processes, or labels a tobacco
product, or
(2) Imports a finished tobacco product
for sale or distribution in the United
States.
Subpart C—Substantial Equivalence
Reports
amozie on DSK9F9SC42PROD with PROPOSALS2
§ 1107.16 Submission of a substantial
equivalence report.
An applicant may submit a SE Report
intended to demonstrate that a new
tobacco product is substantially
equivalent to a predicate tobacco
product. The applicant must submit the
SE Report at least 90 calendar days prior
to the date the applicant intends to
introduce or deliver for introduction a
new tobacco product into interstate
commerce for commercial distribution.
The applicant cannot begin commercial
distribution of the new tobacco product
until FDA has provided the applicant an
order stating that the Agency has
determined that the new tobacco
product is substantially equivalent to a
predicate tobacco product, unless the
new tobacco product has received
authorization to be marketed through
another premarket pathway.
§ 1107.18 Required content and format of
a SE report.
(a) Overview. The SE Report must
provide information uniquely
identifying the new tobacco product and
the predicate tobacco product, and
compare the new tobacco product to
either a grandfathered tobacco product
or a tobacco product that FDA
previously found to be substantially
equivalent. The SE Report must provide
sufficient information as described in
this section to enable FDA to determine
whether the new tobacco product is
substantially equivalent to a tobacco
product that was commercially
marketed in the United States as of
February 15, 2007. If FDA cites
deficiencies and requests information to
support a statement in the SE Report,
the applicant must provide that
information for review to continue, or
FDA may issue an order under
§ 1107.48. FDA will refuse to accept an
SE Report if it does not comply with
this section. The SE Report must
contain the following information:
(1) General information (as described
in paragraph (c) of this section);
(2) Summary (as described in
paragraph (d) of this section);
(3) New tobacco product description
(as described in paragraph (e) of this
section);
(4) Predicate tobacco product
description (as described in paragraph
(f) of this section), including a statement
that the predicate tobacco product has
not been removed from the market at the
initiative of FDA and has not been
determined by judicial order to be
adulterated or misbranded, and the
submission tracking number of the SE
order finding the predicate product SE,
or the submission tracking number of, or
information to support, a grandfathered
determination of the predicate tobacco
product;
(5) Comparison information (as
described in paragraph (g) of this
section);
(6) Comparative testing information
(as described in paragraph (h) of this
section);
(7) Statement of compliance with
applicable tobacco product standards
(as described in paragraph (i) of this
section);
(8) Health information summary or
statement that such information will be
made available upon request (as
described in paragraph (j) of this
section);
(9) Compliance with 21 CFR part 25
(as described in paragraph (k) of this
section); and
(10) Certification statement (as
described in paragraph (l) of this
section).
(b) Format. The applicant must
submit the SE Report using the form(s)
that FDA provides. The SE Report must
contain a comprehensive index and
table of contents, be well-organized and
legible, and be written in English. As
described in § 1107.62, the applicant
must submit the SE Report and all
information supporting the SE Report in
an electronic format that FDA can
process, read, review, and archive,
unless FDA has provided a waiver.
(c) General information. The SE
Report must include the following
information, using the form FDA
provides:
(1) The date the SE Report is
submitted;
(2) Type of submission (e.g., the SE
Report or amendment to a report);
(3) FDA STN if previously assigned;
(4) Any other relevant FDA STN, such
as a request for grandfathered
determination or SE Report previously
found substantially equivalent (if
applicable), and cross-references to
meetings with FDA regarding the new
tobacco product;
(5) Applicant name, address, and
contact information;
(6) Authorized representative or U.S.
agent (for a foreign applicant), including
the name, address, and contact
information;
(7) For both the new and predicate
tobacco products, the following
information to uniquely identify the
products:
(i) Manufacturer;
(ii) Product name, including the brand
and sub brand (or other commercial
name used in commercial distribution);
and
(iii) Product category, product
subcategory, and product properties (if
the product does not have a listed
product property, e.g., ventilation or
characterizing flavor, the report must
state ‘‘none’’ for that property) as
provided in the following table:
Tobacco product category:
Tobacco product subcategory:
Product properties:
(A)Cigarettes ...................................
(1) Combusted, Filtered .................
—Package type (e.g., hard pack, soft pack, clam shell).
—Product quantity (e.g., 20 cigarettes, 25 cigarettes).
—Length (e.g., 89 millimeters (mm), 100 mm).
—Diameter (e.g., 6 mm, 8.1 mm).
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
PO 00000
Frm 00040
Fmt 4701
Sfmt 4702
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
Tobacco product category:
Tobacco product subcategory:
(2) Combusted, Non-filtered ..........
(3) Combusted, Other ....................
(4) Non-Combusted (e.g., a cigarette where the tobacco is heated not burned).
(5) Cigarette, Co-Package .............
(B) Roll-Your-Own Tobacco Products.
(1) Roll-Your-Own Tobacco Filler ..
(2) Rolling Paper ...........................
(3) Filtered Cigarette Tube ............
(4) Non-Filtered Cigarette Tube ....
amozie on DSK9F9SC42PROD with PROPOSALS2
(5) Filter .........................................
(6) Paper Tip .................................
VerDate Sep<11>2014
21:09 Apr 01, 2019
Jkt 247001
PO 00000
Frm 00041
Fmt 4701
12779
Product properties:
—Ventilation (e.g., none, 10%, 25%).
—Characterizing Flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., hard pack, soft pack, clam shell).
—Product quantity (e.g., 20 cigarettes, 25 cigarettes).
—Length (e.g., 89 mm, 100 mm).
—Diameter (e.g., 6 mm, 8.1 mm).
—Characterizing Flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., hard pack, soft pack, clam shell).
—Product quantity (e.g., 20 cigarettes, 25 cigarettes).
—Length (e.g., 89 mm, 100 mm).
—Diameter (e.g., 6 mm, 8.1 mm).
—Ventilation (e.g., none, 10%, 25%).
—Characterizing Flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., hard pack, soft pack, clam shell).
—Product quantity (e.g., 20 cigarettes, 25 cigarettes).
—Length (e.g., 89 mm, 100 mm).
—Diameter (e.g., 6 mm, 8.1 mm).
—Ventilation (e.g., none, 10%, 25%).
—Characterizing Flavor(s) (e.g., none, menthol).
—Source of energy (e.g., charcoal, electrical heater).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
For a new co-packaged tobacco product composed of multiple cigarette tobacco products, include, as applicable, all properties for
each individual tobacco product, as identified in this section.
—Package type (e.g., bag, pouch).
—Product quantity (e.g., 20 g, 40 g).
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, box, booklet).
—Product quantity (e.g., 50 sheets, 200 papers).
—Length (e.g., 79 mm, 100 mm, 110 mm).
—Width (e.g., 28 mm, 33 mm, 45 mm).
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, box).
—Product quantity (e.g., 100 tubes, 200 tubes).
—Length (e.g., 89 mm, 100 mm).
—Diameter (e.g., 6 mm, 8.1 mm).
—Ventilation (e.g., none, 10%, 25%).
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, box).
—Product quantity (e.g., 100 tubes, 200 tubes).
—Length (e.g., 89 mm, 100 mm).
—Diameter (e.g., 6 mm, 8.1 mm).
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, box).
—Product quantity (e.g., 100 filters, 200 filters).
—Length (e.g., 8 mm, 12 mm).
—Diameter (e.g., 6 mm, 8.1 mm).
—Ventilation (e.g., none, 10%, 25%).
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, box).
—Product quantity (e.g., 200 tips, 275 tips).
—Length (e.g., 12 mm, 15 mm).
—Width (e.g., 27 mm).
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
Sfmt 4702
E:\FR\FM\02APP2.SGM
02APP2
12780
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
Tobacco product category:
Tobacco product subcategory:
Product properties:
(7) Roll-Your-Own Co-Package .....
—For a new co-packaged tobacco product composed of multiple
RYO tobacco products, include, as applicable, all properties for
each individual tobacco product (e.g., roll-your own tobacco, rolling
paper, filtered cigarette tube, non-filtered cigarette tube, filter,
paper tip) as identified in this section.
—Package type (e.g., bag, box).
—Product quantity.
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product.
—Package type (e.g., plastic can with metal lid, plastic can with plastic lid).
—Product quantity (e.g., 20 grams (g), 2 ounces).
—Tobacco cut size (e.g., 5 mm, 7 mm).
—Characterizing flavor(s) (e.g., none, menthol, cherry, wintergreen).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., plastic can with metal lid, plastic can with plastic lid).
—Product quantity (e.g., 22.5 g, 20 g).
—Portion count (e.g., 15 pouches, 20 pieces).
—Portion mass (e.g., 1.5 g/pouch, 2 g/piece).
—Portion length (e.g., 15 mm, 20 mm).
—Portion width (e.g., 10 mm, 15 mm).
—Portion thickness (e.g., 5 mm, 7 mm).
—Tobacco cut size (e.g., 5 mm, 7 mm).
—Characterizing flavor(s) (e.g., none, menthol, cherry, wintergreen).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., plastic can with metal lid, plastic can with plastic lid).
—Product quantity (e.g., 20 g, 2 ounces).
—Tobacco cut size (e.g., 5 mm, 7 mm).
—Characterizing flavor(s) (e.g., none, menthol, cherry, wintergreen).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., plastic can with metal lid, plastic can with plastic lid).
—Product quantity (e.g., 22.5 g, 20 g).
—Portion count (e.g., 15 pouches, 20 pieces).
—Portion mass (e.g., 1.5 g/pouch, 2 g/piece).
—Portion length (e.g., 15 mm, 20 mm).
—Portion width (e.g., 10 mm, 15 mm).
—Portion thickness (e.g., 5 mm, 7 mm).
—Tobacco cut size (e.g., 5 mm, 7 mm).
—Characterizing flavor(s) (e.g., none, menthol, cherry, wintergreen).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., plastic can with metal lid, plastic can with plastic lid).
—Product quantity (e.g., 20 g, 2 ounces).
—Tobacco cut size (e.g., 0.05 mm, 0.07 mm).
—Characterizing flavor(s) (e.g., none, menthol, cherry, wintergreen).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., plastic can with metal lid, plastic can with plastic lid).
—Product quantity (e.g., 22.5 g, 20 g).
—Portion count (e.g., 15 sticks, 20 tablets).
—Portion mass (e.g., 1.5 g/strip, 1 g/piece).
—Portion length (e.g., 10 mm, 15 mm).
—Portion width (e.g., 5 mm, 8 mm).
—Portion thickness (e.g., 3 mm, 4 mm).
—Tobacco cut size (e.g., 0.05 mm, 0.07 mm).
—Characterizing flavor(s) (e.g., none, menthol, cherry, wintergreen).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, pouch, wrapped).
—Product quantity (e.g., 20 g, 3 ounces).
—Tobacco cut size (e.g., 0.05 mm, 0.07 mm).
—Characterizing flavor(s) (e.g., none, menthol, cherry, wintergreen).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
(8) Other ........................................
(C) Smokeless Tobacco Products ..
(1) Loose Moist Snuff ....................
(2) Portioned Moist ........................
(3) Snuff .........................................
(4) Loose Snuff ..............................
(5) Portioned Snuff ........................
(6) Loose Dry Snuff .......................
amozie on DSK9F9SC42PROD with PROPOSALS2
(7) Dissolvable ...............................
(8) Loose Chewing Tobacco .........
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
PO 00000
Frm 00042
Fmt 4701
Sfmt 4702
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
Tobacco product category:
Tobacco product subcategory:
Product properties:
(9) Portioned Chewing Tobacco ....
—Package type (e.g., plastic can with metal lid, plastic can with plastic lid).
—Product quantity (e.g., 20 g).
—Portion count (e.g., 10 bits).
—Portion mass (e.g., 2 g/bit).
—Portion length (e.g., 8 mm, 10 mm).
—Portion width (e.g., 6 mm, 8 mm).
—Portion thickness (e.g., 5 mm, 7 mm).
—Characterizing flavor(s) (e.g., none, menthol, cherry, wintergreen).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—For a new co-packaged tobacco product composed of multiple
smokeless tobacco products, include, as applicable, all properties
for each individual tobacco product as identified in this section.
—Package type (e.g., bag, box).
—Product quantity.
—Characterizing flavor(s) (e.g., none, tobacco, menthol).
—Additional properties needed to uniquely identify the tobacco product.
—Package type (e.g., bottle, box).
—Product quantity (e.g., 1 bottle, 5 bottles).
—Characterizing flavor(s) (e.g., none, tobacco, menthol, cherry, wintergreen).
—E-liquid volume (e.g., 10 milliliters (ml)).
—Nicotine concentration (e.g., 0, 0.2 mg/ml).
—PG/VG ratio (e.g., N/A, 0/100, 50/50).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., cartridge).
—Product quantity (e.g., 1 cartridge, 5 cartridges).
—Characterizing flavor(s) (e.g., none, tobacco, menthol, cherry, wintergreen).
—E-liquid volume (e.g., 10 ml).
—Nicotine concentration (e.g., 0, 0.2 mg/ml).
—PG/VG ratio (e.g., N/A, 0/100, 50/50).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., box, none, plastic clamshell).
—Product quantity (e.g., 1 e-cigarette, 5 e-cigarettes).
—Characterizing flavor(s) (e.g., none, tobacco, menthol, cherry, wintergreen).
—Length (e.g., 100 mm, 120 mm).
—Diameter (e.g., 6 mm, 8 mm).
—E-liquid volume (e.g., 2 ml, 5 ml).
—Nicotine concentration (e.g., 0, 0.2 mg/ml).
—PG/VG ratio (e.g., N/A, 0/100, 50/50).
—Wattage (e.g., 100 W, 200 W).
—Battery capacity (e.g., 100 mAh, 200 mAh).
—Additional properties needed to uniquely identify the tobacco product.
—Package type (e.g., box, none, plastic clamshell).
—Product quantity (e.g., 1 e-cigarette, 5 e-cigarettes).
—Characterizing flavor(s) (e.g., none, tobacco, menthol, cherry, wintergreen).
—Length (e.g., 100 mm, 120 mm).
—Diameter (e.g., 8 mm, 14 mm).
—E-liquid volume (e.g., 2 ml, 5 ml).
—Wattage (e.g., 100 Watts (W), 200 W).
—Battery capacity (e.g., 100 mAh, 200 mAh).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., box, none, plastic clamshell).
—Product quantity (e.g., 1 e-cigarette, 5 e-cigarettes).
—Characterizing flavor(s) (e.g., none, tobacco, menthol, cherry, wintergreen).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—For a new co-packaged tobacco product composed of multiple
ENDS tobacco products, include, as applicable, all properties for
each individual tobacco product as identified in this section.
—Package type (e.g., bag, box).
—Product quantity.
—Characterizing flavor(s) (e.g., none, tobacco, menthol, cherry).
(10) Smokeless Co-Package .........
(11) Other ......................................
(D) ENDS (Electronic Nicotine Delivery System).
(1) Open E-Liquid ..........................
(2) Closed E-Liquid ........................
(3) Closed E-Cigarette ...................
(4) Open E-Cigarette .....................
amozie on DSK9F9SC42PROD with PROPOSALS2
(5) ENDS Component ...................
(6) ENDS Co-Package ..................
(7) ENDS Other .............................
VerDate Sep<11>2014
20:34 Apr 01, 2019
12781
Jkt 247001
PO 00000
Frm 00043
Fmt 4701
Sfmt 4702
E:\FR\FM\02APP2.SGM
02APP2
12782
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
Tobacco product category:
Tobacco product subcategory:
(E) Cigars ........................................
(1) Filtered, Sheet-Wrapped Cigar
(2) Unfiltered,
Cigar.
Sheet-Wrapped
(3) Leaf-Wrapped Cigar .................
(4) Cigar Component .....................
(5) Cigar Tobacco Filler .................
(6) Cigar Co-Package ....................
(7) Other ........................................
(F) Pipe Tobacco Products .............
(1) Pipe ..........................................
(2) Pipe Tobacco Filler ..................
(3) Pipe Component ......................
amozie on DSK9F9SC42PROD with PROPOSALS2
(4) Pipe Co-Package .....................
(5) Other ........................................
(G) Waterpipe Tobacco Products ...
VerDate Sep<11>2014
20:34 Apr 01, 2019
(1) Waterpipe .................................
Jkt 247001
PO 00000
Frm 00044
Fmt 4701
Product properties:
—Additional properties needed to uniquely identify the tobacco product.
—Package type (e.g., hard pack, soft pack, clam shell).
—Product quantity (e.g., 20 filtered cigars, 25 filtered cigars).
—Characterizing flavor (e.g., none, menthol).
—Length (e.g., 89 mm, 100 mm).
—Diameter (e.g., 6 mm, 8.1 mm).
—Ventilation (e.g., none, 10%, 25%).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., box, film sleeve).
—Product quantity (e.g., 1 cigar, 5 cigarillos).
—Characterizing flavor (e.g., none, menthol).
—Length (e.g., 100 mm, 140 mm).
—Diameter (e.g., 8 mm, 10 mm).
—Tip (e.g., none, wood tips, plastic tips).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., box, film, sleeve, none).
—Product quantity (e.g., 1 cigar, 5 cigars).
—Characterizing flavor (e.g., none, whiskey).
—Length (e.g., 150 mm, 200 mm).
—Diameter (e.g., 8 mm, 10 mm).
—Wrapper material (e.g., burley tobacco leaf, Connecticut shade
grown tobacco leaf).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., box, booklet).
—Product quantity (e.g., 10 wrappers, 20 leaves).
—Characterizing flavor (e.g., none, menthol, cherry).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, pouch).
—Product quantity (e.g., 20 g, 16 ounces).
—Characterizing flavor (e.g., none, tobacco, menthol, cherry).
—Tobacco cut size (e.g., 5 mm, 10 mm).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—For a new co-packaged tobacco product composed of multiple
cigar tobacco products, include, as applicable, all properties for
each individual tobacco product as identified previously.
—Package type (e.g., bag, box).
—Product quantity.
—Characterizing flavor(s) (e.g., none, tobacco, menthol).
—Additional properties needed to uniquely identify the tobacco product.
—Package type (e.g., box, none).
—Product quantity (e.g., 1 pipe).
—Length (e.g., 200 mm, 300 mm).
—Diameter (e.g., 25 mm).
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, pouch).
—Product quantity (e.g., 20 g, 16 ounces).
—Characterizing flavor(s) (e.g., none, menthol, cavendish, cherry).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bowl, shank, stem, screen, filter).
—Product quantity (e.g., 1 bowl, 1 stem, 100 filters).
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—For a new co-packaged tobacco product composed of multiple pipe
tobacco products, include, as applicable, all properties for each individual tobacco product as identified previously.
—Package type (e.g., bag, box).
—Product quantity.
—Characterizing flavor(s) (e.g., none, tobacco, menthol).
—Additional properties needed to uniquely identify the tobacco product.
—Package type (e.g., box, none).
—Product quantity (e.g., 1 waterpipe).
—Length (e.g., 200 mm, 500 mm).
Sfmt 4702
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
Tobacco product category:
Tobacco product subcategory:
(2) Waterpipe Tobacco Filler .........
(3) Waterpipe Heat Source ...........
(4) Waterpipe Component .............
(5) Waterpipe Co-Package ............
(6) Waterpipe Other .......................
amozie on DSK9F9SC42PROD with PROPOSALS2
Other ...............................................
Other ..............................................
(8) Address and the FDA
Establishment Identifier (FEI) number(s)
of the establishments involved in the
manufacture and/or importation of the
new and predicate tobacco products.
(d) Summary. The SE Report must
include a summary at the beginning of
the SE Report that includes the
following:
(1) A concise description of the
characteristics of the new tobacco
product;
(2) A statement as to whether the
applicant believes the new tobacco
product has the same characteristics as
the predicate tobacco product or has
different characteristics but does not
raise different questions of public
health; and
(3) A concise description of the
similarities and differences between the
new tobacco product and the predicate
tobacco product with respect to their
characteristics (materials, ingredients,
design, composition, heating source, or
other features).
(e) New tobacco product description.
The applicant must identify one new
tobacco product in the SE Report for
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
Product properties:
—Width (e.g., 100 mm, 300 mm).
—Number of hoses (e.g., 1, 2, 4).
—Characterizing flavor(s) (e.g., none, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, pouch).
—Product quantity (e.g., 20 g, 16 ounces).
—Characterizing flavor(s) (e.g., none, tobacco, menthol, apple).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., box, film sleeve, bag, none).
—Product quantity (e.g., 150 g, 680 g).
—Characterizing flavor(s) (e.g., none, menthol, apple).
—Portion count(e.g., 20 fingers, 10 discs, 1 base).
—Portion mass (e.g., 15 g/finger).
—Portion length (e.g., 40 mm, 100 mm).
—Portion width (e.g., 10 mm, 40 mm).
—Portion thickness (e.g., 10 mm, 40 mm).
—Source of energy (e.g., charcoal, battery, electrical).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, box, none).
—Product quantity (e.g., 1 base, 1 bowl, 1 hose, 10 mouthpieces).
—Characterizing flavor(s) (e.g., none, menthol, apple).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—For a new co-packaged tobacco product composed of multiple
waterpipe tobacco products, include, as applicable, all properties
for each individual tobacco product as identified in this section.
—Package type (e.g., bag, box).
—Product quantity.
—Characterizing flavor(s) (e.g., none, tobacco, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
—Package type (e.g., bag, box).
—Product quantity.
—Characterizing flavor(s) (e.g., none, tobacco, menthol).
—Additional properties needed to uniquely identify the tobacco product (if applicable).
comparison to one predicate tobacco
product. The SE Report must describe
the new tobacco product in sufficient
detail to enable FDA to evaluate its
characteristics. This part of the SE
Report must include:
(1) A narrative description of the new
tobacco product and detailed drawings
or schematics of the new tobacco
product, including its container closure
system, illustrating all components or
parts of the product. For a portioned
tobacco product, the SE Report must
also include a diagram illustrating all
components or parts of the individual
unit of use;
(2) A description and the function of
each component or part of the new
tobacco product, and an explanation of
how each component or part is
integrated into the design of the new
tobacco product; and
(3) A concise overview of the process
used to manufacture the new tobacco
product, including the fermentation
process, where applicable, with
information on the type and quantity of
the microbial inoculum and/or
fermentation solutions. If the
PO 00000
Frm 00045
Fmt 4701
12783
Sfmt 4702
manufacturing process for the new
tobacco product does not affect the
characteristics of the new tobacco
product beyond what is described
elsewhere in the SE Report, an applicant
must state that to satisfy this provision.
(f) Description of predicate tobacco
product. (1) The applicant must identify
a predicate tobacco product that is
either a grandfathered tobacco product
or a tobacco product that FDA
previously found to be substantially
equivalent.
(2) A tobacco product to which a new
tobacco product is compared must:
(i) Be in the same category and
subcategory of product as the new
tobacco product;
(ii) Have been either:
(A) Commercially marketed (not
exclusively in a test market) in the
United States as of February 15, 2007,
as shown by either specific information
sufficient to support this in the SE
Report, including a statement that ‘‘I,
(name of responsible official), confirm
that the predicate tobacco product,
(insert name of predicate tobacco
product), was commercially marketed
E:\FR\FM\02APP2.SGM
02APP2
amozie on DSK9F9SC42PROD with PROPOSALS2
12784
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
other than for test marketing as of
February 15, 2007’’, or reference to an
STN for a previous determination by
FDA that the predicate product is
grandfathered; or
(B) Previously determined to be
substantially equivalent by FDA;
(iii) Be an individual product and not
a composite of multiple products;
(iv) Not be the subject of a rescission
order by FDA, as described in § 1107.50;
and
(v) Not have been removed from the
market at the initiative of FDA and not
have been determined by judicial order
to be adulterated or misbranded.
(g) Comparison information. The SE
Report must include a comparison of
the characteristics of the new tobacco
product and the predicate tobacco
product, as described in § 1107.19. If the
new tobacco product has limited
changes to a characteristic(s) when
compared to the predicate tobacco
product, and all other characteristics are
identical (e.g., a change to product
quantity), the applicant must provide
comparison information related to such
characteristic(s), but may certify that the
other characteristics identical under
paragraph (1)(2) of this section. The
applicant must maintain records
supporting the certification consistent
with § 1107.58.
(h) Comparative testing information.
Other than for characteristics that are
identical, and for which the applicant
has certified that the characteristics are
identical under paragraph (1)(2) of this
section, the SE Report must provide
comparative testing information on the
characteristics of the new and predicate
tobacco products, as described in
§ 1107.19, except where the applicant
adequately justifies that such
comparative testing information is not
necessary to demonstrate that the new
product has the same characteristics as
the predicate or does not raise different
questions of public health. The testing
information must:
(1) Include the test protocols,
quantitative acceptance criteria, and test
results (including means and variances,
data sets, and a summary of the results);
(2) Be conducted on a sufficient
sample size and on test samples that
reflect the finished tobacco product
composition and design;
(3) State whether the same test
methods were used for the new tobacco
product and the predicate product, and
if the methods differed, an explanation
as to how the results of the different test
methods can be compared; and
(4) Identify national and international
standards used to test the new and
predicate tobacco products and explain
any deviations from the standard, or
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
state that no standards were used for the
testing.
(i) Statement of compliance with
applicable tobacco product standards.
The SE Report must either:
(1) List and describe the action(s)
taken by the applicant to comply with
applicable requirements under section
907 of the Federal Food, Drug, and
Cosmetic Act; or
(2) State there are no applicable
requirements under section 907 of the
Federal Food, Drug, and Cosmetic Act.
(j) Health information summary or
statement regarding availability of such
information. The SE Report must
include either a health information
summary or a statement that such
information will be made available
upon request, as provided in section
910(a)(4) of the Federal Food, Drug, and
Cosmetic Act, in accord with the
following:
(1) Health information summary. If
including a health information summary
with the SE Report, the applicant must
provide a copy of the full SE Report that
excludes research subject identifiers and
trade secret and confidential
commercial information as defined in
§§ 20.61 and 20.63 of this chapter (21
CFR 20.61 and 20.63); and either
(i) Provide accurate, complete, and
not false or misleading, additional
health information, including
information, research, or data about
adverse health effects, that the applicant
has or knows about concerning the new
tobacco product that is not contained in
the SE Report; or
(ii) Provide the following statement, if
true, about the new tobacco product:
‘‘Applicant does not have or know of
any additional health information,
including information, research or data
regarding adverse health effects, about
the new tobacco product that is the
subject of this SE Report.’’
(2) Statement regarding availability of
health information. If the applicant
chooses to make the health information
available upon request, the SE Report
must include the following statement,
with the appropriate applicant
information inserted as indicated by
parenthetical text, signed by an
authorized representative of the
applicant, made on a separate page of
the SE Report, and clearly identified as
‘‘910(a)(4) health information
statement’’. ‘‘I certify that, in my
capacity as (the position held in
company by person required to submit
the SE Report, preferably the
responsible official of the applicant) of
(company name), I will make available,
upon request, the information identified
in 21 CFR 1107.18(j)(3) within 30
calendar days of a request.’’
PO 00000
Frm 00046
Fmt 4701
Sfmt 4702
(3) Content of health information. The
health information the applicant agrees
to make available in paragraph (j)(2) of
this section must be a copy of the full
SE Report, excluding all research
subject identifiers, trade secrets, and
confidential commercial information, as
defined in 21 CFR 20.61 and 21 CFR
20.63; and either.
(i) Accurate, complete, and not false
or misleading, additional health
information, including information,
research, or data about adverse health
effects, that the applicant has or knows
about concerning the new tobacco
product and that is not contained in the
SE Report; or
(ii) The following statement, if true,
about the new tobacco product.
‘‘(Company name) does not have or
know of any additional health
information, including information,
research or data regarding adverse
health effects about the new tobacco
product that is the subject of the
provided SE Report.’’
(4) Requests for information. All
requests for information under
paragraph (j)(2) of this section must be
made in writing to the authorized
representative of the applicant, whose
contact information will be posted on
the FDA website listing substantial
equivalence determinations. The
applicant must provide FDA any
updated information if the contact
information changes.
(5) No modified risk violations. To the
extent information is included in the
health information summary or health
information provided upon request
under paragraphs (j)(1) and (2) of this
section that is not required by section
910(a)(4) of the Federal Food, Drug, and
Cosmetic Act or paragraph (j) of this
section, that information must not
contain a statement that would cause
the tobacco product to be in violation of
section 911 of the Federal Food, Drug,
and Cosmetic Act upon the introduction
or delivery for introduction of the
proposed new product into interstate
commerce.
(k) Compliance with 21 CFR part 25.
(1) The SE Report must include an
environmental assessment prepared in
accordance with § 25.40 of this chapter,
or a valid claim of categorical exclusion.
If the applicant believes that the action
qualifies for an available categorical
exclusion, the applicant must state
under § 25.15(a) and (d) of this chapter
that the action requested qualifies for a
categorical exclusion, citing the
particular exclusion that is claimed, and
that to the applicant’s knowledge, no
extraordinary circumstances exist under
§ 25.21.
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
(2) The environmental assessment
must include a statement explaining
whether the new tobacco product is
intended to replace the predicate
tobacco product once the new tobacco
product receives market authorization,
is intended to be a line extension of the
predicate tobacco product, is intended
to be introduced as an additional
product by the same manufacturer, or if
the new tobacco product will be
introduced as an additional product but
by a different manufacturer.
(l) Certification Statement. (1) The SE
Report must contain the following
certification, with the appropriate
information inserted (as indicated by
parenthetical text), and be signed by an
authorized representative of the
applicant. ‘‘I (name of responsible
official) on behalf of (applicant), hereby
certify that (applicant) will maintain all
records to substantiate the accuracy of
this SE Report for the period of time
required in § 1107.58 and ensure that
such records remain readily available to
the FDA upon request. I certify that this
information and the accompanying
submission are true and correct, that no
material fact has been omitted, and that
I am authorized to submit this on the
applicant’s behalf. I understand that
under section 1001 of title 18 of the
United States Code anyone who
knowingly and willfully makes a
materially false, fictitious, or fraudulent
statement or representation in any
matter within the jurisdiction of the
executive, legislative, or judicial branch
of the Government of the United States
is subject to criminal penalties.’’
(2) The SE Report must include the
following certification if an applicant
chooses to certify that certain
characteristics are identical in lieu of
providing data for each characteristic of
the new and predicate tobacco products.
This certification must include the
appropriate information inserted (as
indicated by parenthetical text) and be
signed by an authorized representative
of the applicant. ‘‘I, (name of
responsible official), on behalf of (name
of company), certify that (new tobacco
product name) has the following
modification(s) as compared to (name of
predicate tobacco product): (describe
modification(s), e.g., change in product
quantity or change in container closure
system). Aside from these modifications,
the characteristics of (new tobacco
product name) and (name of predicate
tobacco product) are identical. I certify
that (name of company) understands
this means there is no other
modification to the materials,
ingredients, design features, heating
source, or any other feature. I also
certify that (name of company) will
maintain records to support the
12785
comparison information in 21 CFR
1107.19 that substantiate the accuracy of
this statement for the period of time
required in 21 CFR 1107.58, and ensure
that such records remain readily
available to FDA upon request.’’
§ 1107.19
Comparison information.
The SE Report must include a
comparison of the characteristics of the
new tobacco product to the predicate
tobacco product. The comparison
section of the SE Report must be
organized in the following manner:
(a) Comparison of product design. The
SE Report must include descriptions of
the product designs of the new and
predicate tobacco products and identify
any differences. The SE Report must
include, in a tabular format, a side-byside comparison of each design
parameter of the new and predicate
tobacco products. For each design
parameter, the target value and range of
acceptable values, actual measured
value (where applicable), and range of
measured values (where applicable)
with units of measure must be provided.
In addition, for each applicable design
parameter, test data must be provided.
(1) Cigarettes. For cigarettes, the
required design parameter information
to be provided for each predicate and
new tobacco product is as follows:
amozie on DSK9F9SC42PROD with PROPOSALS2
TABLE 1 TO § 1107.19(a)(1)
Provide target specification with upper and lower range limits for:
Provide test data (include test protocols, quantitative acceptance criteria, data sets, and a summary of the results) for:
—Cigarette length (mm)
—Cigarette circumference (mm)
—Cigarette draw resistance (mm H2O)
—Tobacco filler mass (mg)
—Tobacco rod density (g/cubic centimeter (cm3))
—Tobacco moisture (%)
—Filter ventilation (%)
—Tipping paper length (mm)
—Puff count
—Cigarette draw resistance (mm H2O)
—Tobacco filler mass (mg)
—Tobacco moisture (%)
—Filter ventilation (%)
—Cigarette paper base paper basis weight (g/m2))
—Cigarette paper base paper porosity (CU)
—Filter efficiency (%) (If no filter efficiency data is available for the
products, include information sufficient to show that the cigarette filter is unchanged (e.g., denier per filament, total denier, and filter
density))
—Filter pressure drop (mm H2O)
—Cigarette paper base paper basis weight (g/m2)
—Cigarette paper base paper porosity (CU)
—Cigarette paper band width (mm)
—Cigarette paper band space (mm)
—Filter efficiency (%) (If no filter efficiency data is available for the
products, include information sufficient to show that the cigarette filter
is unchanged (e.g., denier per filament, total denier, and filter density))
—Filter length (mm)
—Filter pressure drop (mm H2O)
(2) Smokeless tobacco. For portioned
and non-portioned smokeless tobacco
VerDate Sep<11>2014
21:19 Apr 01, 2019
Jkt 247001
products, the required design parameter
information to be provided for each
PO 00000
Frm 00047
Fmt 4701
Sfmt 4702
predicate and new tobacco product is as
follows:
E:\FR\FM\02APP2.SGM
02APP2
12786
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
TABLE 2 TO § 1107.19(a)(2)
Provide target specification with upper and lower range limits for:
Provide test data (include test protocols, quantitative acceptance criteria, data sets, and a summary of the results) for:
Portioned Smokeless Tobacco Products
—Tobacco cut size (mm)
—Tobacco moisture (%)
—Portion length (mm) (if applicable)
—Portion width (mm) (if applicable)
—Portion mass (mg) (if applicable)
Portion thickness (mm) (if applicable)
Pouch paper wicking
Pouch paper porosity (CU)
Pouch paper basis weight (g/m2)
—Tobacco cut size (mm).
—Tobacco moisture (%).
—Portion mass (mg) (if applicable).
—Pouch paper porosity (CU).
—Pouch paper basis weight (g/m2).
Nonportioned Smokeless Tobacco Products
—Tobacco cut size (mm)
—Tobacco moisture (%)
—Tobacco cut size (mm).
—Tobacco moisture (%).
(3) Roll-your-own tobacco, rolling
papers. For roll-your-own tobacco
rolling papers, the required design
parameter information to be provided
for each predicate and new tobacco
product is as follows:
TABLE 3 TO § 1107.19(a)(3)
Provide target specification with upper and lower range limits for:
Provide test data (include test protocols, quantitative acceptance
criteria, data sets, and a summary of the results) for:
—Paper length(mm)
—Paper width (mm)
—Mass per paper (mg)
—Cigarette paper base paper basis weight (g/m2)
—Cigarette paper base paper porosity (CU)
—Cigarette paper band porosity (CU) (if applicable)
—Cigarette paper band width (mm) (if applicable)
—Cigarette paper band space (mm) (applicable)
—Mass per paper (mg).
—Cigarette paper base paper basis weight (g/m2).
—Cigarette paper base paper porosity (CU).
—Cigarette paper band porosity (CU) (if applicable).
(4) Roll-your-own tobacco, tubes. For
roll-your-own tobacco tubes, the
required design parameter information
to be provided for each predicate and
new tobacco product is as follows:
TABLE 4 TO § 1107.19(a)(4)
Provide target specification with upper and lower range limits for:
Provide test data (include test protocols, quantitative acceptance criteria, data sets, and a summary of the results) for:
—Tube length (mm)
—Tube circumference (mm)
—Total mass (mg)
—Cigarette paper base paper basis weight (g/m2)
—Cigarette paper base paper porosity (CU)
—Cigarette paper band porosity (CU)
—Cigarette paper band width (mm)
—Cigarette paper band space (mm)
—Total mass (mg).
—Cigarette paper base paper basis weight (g/m2).
—Cigarette paper base paper porosity (CU).
—Cigarette paper band porosity (CU).
(5) Roll-your-own tobacco, filtered
tubes. For roll-your-own tobacco filtered
tubes, the required design parameter
information to be provided for each new
predicate and new tobacco product is as
follows:
amozie on DSK9F9SC42PROD with PROPOSALS2
TABLE 5 TO § 1107.19(a)(5)
Provide target specification with upper and lower range limits for:
Provide test data (include test protocols, quantitative acceptance criteria, data sets, and a summary of the results) for:
—Tube length (mm)
—Tube circumference (mm)
—Total mass (mg)
—Tipping paper length (mm)
—Total mass (mg).
—Filter ventilation (%).
—Cigarette paper base paper basis weight (g/m2).
—Cigarette paper base paper porosity (CU).
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
PO 00000
Frm 00048
Fmt 4701
Sfmt 4702
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
12787
TABLE 5 TO § 1107.19(a)(5)—Continued
Provide target specification with upper and lower range limits for:
Provide test data (include test protocols, quantitative acceptance criteria, data sets, and a summary of the results) for:
—Filter ventilation (%)
—Cigarette paper base paper basis weight (g/m2)
—Cigarette paper base paper porosity (CU)
—Cigarette paper band porosity (CU)
—Cigarette paper band width (mm)
—Cigarette paper band space (mm)
—Filter length (mm)
—Filter denier per filament (DPF)
—Filter total denier (g/9000m)
—Filter density (g/cm3)
—Filter pressure drop (mm H2O)
—Cigarette paper band porosity (CU).
—Filter denier per filament (DPF).
—Filter total denier (g/9000m).
—Filter density (g/cm3).
—Filter pressure drop (mm H2O).
(6) Roll-your-own tobacco. For rollyour-own tobacco, the required design
parameter information to be provided
for each predicate and new tobacco
product is as follows:
amozie on DSK9F9SC42PROD with PROPOSALS2
TABLE 6 TO § 1107.19(a)(6)
Provide target specification with upper and lower range limits for:
Provide test data (include test protocols, quantitative acceptance criteria, data sets, and a summary of the results) for:
—Tobacco filler mass (mg)
—Tobacco size (mm)
—Tobacco moisture (%)
—Tobacco filler mass (mg).
—Tobacco size (mm).
—Tobacco moisture (%).
(b) Comparison of heating sources.
The SE Report must include a
description of the heating source for the
new and predicate tobacco products and
identify any differences, or state that
there is no heating source.
(c) Comparison of product
composition. The SE Report must
include descriptions of the product
composition of the new and predicate
tobacco products and identify any
differences. The SE Report must
include, in a tabular format, a side-byside comparison of the materials and
ingredients for each component or part
of the new and predicate tobacco
products. For each material and
ingredient quantity, the target value and
range of acceptable values, actual
measured value (where applicable), and
range of measured values (where
applicable) reported as mass per
component or part, must be provided.
(1) Materials. For each material in the
products include:
(i) The material name and common
name(s), if applicable;
(ii) The component or part of the
tobacco product where the material is
located;
(iii) The subcomponent or subpart
where the material is located, if
applicable;
(iv) The function of the material;
(v) The quantities (including ranges or
means, acceptance limits) of the
material(s) in each new tobacco product
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
and predicate tobacco product (with any
specification variation, if applicable);
(vi) The specification(s) (including
quality/grades, suppliers) used for the
new tobacco product and predicate
tobacco product (with any specification
variations, if applicable); and
(vii) Any other material properties
necessary to characterize the new and
predicate tobacco products.
(2) Ingredients other than tobacco. For
ingredients other than tobacco in each
material and/or component or part of
the product include:
(i) The International Union of Pure
and Applied Chemistry (IUPAC)
chemical name and common name, if
applicable;
(ii) The Chemical Abstracts Service
(CAS) number(s) or FDA Unique
Ingredient Identifier (UNII);
(iii) The function of the ingredient;
(iv) The quantity with the unit of
measure (including ranges or means,
acceptance limits) of the material(s) in
the new tobacco product and predicate
tobacco product reported as mass per
gram of tobacco for non-portioned
tobacco products and as mass per
portion for portioned tobacco products
(with any specification variation, if
applicable);
(v) The specification(s) (including
purity or grade and supplier);
(vi) For complex purchased
ingredients, each single chemical
substance reported separately; and
PO 00000
Frm 00049
Fmt 4701
Sfmt 4702
(vii) Any other ingredient information
necessary to characterize the new and
predicate tobacco products.
(3) Tobacco ingredients. For tobacco
include:
(i) The type, including grade and
variety;
(ii) The quantity with the unit of
measure (including ranges or means,
acceptance limits) of tobacco in the new
tobacco product and predicate tobacco
product reported as mass per gram of
tobacco for non-portioned tobacco
products and as mass per portion for
portioned tobacco products (with any
specification variation, if applicable);
(iii) The specification of tobacco used
for the new tobacco product and the
predicate tobacco product (with any
specification variation, if applicable);
(iv) A description of any genetic
engineering of the tobacco; and
(v) Any other information necessary
to characterize the new and predicate
tobacco products.
(vi) If the new tobacco product does
not contain tobacco, then include a
statement that the new tobacco product
does not contain tobacco.
(4) Container closure system. A
description of the container closure
system for the new and predicate
tobacco products, including a side-byside quantitative comparison of the
components and materials and
annotated illustrations.
(d) Comparison of other features. The
SE Report must include descriptions of
any other features of the new and
E:\FR\FM\02APP2.SGM
02APP2
amozie on DSK9F9SC42PROD with PROPOSALS2
12788
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
predicate tobacco products, such as
those described in this section, and
identify any differences. If a specific
feature specified in this section is not
applicable to the product design, this
must be stated clearly. If FDA requests
a scientific justification explaining why
a feature is not applicable, the applicant
must provide the justification to FDA.
The comparison of other features must
include information on:
(1) Constituents. HPHCs and other
constituents, as appropriate, to
demonstrate that:
(i) The new tobacco product has the
same characteristics as the predicate
tobacco product, or
(ii) Any differences in characteristics
between the new and predicate product
do not cause the new tobacco product
to raise different questions of public
health, including:
(A) The constituent names in
alphabetical order;
(B) The common name(s);
(C) The Chemical Abstract Services
number(s);
(D) The mean quantity and variance
with unit of measure;
(E) The number of samples and
measurement replicates for each sample;
(F) The analytical methods used and
associated reference(s);
(G) The testing laboratory or
laboratories and documentation
showing that the laboratory or
laboratories is (or are) accredited by a
nationally or internationally recognized
external accreditation organization;
(H) Length of time between dates of
manufacture and date(s) of testing;
(I) Storage conditions of the tobacco
product before it was tested; and
(J) Full test data (including test
protocols, any deviation(s) from the test
protocols, quantitative acceptance (pass/
fail) criteria and complete data sets) for
all testing performed.
(2) Any other features. A description
and comparison of any other features of
the new tobacco product and the
predicate tobacco product.
(e) Stability information. For
smokeless tobacco products and tobacco
products that contain fermented
tobacco, the SE Report must contain
information on the stability of the new
and predicate tobacco products,
including the following information:
(1) A description of how the stability
is indicated on the tobacco product, and
an explanation as to whether the
stability testing is identical for the
predicate and the new tobacco product;
(2) Any known or expected impacts of
the differences between the new and
predicate products on the product
stability. If no impact is known or
expected, state that. For those products
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
that contain fermented tobacco, the SE
Report must provide information on the
fermentation processing steps, including
the composition of the inoculum, with
species name(s) and concentration(s);
pH; temperature; moisture content;
water activity; duration; and added
ingredients;
(3) Detailed stability testing, including
test protocols, quantitative acceptance
criteria, data sets, and a summary of the
results for all stability testing
performed. Stability testing must be
performed at the beginning (zero time),
middle, and end of the expected storage
time for the chemical and microbial
endpoints as follows: Microbial content
data including total aerobic microbial
count and total yeast and mold count
along with identification of detected
microbiological organisms by genus and
species names (if applicable); pH;
moisture content; water activity;
tobacco-specific nitrosamines (total, Nnitrosonornicotine (NNN), 4methylnitrosamino)-1-(3-pydridyl)-1butanone) (NNK)); nitrate and nitrite
levels; preservatives and microbial
metabolic inhibitors (if any); and
method of heat treatment or
pasteurization used to reduce microbial
loads;
(4) Testing information, including the
storage conditions for samples retained
for testing; identification of the test
methods used; a statement that the
testing was performed on a tobacco
product in the same container closure
system in which the tobacco product is
intended to be marketed; and support
for the expiration date (e.g., by showing
that an adequate number of batches was
tested);
(5) Stability testing laboratory or
laboratories used and documentation
showing that the laboratory or
laboratories is (or are) accredited by a
nationally or internationally recognized
external accreditation organization; and
(6) Identification of microbiological
organisms by genus and species names,
where applicable, and culture collection
number either used during the
manufacturing process and/or detected
through stability testing.
(f) Applicant’s basis for substantial
equivalence determination. The
applicant must state that the new
tobacco product has either:
(1) The same characteristics as the
predicate tobacco product and the basis
for this determination, or
(2) Different characteristics than the
predicate tobacco product. Where an
applicant states that its new tobacco
product has different characteristics
than the predicate tobacco product, the
applicant must also include an
explanation as to why a difference in
PO 00000
Frm 00050
Fmt 4701
Sfmt 4702
any of the following characteristics do
not cause the new product to raise
different questions of public health:
Product design (§ 1107.19(a)); heating
source (§ 1107.19(b)); materials and
ingredients (§ 1107.19(c)); and other
features (§ 1107.19(d)). In addition, to
demonstrate that a new tobacco product
with different characteristics is
substantially equivalent, an applicant
must also explain why any differences
in the manufacturing process between
the new tobacco product and the
predicate tobacco product does not raise
different questions of public health
(§ 1107.18(e)). Similarly, for smokeless
tobacco products, an applicant must
explain why any difference in stability
between the new tobacco product and
the predicate tobacco product does not
raise different questions of public health
(§ 1107.19(e)).
(g) Comparison to grandfathered
product. If the applicant is comparing
the new tobacco product to a predicate
tobacco product that FDA has
previously found to be substantially
equivalent, FDA may request that the
applicant include information related to
the original grandfathered tobacco
product for that predicate, even if the
grandfathered tobacco product is back
several predicate tobacco products. FDA
will request this information when
necessary to ensure that any order the
Agency may issue finding the new
tobacco product substantially equivalent
complies with section 910(a)(2)(A)(i)(I)
of the Federal Food, Drug, and Cosmetic
Act. FDA may need to review the first
SE Report that received a finding of
substantial equivalence using the
grandfathered product as a predicate
tobacco product in order to make this
finding.
§ 1107.20
Amendments.
(a) Except as provided in paragraphs
(b) and (c) of this section, the applicant
may submit an amendment to an SE
Report in accordance with subpart C of
this part. If an applicant chose to submit
a health information summary with its
SE Report under § 1107.18(j)(1), the
applicant must submit with the
amendment a redacted copy of the
amendment that excludes research
subject identifiers and trade secret and
confidential commercial information as
defined in 21 CFR 20.61 and 20.63.
(b) An applicant may not amend an
SE Report to change the predicate
tobacco product.
(c) An applicant may not amend an
SE Report after FDA has closed the SE
Report under § 1107.44 or it has been
withdrawn under § 1107.22.
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
(4) A certification that no
modifications have been made to the
new tobacco product since the SE
Report was submitted to FDA.
(d) In general, amendments will be
reviewed in the next review cycle as
described in § 1107.42.
§ 1107.22
Withdrawal by applicant.
(a) An applicant may at any time
make a written request to withdraw an
SE Report for which FDA has not issued
an order. The withdrawal request must
state:
(1) Whether the withdrawal is due to
a health or safety concern related to the
tobacco product;
(2) The submission tracking number;
and
(3) The name of the new tobacco
product that is the subject of the SE
Report.
(b) An SE Report will be considered
withdrawn when FDA issues a notice
stating the SE Report has been
withdrawn.
(c) The SE Report is an agency record,
even if withdrawn. FDA will retain the
withdrawn SE Report under Federal
Agency records schedules. The
availability of the withdrawn SE Report
will be subject to FDA’s public
information regulations in § 20.45 of
this chapter.
amozie on DSK9F9SC42PROD with PROPOSALS2
§ 1107.24
Report.
Change in ownership of an SE
An applicant may transfer ownership
of its SE Report. On or before the time
of transfer, the new and former
applicants are required to submit
information to FDA as follows:
(a) The former applicant must sign
and submit a notice to FDA that states
that all of the former applicant’s rights
and responsibilities relating to the SE
Report have been transferred to the new
applicant. This notice must identify the
name and address of the new applicant
and the SE Report transferred.
(b) The new applicant must sign and
submit a notice to FDA containing the
following:
(1) The new applicant’s commitment
to agreements, promises, and conditions
made by the former applicant and
contained in the SE Report;
(2) The date that the change in
ownership is effective;
(3) Either a statement that the new
applicant has a complete copy of the SE
Report and order (if applicable),
including amendments and records that
are required to be kept under § 1107.58,
or a request for a copy of the SE Report
from FDA’s files by submitting a request
in accordance with 21 CFR part 20. In
accordance with the Freedom of
Information Act, FDA will provide a
copy of the SE Report to the new
applicant under the fee schedule in
FDA’s public information regulations in
§ 20.45 of this chapter; and
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
Subpart D—FDA Review
§ 1107.40 Communications between FDA
and applicants.
(a) General principles. During the
course of reviewing an SE Report, FDA
may communicate with applicants
about relevant matters, including
scientific, medical, and procedural
issues that arise during the review
process. These communications may
take the form of telephone
conversations, letters, or emails, and
will be documented in the SE Report in
accordance with § 10.65 of this chapter.
(b) Meeting. Meetings between FDA
and applicants may be held to discuss
scientific and other issues. Requests for
meetings will be directed to the Office
of Science, and FDA will make every
attempt to grant requests for meetings
that involve important issues.
(c) Acknowledgement of an SE Report.
After receiving an SE Report under
§ 1107.18, FDA will either refuse to
accept the SE Report or issue an
acknowledgement letter.
(d) Notification of deficiencies in a SE
Report submitted under § 1107.18. FDA
will make reasonable efforts to
communicate to applicants the
procedural, administrative, or scientific
deficiencies found in an SE Report and
any additional information and data
needed for the Agency’s review. The
applicant must also provide additional
comparison information under
§ 1107.19 if requested by FDA.
(e) Withdrawal of SE Report. An SE
Report will be considered withdrawn
when FDA issues a notice stating that
the SE Report has been withdrawn.
§ 1107.42
Review cycles.
(a) Initial review cycle. FDA intends to
review the SE Report and either
communicate with the applicant as
described in § 1107.40 or take an action
under § 1107.44 within 90 calendar days
of FDA’s receipt of the SE Report, or
within 90 days of determining that the
predicate was found to be commercially
marketed in the United States as of
February 15, 2007 (if applicable),
whichever is later. This 90-day period is
called the ‘‘initial review cycle.’’
(b) Additional review cycles. If FDA
issues a deficiency notification under
§ 1107.40(d) during the initial review
cycle, FDA will stop reviewing the SE
Report until it receives a response from
the applicant or the timeframe specified
in the notification of deficiencies for
response has elapsed. If the applicant
PO 00000
Frm 00051
Fmt 4701
Sfmt 4702
12789
fails to respond within the time period
provided in the notification of
deficiency, FDA will issue an order
denying marketing authorization under
the criteria set forth in § 1107.48. If the
applicant’s response to the notification
of deficiencies provides the information
FDA requested, but FDA identifies
additional deficiencies, FDA may issue
an additional deficiency notification.
Each response will begin a new 90-day
review cycle.
(c) Inadequate response. If the
applicant’s response to FDA’s
deficiency notification(s) does not
provide the information FDA requested,
or the applicant provides information
but the SE Report is still deficient, FDA
will issue an order denying market
authorization under the criteria set forth
in § 1107.48. At any time before FDA
issues an order, an applicant may make
a written request to withdraw a SE
Report under § 1107.22.
§ 1107.44
FDA action on an SE Report.
After receipt of an SE Report, FDA
will:
(a) Refuse to accept the SE Report if
it does not comply with § 1107.18;
(b) Request additional information as
provided in § 1107.40(d);
(c) Issue a letter administratively
closing the SE Report if it is not possible
to make a determination on an SE
Report;
(d) Issue a letter canceling the SE
Report if FDA finds the SE Report was
created in error;
(e) Issue an order as described in
§ 1107.46 finding the new tobacco
product to be substantially equivalent
and in compliance with the
requirements of the Federal Food, Drug,
and Cosmetic Act; or
(f) Issue an order as described in
§ 1107.48 denying marketing
authorization because the new tobacco
product is:
(1) Not substantially equivalent to a
tobacco product commercially marketed
in the United States on February 15,
2007, or
(2) Not in compliance with the
requirements of the Federal Food, Drug,
and Cosmetic Act.
§ 1107.46 Issuance of an order finding a
new tobacco product substantially
equivalent.
If FDA finds that the information
submitted in the SE Report establishes
that the new tobacco product is
substantially equivalent to a predicate
tobacco product that was commercially
marketed in the United States on
February 15, 2007, and finds that the
new tobacco product is in compliance
with the requirements of the Federal
E:\FR\FM\02APP2.SGM
02APP2
12790
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
Food, Drug, and Cosmetic Act, FDA will
send the applicant an order authorizing
marketing of the product. A marketing
authorization order becomes effective
on the date the order is issued.
§ 1107.48 Issuance of an order denying
marketing authorization.
(a) General. FDA will issue an order
that the new tobacco product cannot be
marketed if FDA finds that:
(1) The information submitted in the
SE Report does not establish that the
new tobacco product is substantially
equivalent to a predicate tobacco
product that was commercially
marketed in the United States on
February 15, 2007; or
(2) The new tobacco product is not in
compliance with the Federal Food,
Drug, and Cosmetic Act.
(b) Basis for order. The order will
describe the basis for denying marketing
authorization.
amozie on DSK9F9SC42PROD with PROPOSALS2
§ 1107.50
Rescission of order.
(a) Grounds for rescinding a
substantially equivalent order. FDA may
rescind a substantial equivalence order
allowing a new tobacco product to be
marketed if FDA determines that:
(1) The tobacco product for which the
order has been issued:
(i) Does not have the same
characteristics as the predicate tobacco
product; or
(ii) Has different characteristics and
there is insufficient information
demonstrating that it is not appropriate
to require a premarket tobacco product
application under section 910(b) of the
Federal Food, Drug, and Cosmetic Act
because the product does not raise
different questions of public health; or
(2) The SE Report (including any
submitted amendments) contains an
untrue statement of material fact; or
(3) Concerning a SE Report that
compared the new tobacco product to a
tobacco product that FDA previously
found substantially equivalent:
(i) The predicate tobacco product
relied on in the SE Report has been
found ineligible because its substantial
equivalence SE Report (including any
amendments) contains an untrue
statement of material fact; or
(ii) A predicate tobacco product on
which any of the previous substantial
equivalence determinations was based,
going back to the original grandfathered
product, has been found ineligible
because its substantial equivalence SE
Report (including any amendments)
contains an untrue statement of material
fact; or
(4) FDA or the applicant has removed
from the market, due to a health or
safety concern related to the tobacco
product:
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
(i) The predicate tobacco product on
which the substantial equivalence
determination is based; or
(ii) A predicate tobacco product on
which any of the previous substantial
equivalence determinations is based,
going back to the original grandfathered
product, if the substantial equivalence
SE Report compared the new tobacco
product to a tobacco product that FDA
previously found substantially
equivalent.
(b) Opportunity for a hearing. In
general, FDA will rescind an order only
after notice and opportunity for a
hearing under part 16 of this chapter.
However, FDA may rescind a
substantially equivalent order prior to
notice and opportunity for a hearing
under part 16 of this chapter if it finds
that there is a reasonable probability
that continued marketing of the tobacco
product presents a serious risk to public
health. In that case, FDA will provide
the manufacturer an opportunity for a
hearing as soon as possible after the
rescission.
Subpart E—Miscellaneous
§ 1107.58
Record retention.
Each applicant that receives an order
under § 1107.46 authorizing the
marketing of a new tobacco product
must maintain all records required by
this subpart and that support the SE
Report for a substantial equivalence
order. These records must be legible, in
the English language, and available for
inspection and copying by officers or
employees duly designated by the
Secretary. All records must be retained
for a period of not less than 4 years from
the date of the order even if such
product is discontinued.
§ 1107.60
Confidentiality.
(a) General. FDA will determine the
public availability of any part of an SE
Report and other content related to such
an SE Report under this section and part
20 of this chapter.
(b) Confidentiality of data and
information prior to an order. Prior to
issuing an order under this section:
(1) FDA will not publicly disclose the
existence of an SE Report unless:
(i) The tobacco product has been
introduced or delivered for introduction
into interstate commerce for commercial
distribution; or
(ii) The applicant has publicly
disclosed or acknowledged the
existence of the SE Report (as such
disclosure is defined in § 20.81 of this
chapter), or has authorized FDA in
writing to publicly disclose or
acknowledge, that the applicant has
submitted the SE Report to FDA;
PO 00000
Frm 00052
Fmt 4701
Sfmt 4702
(2) FDA will not disclose the
existence of or contents of an FDA
communication with an applicant
regarding its SE Report except to the
extent that the applicant has publicly
disclosed or acknowledged, or
authorized FDA in writing to publicly
disclose or acknowledge, the existence
of or contents of that particular FDA
communication.
(3) FDA will not disclose information
contained in an SE Report unless the
applicant has publicly disclosed or
acknowledged, or authorized FDA in
writing to publicly disclose or
acknowledge, that particular
information. If the applicant has
publicly disclosed or acknowledged, or
authorized FDA in writing to publicly
disclose or acknowledge, that particular
information contained in an SE Report,
FDA may disclose that particular
information.
(c) Disclosure of data and information
after an order under § 1107.46. After
FDA issues an order under § 1107.46
finding a new tobacco product
substantially equivalent, it will make
the following information related to the
SE Report and order available for public
disclosure upon request or at FDA’s
own initiative, including information
from amendments to the SE Report and
FDA’s reviews of the SE Report:
(1) All data previously disclosed to
the public, as such disclosure is defined
in § 20.81 of this chapter;
(2) Any protocol for a test or study,
except to the extent it is shown to fall
within the exemption established for
trade secrets and confidential
commercial information in § 20.61 of
this chapter;
(3) Information and data submitted to
demonstrate that the new tobacco
product does not raise different
questions of public health, except to the
extent it is shown to fall within the
exemptions established in § 20.61 of this
chapter for trade secrets and
confidential commercial information, or
in § 20.63 of this chapter for personal
privacy;
(4) Correspondence between FDA and
the applicant, including any requests
FDA made for additional information
and responses to such requests, and all
written summaries of oral discussions
between FDA and the applicant, except
to the extent it is shown to fall within
the exemptions in § 20.61 of this chapter
for trade secrets and confidential
commercial information, or in § 20.63 of
this chapter for personal privacy; and
(5) In accordance with § 25.51 of the
chapter (21 CFR 25.51), the
environmental assessment or, if
applicable, the claim of categorical
exclusion from the requirement to
E:\FR\FM\02APP2.SGM
02APP2
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 / Proposed Rules
amozie on DSK9F9SC42PROD with PROPOSALS2
submit an environmental assessment
under part 25 of this chapter.
(d) Disclosure of data and information
after an order under § 1107.48. After
FDA issues an order under § 1107.48
(denying marketing authorization), FDA
may make certain information related to
the SE Report and the order available for
public disclosure upon request or at
FDA’s own initiative except to the
extent the information is otherwise
exempt from disclosure under part 20 of
this chapter. Information FDA may
disclose includes the tobacco product
category (e.g., cigarette), tobacco
product subcategory (e.g., filtered),
package size, and the basis for the order
denying marketing authorization.
(e) Health information summary or
statement. Health information required
by section 910(a)(4) of the Federal Food,
Drug, and Cosmetic Act, if submitted as
part of the SE Report (which includes
any amendments), will be disclosed
within 30 calendar days of issuing a
substantially equivalent order. If the
applicant has instead submitted a
910(a)(4) statement as provided in
§ 1107.18(j)(2), FDA will make publicly
available on FDA’s website the
VerDate Sep<11>2014
20:34 Apr 01, 2019
Jkt 247001
responsible official to whom a request
for health information may be made.
§ 1107.62
Electronic submission.
(a) Electronic format requirement.
Applicants submitting any documents
to the Agency under this part must
provide all required information to FDA
using the Agency’s electronic system,
except as provided in paragraph (b) of
this section. The SE Report and all
supporting information must be in an
electronic format that FDA can process,
read, review, and archive.
(b) Waivers from electronic format
requirement. An applicant may submit
a written request that is legible and
written in English, to the Center for
Tobacco Products asking that FDA
waive the requirement for electronic
format and content. Waivers will be
granted if use of electronic means is not
reasonable for the person requesting the
waiver. To request a waiver, applicants
can send the written request to the
address included on our website
(www.fda.gov/tobaccoproducts). The
request must include the following
information:
(1) The name and address of the
applicant, list of individuals authorized
PO 00000
Frm 00053
Fmt 4701
Sfmt 9990
12791
for the applicant to serve as the contact
person, and contact information. If the
applicant has submitted a SE Report
previously, the regulatory
correspondence must also include any
identifying information for the previous
submission; and
(2) A statement that creation and/or
submission of information in electronic
format is not reasonable for the person
requesting the waiver, and an
explanation of why creation and/or
submission in electronic format is not
reasonable. This statement must be
signed by the applicant or by an
employee of the applicant who is
authorized to make the declaration on
behalf of the applicant.
(c) Paper submission. An applicant
who has obtained a waiver from filing
electronically must send a written SE
Report through the Document Control
Center to the address provided in the
FDA documentation granting the
waiver.
Dated: March 21, 2019.
Scott Gottlieb,
Commissioner of Food and Drugs.
[FR Doc. 2019–05787 Filed 3–28–19; 11:15 am]
BILLING CODE 4164–01–P
E:\FR\FM\02APP2.SGM
02APP2
Agencies
[Federal Register Volume 84, Number 63 (Tuesday, April 2, 2019)]
[Proposed Rules]
[Pages 12740-12791]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-05787]
[[Page 12739]]
Vol. 84
Tuesday,
No. 63
April 2, 2019
Part III
Department of Health and Human Services
-----------------------------------------------------------------------
Food and Drug Administration
-----------------------------------------------------------------------
21 CFR Parts 16 and 1107
Content and Format of Substantial Equivalence Reports; Food and Drug
Administration Actions on Substantial Equivalence Reports; Proposed
Rule
Federal Register / Vol. 84, No. 63 / Tuesday, April 2, 2019 /
Proposed Rules
[[Page 12740]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 16 and 1107
[Docket No. FDA-2016-N-3818]
RIN 0910-AH89
Content and Format of Substantial Equivalence Reports; Food and
Drug Administration Actions on Substantial Equivalence Reports
AGENCY: Food and Drug Administration, HHS.
ACTION: Proposed rule.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is issuing a proposed
rule to establish requirements for the content and format of reports
intended to establish the substantial equivalence of a tobacco product
(SE Reports). The proposed rule would establish the information an SE
Report must include so that FDA may make a substantial equivalence
determination. In addition, the proposed rule would establish the
general procedures FDA intends to follow when evaluating SE Reports,
including procedures that would address communications with the
applicant and the confidentiality of data in an SE Report. The proposed
rule is intended to provide more clarity to applicants and support
efficient and predictable reviews of SE Reports.
DATES: Submit either electronic or written comments on the proposed
rule by June 17, 2019. Submit comments on information collection issues
under the Paperwork Reduction Act of 1995 by May 2, 2019.
ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. Electronic comments
must be submitted on or before June 17, 2019. The https://www.regulations.gov electronic filing system will accept comments until
midnight Eastern Time at the end of June 17, 2019. Comments received by
mail/hand delivery/courier (for written/paper submissions) will be
considered timely if they are postmarked or the delivery service
acceptance receipt is on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2016-N-3818 for ``Content and Format of Substantial Equivalence
Reports; Food and Drug Administration Actions on Substantial
Equivalence Reports.'' Received comments will be placed in the docket
and, except for those submitted as ``Confidential Submissions,''
publicly viewable at https://www.regulations.gov or at the Dockets
Management Staff between 9 a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852.
Submit comments on information collection issues to the Office of
Management and Budget in the following ways: Fax to the Office of
Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax:
202-395-7285, or email to [email protected]. All comments
should be identified with the title, ``Substantial Equivalence Reports
for Tobacco Products.''
FOR FURTHER INFORMATION CONTACT: Annette Marthaler or Daniel Gittleson,
Office of Regulations, Center for Tobacco Products, Food and Drug
Administration, Document Control Center, Bldg. 71, Rm. G335, 10903 New
Hampshire Ave., Silver Spring, MD 20993-0002, 877-287-1373,
[email protected].
SUPPLEMENTARY INFORMATION:
Table of Contents
Executive Summary
I. Background
II. Legal Authority
III. Description of Proposed Regulations
A. General (Proposed Subpart B)
B. Substantial Equivalence Reports (Proposed Subpart C)
C. FDA Review (Proposed Subpart D)
D. Miscellaneous (Proposed Subpart E)
IV. Other Issues for Consideration
V. Paperwork Reduction Act of 1995
VI. Executive Order 13132: Federalism
VII. Consultation and Coordination with Indian Tribal Governments
VIII. Analysis of Environmental Impact
[[Page 12741]]
IX. Economic Analysis of Impacts
X. References
XI. Effective Datep
Executive Summary
Purpose of the Regulatory Action
This proposed rule would establish requirements related to the
content and format of SE Reports, including the information that SE
Reports must contain. FDA is basing this proposed rule on the
experience the Agency has in reviewing thousands of SE Reports since
2010. The SE Reports that FDA has seen to date range widely in the
level of detail included. For example, some have very little
information on the comparison of the new tobacco product with a
predicate tobacco product while other SE Reports are much more detailed
in describing how the new tobacco product compares to the identified
predicate tobacco product and provide supporting information. This wide
variation in the depth of content may be due, at least in part, to
confusion about what information FDA needs from applicants to make a
substantial equivalence finding. FDA's experience reviewing this wide
range of SE Reports has been helpful in developing this proposed rule,
which describes in detail the information that an applicant would be
required to include in an SE Report.
The proposed rule also addresses issues such as communications with
the applicant, the retention of records that support the SE Report,
confidentiality of SE Report information, and electronic submission of
the SE Report and amendments. The proposed rule is intended to provide
both applicants and FDA with more certainty about the content and
format of SE Reports and FDA's review of the SE Reports. The proposed
rule is also intended to provide more clarity to applicants and help
ensure that the SE pathway for premarket review of a new tobacco
product is used when appropriate, e.g., when there is a valid predicate
tobacco product to which the new product can be scientifically compared
and support efficient and predictable reviews.
Legal Authority
This proposed rule is being issued based upon FDA's authority to
require premarket review of new tobacco products under sections 905(j)
and 910(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21
U.S.C. 387e(j) and 387j(a)), FDA's authority to require reports under
section 909(a) of the FD&C Act (21 U.S.C. 387i(a)), FDA's authorities
related to adulterated and misbranded tobacco products under sections
902 and 903 (21 U.S.C. 387b and 387c), as well as FDA's rulemaking and
inspection authorities under sections 701(a) and 704 of the FD&C Act
(21 U.S.C. 371(a) and 374).
Summary of the Major Provisions
This proposed rule would establish content and format requirements
for SE Reports. Under the proposed rule, an SE Report must provide
information comparing the new tobacco product to a predicate tobacco
product, including information that would enable FDA to uniquely
identify the new tobacco product and the predicate tobacco product. The
proposed requirements would help ensure that an SE Report provides
information necessary for FDA to determine whether the new tobacco
product is substantially equivalent to a tobacco product commercially
marketed in the United States as of February 15, 2007 (as required by
section 910(a)(2)(A) of the FD&C Act).
In addition, the proposed rule would explain how an applicant can
amend or withdraw an SE Report, and explain how an applicant may
transfer ownership of an SE Report to a new applicant. The proposed
rule also would address FDA communications with applicants on SE
Reports, including when FDA would issue deficiency notifications;
explain FDA review cycles; and identify actions that FDA may take on SE
Reports. The proposed rule would address when FDA may rescind an SE
order and explain how long an applicant must maintain records related
to the SE Report. The proposed rule also would explain FDA's disclosure
provisions and provide for electronic submission of SE Reports, unless
the applicant requests a waiver. FDA is basing the proposed rule on our
experience reviewing SE Reports, and the proposed rule is intended to
provide both applicants and FDA with more certainty related to the
information needed to demonstrate substantial equivalence and FDA's
review processes with the goal of an efficient and predictable review
process for SE Reports.
Costs and Benefits
This proposed rule would impose compliance costs on affected
entities to read and understand the rule, establish or revise internal
procedures, and fill out a form for SE Reports. We estimate that the
present value of industry compliance costs ranges from $0.60 million to
$2.64 million, with a primary estimate of $1.61 million at a 3 percent
discount rate, and from $0.56 million to $2.32 million, with a primary
estimate of $1.43 million at a 7 percent discount rate over 10 years.
Annualized industry compliance costs over 10 years range from $0.07
million to $0.31 million, with a primary estimate of $0.19 million at a
3 percent discount rate and from $0.08 million to $0.33 million, with a
primary estimate of $0.20 at a 7 percent discount rate.
The benefits of this proposed rule are potential time-savings to
industry and cost-savings to government. This proposed rule clarifies
when applicants may certify that certain characteristics are identical
in the new tobacco product and the predicate tobacco product.
Certifying may save applicants time in preparing their SE Reports. In
this proposed rule, we intend to shorten review times for SE Reports.
In addition, based on our experience with prior SE Reports, we believe
this proposed rule would lead to better SE Reports, saving us time in
review and requiring fewer staff to review SE Reports, which would
result in cost-savings. We estimate that the present value of
government cost-savings ranges from $15 million to $198 million, with a
primary estimate of $62 million at a 3 percent discount rate, and from
$12 million to $163 million, with a primary estimate of $51 million at
a 7 percent discount rate over 10 years. Annualized government cost-
savings over 10 years range from $1.7 million to $23.2 million, with a
primary estimate of $7.2 million at both 3 and 7 percent discount
rates.
The qualitative benefits of this proposed rule include additional
clarity to industry about the requirements for the content and format
of SE Reports. The proposed rule would also establish the general
procedures we intend to follow in reviewing and communicating with
applicants. In addition, this proposed rule would make the SE pathway
more predictable.
[[Page 12742]]
Table 1--Summary of Annualized Costs and Benefits of the Proposed Rule
[$2016 over 10 years]
--------------------------------------------------------------------------------------------------------------------------------------------------------
Low (3%) Medium (3%) High (3%) Low (7%) Medium (7%) High (7%)
--------------------------------------------------------------------------------------------------------------------------------------------------------
Costs................................................... $0.07 $0.19 $0.31 $0.08 $0.20 $0.33
Benefits................................................ 1.7 7.2 23.2 1.7 7.2 23.2
Net Benefits (rounded).................................. 1.7 7.1 22.9 1.7 7.0 22.9
--------------------------------------------------------------------------------------------------------------------------------------------------------
I. Background
The Family Smoking Prevention and Tobacco Control Act (Tobacco
Control Act) (Pub. L. 111-31) was enacted June 22, 2009, and provided
FDA the authority to regulate tobacco products under the FD&C Act. The
FD&C Act, as amended by the Tobacco Control Act, requires that before a
new tobacco product may be introduced into interstate commerce for
commercial distribution in the United States, the new tobacco product
must undergo premarket review by FDA. Section 910(a)(1) of the FD&C Act
defines a ``new tobacco product'' as: (1) Any tobacco product
(including those products in test markets) that was not commercially
marketed in the United States as of February 15, 2007, or (2) any
modification (including a change in design, any component, any part, or
any constituent, including a smoke constituent, or in the content,
delivery or form of nicotine, or any other additive or ingredient) of a
tobacco product where the modified product was commercially marketed in
the United States after February 15, 2007.
The FD&C Act establishes three premarket review pathways for a new
tobacco product:
Submission of a premarket tobacco application under
section 910(b);
Submission of a report intended to demonstrate that the
new tobacco product is substantially equivalent to a predicate tobacco
product under section 905(j)(1)(A) (``SE Report''); and
Submission of a request for an exemption under section
905(j)(3) (implemented at Sec. 1107.1 (21 CFR 1107.1)).
Under section 910(a)(2)(B) of the FD&C Act, a manufacturer of a
tobacco product that was first introduced or delivered for introduction
into interstate commerce for commercial distribution after February 15,
2007, and prior to March 22, 2011, that submitted an SE Report \1\
prior to March 23, 2011, may continue to market the tobacco product
unless FDA issues an order that the tobacco product is not
substantially equivalent. For any new tobacco product introduced into
commercial distribution on or after March 22, 2011, or for which a
substantial equivalence report was not submitted by March 23, 2011, a
manufacturer must first submit a premarket application under section
910 for the new tobacco product to FDA, and FDA must issue an order
authorizing the commercial distribution of the new tobacco product or
find the product exempt from the requirements of substantial
equivalence under section 910(a)(2)(A) of the FD&C Act, before the
product may be introduced into commercial distribution. If a new
tobacco product is marketed without an order or a finding of exemption
from substantial equivalence, it is adulterated under section 902 of
the FD&C Act and misbranded under section 903 of the FD&C Act and
subject to enforcement action.
---------------------------------------------------------------------------
\1\ In this proposed rule, FDA refers to ``SE applications'' as
``SE Reports,'' but the terms both refer to a premarket submission
under section 905(j)(1)(A) of the FD&C Act.
---------------------------------------------------------------------------
Since 2010, FDA has received more than 5,000 premarket
applications. Almost all of the premarket applications have been SE
Reports. To assist manufacturers in preparing SE Reports, FDA has
issued guidance documents; \2\ conducted Webinars; met with
manufacturers; posted technical project lead reviews (which describe
the administrative, compliance, and substantive scientific reviews
completed on a specific SE Report), general information about not
substantially equivalent (NSE) determinations, and orders (FDA posts
the NSE orders for provisional tobacco products,\3\ and SE orders for
all tobacco products); and issued letters outlining deficiencies in
individual tobacco product SE Reports. Manufacturers are now more
informed about what an SE Report should contain, and FDA is more
informed about the range of tobacco products and changes made to these
products and the data needed to demonstrate substantial equivalence.
The proposed rule is based on this experience and would establish
requirements related to the substantial equivalence premarket pathway
and provide both manufacturers and FDA with more certainty related to
the information needed to demonstrate substantial equivalence and FDA's
review processes.
---------------------------------------------------------------------------
\2\ The guidance documents include: ``Section 905(j) Reports:
Demonstrating Substantial Equivalence for Tobacco Products''
(January 2011); ``Establishing That a Tobacco Product Was
Commercially Marketed in the United States as of February 15, 2007''
(September 2014); ``Demonstrating the Substantial Equivalence of a
New Tobacco Product: Responses to Frequently Asked Questions''
(December 2016); and ``Meetings with Industry and Investigators on
the Research and Development of Tobacco Products'' (July 2016).
These guidance documents may be accessed at https://www.fda.gov/TobaccoProducts/Labeling/RulesRegulationsGuidance/default.htm.
\3\ ``Provisional'' tobacco products refer to those tobacco
products that were first introduced or delivered for introduction
into interstate commerce for commercial distribution in the United
States after February 15, 2007, and prior to March 22, 2011, and for
which a 905(j) (Substantial Equivalence) Report was submitted no
later than March 22, 2011.
---------------------------------------------------------------------------
II. Legal Authority
As described in the following paragraphs, FDA is proposing this
rule to prescribe the content, form, and manner of reports intended to
demonstrate the substantial equivalence of a new tobacco product to a
predicate tobacco product, as well as to establish other requirements
related to SE Reports including requirements for keeping records,
making reports, and providing information essential to FDA's
implementation of the FD&C Act. In accordance with section 5 of the
Tobacco Control Act, FDA intends that the requirements that would be
established by this proposed rule be severable and that the
invalidation of any provision of this proposed rule would not affect
the validity of any other part of this rule.
Section 910(a)(2) of the FD&C Act requires a new tobacco product to
be the subject of a premarket tobacco application (PMTA) order unless
FDA has issued an SE order authorizing its commercial distribution or
the tobacco product is exempt from substantial equivalence. To satisfy
the requirement of premarket review, a manufacturer may submit a report
intended to demonstrate the substantial equivalence of a new tobacco
product to a predicate tobacco product under section 905(j) of the FD&C
Act. Section 905(j) provides that FDA may prescribe the form and
[[Page 12743]]
manner of the substantial equivalence report, and section 910(a)(4)
requires that as part of the 905(j) report, the manufacturer provide an
adequate summary of any health information related to the new tobacco
product or state that such information will be made available upon
request.
Based on the information provided by the applicant, section
910(a)(3)(A) of the FD&C Act authorizes FDA to issue an order finding
substantial equivalence when FDA finds that the new tobacco product is
in compliance with the requirements of the FD&C Act and either: (1) Has
the same characteristics as the predicate tobacco product or (2) has
different characteristics and the information submitted contains
information, including clinical data if deemed necessary by FDA, that
demonstrates that it is not appropriate to regulate the product under
(the premarket tobacco application or ``PMTA'' provisions) because the
product does not raise different questions of public health.
Section 909(a) of the FD&C Act authorizes FDA to issue regulations
requiring tobacco product manufacturers or importers to maintain such
records, make such reports, and provide such information as may be
reasonably required to assure that their tobacco products are not
adulterated or misbranded and to otherwise protect public health.
Under section 902(6)(A) of the FD&C Act, a tobacco product is
adulterated if it is required to have premarket review and does not
have an order in effect under section 910(c)(1)(A)(i) of the FD&C Act.
Under section 903(a)(6) of the FD&C Act, a tobacco product is
misbranded if a notice or other information respecting it was not
provided as required by section 905(j) of the FD&C Act. In addition, a
tobacco product is misbranded if there is a failure or refusal to
furnish any material or information required under section 909 (section
903(a)(10)(B) of the FD&C Act).
Section 701(a) of the FD&C Act gives FDA general rulemaking
authority to issue regulations for the efficient enforcement of the
FD&C Act, and section 704 of the FD&C Act provides FDA with general
inspection authority.
III. Description of Proposed Regulations
The proposed rule would add subparts B through E to current part
1107 of Title 21. The requirements set out in this proposed rule would
not apply to provisional SE Reports or to any SE Report submitted
before the effective date of any final rule associated with this
proposed rulemaking. FDA has published a final rule extending the
Agency's ``tobacco product'' authorities in the FD&C Act to all
categories of products that meet the statutory definition of ``tobacco
product'' in the FD&C Act, except accessories of such newly deemed
tobacco products (``Deeming Tobacco Products To Be Subject to the
Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking
Prevention and Tobacco Control Act; Restrictions on the Sale and
Distribution of Tobacco Products and Required Warning Statements for
Tobacco Products'' (81 FR 28974, May 10, 2016) (the Deeming final
rule)). This proposed rule would apply to SE Reports for all tobacco
products submitted after the final rule is effective, including the
newly deemed tobacco products, that FDA regulates under Chapter IX of
the FD&C Act. Proposed subparts D and E set out FDA's review processes
and would be applicable to FDA's review of SE Reports after the
effective date of any final rule. The proposed rule also would amend
Sec. 16.1 (21 CFR 16.1) to add a reference to proposed Sec. 1107.50
(this proposed section would address rescission of an SE order).
A. General (Proposed Subpart B)
1. Scope (Proposed Sec. 1107.10)
According to proposed Sec. 1107.10, subparts B through E would
establish the procedures and requirements for the submission of an SE
Report under sections 905 and 910 of the FD&C Act, the basic criteria
for establishing substantial equivalence, and the general procedures
FDA intends to follow when evaluating SE Reports.
2. Definitions (Proposed Sec. 1107.12)
Proposed Sec. 1107.12 sets forth the meaning of terms as they
apply to proposed subparts B through E of part 1107. Proposed Sec.
1107.12 includes the following definitions from the FD&C Act:
Additive. As defined in section 900(1) of the FD&C Act (21
U.S.C. 387), ``additive'' means any substance the intended use of which
results or may reasonably be expected to result, directly or
indirectly, in its becoming a component or otherwise affecting the
characteristic of any tobacco product (including any substances
intended for use as a flavoring or coloring or in producing,
manufacturing, packing, processing, preparing, treating, packaging,
transporting, or holding), except that such term does not include
tobacco or a pesticide chemical residue in or on raw tobacco or a
pesticide chemical.
An additive can be a type of ingredient in a tobacco product; an
example is methyl salicylate in smokeless tobacco, which can serve as
an absorption enhancer and affect the characteristics of the tobacco
product by changing the rate of absorption into the body. Tobacco is
not an additive.
Brand. As defined in section 900(2) of the FD&C Act,
``brand'' means a variety of tobacco product distinguished by the
tobacco used, tar content, nicotine content, flavoring used, size,
filtration, packaging, logo, registered trademark, brand name,
identifiable pattern of colors, or any combination of such attributes.
Characteristic. As defined in section 910(a)(3)(B) of the
FD&C Act, ``characteristic'' means the materials, ingredients, design,
composition, heating source, or other features of a tobacco product.
All of the terms used in the definition of characteristic (materials,
ingredients, design, etc.) are defined in proposed Sec. 1107.12.
Distributor. As defined in section 900(7) of the FD&C Act,
``distributor'' means any person who furthers the distribution of a
tobacco product, whether domestic or imported, at any point from the
original place of manufacture to the person who sells or distributes
the product to individuals for personal consumption. Common carriers
are not considered distributors for the purposes of this part.
New tobacco product. As defined in section 910(a)(1) of
the FD&C Act, ``new tobacco product'' means: (1) Any tobacco product
(including those products in test markets) that was not commercially
marketed in the United States as of February 15, 2007, or (2) any
modification (including a change in design, any component, any part, or
any constituent, including a smoke constituent, or in the content,
delivery or form of nicotine, or any other additive or ingredient) of a
tobacco product where the modified product was commercially marketed in
the United States after February 15, 2007.
Under the FD&C Act, and as reflected in the proposed definition,
new tobacco products include those that are new because they have been
rendered new through any modification (including a change in design,
any component, any part, or any constituent, including a smoke
constituent, or in the content, delivery or form of nicotine, or any
other additive or ingredient) of a tobacco product where the modified
product was commercially marketed in the United States after February
15, 2007 (21 U.S.C. 387j(a)(1)(B)). For example, modifications to
cigarette paper, container closure systems (e.g.,
[[Page 12744]]
change from glass to plastic e-liquid vials or from plastic to tin
container closures), product quantity, specifications that change
characteristics (e.g., a modification to a different tobacco cut size)
would render a tobacco product new.
Manufacturers sometimes co-package tobacco products. Co-packaging
two or more legally marketed tobacco products, where there are no
changes, including no change to the container closure system(s), does
not result in a new tobacco product. Examples include a carton of
cigarette packs and a variety pack of three smokeless tins shrink-
wrapped together where the cigarette packs and smokeless tins,
respectively, could be legally marketed separately. However, if a
manufacturer wishes to co-package two or more tobacco products
(including their respective container closure systems), premarket
review is required for any new tobacco product that the manufacturer
intends to include in the co-package. An example includes shrink-
wrapping grandfathered tobacco filler (in its unmodified container
closure system) with new rolling papers; here premarket authorization
would be required for the rolling papers. In addition, co-packaging two
or more tobacco products within the same container closure system
results in a new tobacco product, unless such co-packaged product is
grandfathered. Examples include an RYO kit where rolling papers are
placed inside the tin of tobacco filler and shrink-wrapping together
two soft-packs of cigarettes, neither of which had been individually
shrink-wrapped prior to being co-packaged. FDA invites comment on
approaches to its review of these types of SE Reports, including, where
relevant, how co-packaging products impacts consumer use and behavior.
In addition, for purposes of determining whether a tobacco product
is new under section 910 of the FD&C Act, and therefore requires
premarket authorization prior to marketing, a ``tobacco product'' can
be considered to encompass the whole product (e.g., a pack of
cigarettes or a tin of loose tobacco), and is not limited to a single
unit or portion of the whole product (e.g., a single cigarette or a
single snus pouch). See Philip Morris USA Inc. v. U.S. Food & Drug
Admin., 202 F. Supp. 3d 31, 55-57 (D.D.C. 2016). Consequently, a change
in product quantity (e.g., decreasing the weight of a smokeless package
from 24 grams to 15 grams) results in a new tobacco product subject to
premarket review since such a modification ``necessarily entails a
change in the amount of the constituent ingredients and additives
within the tobacco product, including nicotine'' (id. at 56).
FDA also considers a tobacco product marketed exclusively in test
markets on February 15, 2007, to be a new tobacco product that is
subject to premarket review by FDA. In addition, such test marketed
products cannot serve as valid predicate products in an SE Report. A
tobacco product that the applicant intends to test market after
February 15, 2007, is also a new tobacco product subject to premarket
review under section 910(a) of the FD&C Act because it was not
commercially marketed in the United States as of February 15, 2007.
Because the terms ``test marketing'' and ``commercially marketed''
are not interchangeable, FDA is considering whether it would be useful
to applicants for the rule to further expand on or define the terms
``test marketing'' and ``commercially marketed.'' Specifically, FDA is
considering whether to add the following definition of test marketing:
``test marketing'' means distributing or offering for sale (which may
be shown by advertisements, etc.) a tobacco product in the United
States for the purpose of determining consumer response or other
consumer reaction to the tobacco product, with or without the user
knowing it is a test product, in which any of the following criteria
apply:
Offered in a limited number of regions;
Offered for a limited time; or
Offered to a chosen set of the population or specific
demographic group.
FDA is considering whether to define ``commercially marketed'' as
offering a tobacco product for sale to consumers in all or in parts of
the United States. Factors FDA may consider include advertising or
other means used to communicate that the tobacco product was available
for purchase, including dated advertisements, dated catalog pages,
dated promotional material, dated trade publications, dated bills of
lading, dated freight bills, dated waybills, dated invoices, dated
purchase orders, dated manufacturing documents, inventory lists, or any
other document that demonstrates that the product was commercially
marketed (other than exclusively in test markets) in the United States
as of February 15, 2007. FDA invites comment on what evidence would be
sufficient to demonstrate that a product was commercially marketed
(other than in test markets) as of February 15, 2007.
FDA is inviting comments on: (1) Whether the rule should further
expand on the interpretation or include definitions of these terms, (2)
the substance of the definitions, if included, and (3) whether or not
the approach described is adequate to protect the public health.
Package or packaging. As defined in section 900(13) of the
FD&C Act, ``package'' or ``packaging'' means a pack, box, carton, or
container of any kind or, if no other container, any wrapping
(including cellophane) in which a tobacco product is offered for sale,
sold, or otherwise distributed to consumers. A subset of package is the
container closure system (also defined in this proposed rule). For
example, the carton holding multiple soft packs of cigarettes is
considered the package, and each soft pack with surrounding cellophane
is considered the container closure system. Packaging that constitutes
the container closure system is intended or reasonably expected to
affect or alter the performance, composition, constituents, or
characteristics of the tobacco product (e.g., leaching substances that
are then incorporated into a tobacco product), but packaging that is
not the container closure system is not intended or reasonably expected
to affect or alter the performance, composition, constituents, or
characteristics of the tobacco product.
Substantial equivalence or substantially equivalent. As
defined in section 910(a)(3)(A) of the FD&C Act, the term ``substantial
equivalence'' or ``substantially equivalent'' means, with respect to
the tobacco product being compared to the predicate tobacco product,
that FDA, by order, has found that the tobacco product:
[cir] Has the same characteristics as the predicate tobacco product
or
[cir] Has different characteristics and the information submitted
contains information, including clinical data if deemed necessary by
FDA that demonstrates that it is not appropriate to require premarket
review under section 910(a), (b) and (c) of the FD&C Act because the
product does not raise different questions of public health.
FDA notes that this proposed rule does not include a proposed
interpretation of ``same characteristics'' and ``different
characteristics'' under section 910(a)(3)(A) of the FD&C Act.\4\
However, FDA recognizes that stakeholders have requested additional
clarity on these terms. FDA continues to consider the appropriate
implementation of these terms, as well as public feedback the Agency
has received on the terms during workshops
[[Page 12745]]
and in response to other Federal Register notices (e.g., most recently,
in response to a notice related to the Paperwork Reduction Act, 83 FR
45251, September 6, 2018). For example, FDA is considering whether the
``same characteristics'' prong might be appropriate for new tobacco
products that are so similar to the predicate product that FDA would
not need scientific information to determine whether the new product
raises different questions of public health. Examples of changes
between the new and predicate products that might be appropriate to
proceed through ``same characteristics,'' either individually or in
combination, include, non-exhaustively: (1) A change in product
quantity between the new and predicate tobacco products; (2) a change
in container closure system for non-moist tobacco products; (3)
decreases in the total amount of tobacco in the new tobacco product
without any corresponding changes in other ingredients or
characteristics of the new tobacco product; and (4) changes in the non-
combusted portion of a cigarette, for example, a change in tipping
paper color from plain to cork, or a change in adhesive, or the removal
of a dye or ink.
---------------------------------------------------------------------------
\4\ FDA notes that products with identical characteristics are
not new products, and thus are not required to undergo premarket
review.
---------------------------------------------------------------------------
Under this approach, a new product would have ``different
characteristics'' if a product were dissimilar enough from the
predicate product that FDA could not determine without scientific
information whether the new product raised different questions of
public health. Examples of changes between the new and predicate
products that might be appropriate to proceed through ``different
characteristics,'' either individually or in the aggregate, include,
non-exhaustively:
A change in filter or ventilation of a combusted tobacco
product, because such a change has the potential to affect the public
health analysis required to assess substantial equivalence, such that
FDA would need scientific information to determine whether the new
product raises different questions of public health. For example, in
some circumstances, a change in filter could result in an increase in
ventilation and a change in harmful or potentially harmful constituent
(HPHC) exposure levels to the user, with effects on the public health
impact of the product. It is possible that in some other circumstances,
a change in filter would not have results that would affect the public
health impact of the product.
A change in container closure system for a moist smokeless
tobacco product, because FDA would need scientific information to
determine, for example, whether or not such differences could result in
a change in tobacco product stability that would increase HPHC levels
and exposures to the user.
A change in characterizing flavor in the new product
because FDA would need scientific information to determine, for
example, whether or not such differences could affect use behaviors.
FDA notes that these examples are illustrative only and are not
intended to convey that any differences specific to an individual case
would or would not be appropriate to proceed through the ``different
characteristics'' approach or result in a determination of SE.
When a new product has different characteristics, FDA would
evaluate whether the difference(s) in characteristics, individually and
in the aggregate, do not cause the new product to raise different
questions of public health. In determining if a new product raises
different questions of public health, FDA may consider, among other
things, whether one or more of the following is the case, as compared
to the predicate product, (1) the new product has the potential to
increase HPHC yields, and, if so, the degree of such an increase; (2)
the new product has the potential to increase toxicity; (3) the new
product has the potential to increase initiation; (4) the new product
has the potential to increase abuse liability; (5) the new product has
the potential to increase dependence; or (6) the new product has the
potential to decrease cessation. Based on this analysis, FDA will
determine whether the applicant has demonstrated that any differences
do not cause the new product to raise different questions of public
health.
Please note that FDA is including these examples based on the
Agency's experience to date in reviewing SE reports, and for purposes
of soliciting comments on this approach, and FDA will continue to
review each SE Report and make an SE determination on the basis of the
information included in that SE Report. FDA invites comment on the
terms ``same characteristics'' and ``different characteristics,'' the
potential approach discussed above, and any alternative approaches to
interpretation of these terms, including examples of new tobacco
products that would have the ``same characteristics'' as the predicate,
as well as new tobacco products that would have ``different
characteristics'' from the predicate. While the rule proposes that
certain information would be required for reports submitted under
either the same characteristics or different characteristics prong, we
welcome comments on what information would need to be included under
either or both prongs if the approach described above, or an
alternative approach, is implemented. FDA also invites comment on how
we might evaluate different questions of public health. In your
comment, please include your reasoning for how you would distinguish
the scope of the same characteristics prong from the different
characteristics prong, i.e., when an applicant might claim that a
proposed new tobacco product is substantially equivalent to a predicate
tobacco product because it has the ``same'' characteristics. FDA will
consider all comments and will seek to provide additional clarity in
the final rule, if possible.
Tobacco product. As defined in section 201(rr) of the FD&C
Act (21 U.S.C. 321(rr)), the term ``tobacco product'' means any product
that is made or derived from tobacco that is intended for human
consumption, including any component, part, or accessory of a tobacco
product (except for raw materials other than tobacco used in
manufacturing a component, part, or accessory of a tobacco product).
The term ``tobacco product'' does not mean an article that is a drug
under section 201(g)(1), a device under section 201(h), or a
combination product described in section 503(g) of the FD&C Act (21
U.S.C. 353(g)). As explained in the definition of ``new tobacco
product,'' FDA 's interpretation is that the tobacco product
encompasses the whole product and is not limited to a single unit or
portion of the whole product.
Tobacco product manufacturer. As defined in section
900(20) of the FD&C Act, the term ``tobacco product manufacturer''
means any person, including a repacker or relabeler, who: (1)
Manufactures, fabricates, assembles, processes, or labels a tobacco
product or (2) imports a finished tobacco product for sale or
distribution in the United States. FDA interprets ``manufactures,
fabricates, assembles, processes, or labels'' as including, but not
being limited to: (a) Repackaging or otherwise changing the container,
wrapper, or labeling of any tobacco product package; (b) reconstituting
tobacco leaves; or (c) applying any chemical, additive, or substance to
the tobacco leaf other than potable water in the form of steam or mist.
Manufacturing activities typically do not include the activities of de-
stemming, drying, or packaging tobacco leaves; mechanically removing
foreign material from tobacco leaves; and humidifying tobacco leaves
with nothing other than potable water in the
[[Page 12746]]
form of steam or mist. A proposed definition for the term ``finished
tobacco product'' is also included in the proposed rule.
In addition, FDA proposes the following definitions:
Accessory. FDA proposes to define ``accessory'' as any
product that is intended or reasonably expected to be used with or for
the human consumption of a tobacco product; does not contain tobacco
and is not made or derived from tobacco; and meets either of the
following:
[cir] Is not intended or reasonably expected to affect or alter the
performance, composition, constituents, or characteristics of a tobacco
product; or
[cir] Is intended or reasonably expected to affect or maintain the
performance, composition, constituents, or characteristics of a tobacco
product but solely controls moisture and/or temperature of a stored
product; or solely provides an external heat source to initiate but not
maintain combustion of a tobacco product.
Examples of accessories are ashtrays and spittoons because they do
not contain tobacco, are not derived from tobacco, and do not affect or
alter the performance, composition, constituents, or characteristics of
a tobacco product. Examples of accessories also include humidors or
refrigerators that solely control the moisture and/or temperature of a
stored product and conventional matches and lighters that solely
provide an external heat source to initiate but not maintain combustion
of a tobacco product. This proposed definition is also in accord with
the definition included in the Deeming final rule.
Applicant. FDA proposes to define ``applicant'' as any
manufacturer of tobacco products who is subject to chapter IX of the
FD&C Act that submits a premarket application to receive marketing
authorization for a new tobacco product. For the purposes of part 1107,
a premarket application refers to an SE Report or an exemption request.
Commercial distribution. FDA proposes to define
``commercial distribution'' as any distribution of a tobacco product to
consumers or to another person through sale or otherwise. This term
does not include transfers of a tobacco product between registered
establishments within the same parent, subsidiary, and/or affiliate
company, nor does it include providing a tobacco product for product
testing where such products are not made available for consumption or
resale. This term would exclude the handing or transfer of a tobacco
product from one consumer to another for personal consumption. For
foreign establishments, the term ``commercial distribution'' has the
same meaning except the term does not include distribution of any
tobacco products that are neither imported nor offered for import into
the United States. This term is intended to include a tobacco product
that is test marketed after February 15, 2007, and this term would
encompass distribution of free samples (e.g., smokeless products). FDA
intends to limit our enforcement of the requirements of section 910 and
905(j) to finished tobacco products (see the Guidance for Industry and
FDA Staff entitled ``Section 905(j) Reports: Demonstrating Substantial
Equivalence for Tobacco Products'' (76 FR 789, January 6, 2011); see
also Deeming final rule, 81 FR at 29019).
Component or part. FDA proposes to define ``component or
part'' as any software or assembly of materials intended or reasonably
expected: (1) To alter or affect the tobacco product's performance,
composition, constituents, or characteristics or (2) to be used with or
for the human consumption of a tobacco product. Component or part
excludes anything that is an accessory of a tobacco product. A
container closure system (which would also be defined in this proposed
section) is considered a component or part. With respect to these
definitions, FDA notes that ``component'' and ``part'' are separate and
distinct terms within chapter IX of the FD&C Act. However, for purposes
of this proposed rule, FDA is using the terms ``component'' and
``part'' interchangeably and without emphasizing a distinction between
the terms. FDA may clarify the distinctions between ``component'' and
``part'' in the future. This proposed definition and approach are in
accord with the Deeming final rule. FDA invites comments on this
approach.
Composition. FDA proposes to define ``composition'' as all
of the materials in a tobacco product, including ingredients,
additives, and biological organisms. The term also includes the manner
in which these ingredients, additives, biological organisms, etc., are
arranged and integrated to produce a tobacco product. Composition
refers primarily to the chemical and biological properties of a tobacco
product, whereas design refers to the physical properties of a tobacco
product. A biological organism refers to any living biological entity,
such as an animal, plant, fungus, or bacterium.
Constituent. FDA proposes to define ``constituent'' as any
chemical or chemical compound in a tobacco product that is or
potentially is inhaled, ingested, or absorbed into the body, any
chemical or chemical compound in an emission from a tobacco product, or
any chemical or chemical compound in mainstream or sidestream tobacco
smoke that either transfers from any component of the tobacco product
to the smoke or that is formed by the combustion or heating of tobacco,
additives, or other component of the tobacco product. Examples of
constituents include harmful or potentially harmful constituents, total
particulate matter, nicotine-free dry particulate matter, and water. A
constituent also could include any other chemical or chemical compound
contained in or produced by a tobacco product under conditions of use.
Container closure system. FDA proposes to define
``container closure system'' as any packaging materials that are a
component or part of a tobacco product.
Examples of a container closure system include the blister pack
around a dissolvable tablet (in this example, if there is a box around
a blister pack, the box is not considered a container closure system if
it is not intended or reasonably expected to alter or affect the
dissolvable tablet), the can that contains and protects a moist snuff
product, and the plastic-wrapped hard pack or soft pack used to contain
and protect cigarettes. In the context of determining whether a product
is substantially equivalent as defined in section 910(a)(3)(A) of the
FD&C Act, a container closure system is a component or part of a
tobacco product because of its potential to alter or affect the
performance, composition, constituents, or other physical
characteristics of the product. For example, if a change in the
container closure system could affect the chemistry of the product, FDA
could require the applicant to demonstrate that the change in the
container closure system does not cause the new tobacco product to
raise different questions of public health. Although the FD&C Act does
not itself define ``component'' or ``part,'' FDA recently promulgated
definitions for these terms in the Deeming final rule. According to 21
CFR 1100.3, ``component or part'' means any software or assembly of
materials intended or reasonably expected: (1) To alter or affect the
tobacco product's performance, composition, constituents, or
characteristics or (2) to be used with or for the human consumption of
a tobacco product. Component or part excludes anything that is an
accessory
[[Page 12747]]
of a tobacco product.\5\ The same definitions are also reflected in
this rule's proposed Sec. 1107.12.
---------------------------------------------------------------------------
\5\ ``Accessory'' is defined as any product that is intended or
reasonably expected to be used with or for the human consumption of
a tobacco product; does not contain tobacco and is not made or
derived from tobacco; and meets either of the following: (1) Is not
intended or reasonably expected to affect or alter the performance,
composition, constituents, or characteristics of a tobacco product
or (2) is intended or reasonably expected to affect or maintain the
performance, composition, constituents, or characteristics of a
tobacco product but solely controls moisture and/or temperature of a
stored tobacco product or solely provides an external heat source to
initiate but not maintain combustion of a tobacco product (Sec.
1100.3).
---------------------------------------------------------------------------
In addition, considering a distinct subset of packaging (i.e.,
container closure system) to be a component or part is consistent with
the FD&C Act. For example, section 900(1) of the FD&C Act defines an
``additive'' as any substance the intended use of which results or may
reasonably be expected to result, directly or indirectly, in its
becoming a component or otherwise affecting the characteristic of any
tobacco product (including any substance intended for use as a
flavoring or coloring or in producing, manufacturing, packing,
processing, preparing, treating, packaging, transporting, or holding),
except that such term does not include tobacco or a pesticide chemical
residue in or on raw tobacco or a pesticide chemical. This definition
further evinces Congress's understanding that packaging is not entirely
separable from the tobacco product. Finally, the definition of
``package'' in section 900(13) of the FD&C Act does not dictate a
contrary result, and can be reasonably interpreted to mean that a
distinct subset of packaging is also a component or part of a tobacco
product.
According to the proposed definition above, packaging constitutes a
container closure system if it is intended or reasonably expected to
affect or alter the performance, composition, constituents, or
characteristics of a tobacco product, even if it is also used to
protect or contain the tobacco product. For example, packaging
materials constitute a container closure system if substances within
that packaging are intended or reasonably expected to affect product
moisture, e.g., when the manufacturer changes the package of a moist
snuff from plastic to fiberboard, which can affect microbial stability
and TSNA formation during storage. Another example of this is when
menthol or other ingredients are applied to the inner foil to become
incorporated into the consumed product (Ref. 1). Packaging materials
may also be intended or reasonably expected to affect the
characteristics of a tobacco product by impacting the rate of leaching
into, and ultimately, the amount of substances found in, the consumable
tobacco product. In fact, it has been demonstrated that compounds in
packaging materials may also diffuse into snuff and affect its
characteristics (Ref. 2). Thus, for example, packaging material that
affects the characteristics of a tobacco product by impacting the
moisture level or shelf life of a tobacco product is a container
closure system (e.g., a plastic versus a metal container of smokeless
tobacco). A difference in tobacco moisture is reasonably expected to
affect microbial growth in the product, extraction efficiency, and
total exposure to nicotine or the carcinogens N-nitrosonornicotine
(NNN) or 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) (Ref.
26).
Treating a distinct subset of packaging as a component or part thus
furthers the fundamental purpose of the Tobacco Control Act to protect
the public health. This interpretation is also consistent with the
broad definition of ``tobacco product,'' as well the definition of
``additive,'' which includes any substance that may be reasonably
expected to result, directly or indirectly, in its becoming a component
or otherwise affecting the characteristics of any tobacco product--and
not just substances that do in fact have such effects. This shows that
Congress did not intend for FDA to be required to show that a container
closure system did in fact alter or affect the tobacco product's
performance, composition, constituents, or other characteristics.
Indeed, if FDA were to adopt a narrow construction of ``tobacco
product'' to exclude these materials, the Agency's ability to evaluate
whether the differences between the new and predicate tobacco product
cause the new tobacco product to raise different questions of public
health would be impeded, thereby leaving the Agency unable to fully
execute its mission to protect the public health.
Design. FDA proposes to define ``design'' to mean the form
and structure concerning, and the manner in which, components or parts,
ingredients, software, and materials are integrated to produce a
tobacco product. This term refers to the physical properties of a
tobacco product. Examples of design features include tip ventilation,
paper porosity, tobacco cut width, and filter efficiency.
Finished tobacco product. FDA proposes to define
``finished tobacco product'' to mean a tobacco product, including all
components and parts, sealed in final packaging (e.g., filters or
filter tubes sold separately to consumers or as part of kits).
Grandfathered tobacco product. FDA proposes to define a
``grandfathered tobacco product'' to mean a tobacco product that was
commercially marketed in the United States on February 15, 2007. This
term does not include tobacco products exclusively marketed in a test
market as of that date. FDA interprets the phrase ``as of February 15,
2007,'' as meaning that the tobacco product was commercially marketed
in the United States ``on February 15, 2007,'' and the proposed
definition reflects this interpretation (see the final guidance
entitled ``Establishing That a Tobacco Product Was Commercially
Marketed in the United States as of February 15, 2007'' (79 FR 58358,
September 29, 2014)). A grandfathered tobacco product is not subject to
the premarket requirements of section 910 of the FD&C Act.
Harmful or potentially harmful constituent (HPHC). FDA
proposes to define ``harmful or potentially harmful constituent'' as
any chemical or chemical compound in a tobacco product or tobacco smoke
or emission that: (1) Is or that potentially could be inhaled,
ingested, or absorbed into the body, including as an aerosol (vapor) or
any other emission and (2) causes or has the potential to cause direct
or indirect harm to users or nonusers of tobacco products.
FDA has previously discussed HPHCs in FDA guidance documents (see
the final guidance entitled ``Harmful and Potentially Harmful
Constituents' in Tobacco Products as Used in Section 904(e) of the
Federal Food, Drug, and Cosmetic Act'' (76 FR 5387, January 31, 2011;
revised guidance issued August 2016)). The current established list of
HPHCs can be found on FDA's website at https://www.fda.gov/TobaccoProducts/Labeling/RulesRegulationsGuidance/ucm297786.htm (77 FR
20034, April 3, 2012). In addition, since the inception of the SE
program for tobacco products, HPHCs have been considered ``other
features,'' and the proposed definition of ``other features'' in this
rule would include HPHCs (see the final guidance entitled ``Section
905(j) Reports: Demonstrating Substantial Equivalence for Tobacco
Products,'' (January 5, 2011)).
Health information summary. FDA proposes to define
``health information summary'' to mean a summary, submitted by the
applicant under section 910(a)(4) of the FD&C Act, of any health
information related to the new tobacco product. This would
[[Page 12748]]
include detailed information concerning adverse health effects of the
new tobacco product. For example, information concerning adverse health
effects includes specific adverse events that have been reported to the
applicant and also includes any research or data concerning adverse
health effects of which the applicant is aware.
Health information statement. FDA proposes to define
``health information statement'' to mean a statement, made under
section 910(a)(4) of the FD&C Act that health information related to
the new tobacco product would be made available upon request by any
person. Like the health information summary, the health information
provided to a person requesting it would be required to include any
health information related to the new tobacco product, including
detailed information regarding data concerning adverse health effects
of the new tobacco product.
Heating source. FDA proposes to define ``heating source''
as the source of energy that is used to burn or heat a tobacco product.
An example of a heating source is a flame.
Ingredient. FDA proposes to define ``ingredient'' as
tobacco, substances, compounds, or additives added to the tobacco,
paper, filter, or any other component or part of a tobacco product,
including substances and compounds reasonably expected to be formed
through a chemical reaction during tobacco product manufacturing. For
example, an ingredient may be a single chemical substance, leaf
tobacco, or the product of a reaction, such as a chemical reaction, in
manufacturing. Examples of substances and compounds (ingredients)
reasonably expected to be formed through a chemical reaction during
tobacco product manufacturing include the following:
[cir] The reaction of sugars with amines to form families of
compounds with new carbon-nitrogen bonds, including Maillard reaction
products and Amadori compounds.
[cir] The reaction of sodium hydroxide with citric acid to form
sodium citrate.
[cir] The production of ethyl alcohol, a residual solvent, from
ethyl acetate during production of tipping paper adhesive.
[cir] Products of thermolytic reactions, such as the production of
carboxylic acids from sugar esters.
[cir] Products of enzymatically or nonenzymatically catalyzed
reactions, such as the hydrolytic production of flavor or aroma
precursors from nonvolatile glucosides.
[cir] Products of acid-base reactions, such as removal of a proton
from protonated nicotine to generate the basic form of nicotine
(``free'' nicotine).
Material. FDA proposes to define ``material'' to mean an
assembly of ingredients. Materials are assembled to form the tobacco
product or components or parts of tobacco products. For example,
material would include the glue or paper pulp for a cigarette where the
paper pulp includes multiple ingredients (e.g., multiple types of
tobacco, water, and flavors) assembled into the paper (or pulp
depending on the water content).
Other features. FDA proposes to define ``other features''
to mean any distinguishing qualities of a tobacco product similar to
those specifically enumerated in section 910(a)(3)(B) of the FD&C Act.
The definition would include: (1) HPHCs (note that the definition of
new tobacco product includes any modification to any constituents,
including smoke constituents, section 910(a)(1)(B) of the FD&C Act) and
(2) any other product characteristics that relate to the chemical,
biological, and physical properties of the tobacco product that are
necessary for SE Report review. As described in the proposed definition
of HPHC, HPHC information is necessary to provide a complete comparison
between the new and predicate tobacco products: HPHCs are a subset of
the chemical and chemical compounds in a tobacco product or tobacco
smoke or emission. As such, HPHC information for the new and predicate
tobacco products is necessary for FDA to determine whether the new
tobacco product raises different questions of public health. Other
features also would encompass other product characteristics that relate
to the chemical, biological, and physical properties that would not be
addressed as a material, ingredient, design, composition, or heating
source.
Predicate tobacco product. FDA proposes to define
``predicate tobacco product'' to mean a tobacco product that is a
grandfathered tobacco product or a tobacco product that FDA has
previously found to be substantially equivalent under section
910(a)(2)(A)(i) of the FD&C Act. This proposed definition is also based
on language in section 905(j)(1)(A)(i) of the FD&C Act.
Submission tracking number or STN means the number that
FDA assigns to submissions that are received from a manufacturer of
tobacco products, such as SE Reports and requests for grandfather
determinations.
Substantial equivalence report or SE Report. FDA proposes
to define ``substantial equivalence report'' (also known as a 905(j)
report) or SE Report to mean a submission under section 905(j)(1)(A)(i)
of the FD&C Act that includes the basis for the applicant's
determination that a new tobacco product is substantially equivalent to
a predicate tobacco product. This term includes the initial SE Report
and all subsequent amendments (e.g., amendments include information an
applicant submits in response to a deficiency letter).
B. Substantial Equivalence Reports (Proposed Subpart C)
1. Submission of a Substantial Equivalence Report (Proposed Sec.
1107.16)
Proposed Sec. 1107.16 explains the basic timeframes that would be
required for submitting an SE Report to FDA before commencing
commercial distribution of a new tobacco product. An applicant may
submit an SE Report to demonstrate that a new tobacco product is
substantially equivalent to a predicate tobacco product (an applicant
could also consider whether the exemption under Sec. 1107.1 or an
application under section 910(b) of the FD&C Act is a more appropriate
premarket pathway for the applicant's new tobacco product). If an
applicant chooses to submit an SE Report for a new tobacco product, it
must do so at least 90 calendar days before the date the applicant
intends to begin commercial distribution of the product (see section
905(j)(1) of the FD&C Act). The proposed rule also provides that an
applicant may not begin commercial distribution of the new tobacco
product that is the subject of the SE Report until FDA has issued an
order stating that the Agency has determined that the new tobacco
product is substantially equivalent to a predicate tobacco product
(unless the new tobacco product has received authorization to be
marketed through another premarket pathway, i.e., PMTA or exemption
from substantial equivalence). Otherwise, the new tobacco product is
both adulterated and misbranded (sections 902(6)(A) and 903(a)(6) of
the FD&C Act) and subject to enforcement action.
2. Required Content and Format of an SE Report (Proposed Sec. 1107.18)
Since March 22, 2011 (the date that SE Reports for provisional
tobacco products were required to be submitted), FDA has gained
considerable experience in reviewing more than 3,000 SE Reports
submitted under sections 905(j) and 910(a) of the FD&C Act. As a
result, FDA has identified information essential to the review of SE
Reports, which is reflected
[[Page 12749]]
in the content and format requirements of proposed Sec. 1107.18.
a. Overview. Proposed Sec. 1107.18(a) provides an overview of the
requirements for the content and format of an SE Report. Proposed Sec.
1107.18(a) would provide that the SE Report include information that
would enable FDA to uniquely identify the new tobacco product and the
predicate tobacco product and compare the new tobacco product to a
predicate tobacco product. This information is necessary for FDA both
in reviewing the SE Report so that we can understand the comparison and
also to issue an order that appropriately identifies the tobacco
product that is subject to the order. Providing sufficient information
as described in proposed Sec. 1107.18 would help enable FDA to
determine whether the new tobacco product is substantially equivalent
to a tobacco product commercially marketed in the United States as of
February 15, 2007 (as required by section 910(a)(2)(A) of the FD&C
Act).
The proposed provision would require that the SE Report contain the
following elements:
General information (described in proposed Sec.
1107.18(c));
Summary (described in proposed Sec. 1107.18(d));
New tobacco product description (described in proposed
Sec. 1107.18(e));
Predicate tobacco product description (described in
proposed Sec. 1107.18(f)). This would include a statement that the
predicate tobacco product has not been removed from the market at the
initiative of FDA and has not been determined by judicial order to be
adulterated or misbranded, and the STN of the SE order finding the
predicate tobacco product SE, or the STN of, or specific information
sufficient to support, a grandfathered determination of the predicate
tobacco product. If the SE Report includes information on the
grandfathered status of the predicate tobacco product (but FDA has not
yet made a grandfathered determination \6\), FDA would make the
grandfathered determination before beginning substantive scientific
review of the SE Report to ensure that the predicate tobacco product is
valid;
---------------------------------------------------------------------------
\6\ FDA discusses the information the Agency will consider,
along with Agency's general thinking on grandfathered
determinations, in the guidance document, ``Establishing That a
Tobacco Product Was Commercially Marketed in the United States as of
February 15, 2007'' (79 FR 58358, September 29, 2014).
---------------------------------------------------------------------------
Comparison information (described in proposed Sec.
1107.18(g));
Comparative testing information (described in proposed
Sec. 1107.18(h))
Statement of compliance with applicable tobacco product
standards under section 907 of the FD&C Act (21 U.S.C. 387g) (described
in proposed Sec. 1107.18(i));
Health summary or statement regarding the availability of
such information as required by section 910(a)(4) of the FD&C Act
(described in proposed Sec. 1107.18(j));
Compliance with part 25 (21 CFR part 25) (environmental
impact considerations) (described in proposed Sec. 1107.18(k)); and
Certification statement (described in proposed Sec.
1107.18(l)).
If the SE Report were missing any of these items, the Agency would,
under proposed Sec. 1107.44(a), refuse to accept the SE Report for
review.
b. General Format. Proposed Sec. 1107.18(b) provides the general
requirements for the format of the SE Report and would require the
applicant to submit the SE Report with the appropriate FDA form (Refs.
3 and 4). Proposed Sec. 1107.18(b) would require the SE Report and any
amendments to contain a comprehensive index and table of contents and
be well organized, legible, and written in the English language. For
any foreign language documents, the original foreign language document
must be accompanied by the English translation and a certification by
the applicant or responsible official authorized to represent the
applicant that the translation into English is accurate. The
comprehensive index would include the listing of files and data
associated with those files (e.g., for an SE Report that is
electronically submitted, the comprehensive index would include the
listing of files and associated metadata).
As described in proposed Sec. 1107.62, FDA is proposing that, for
an SE Report and supporting documents to be accepted by FDA, the SE
Report and documents must be submitted to FDA in an electronic format
that the Agency can process, read, review, and archive, unless the
Agency has previously granted a waiver from these requirements. FDA
will not act on an SE Report until the Center for Tobacco Product's
(CTP's) Document Control Center has received an SE Report that the
Agency can process, read, review, and archive. Applicants that are
unable to submit their reports in electronic format would be advised to
consult proposed Sec. 1107.62, which explains how the applicant may
obtain a waiver from the electronic filing requirement. FDA intends to
provide information on our website about technical specifications
related to submission, including the electronic formats, which would
allow FDA to process, read, review, and archive the SE Report.
Providing technical specifications information on our website enables
FDA to periodically update the electronic formats that we are capable
of accepting so that we can accommodate quickly evolving technology.
The requirements in proposed Sec. 1107.18(b) and 1107.62 are
intended to address some of the problems we have seen with SE Reports.
For example, some SE Reports have been submitted to FDA in a
proprietary format or password protected without providing FDA access
or password information. Following up with an applicant to obtain
access or password information takes time and contributes to delays. In
addition, some electronic submissions have not been in a static format,
and thus, the pages reformat, renumber, re-bullet, or re-date each time
the document is accessed. Receiving SE Reports with these issues
affects our ability to cross-reference, share, and efficiently evaluate
information. Lastly, because FDA is required under regulations
governing Federal records to maintain many files long term, and in a
``sustainable'' format (for more information on sustainable formats,
please refer to National Archives and Record Administration Bulletin
2014-04, https://www.archives.gov/records-mgmt/bulletins/2014/2014-04.html), proposed Sec. 1107.18(b) would ensure that these files can
be managed, opened, and read by the Agency for the duration of the
retention period.
c. General information. Proposed Sec. 1107.18(c) lists the
information that the SE Report would be required to include. This
information includes general administrative information that must
specify the type of submission (e.g., SE Report); the new tobacco
product with unique identification and the predicate tobacco product
with unique identification (to enable us to identify the new tobacco
product as well as identify the predicate product), as well as contact
information. The SE Report must include the following information using
the FDA-provided forms, as appropriate:
The date the SE Report is submitted (using the applicant-
generated submittal date, i.e., the date the applicant assigns to it,
which for a paper submission is the date typically located at the top
of a cover letter, and for an electronic submission is the date when
the document is uploaded to FDA's electronic submission system);
Type of submission (e.g., SE Report or amendment to an SE
Report);
Previously assigned FDA STN, where applicable (e.g., in
cases where
[[Page 12750]]
the applicant is submitting an amendment to an SE Report, the Agency
has assigned a number in advance, or the applicant is referencing a
previously denied SE Report);
Any other relevant FDA STN, such as a request for a
grandfathered determination, and cross-references to meetings regarding
the new tobacco product (e.g., if FDA issues an order denying marketing
authorization for a tobacco product and meets with the applicant about
it before the applicant submits a new SE Report, the meeting should be
referenced in the new SE Report);
The name, address, and contact information for the
applicant and the authorized representative or authorized U.S. agent
(for a foreign applicant). FDA would require identification of an
authorized representative or, for foreign applicants, authorized U.S.
agent to help FDA ensure adequate notice is provided to applicants of
official Agency communications. In particular, FDA may be unable to
confirm that adequate notice of Agency action or correspondence
concerning premarket submissions is provided to foreign applicants as
FDA cannot necessarily confirm receipt of correspondence sent
internationally. Accordingly, the designation of a U.S. agent provides
an official contact to the Agency who can receive the information or
documentation on behalf of the applicant. Providing notice regarding
that SE Report to the U.S. agent would constitute notice to the foreign
applicant. FDA requires identification of a U.S. agent to assist FDA in
communicating with the foreign applicant and help permit the Agency to
efficiently process SE Reports and avoid delays. In many instances
during the SE Report review process, FDA has reached out numerous times
to a foreign applicant and has either been unable to speak with the
applicant or was unable to directly communicate questions and/or
concerns. This impediment has resulted in delays or terminations in the
review of specific SE Reports and a slowdown of the premarket
application process as a whole. A U.S. agent would act as a
communications link between FDA and the applicant and would facilitate
timely correspondence between FDA and foreign applicants, including
responding to questions concerning pending applications and, if needed,
assisting FDA in scheduling meetings with the foreign applicants to
resolve outstanding issues before agency action is taken. In addition,
the authorized representative or U.S. agent would be authorized to act
on behalf of the applicant for that specific SE Report.
For both the new and predicate tobacco product,
information needed to uniquely identify the products, including:
[cir] The manufacturer;
[cir] Product name, including the brand and sub brand;
[cir] Product category; product subcategory; and product
properties, as provided in table 2. The applicant would select and
provide for both the new and predicate tobacco products the appropriate
category, subcategory, and product properties (if the product does not
have a listed product property, e.g., ventilation or characterizing
flavor, the report must state ``none'' for that property):
Table 2--Tobacco Product Category, Subcategory, and Product Properties
Information
------------------------------------------------------------------------
Tobacco product
Tobacco product category subcategory Product properties
------------------------------------------------------------------------
Cigarettes.................... Combusted, --Package type (e.g.,
Filtered. hard pack, soft
pack, clam shell).
--Product quantity
(e.g., 20
cigarettes, 25
cigarettes).
--Length (e.g., 89
millimeter (mm), 100
mm).
--Diameter (e.g., 6
mm, 8.1 mm).
--Ventilation (e.g.,
none, 10%, 25%).
--Characterizing
Flavor(s) \7\ (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Combusted, non- --Package type (e.g.,
filtered. hard pack, soft
pack, clam shell).
--Product quantity
(e.g., 20
cigarettes, 25
cigarettes).
--Length (e.g., 89
mm, 100 mm).
--Diameter (e.g., 6
mm, 8.1 mm).
--Characterizing
Flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Combusted, Other. --Package type (e.g.,
hard pack, soft
pack, clam shell).
--Product quantity
(e.g., 20
cigarettes, 25
cigarettes).
--Length (e.g., 89
mm, 100 mm).
--Diameter (e.g., 6
mm, 8.1 mm).
--Ventilation (e.g.,
none, 10%, 25%).
--Characterizing
Flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Non-Combusted --Package type (e.g.,
(e.g., a hard pack, soft
cigarette where pack, clam shell).
the tobacco is
only heated not
burned).
--Product quantity
(e.g., 20
cigarettes, 25
cigarettes).
--Length (e.g., 89
mm, 100 mm).
--Diameter (e.g., 6
mm, 8.1 mm).
--Ventilation (e.g.,
none, 10%, 25%).
--Characterizing
Flavor(s) (e.g.,
none, menthol).
--Source of energy
(e.g., charcoal,
electrical heater).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Cigarette, Co- --For a new co-
Package. packaged tobacco
product composed of
multiple cigarette
tobacco products,
include, as
applicable, all
properties for each
individual tobacco
product, as
identified above.
Roll-Your-Own (RYO) Tobacco RYO Tobacco --Package type (e.g.,
Products. Filler. bag, pouch).
[[Page 12751]]
--Product quantity
(e.g., 20 g, 40 g).
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Rolling Paper.... --Package type (e.g.,
bag, box, booklet).
--Product quantity
(e.g., 50 sheets,
200 papers).
--Length (e.g., 79
mm, 100 mm, 110 mm).
--Width (e.g., 28 mm,
33 mm, 45 mm).
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Filtered --Package type (e.g.,
Cigarette Tube. bag, box).
--Product quantity
(e.g., 100 tubes,
200 tubes).
--Length (e.g., 89
mm, 100 mm).
--Diameter (e.g., 6
mm, 8.1 mm).
--Ventilation (e.g.,
none, 10%, 25%).
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Non-Filtered --Package type (e.g.,
Cigarette Tube. bag, box).
--Product quantity
(e.g., 100 tubes,
200 tubes).
--Length (e.g., 89
mm, 100 mm).
--Diameter (e.g., 6
mm, 8.1 mm).
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Filter........... --Package type (e.g.,
bag, box).
--Product quantity
(e.g., 100 filters,
200 filters).
--Length (e.g., 8 mm,
12 mm).
--Diameter (e.g., 6
mm, 8.1 mm).
--Ventilation (e.g.,
none, 10%, 25%).
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Paper Tip........ --Package type (e.g.,
bag, box).
--Product quantity
(e.g., 200 tips, 275
tips).
--Length (e.g., 12
mm, 15 mm).
--Width (e.g., 27
mm).
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
RYO Co-Package... --For a new co-
packaged tobacco
product composed of
multiple RYO tobacco
products, include,
as applicable, all
properties for each
individual tobacco
product (e.g., RYO
tobacco, rolling
paper, filtered
cigarette tube, non-
filtered cigarette
tube, filter, paper
tip) as identified
above.
Other............ --Package type (e.g.,
bag, box).
--Product quantity.
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product.
Smokeless Tobacco Products.... Loose Moist Snuff --Package type (e.g.,
plastic can with
metal lid, plastic
can with plastic
lid).
--Product quantity
(e.g., 20 grams (g),
2 ounces).
--Tobacco cut size
(e.g., 5 mm, 7 mm).
--Characterizing
flavor(s) (e.g.,
none, menthol,
cherry,
wintergreen).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Portioned Moist --Package type (e.g.,
Snuff. plastic can with
metal lid, plastic
can with plastic
lid).
----Product quantity
(e.g., 22.5 g, 20
g).
--Portion count
(e.g., 15 pouches,
20 pieces).
--Portion mass (e.g.,
1.5 g/pouch, 2 g/
piece).
--Portion length
(e.g., 15 mm, 20
mm).
--Portion width
(e.g., 10 mm, 15
mm).
--Portion thickness
(e.g., 5 mm, 7 mm).
--Tobacco cut size
(e.g., 5 mm, 7 mm).
--Characterizing
flavor(s) (e.g.,
none, menthol,
cherry,
wintergreen).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Loose Snus....... --Package type (e.g.,
plastic can with
metal lid, plastic
can with plastic
lid).
[[Page 12752]]
--Product quantity
(e.g., 20 g, 2
ounces).
--Tobacco cut size
(e.g., 5 mm, 7 mm).
--Characterizing
flavor(s) (e.g.,
none, menthol,
cherry,
wintergreen).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Portioned Snus... --Package type (e.g.,
plastic can with
metal lid, plastic
can with plastic
lid).
--Product quantity
(e.g., 22.5 g, 20
g).
--Portion count
(e.g., 15 pouches,
20 pieces).
--Portion mass (e.g.,
1.5 g/pouch, 2 g/
piece).
--Portion length
(e.g., 15 mm, 20
mm).
--Portion width
(e.g., 10 mm, 15
mm).
--Portion thickness
(e.g., 5 mm, 7 mm).
--Tobacco cut size
(e.g., 5 mm, 7 mm).
--Characterizing
flavor(s) (e.g.,
none, menthol,
cherry,
wintergreen).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Loose Dry Snuff.. --Package type (e.g.,
plastic can with
metal lid, plastic
can with plastic
lid).
--Product quantity
(e.g., 20 g, 2
ounces).
--Tobacco cut size
(e.g., 0.05 mm, 0.07
mm).
--Characterizing
flavor(s) (e.g.,
none, menthol,
cherry,
wintergreen).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Dissolvable...... --Package type (e.g.,
plastic can with
metal lid, plastic
can with plastic
lid).
--Product quantity
(e.g., 22.5 g, 20
g).
--Portion count
(e.g., 15 sticks, 20
tablets).
--Portion mass (e.g.,
1.5 g/strip, 1.0 g/
piece).
--Portion length
(e.g., 10 mm, 15
mm).
--Portion width
(e.g., 5 mm, 8 mm).
--Portion thickness
(e.g., 3 mm, 4 mm).
--Tobacco cut size
(e.g., 0.05 mm, 0.07
mm).
--Characterizing
flavor(s) (e.g.,
none, menthol,
cherry,
wintergreen).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Loose Chewing --Package type (e.g.,
Tobacco. bag, pouch,
wrapped).
--Product quantity
(e.g., 20 g, 3
ounces).
--Tobacco cut size
(e.g., 0.05 mm, 0.07
mm).
--Characterizing
flavor(s) (e.g.,
none, menthol,
cherry,
wintergreen).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Portioned Chewing --Package type (e.g.,
Tobacco. plastic can with
metal lid, plastic
can with plastic
lid).
--Product quantity
(e.g., 20 g).
--Portion count
(e.g., 10 bits).
--Portion mass (e.g.,
2 g/bit).
--Portion length
(e.g., 8 mm, 10 mm).
--Portion width
(e.g., 6 mm, 8 mm).
--Portion thickness
(e.g., 5 mm, 7 mm).
--Characterizing
flavor(s) (e.g.,
none, menthol,
cherry,
wintergreen).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Smokeless Co- --For a new co-
Package. packaged tobacco
product composed of
multiple smokeless
tobacco products,
include, as
applicable, all
properties for each
individual tobacco
product as
identified above.
Other............ --Package type (e.g.,
bag, box).
--Product quantity.
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol).
--Additional
properties needed to
uniquely identify
the tobacco product.
ENDS (Electronic Nicotine Open E-Liquid --Package type (e.g.,
Delivery System). (e.g., an e- bottle, box).
liquid in a
bottle with a
removable cap).
--Product quantity
(e.g., 1 bottle, 5
bottles).
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol, cherry,
wintergreen).
--E-liquid volume
(e.g., 10 ml).
--Nicotine
concentration (e.g.,
0, 0.2 mg/ml).
--PG/VG ratio (e.g.,
N/A, 0/100, 50/50).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
[[Page 12753]]
Closed E-Liquid --Package type (e.g.,
(e.g., a sealed cartridge).
cartridge for
use in an e-
cigarette).
--Product quantity
(e.g., 1 cartridge,
5 cartridges).
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol, cherry,
wintergreen).
--E-liquid volume
(e.g., 10 ml).
--Nicotine
concentration (e.g.,
0, 0.2 mg/ml).
--PG/VG ratio (e.g.,
N/A, 0/100, 50/50).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Closed E- --Package type (e.g.,
Cigarette (e.g., box, none, plastic
a cigalike). clamshell).
--Product quantity
(e.g., 1 e-
cigarette, 5 e-
cigarettes).
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol, cherry,
wintergreen).
--Length (e.g., 100
mm, 120 mm).
--Diameter (e.g., 6
mm, 8 mm).
--E-liquid volume
(e.g., 2 ml, 5 ml).
--Nicotine
concentration (e.g.,
0, 0.2 mg/ml).
--PG/VG ratio (e.g.,
N/A, 0/100, 50/50).
--Wattage (e.g., 100
W, 200 W).
--Battery capacity
(e.g., 100 mAh, 200
mAh).
--Additional
properties needed to
uniquely identify
the tobacco product.
Open E-Cigarette --Package type (e.g.,
(e.g., a tank box, none, plastic
system). clamshell).
--Product quantity
(e.g., 1 e-
cigarette, 5 e-
cigarettes).
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol, cherry,
wintergreen).
--Length (e.g., 100
mm, 120 mm).
--Diameter (e.g., 8
mm, 14 mm).
--E-liquid volume
(e.g., 2 ml, 5 ml).
--Wattage (e.g., 100
W, 200 W).
--Battery capacity
(e.g., 100 mAh, 200
mAh).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
ENDS Component... --Package type (e.g.,
box, none, plastic
clamshell).
--Product quantity
(e.g., 1 e-
cigarette, 5 e-
cigarettes).
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol, cherry,
wintergreen).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
ENDS Co-Package.. --For a new co-
packaged tobacco
product composed of
multiple ENDS
tobacco products,
include, as
applicable, all
properties for each
individual tobacco
product as
identified above.
ENDS Other....... --Package type (e.g.,
bag, box).
--Product quantity.
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol, cherry).
--Additional
properties needed to
uniquely identify
the tobacco product.
Cigars........................ Filtered, Sheet- --Package type (e.g.,
Wrapped Cigar. hard pack, soft
pack, clam shell).
--Product quantity
(e.g., 20 filtered
cigars, 25 filtered
cigars).
--Characterizing
flavor (e.g., none,
menthol).
--Length (e.g., 89
mm, 100 mm).
--Diameter (e.g., 6
mm, 8.1 mm).
--Ventilation (e.g.,
none, 10%, 25%).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Unfiltered, Sheet- --Package type (e.g.,
Wrapped Cigar. box, film sleeve).
--Product quantity
(e.g., 1 cigar, 5
cigarillos).
--Characterizing
flavor (e.g., none,
menthol).
--Length (e.g., 100
mm, 140 mm).
--Diameter (e.g., 8
mm, 10 mm).
--Tip (e.g., none,
wood tips, plastic
tips).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Leaf-Wrapped --Package type (e.g.,
Cigar. box, film, sleeve,
none).
--Product quantity
(e.g., 1 cigar, 5
cigars).
--Characterizing
flavor (e.g., none,
whiskey).
--Length (e.g., 150
mm, 200 mm).
--Diameter (e.g., 8
mm, 10 mm).
[[Page 12754]]
--Wrapper material
(e.g., burley
tobacco leaf,
Connecticut shade
grown tobacco leaf).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Cigar Component.. --Package type (e.g.,
box, booklet).
--Product quantity
(e.g., 10 wrappers,
20 leaves).
--Characterizing
flavor (e.g., none,
menthol, cherry).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Cigar Tobacco --Package type (e.g.,
Filler. bag, pouch).
--Product quantity
(e.g., 20 g, 16
ounces).
--Characterizing
flavor (e.g., none,
tobacco, menthol,
cherry).
--Tobacco cut size
(e.g., 5 mm, 10 mm).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Cigar Co-Package. --For a new co-
packaged tobacco
product composed of
multiple cigar
tobacco products,
include, as
applicable, all
properties for each
individual tobacco
product as
identified above.
Other............ --Package type (e.g.,
bag, box).
--Product quantity.
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol).
--Additional
properties needed to
uniquely identify
the tobacco product.
Pipe Tobacco Products......... Pipe............. --Package type (e.g.,
box, none).
--Product quantity
(e.g., 1 pipe).
--Length (e.g., 200
mm, 300 mm).
--Diameter (e.g., 25
mm).
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Pipe Tobacco --Package type (e.g.,
Filler. bag, pouch).
--Product quantity
(e.g., 20 g, 16
ounces).
--Characterizing
flavor(s) (e.g.,
none, menthol,
Cavendish, cherry).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Pipe Component... --Package type (e.g.,
bowl, shank, stem,
screen, filter).
--Product quantity
(e.g., 1 bowl, 1
stem, 100 filters).
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Pipe Co-Package.. --For a new co-
packaged tobacco
product composed of
multiple pipe
tobacco products,
include, as
applicable, all
properties for each
individual tobacco
product as
identified above.
Other............ --Package type (e.g.,
bag, box).
--Product quantity.
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol).
--Additional
properties needed to
uniquely identify
the tobacco product.
Waterpipe Tobacco Products.... Waterpipe........ --Package type (e.g.,
box, none).
--Product quantity
(e.g., 1 waterpipe).
--Length (e.g., 200
mm, 500 mm).
--Width (e.g., 100
mm, 300 mm).
--Number of hoses
(e.g., 1, 2, 4).
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Waterpipe Tobacco --Package type (e.g.,
Filler. bag, pouch).
--Product quantity
(e.g., 20 g, 16
ounces).
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol, apple).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Waterpipe Heat --Package type (e.g.,
Source. box, film sleeve,
bag, none).
--Product quantity
(e.g., 150 g, 680
g).
--Characterizing
flavor(s) (e.g.,
none, menthol,
apple).
--Portion count
(e.g., 20 fingers,
10 discs, 1 base).
--Portion mass (e.g.,
15 g/finger).
--Portion length
(e.g., 40 mm, 100
mm).
--Portion width
(e.g., 10 mm, 40
mm).
--Portion thickness
(e.g., 10 mm, 40
mm).
--Source of energy
(e.g., charcoal,
battery,
electrical).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
[[Page 12755]]
Waterpipe --Package type (e.g.,
Component. bag, box, none).
--Product quantity
(e.g., 1 base, 1
bowl, 1 hose, 10
mouthpieces).
--Characterizing
flavor(s) (e.g.,
none, menthol,
apple).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Waterpipe Co- --For a new co-
Package. packaged tobacco
product composed of
multiple waterpipe
tobacco products,
include, as
applicable, all
properties for each
individual tobacco
product as
identified above.
Waterpipe Other.. --Package type (e.g.,
bag, box).
--Product quantity.
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Other......................... Other............ --Package type (e.g.,
bag, box).
--Product quantity.
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
------------------------------------------------------------------------
\7\ Characterizing flavors may include those added to certain components
or parts (e.g., paper) of the tobacco product. If there is no
characterizing flavor, the application must state ``none.''
The applicant would be required to include any additional
properties needed to uniquely identify the tobacco product, if
applicable (e.g., use of product descriptors such as ``premium'' would
be required to be identified). Proposed Sec. 1107.18(c)(8) would also
require the address of the facilities involved in the manufacture of
the tobacco products and any Facility Establishment Identifier number.
This information would assist the Agency in making environmental impact
considerations and determinations under part 25 by helping FDA
understand the scale of products that would be manufactured.
d. Summary. Proposed Sec. 1107.18(d) would require a summary at
the beginning of the SE Report. This summary portion of the SE Report
would act as an abstract designed to orient reviewers to the contents
of the SE Report. Under proposed Sec. 1107.18(d), the summary would be
required to include three elements. First, the summary would be
required to include a concise description of the characteristics of the
new tobacco product. As stated in section 910(a)(3)(B) of the FD&C Act,
characteristics means ``the materials, ingredients, design,
composition, heating source, or other features of a tobacco product,''
all of which are defined in proposed Sec. 1107.12. Second, the summary
would also be required to include the applicant's basis for whether the
new tobacco product has the same characteristics as the predicate
tobacco product or has different characteristics from the predicate
tobacco product which the applicant believes do not cause the new
tobacco product to raise different questions of public health. Third,
with respect to those characteristics, the summary would be required to
include a description of the similarities and differences between the
new tobacco product and the predicate tobacco product.
e. New tobacco product description. Proposed Sec. 1107.18(e) sets
forth the information that would be required in the description of the
new tobacco product. Based on our experience reviewing SE Reports, FDA
has found that, to have a meaningful scientific comparison, a new
tobacco product should be compared to a single predicate product (this
is discussed in more detail at proposed Sec. 1107.18(f), the section
of this document describing the predicate tobacco description).
Accordingly, proposed Sec. 1107.18(e) would require the applicant to
identify the new tobacco product in the SE Report for comparison to one
predicate tobacco product. As is currently the practice, applicants may
continue to bundle groups of SE Reports submitted under proposed Sec.
1107.18 that have the same proposed modifications (e.g., a change in
ingredient supplier that results in a new tobacco product). As
discussed previously, co-packaging two or more tobacco products may
result in a new tobacco product.
Proposed Sec. 1107.18(e) would require that the SE Report describe
the new tobacco product in sufficient detail to enable FDA to
understand and evaluate the characteristics of the new tobacco product
in comparison to the predicate. Specifically, the Agency proposes that
this section of the SE Report include the following information:
A narrative description of the new tobacco product, as
well as detailed drawings or schematics. The drawings would be required
to identify the container closure system and illustrate all of the
product's components. As defined in proposed Sec. 1107.12, a
``component or part'' of a tobacco product is any software or assembly
of materials intended or reasonably expected: (1) To alter or affect
the tobacco product's performance, composition, constituents, or
characteristics or (2) to be used with or for the human consumption of
a tobacco product. The definition excludes anything that is an
accessory of a tobacco product. For example, an applicant submitting an
SE Report for a pouched snus product would illustrate all the
components and parts of the product, including the pouch material and
tobacco filler. The narrative description would identify all the
components, e.g., for a cigarette, the applicant would identify the
rod, and the rod's paper and filler, and so on.
A description of and the function for each component or
part of the new tobacco product as well as an explanation of how each
component or part is integrated into the product design.
If the manufacturing process for the new tobacco product
could affect the characteristics of the new product, an applicant would
be required to provide an overview of the manufacturing process. This
overview would not need to be an exhaustive discussion but enough
information to enable FDA to fully understand and compare the
characteristics that can be affected by the manufacturing process of
the new
[[Page 12756]]
tobacco product and the predicate tobacco product. FDA has found during
reviews of SE Reports that changes in manufacturing, including
fermentation, may impact the characteristics of the tobacco product,
e.g., the quantities of nicotine (total and free), as well as HPHCs
such as tobacco-specific N-nitrosamines (TSNAs). Such changes could
cause the new product to raise different questions of public health,
e.g., fermentation can increase the levels of nicotine, which impacts
dependence and cessation (Refs. 36 and 37), and an increase in TSNAs
may increase the risk for certain types of cancer (Ref. 38). Thus, if
fermentation is used in the manufacturing process for the new tobacco
product, then the SE Report would be required to describe the process,
including the type and quantity of the microbial inoculum and/or
fermentation solutions (fermentation is typically used in smokeless
tobacco products, and the hot and sticky environment associated with
fermentation may contribute to bacteria and growth of contaminants,
which is a major health and safety concern). If the manufacturing
process for the new tobacco product does not affect the characteristics
of the new product beyond what is described elsewhere in the SE Report,
an applicant would be required to state that to satisfy this provision.
f. Description of the predicate tobacco product. Under proposed
Sec. 1107.18(f), the SE Report would be required to include a section
describing the predicate tobacco product. Under proposed Sec.
1107.18(f)(1), the applicant would be required to identify one
predicate tobacco product that is either a grandfathered tobacco
product or a tobacco product that FDA previously found to be
substantially equivalent to a predicate tobacco product. The applicant
may reference the STN if FDA has already made a grandfathered
determination, or provide specific information sufficient to support a
grandfathered determination (see the final guidance entitled
``Establishing That a Tobacco Product Was Commercially Marketed in the
United States as of February 15, 2007'' (79 FR 58358, September 29,
2014)). If the SE Report includes information to demonstrate the
grandfathered status of the predicate product, FDA intends to make the
grandfathered determination on that predicate tobacco product before
beginning substantive scientific review of the SE Report.
As with any new tobacco product, applicants who wish to use the SE
pathway to obtain marketing authorization for new co-packaged products
would have to identify a single predicate tobacco product for each new
tobacco product. An applicant could use a co-packaged product as a
predicate so long as it is a valid predicate; however, an applicant
would not be required to use a co-packaged product as its predicate
tobacco product.
FDA invites comments on this approach or any recommended
alternative approaches for co-packaged products.
Proposed Sec. 1107.18(f)(2)(i) would require that the predicate
tobacco product chosen by the applicant be in the same category (e.g.,
cigarette, smokeless) and subcategory (e.g., filtered, non-filtered) as
the new tobacco product to provide a meaningful starting point for our
substantial equivalence review. This proposed requirement reflects
FDA's experience, which has been that if the predicate and new tobacco
products differ on these points, it is highly unlikely that we would be
able to find that the SE Report demonstrates the substantial
equivalence of the new tobacco product to the predicate tobacco
product. For example, when an SE Report includes a predicate and new
tobacco product that are in different categories (e.g., a comparison of
a combusted tobacco product to a smokeless product), the considerable
differences between the products in almost every characteristic will
raise different questions of public health (e.g., an applicant
attempting to compare a smokeless moist snuff predicate to a new
combusted filtered cigarette would likely not be able to demonstrate
that the cigarette does not raise different questions of public health
as compared to the smokeless moist snuff, as the properties and
characteristics of the two products are so vastly different. For
example, an applicant would not be able to show that a ventilation of
25 percent would not cause the cigarette to raise different questions
of public health given that the smokeless moist snuff has no
ventilation characteristic with which to compare). These drastic
differences in characteristics make it very hard for applicants to
provide the evidence necessary to show that these differences do not
cause the new product to raise different questions of public health
because addressing the uncertainty in the influence on adverse health
impact on the user, product use, initiation, and cessation would often
require complex clinical studies.
In addition, under proposed Sec. 1107.18(f)(2)(ii), the predicate
must have been either commercially marketed (not exclusively in a test
market) in the United States as of February 15, 2007 (a grandfathered
predicate tobacco product), or have been previously determined to be
substantially equivalent by FDA. If the SE Report is using a
grandfathered predicate tobacco product, the SE Report must include a
statement that ``I, (name of responsible official), confirm that the
predicate tobacco product, (insert name of predicate tobacco product),
was commercially marketed other than for test marketing as of February
15, 2007'' or reference the STN for a previous determination by FDA
that the predicate tobacco product is grandfathered. The statement
would be a means of ensuring that the applicant understands that the
product must have been commercially marketed on February 15, 2007, to
be considered grandfathered, and supports the information provided in
proposed Sec. 1107.18(f)(1).
Under proposed Sec. 1107.18(f)(2)(iii), the applicant would be
required to identify a predicate tobacco product that is an individual
product. As previously discussed, an applicant could use a co-packaged
product as a predicate so long as it is a valid predicate (e.g., on the
market as of February 15, 2007, or one that was previously found SE).
However, a predicate could not be a fictional product made up by
combining characteristics of two or more products that are
grandfathered or have been found SE. In addition, under proposed Sec.
1107.18(f)(2)(iv) and (v), the predicate tobacco product could not be
the subject of a rescission order by FDA as described in proposed Sec.
1107.50 and could not have been removed from the market at the
initiative of FDA or have been determined by judicial order to be
adulterated or misbranded. These proposed requirements are intended to
minimize some of the problems with predicate tobacco products that FDA
has identified during SE Report reviews which prevent us from
proceeding with an SE review.
g. Comparison information. Proposed Sec. 1107.18(g) states that
the SE Report would be required to include a comparison of the
characteristics of the new tobacco product and the predicate tobacco
product, as described in proposed Sec. 1107.19. FDA expects this
comparison to be a significant part of an SE Report as it would be
expected to describe in detail how the product characteristics of the
new tobacco product compare to the product characteristics of the
predicate tobacco product.\8\ If the new tobacco product
[[Page 12757]]
has some characteristics that are not identical to the predicate, but
some characteristics that are identical, the applicant must provide
comparison information related to the characteristics that are not
identical, but may certify that the other characteristics are identical
under proposed Sec. 1107.18(l)(2).
---------------------------------------------------------------------------
\8\ FDA notes that some applications may use surrogate tobacco
products for discrete parts of an SE application. A surrogate is a
tobacco product for which an applicant provides data it would like
to extrapolate to the new, predicate tobacco product or both new and
predicate tobacco products. However, the surrogate tobacco product
is neither the new or predicate tobacco product (a grandfathered
determination is not necessary for surrogate tobacco products as it
is not a predicate tobacco product). Data for a surrogate tobacco
product is provided in place of data or to provide a bridge between
data for the new or predicate tobacco product. A surrogate tobacco
product is used when there is inadequate data available for the new
or predicate tobacco product; data for a surrogate tobacco product
supplement the data for a new or predicate tobacco product. Unlike
predicate tobacco products, surrogate tobacco product data may be in
place at the start of substantive scientific review or may be
provided in response to a deficiency letter. FDA invites comments on
the use of surrogate tobacco products.
---------------------------------------------------------------------------
For example, if the modification between the new and predicate
product is a change to fire standard compliant (FSC) paper, the SE
Report would state and provide comparison information on the difference
of the non-FSC to FSC paper, the change in filtration (e.g., if there
is a change in filtration due to the change made to the paper), and the
change in tobacco blend (e.g., if there is a change in blend made with
the change to the paper), but the SE Report could then include a
certification that all other characteristics of the new and predicate
product, other than the modified paper, filtration, and blend, are
identical. Another example is a change in product quantity (e.g., an
increase from 20 grams to 35 grams of loose moist snuff). In this
scenario, if the per weight composition has not changed, the applicant
could provide comparison information on only the characteristics that
differ between the new and predicate product, and include a
certification under proposed Sec. 1107.18(l)(2) that all other
characteristics are identical. A third example would be a container
closure system (CCS) substitution of a bag for a box. In this case, the
SE Report would provide comparison information on the change in CCS and
the SE Report could then include a certification under proposed Sec.
1107.18(l)(2) that the characteristics of all non-CCS items have not
changed (e.g., rolling papers are identical between the new and
predicate product). The applicant would be required to maintain records
supporting the certification consistent with proposed Sec. 1107.58.
h. Comparative testing information. Other than for characteristics
that are identical (and for which the applicant has certified that the
characteristics are identical under paragraph (l)(2)), proposed Sec.
1107.18(h) would require the SE Report to include testing information
on the characteristics of the new and predicate tobacco products as
described in section Sec. 1107.19, except where the applicant
adequately justifies that such comparative testing information is not
necessary to demonstrate that the new product: (1) Has the same
characteristics as the predicate or (2) does not raise different
questions of public health. For example, it may not always be necessary
to provide comparative testing information on the heating source.
Comparative testing supports the SE Report by showing the
information contained in the SE Report is meaningful and accurate and,
where applicable, helps demonstrate that the different
characteristic(s) in a new tobacco product does not raise different
questions of public health. FDA's experience has been that the summary
data provided in some SE Reports has been miscalculated, and thus, a
substantial equivalence determination was not supportable. To ensure
the accuracy of the data provided, FDA has needed to review the
experimental data.
Accordingly, proposed Sec. 1107.18(h)(1) would require that the SE
Report include test protocols, quantitative acceptance criteria, and
test results (including means and variances, data sets, and a summary
of the results). Under proposed Sec. 1107.18(h)(2), the testing would
be required to be conducted on a sufficient sample size and on samples
that reflect the final tobacco product composition and design. Proposed
Sec. 1107.18(h)(3) would require the SE Report to state whether the
testing method for the new and predicate products are the same and, if
they differ, to explain how the results of the different test methods
can be compared. Under proposed Sec. 1107.18(h)(4), the SE Report also
must identify any national and international standards used to test the
new and predicate tobacco products and explain any deviations.\9\ If no
standards were used for testing, the SE Report would be required to
state so. There are multiple ways to satisfy this comparative testing
requirement that may not require comparative testing on the specific
characteristic that is different between the new and predicate tobacco
product. For example, if an applicant is proposing to modify the
container closure system of a smokeless tobacco product for loose moist
snuff, rather than supply testing information on the container closure
system, the applicant could demonstrate that the ingredients,
constituents, moisture, and stability of the loose tobacco within the
container closure system are not affected by the change in container
closure system in a way that would cause the new product to raise
different questions of public health. As testing information on the
ingredients, constituents, moisture, and stability information would
already be required for the smokeless tobacco product, additional
comparative testing information on differences in the container closure
system would not be required. Instead the applicant would state that
this information is already covered by the submission of the
ingredients, constituents, moisture, and stability information within
the SE Report.
---------------------------------------------------------------------------
\9\ In the guidance document entitled, ``Section 905(j) Reports:
Demonstrating Substantial Equivalence for Tobacco Products''
(January 2011), FDA provided some examples of standards that might
be used to support an SE application.
---------------------------------------------------------------------------
i. Statement of compliance with applicable tobacco product
standards. As required by section 905(j)(1)(B) of the FD&C Act, under
proposed Sec. 1107.18(i), the SE Report must list and describe the
action(s) that the applicant has taken to comply with the requirements
under section 907 of the FD&C Act (tobacco product standards) that are
applicable to the tobacco product. In the alternative, the SE Report
must state that there are no requirements under section 907 that are
applicable to the new tobacco product. For SE Reports that are
submitted after the finalization of this rule, but still pending after
issuance of any future tobacco product standards, FDA invites public
comments on how such pending SE Reports should be considered or handled
in relation to the satisfaction of the requirement for a statement of
compliance with applicable tobacco product standards.
j. Health information summary or statement regarding availability
of such information. As required by section 910(a)(4) of the FD&C Act,
the SE Report must include either an adequate summary of any health
information related to the new tobacco product or a statement that such
information would be made available upon request by any person.
Proposed Sec. 1107.18(j) would codify this statutory requirement and
ensure that applicants provide adequate information as required by
section 910(a)(4). Under proposed Sec. 1107.18(j)(1), if the applicant
chooses to provide a health information summary, the applicant would be
required to provide a redacted version of the full SE Report that
excludes research subject identifiers and trade secret and confidential
commercial information as defined in Sec. Sec. 20.61 and
[[Page 12758]]
20.63 (21 CFR 20.61 and 20.63). FDA believes that an SE Report redacted
in the manner described would generally provide an adequate summary of
any health information related to the new tobacco product, as well as
detailed information regarding data concerning adverse health effects
of the new tobacco product. The redacted SE Report would be required to
be submitted with the original submission, and a redacted copy of an
amendment would be required with the submission of any amendment to the
SE Report.
In addition, to the extent that there is additional health
information about the new tobacco product, including any information,
research (e.g., published or unpublished research, internal reports or
analyses), or data about adverse health effects, that the applicant has
or knows about and that is not contained in the SE Report, the
applicant would be required to provide such accurate and complete, and
not false or misleading, information in the health information summary.
If there is no such additional health information, the SE Report would
be required to include a statement that the company does not have and
does not know of any such additional health information. FDA would post
the health information summary, including the redacted SE Report, and
any additional health information provided by the applicant on FDA's
website.
Under proposed Sec. 1107.18(j)(2), if the applicant chooses to
make the health information available upon request, the SE Report would
be required to include a certification statement made by an authorized
representative of the applicant that an adequate summary of any health
information related to the new tobacco product, including detailed
information regarding data concerning adverse health effects of the new
tobacco product, would be made available to a requestor within 30
calendar days of a request. The certification is intended to ensure
that applicants understand that they are responsible for providing this
information upon request.
Under proposed Sec. 1107.18(j)(3), the health information the
applicant would need to make available would be a copy of the full SE
Report (which includes any amendments), excluding research subject
identifiers and trade secret and confidential commercial information as
defined in Sec. Sec. 20.61 and 20.63. To the extent that the applicant
has or knows of any additional health information, including any
information, research, or data regarding adverse health effects that is
not contained in the SE Report, the applicant would also provide the
requester such accurate and complete, and not false or misleading,
information. If there is no such additional health information, the
applicant would provide the requester with a statement that the company
does not have and does not know of any such additional health
information.
Proposed Sec. 1107.18(j)(4) would provide that requests for health
information be made to the authorized representative of the applicant,
whose contact information the applicant would provide to FDA. FDA
intends to make this contact information available on FDA's website.
The applicant would be required to update this contact information with
FDA whenever necessary (e.g., the identified authorized representative
is no longer with the company or the address or telephone information
changes). If an applicant elects to include the statement in their SE
Report, the applicant would be required to provide the information to
persons who request it. Applicants would not be permitted to later
amend SE Reports on which FDA has issued a marketing order to choose
instead to submit a health information summary. Therefore, applicants
that provide the statement instead of providing the summary to FDA as
part of the SE Report must be prepared to provide the information
required under section 910(a)(4) of the FD&C Act, as implemented
through proposed Sec. 1107.18(j).
Under proposed Sec. 1107.18(j)(5), to the extent information is
included in the health information summary or the health information
provided upon request under paragraphs (j)(1) and (2) of this section
that is not required by section 910(a)(4) of the Federal Food, Drug,
and Cosmetic Act or paragraph (j) of this section, that information
cannot contain a statement that would cause the proposed new tobacco
product to be in violation of section 911 of the FD&C Act (21 U.S.C.
387k) upon the introduction or delivery for introduction of the
proposed new product into interstate commerce. If an applicant includes
such a statement in its health information summary or in the health
information the applicant provides upon request, the review of the
applicant's SE Report may be delayed.
FDA would generally not consider a statement of relative risk to be
required by section 910(a)(4) of the FD&C Act or paragraph (j) of this
section if the risk being conveyed is unrelated to the applicant's
demonstration that the new product is substantially equivalent and
FDA's review of the SE Report. For example, if an applicant submitted
an SE Report for a new smokeless tobacco product and identified a
smokeless tobacco product as the predicate product, a statement
comparing the tar in the new smokeless tobacco product to the tar in a
cigarette would generally be unrelated to the applicant's demonstration
that the new product is substantially equivalent and FDA's review of
the SE Report.
For the purposes of Sec. 1107.18(j), any statement an applicant is
required to include in a health information summary or the health
information provided in response to a request--including statements
made in an SE Report (e.g., comparisons of HPHCs between the new and
predicate tobacco products)--typically would not cause the proposed new
tobacco product to be in violation of section 911 of the FD&C Act upon
introduction or delivery for introduction of the proposed new product
into interstate commerce. Congress required applicants to submit health
information summaries with their SE Reports or to provide such
information upon request. Nothing in section 911 of the FD&C Act
suggests that Congress intended for that provision to impede an
applicant's ability to fulfill its obligations under section 910(a)(4)
of the FD&C Act.
k. Compliance with part 25. An applicant must include an
environmental assessment (EA) prepared in accordance with Sec. 25.40
or a valid claim of a categorical exclusion, if applicable. (Under
Sec. 25.15(a), all submissions requesting FDA action require the
submission of either a claim of categorical exclusion or an EA.) In
accordance with Sec. 25.40(a), an environmental assessment must
include, at a minimum, brief discussions of the need for the proposed
action, of alternatives as required by section 102(2)(E) of the
National Environmental Policy Act (NEPA), of the environmental impacts
of the proposed action and alternatives, a listing of the agencies and
persons consulted, and the relevant environmental issues relating to
the use and disposal from use. Although applicants may wish to review
the categorical exclusions specific to tobacco product applications at
Sec. 25.35, the only categorical exclusion currently available for an
order authorizing the marketing of a new tobacco product is found at
Sec. 25.35(a), and applies only to orders finding provisional products
substantially equivalent. If the applicant believes the action would
qualify for an available categorical exclusion, the applicant would be
required to state under Sec. 25.15(a) and (d) that the action
qualifies for a categorical exclusion, cite to the claimed exclusion,
and state that to the applicant's knowledge no
[[Page 12759]]
extraordinary circumstances exist under Sec. 25.21.
To evaluate the environmental impact (as described in Sec.
25.40(a)), information that addresses the status of the new tobacco
product relative to the predicate tobacco product would be required.
Accordingly, the environmental assessment would be required to include
a statement indicating whether the new tobacco product is intended to:
(1) Replace the predicate tobacco product once the new tobacco product
receives market authorization and is commercially marketed; (2) be a
line extension of the predicate tobacco product; (3) be marketed along
with the predicate product by the same manufacturer; and/or (4) be
marketed along with the predicate tobacco product by a different
manufacturer (e.g., by a manufacturer other than the manufacturer of
the predicate tobacco product). This statement would be included in the
section on the need for the proposed action and would help FDA
understand the environmental impact of an SE order by understanding the
marketing intention for the new and predicate tobacco products. The
marketing authorization of a new tobacco product may have a different
impact if the new tobacco product is intended to be marketed along with
the predicate tobacco product than if the new tobacco product is
intended to replace a predicate tobacco product.
l. Certification statement. Proposed Sec. 1107.18(l)(1) would
require that an applicant include in the SE Report a specific statement
certifying that the applicant would maintain all records to
substantiate the accuracy of the report consistent with the record
retention requirements in proposed Sec. 1107.58, that, to the best of
their knowledge, the information and accompanying submission are true
and correct, no material fact has been omitted, the signer is
authorized to submit the information on the applicant's behalf, and
that the signer understands that anyone who knowingly and willfully
makes a materially false, fictitious, or fraudulent statement or
representation in any matter within the jurisdiction of the executive,
legislative, or judicial branch of the Government of the United States
is subject to criminal penalties (under 18 U.S.C. 1001). The
certification is intended to provide FDA with additional assurance that
the applicant has fully considered the SE Report and its contents, that
the applicant believes there is a basis for making the findings
required by section 910(a)(2) of the FD&C Act, and that the applicant
understands the potential consequences of submitting false information
to the U.S. Government.
In addition, under proposed Sec. 1107.18(l)(2), if an SE Report
states that the new tobacco product has certain characteristics that
are identical to the predicate tobacco product (though not all
characteristics, such that the product would not be ``new''), an
applicant can choose to submit a certification in lieu of providing
information for each characteristic of the new and predicate tobacco
products. FDA would permit the applicant to certify that the other
characteristics are identical as long as the applicant maintains
supporting documentation, including the records demonstrating the
comparison information detailed in proposed Sec. 1107.19. The records
would be required to be maintained consistent with proposed Sec.
1107.58. The certification must be signed by an authorized
representative of the applicant.
3. Comparison Information (Proposed Sec. 1107.19)
This proposed section describes the comparison information that
would be required in the SE Report. Comparative testing supports the SE
Report by showing the information contained in the SE Report is
meaningful and accurate; where applicable, the testing also helps
demonstrate that the different characteristic(s) in a new tobacco
product does not raise different questions of public health. FDA
requests public comments on the quantitative and qualitative
differences in each of the design parameters for each of the tobacco
product categories identified below as well as data to support such
values or characteristics.
a. Product design. Proposed Sec. 1107.19(a) would require the SE
Report to include descriptions of the product designs of the new and
predicate tobacco products and identify any differences. This proposed
section would require that the information be in a tabular format with
a side-by-side comparison of each design parameter of the new and
predicate tobacco products. The SE report would also be required to
include for each design parameter a target value and range of
acceptable values, actual measured value (if applicable), and ranges of
measured values (if applicable) with units of measure. The report would
also be required to include test data for each applicable design
parameter. Proposed Sec. 1107.19(a)(1)-(6) would establish the
required design parameter information for the tobacco product category,
as follows:
For cigarettes, the required design parameter information to be
provided for each predicate and new tobacco product would be:
Table 3--Required Design Parameter Information for Cigarettes
------------------------------------------------------------------------
Provide test data (include
test protocols, quantitative
Provide target specification with upper acceptance criteria, data
and lower range limits for: sets, and a summary of the
results) for:
------------------------------------------------------------------------
--Cigarette length (mm) --Puff count.
--Cigarette circumference (mm) --Cigarette draw resistance
(mm H2O).
--Cigarette draw resistance (mm H2O) --Tobacco filler mass (mg).
--Tobacco filler mass (mg) --Tobacco moisture (%).
--Tobacco rod density (g/cubic centimeter --Filter ventilation (%).
(cm3))
--Tobacco moisture (%) --Cigarette paper base paper
basis weight (g/m2).
--Filter ventilation (%) --Cigarette paper base paper
porosity (CU).
--Tipping paper length (mm) --Cigarette paper band
porosity (CU).
--Cigarette paper base paper basis weight --Filter efficiency (%) [If
(g/meter squared(m2)) no filter efficiency data
is available for the
products, include
information sufficient to
show that the cigarette
filter is unchanged (e.g.,
denier per filament, total
denier, and filter
density)].
--Filter pressure drop (mm
H2O).
--Cigarette paper base paper porosity (CU)
--Cigarette paper band porosity (CU)
--Cigarette paper band width (mm)
--Cigarette paper band space (mm)
[[Page 12760]]
--Filter efficiency (%) (If no filter
efficiency data is available for the
products, include information sufficient
to show that the cigarette filter is
unchanged (e.g., denier per filament,
total denier, and filter density))
--Filter length (mm)
--Filter pressure drop (mm H2O)
------------------------------------------------------------------------
FDA is proposing to require that these parameters be included for
cigarettes because variations in these parameters may cause the new
tobacco product to raise different questions of public health, as
described below:
A difference in cigarette length may alter tobacco
biomarker levels (Ref. 5).
A difference in cigarette circumference may affect filter
efficiency and, in turn, smoke constituent yields (Ref. 6).
A difference in puff count can directly affect smoke
constituent yields (Ref. 7).
A difference in cigarette draw resistance may result in
differences in the difficulty of pulling air through the tobacco rod
and, in turn, affect smoke constituent yields (Ref. 8).
A difference in tobacco filler mass may affect smoke
constituent yields (Refs. 9 and 10).
A difference in tobacco rod density may modify burn
properties and smoke constituent yields (Refs. 11 and 12).
A difference in tobacco moisture may affect puff count
(Refs. 13-15).
A difference in cigarette paper base paper basis weight
may affect puff count and smoke constituent yields (Ref. 16).
A difference in cigarette paper base paper porosity may
affect smoke constituent yields (Ref. 16).
A difference in cigarette paper band porosity may affect
smoke constituent yields since band porosity allows for the overall
assessment of the weighted change in air flow through the cigarette
paper during active puffing (Refs. 18, 19, and 38).
A difference in cigarette paper band width may affect
ventilation and, in turn, smoke constituent yields (Ref. 20).
A difference in cigarette paper band space may affect
ignition propensity and, in turn, puff count (Ref. 21).
A difference in filter efficiency may affect smoke
constituent yields (Refs. 18 and 20).
A difference in denier per filament may affect filter
efficiency and, in turn, smoke constituent yields (Ref. 22).
A difference in total denier may affect filter efficiency
and, in turn, smoke constituent yields (Ref. 22).
A difference in filter density may affect filter
efficiency and, in turn, smoke constituent yields (Ref. 22).
A difference in filter pressure drop may affect smoke
constituent yields (Ref. 23, slide 40).
A difference in filter length may affect filter efficiency
and, in turn, smoke constituent yields (Ref. 22).
A difference in filter ventilation may affect smoke
constituent yields (Ref. 6).
A difference in tipping paper length may affect smoke
constituent yields (Ref. 24).
For portioned and non-portioned smokeless tobacco products, the
required design parameter information to be provided for each predicate
and new tobacco product would be:
Table 4--Required Design Parameter Information for Portioned and Non-
Portioned Smokeless Tobacco Products
------------------------------------------------------------------------
Provide test data (include
test protocols, quantitative
Provide target specification with upper acceptance criteria, data
and lower range limits for: sets, and a summary of the
results) for:
------------------------------------------------------------------------
Portioned Smokeless Tobacco Products
------------------------------------------------------------------------
--Tobacco cut size (mm) --Tobacco cut size (mm).
--Tobacco moisture (%) --Tobacco moisture (%).
--Portion length (mm) (if applicable) --Portion mass (mg) (if
applicable).
--Portion width (mm) (if applicable) --Pouch paper porosity (CU).
--Portion mass (mg) (if applicable) --Pouch paper basis weight
(g/m2).
--Portion thickness (mm) (if applicable).
--Pouch paper wicking.
--Pouch paper porosity (CU).
--Pouch paper basis weight (g/m2).
------------------------------------------------------------------------
Non-portioned Smokeless Tobacco Products
------------------------------------------------------------------------
--Tobacco cut size (mm). --Tobacco cut size (mm).
--Tobacco moisture (%). --Tobacco moisture (%).
------------------------------------------------------------------------
FDA is proposing to require that these parameters be included for
smokeless tobacco products because variations in these parameters may
cause the new tobacco product to raise different questions of public
health, as described below:
A difference in tobacco cut size may alter the surface
area and accessibility of saliva to get to the surfaces of the tobacco,
thereby affecting the amount and rate of constituents released from the
product (Ref. 25).
A difference in tobacco moisture may affect microbial
growth in the product, extraction efficiency, and total exposure to
nicotine, NNN, and NNK (Ref. 26).
[[Page 12761]]
A difference in portion mass may affect user exposure to
the tobacco product and, in turn, exposure to the HPHCs contained in
each portion (Ref. 27).
A difference in portion length as it relates to portion
size may affect the amount of constituents in each portion (Ref. 27).
A difference in portion width may result in a surface area
difference, which is proportional to the amount and rate of
constituents released from the product (Ref. 28).
A difference in portion thickness may result in a surface
area difference, which is directly proportional to the amount and rate
of constituents released from the product (Ref. 28).
A difference in pouch paper basis weight may alter the
interactions between the tobacco and oral cavity, thereby affecting the
amount and rate of constituents released from the product (Ref. 29).
A difference in pouch paper porosity may alter the
interactions between the tobacco and oral cavity, thereby affecting the
amount and rate of constituents released from the product (Ref. 29).
For RYO tobacco rolling papers, the required design parameter
information to be provided for each predicate and new tobacco product
would be:
Table 5--Required Design Parameter Information for RYO Tobacco Rolling
Papers
------------------------------------------------------------------------
Provide test data (include
test protocols, quantitative
Provide target specification with upper acceptance criteria, data
and lower range limits for: sets, and a summary of the
results) for:
------------------------------------------------------------------------
--Paper length (mm). --Mass per paper (mg).
--Paper width (mm). --Cigarette paper base paper
basis weight (g/m2).
--Mass per paper (mg). --Cigarette paper base paper
porosity (CU).
--Cigarette paper base paper basis weight --Cigarette paper band
(g/m)2. porosity (CU) (if
applicable).
--Cigarette paper base paper porosity
(CU).
--Cigarette paper band porosity (CU) (if
applicable).
--Cigarette paper band width (mm) (if
applicable).
--Cigarette paper band space (mm)
(applicable).
------------------------------------------------------------------------
FDA is proposing to require that these parameters be included for
rolling papers because variations in these parameters may cause the new
tobacco product to raise different questions of public health, as
described below:
A difference in overall length may alter the surface area
that is available for tobacco packing, thereby affecting the smoke
constituent yields (Ref. 23, slide 46).
A difference in overall width may alter the surface area
that is available for tobacco packing, thereby affecting the smoke
constituent yields (Ref. 23, slide 46).
A difference in total mass per pack may be a result of a
surface area or basis weight difference and, in turn, may affect puff
count and smoke constituent yields (Refs. 16 and 23 (slide 46)).
A difference in RYO paper base paper basis weight may
affect puff count and smoke constituent yields (Ref. 16).
A difference in RYO paper base paper porosity may affect
smoke constituent yields (Ref. 16).
A difference in RYO paper band porosity may affect smoke
constituent yields because band porosity allows for the overall
assessment of the weighted change in air flow through the cigarette
paper during active puffing (Refs. 17 and 37).
A difference in RYO paper band width may affect
ventilation and, in turn, smoke constituent yields (Ref. 20).
A difference in RYO paper band space may affect ignition
propensity and, in turn, puff count (Ref. 21).
For RYO tobacco tubes, the required design parameter information to
be provided for each predicate and new tobacco product is as follows:
Table 6--Required Design Parameter Information for RYO Tobacco Tubes
------------------------------------------------------------------------
Provide test data (include
test protocols, quantitative
Provide target specification with upper acceptance criteria, data
and lower range limits for: sets, and a summary of the
results) for:
------------------------------------------------------------------------
--Tube length (mm). --Total mass (mg).
--Tube circumference (mm). --Cigarette paper base paper
basis weight (g/m2).
--Total mass (mg). --Cigarette paper base paper
porosity (CU).
--Cigarette paper base paper basis weight --Cigarette paper band
(g/m2). porosity (CU).
--Cigarette paper base paper porosity
(CU).
--Cigarette paper band porosity (CU).
--Cigarette paper band width (mm).
--Cigarette paper band space (mm).
------------------------------------------------------------------------
For RYO tobacco filtered tubes, the required design parameter
information to be provided for each new predicate and new tobacco
product would be:
Table 7--Required Design Parameter Information for RYO Tobacco Filtered
Tubes
------------------------------------------------------------------------
Provide test data (include
test protocols, quantitative
Provide target specification with upper acceptance criteria, data
and lower range limits for: sets, and a summary of the
results) for:
------------------------------------------------------------------------
--Tube length (mm). --Total mass (mg).
--Tube circumference (mm). --Filter ventilation (%).
--Total mass (mg). --Cigarette paper base paper
basis weight (g/m2).
--Tipping paper length (mm). --Cigarette paper base paper
porosity (CU).
[[Page 12762]]
--Filter ventilation (%). --Cigarette paper band
porosity (CU).
--Cigarette paper base paper basis weight --Filter denier per filament
(g/m2). (DPF).
--Cigarette paper base paper porosity --Filter total denier (g/
(CU). 9000m).
--Cigarette paper band porosity (CU). --Filter density (g/cm3).
--Cigarette paper band width (mm). --Filter pressure drop (mm
H2O).
--Cigarette paper band space (mm).
--Filter length (mm).
--Filter denier per filament (DPF).
--Filter total denier (g/9000m).
--Filter density (g/cm3).
--Filter pressure drop (mm H2O).
------------------------------------------------------------------------
FDA is proposing to require that these parameters be included for
RYO tobacco tubes because variations in these parameters may cause the
new tobacco product to raise different questions of public health, as
described below:
A difference in tube length may alter tobacco biomarker
levels (Ref. 5).
A difference in tube circumference may affect filter
efficiency and, in turn, smoke constituent yields (Ref. 6).
A difference in total mass per pack may be a result of a
surface area or basis weight difference and, in turn, may affect puff
count and smoke constituent yields (Refs. 16 and 23 (slide 46)).
A difference in tube paper base paper basis weight may
affect puff count and smoke constituent yields (Ref. 16).
A difference in tube paper base paper porosity may affect
smoke constituent yields (Ref. 16).
A difference in tube paper band porosity may affect smoke
constituent yields since band porosity allows for the overall
assessment of the weighted change in air flow through the cigarette
paper during active puffing (Refs. 17 and 37).
A difference in tube paper band width may affect
ventilation and, in turn, smoke constituent yields (Ref. 20).
A difference in tube paper band space may affect ignition
propensity and, in turn, puff count (Ref. 21).
A difference in filter efficiency may affect smoke
constituent yields (Ref. 13).
A difference in denier per filament may affect filter
efficiency and, in turn, smoke constituent yields (Ref. 22).
A difference in total denier may affect filter efficiency
and, in turn, smoke constituent yields (Ref. 33).
A difference in filter density may affect filter
efficiency and, in turn, smoke constituent yields (Ref. 32).
A difference in filter pressure drop may affect smoke
constituent yields (Ref. 23, slide 40).
A difference in filter length may affect filter efficiency
and, in turn, smoke constituent yields (Ref. 32).
A difference in ventilation may affect smoke constituent
yields (Ref. 24).
A difference in tipping paper length may affect smoke
constituent yields (Ref. 24).
For RYO tobacco, the required design parameter information to be
provided for each predicate and new tobacco product would be:
Table 8--Required Design Parameter Information for RYO Tobacco
------------------------------------------------------------------------
Provide test data (include
test protocols, quantitative
Provide target specification with upper acceptance criteria, data
and lower range limits for: sets, and a summary of the
results) for:
------------------------------------------------------------------------
--Tobacco filler mass (mg). --Tobacco filler mass (mg).
--Tobacco cut size (mm). --Tobacco cut size (mm).
--Tobacco moisture (%). --Tobacco moisture (%).
------------------------------------------------------------------------
FDA is proposing to require that these RYO tobacco parameters be
included for RYO tobacco because variations in these parameters may
cause the new tobacco products to raise different questions of public
health, as described below:
A difference in tobacco filler mass may affect smoke
constituent yields when used with rolling paper (Ref. 9).
A difference in tobacco cut width alters the size of the
tobacco pieces, which may result in more particulate matter (Ref. 30).
A difference in moisture may affect smoke composition
(Ref. 13).
For tobacco products not specifically identified (e.g., ENDS,
cigars) FDA invites comments and information on the parameters that may
be needed to support an SE Report.
b. Heating source. Proposed Sec. 1107.19(b) would require that the
SE Report include a description of any heating source for both the new
and predicate tobacco products (e.g., burning coal, electric, chemical
reaction, carbon tip) and identify any differences. If there is no
heating source for the new and predicate tobacco products, the SE
Report would be required to state that.
c. Product composition. Proposed Sec. 1107.19(c) would require
that the SE Report include descriptions of the product composition of
the new and predicate tobacco products and identify any differences.
The information would be required to be in tabular format with a side-
by-side comparison of the materials and ingredients for each component
or part of the new and predicate tobacco products. Under the proposed
rule, the SE Report would be required to provide for each material and
ingredient the following information: The quantity, the target value
and range of acceptable values, actual measured value (where
applicable), and range of measured values (where applicable) reported
as mass per component or part.
Proposed Sec. 1107.19(c)(1) would require that the SE Report
include the following information for each material in the product:
The material name and common name (if applicable);
The component or part where it is located;
[[Page 12763]]
The subcomponent or subpart where it is located (if
applicable);
The function of the material;
Quantities (including ranges or means and acceptance
limits) with identification of any specification variation between the
new tobacco product and predicate tobacco product;
Specifications (including quality, grades, and suppliers)
used for the new tobacco product and the predicate (including any
specification variations, if applicable); and
Any other material properties necessary to characterize
the new and predicate tobacco products.
Proposed Sec. 1107.19(c)(2) would require that the SE Report
include information on ingredients other than tobacco (information on
tobacco ingredients is addressed in proposed Sec. 1107.19(c)(3)).
Required information would include:
International Union of Pure and Applied Chemistry chemical
name and common name (if applicable);
Chemical Abstracts Service (CAS) number(s) or FDA Unique
Ingredients Identifier;
The function of the ingredient;
The quantity with the unit of measure (including ranges or
means, and acceptance limits) of the materials in the new tobacco
product and predicate tobacco product (with any specification
variation, if applicable);
The specifications (including purity or grade and
supplier);
For complex purchased ingredients, each single chemical
substance reported separately; and
Any other ingredient information necessary to characterize
the new and predicate tobacco products.
Proposed Sec. 1107.19(c)(3) would require information on tobacco
ingredients. This information would include the following:
The type of tobacco, including grade and variety. This
impacts the characteristics of the products because different grades
have different constituent profiles (the SE Report would need to
include information on the applicant's grading system so that FDA
understands the grade);
The quantity, with the unit of measure (including ranges
or means, and acceptance limits), of tobacco in the new and predicate
tobacco products (with a specification variation, if applicable);
The specification of tobacco used for the new tobacco
product and predicate tobacco product (with any specific variation, if
applicable);
A description of any genetic engineering that impacts
characteristics, because genetic engineering affects the constituent
profile; and
Any other information about tobacco ingredients necessary
to characterize the new and predicate tobacco products.
If the new tobacco product does not contain tobacco (e.g., rolling
paper or tipping paper), this section of the report would be required
to state that.
FDA is proposing that ingredient quantities under proposed Sec.
1107.19(c)(2) and (3) be reported as mass per gram of tobacco for non-
portioned tobacco products and as mass per portion for portioned
tobacco products. These specific measurements provide consistent,
complete information that would allow FDA to understand the ingredient
quantities. In contrast, if ingredient quantities were reported as
percentages, FDA would have to make assumptions about the denominator
used to calculate the percentage. For example, if xylitol were reported
as 10 percent of a portioned moist snuff, FDA would not able to
determine if xylitol was 10 percent of the mass of the tobacco filler
or of the entire product (containing filler, paper, etc.).
Proposed Sec. 1107.19(c)(4) would require that the SE Report
include a description of the container closure system for the new and
predicate tobacco products, including a side-by-side quantitative
comparison of the subcomponents or subparts and materials and annotated
illustrations.
d. Other features. Proposed Sec. 1107.19(d) would require that the
SE Report include descriptions of any other applicable features of the
new and predicate tobacco products and identify any differences that
exist. If a specific feature described in proposed Sec. 1107.19(d) is
not applicable to the new tobacco product, the SE Report would be
required to state as such. In response, FDA may request a scientific
explanation for why a particular feature is not applicable, and under
proposed Sec. 1107.19(d) the applicant would be required to provide
that information to FDA. The SE Report must also address any other
product characteristics that relate to the chemical, physical or
biological properties of the tobacco product and are necessary for SE
Report review.
Specifically, proposed Sec. 1107.19(d)(1) would require that the
SE Report include HPHC and other constituent information as appropriate
to demonstrate that: (1) The new tobacco product has the same
characteristics as the predicate tobacco product or (2) any differences
in characteristics between the new and predicate tobacco product do not
cause the new tobacco product to raise different questions of public
health, as follows:
Constituent names in alphabetical order,
Common names,
CAS number,
Mean quantity and variance with unit of measure,
Number of samples and measurement replicates for each
sample,
Analytical methods used, description and associated
reference(s),
Testing laboratory(ies) and accreditation information,
Length of time between dates of manufacture and dates of
testing,
Storage conditions of the tobacco product before it was
tested, and
Full test data (including test protocols, any deviations
from the test protocols, quantitative acceptance (pass/fail) criteria,
and complete data sets) for all testing performed.
For combusted tobacco products, constituent smoke yields from the
new and predicate products would need to be determined using intense
and non-intense smoking regimens.\10\ Two smoking regimens are required
in order to understand the way that constituent yields delivered by a
tobacco product can change over a range of different smoking
conditions. If constituent yields were only reported from a single
smoking regimen, FDA would have limited and potentially misleading
information about constituent yields produced by a given tobacco
product. Many studies demonstrate that different smoking regimens
result in different constituent yields from the same product (Refs. 31
and 32). By requiring both an intense and a non-intense smoking
regimen, FDA would have a better understanding of quantities of each
constituent that may be produced by the tobacco product when smoked
under different conditions. If an alternative to these smoking regimens
is used, the applicant would be required to provide an explanation of
why the alternative provides comparable results to the intense and non-
intense smoking regimens.
---------------------------------------------------------------------------
\10\ These refer to regimens by the International Organization
for Standardization and Health Canada.
---------------------------------------------------------------------------
FDA is proposing that the HPHC information in an SE Report for a
new cigarette include, at a minimum, a comparison of the quantities of
nicotine-dry particulate matter, total particulate matter, carbon
monoxide, and nicotine (total) in the mainstream smoke of the new
tobacco product with that of the predicate tobacco product, using both
intense and non-intense smoking regimens. Further, additional HPHC
[[Page 12764]]
yields may need to be reported in order to demonstrate that: (1) The
new tobacco product has the same characteristics as the predicate
tobacco product or (2) any differences in characteristics do not cause
the new tobacco product to raise different questions of public health.
For example, blend differences may require reporting of HPHC yields
specific to the differences in tobacco blends. Studies show that the
mainstream smoke of burley and reconstituted tobaccos contains much
higher TSNA levels than the mainstream smoke of bright and oriental
tobacco, whereas the mainstream smoke of bright tobacco contains higher
benzo[a]pyrene levels than other tobacco types (Refs. 33 and 34).
Reconstituted tobacco can produce high levels of carbon monoxide,
nitrogen oxides, and TSNAs during combustion (Ref. 8). Smoke from
cigarettes made from expanded stems is higher in carbon monoxide,
nitrous oxides, formaldehyde, tar, benzo[a]anthracene, and
benzo[a]pyrene than smoke from cigarettes made of puffed tobacco,
expanded tobacco, or freeze-dried tobacco (Ref. 30). Similarly,
addition of sugar or corn syrup to a tobacco product may increase HPHCs
such as formaldehyde and may therefore require additional HPHC
measurements (Ref. 35). Or, if the new tobacco product contains
significantly more guar gum (a binder in rod paper and tobacco blends)
than the predicate product, additional HPHC yields may be required to
be reported because pyrolysis of guar gum may form formaldehyde,
acetaldehyde, acetone, benzene, cresol, and toluene (Refs. 39-41).
Based on its experience reviewing new tobacco products, FDA has
found significant increases in HPHCs (e.g., TSNAs and polycyclic
aromatic hydrocarbons (PAHs)) in cigarettes due to changes in types of
tobacco when compared to a predicate tobacco product. For all new
cigarettes that have a substantial increase in other types of tobacco,
to support a finding of SE the applicant should include a comparison of
TSNAs and PAHs in the mainstream smoke of the new tobacco product with
that of the predicate tobacco product using both intense and non-
intense smoking regimens. Depending on the specific differences between
the new and predicate products, quantities of additional HPHCs in
mainstream smoke may be required to be reported.
For a smokeless tobacco product, the HPHC information in an SE
Report would need to include a comparison of the quantities of total
and free nicotine, total TSNAs, NNN, and NNK in the tobacco of the
products. Depending on the specific differences between the new and
predicate products, the applicant may be required to report quantities
of additional HPHCs in the product.
Proposed Sec. 1107.19(d)(2) would require that the SE Report
include a description and comparison of any other features of the new
and predicate tobacco products.
Proposed Sec. 1107.19(e) would require stability information for
smokeless tobacco products and any tobacco product that contains
fermented tobacco. As described in more detail in the following
paragraphs, stability information is a particular concern with
smokeless tobacco products and other tobacco products that contain
fermented tobacco because the characteristics of these products can be
affected by the manufacturing process, storage conditions, and length
of time on a shelf. Accordingly, proposed Sec. 1107.19(e) would
require stability information for the new and predicate tobacco
products, including:
A description of how stability is indicated and whether
stability testing is identical for the predicate and new tobacco
products (proposed Sec. 1107.19(e)(i));
Any known or expected impacts on product stability due to
differences between the new and predicate products (if there are none,
the SE Report would state that) (proposed Sec. 1107.19(e)(ii)). For
example, for products that contain fermented tobacco, the SE Report
would be required to provide information on the fermentation processing
steps, including the following:
[cir] Composition of the inoculum including species name(s) and
concentration(s)
[cir] pH
[cir] Temperature
[cir] Moisture content
[cir] Water activity
[cir] Duration
[cir] Ingredients added.
FDA is proposing to require that this information be submitted in
the SE Report because these parameters of the fermentation process can
result in different degrees of change in the chemical constituents of
the tobacco (Refs. 42 and 43) and affect the type and amount of
microorganisms in the final product (Ref. 44), thereby affecting the
stability of the product, which could change the characteristics of the
tobacco product, which may cause the new tobacco product to raise
different questions of public health. In addition, the type and amount
of the fermentation inoculum can be used to control or affect the
fermentation process and thus, can change the product as a result of
directed fermentation, which could cause the new tobacco product to
raise different questions of public health (Ref. 45).
Detailed stability testing information, including test
protocols, quantitative acceptance criteria, data sets, and a summary
of the results for all stability testing performed (proposed Sec.
1107.19(e)(iii)). Stability testing would be required to be performed
at the beginning (zero time), middle, and end of the expected storage
time for the following chemical and microbial endpoints:
[cir] Microbial content data, including total aerobic microbial count
and total yeast and mold count, along with identification of detected
microbiological organisms by genus and species names (if applicable)
[cir] pH
[cir] Moisture content
[cir] Water activity
[cir] Tobacco-specific nitrosamines (TSNAs, including total, NNN, and
NNK)
[cir] Nitrate and nitrite levels
[cir] Preservatives and microbial metabolic inhibitors, if any
[cir] Method of heat treatment or pasteurization used to reduce
microbial loads.
The proposed rule would require this information because product
stability is affected by factors such as the fermentation and
stabilization processes (if applicable), addition of chemical additives
to control microbial activity (e.g., preservatives, metabolic
inhibitors, humectants), and water activity (aw) of the
product (Refs. 42, 46-48). Additionally, factors such as nitrate/
nitrite concentrations, moisture content, microbial content, storage
temperature, and pH are reported to influence the microbial stability
and TSNA formation during storage of tobacco products (Refs. 49-53).
Storage conditions for samples retained for testing,
identifying the test methods used, along with testing of the tobacco
product in the same container closure system as that in which the
tobacco product is intended to be marketed, and testing supporting the
expiration date (proposed Sec. 1107.19(e)(iv)). Accelerated studies,
combined with basic stability information, could be used to support
tentative expiration dates provided full shelf life studies are not yet
available but are being conducted. Where data from accelerated studies
are used to project a tentative expiration date that is beyond a date
supported by actual shelf-life studies, stability studies would need to
be conducted to support the SE
[[Page 12765]]
Report, including tobacco product testing at appropriate intervals,
until the tentative expiration date could be verified or the
appropriate expiration date could be determined.
Proposed Sec. 1107.19(e)(v) and (vi) would require information on
the stability testing laboratory and identification of the
microbiological organisms by genus and species names, where applicable,
along with the culture collection number either used during the
manufacturing process and/or detected through stability testing.
Proposed Sec. 1107.19(f) would require applicants to state that
the new tobacco product has either: (1) The same characteristics as the
predicate tobacco product and the basis for this determination or (2)
different characteristics than the predicate tobacco product. Where an
applicant states that its new tobacco product has different
characteristics than the predicate tobacco product, the applicant must
also include an explanation as to why a difference in any of the
following characteristics do not cause the new product to raise
different questions of public health: Product design (see Sec.
1107.19(a)); heating source (see Sec. 1107.19(b)); materials and
ingredients (see Sec. 1107.19(c)); and other features (see Sec.
1107.19(d)). In addition, in order to demonstrate that a new tobacco
product with different characteristics is substantially equivalent, an
applicant must also explain why any differences in the manufacturing
process that could affect the characteristics of the new product do not
cause the new product to raise different questions of public health
(see Sec. 1107.18(e)). Similarly, for smokeless tobacco products, an
applicant must explain why any difference in stability between the new
tobacco product and the predicate tobacco product does not raise
different questions of public health (see Sec. 1107.19(e)).
Proposed Sec. 1107.19(g) would explain that, if the applicant is
comparing the new tobacco product to a predicate product that FDA has
previously found to be substantially equivalent to another product, FDA
may request that the applicant include information related to the
original grandfathered tobacco product. Although an applicant can
support a showing of SE by comparing the new tobacco product to a
tobacco product that is grandfathered or that FDA has previously found
SE, in order to issue an SE order, FDA must find that the new tobacco
product is substantially equivalent to a tobacco product commercially
marketed in the United States as of February 15, 2007 (see section
910(a)(2)(A)(i)(I) of the FD&C Act). This statutory provision helps FDA
ensure that new tobacco products using the substantial equivalence
pathway and relying on predicate tobacco products previously found SE
do not vary so much from the original grandfathered tobacco product
that the new product would actually raise different questions of public
health compared to the originally grandfathered tobacco product. New
products with differences that may appear only incremental when a new
tobacco product is compared to a predicate product previously found SE
may actually have had significant changes when compared to the
grandfathered tobacco product.
Because the statute permits applicants to compare to either a
grandfathered tobacco product or one that FDA has previously found SE
(section 905(j)(1)(A)(i)) but also requires FDA to make an SE
determination by comparing the new tobacco product to the grandfathered
tobacco product (section 910(a)(2)(A)(i)(I)), FDA is proposing the
approach in Sec. 1107.19(g). To meet its statutory obligation, FDA may
need to look back to previously submitted SE Reports in the SE chain
that rely on the original grandfathered product in order to issue an SE
order. Manufacturers have been on notice since the passage of the
Tobacco Control Act that FDA must make the comparison between the new
tobacco product and the original grandfathered tobacco product, and in
doing so, may need to rely on previously submitted SE Reports, even if
submitted by a different manufacturer than the applicant at hand.
Accordingly, for SE Reports that compare the new tobacco product to
a predicate tobacco product that FDA previously found substantially
equivalent, proposed Sec. 1107.19(g) states that, if requested by FDA,
the applicant would be required to provide information related to the
original grandfathered tobacco product, even if the grandfathered
tobacco product is several tobacco products removed from the predicate
identified by the applicant. FDA would request this information when
necessary to ensure that any order issued by the Agency complies with
section 910(a)(2)(A)(i)(I) of the FD&C Act. Before requesting this
information from the applicant, FDA would review other relevant SE
Reports in the chain, for example, the first SE Report that received an
SE order using the grandfathered product as a predicate product to make
this finding. If FDA is unable to look back to data provided to the
Agency regarding the grandfathered product and the applicant does not
provide the information, FDA would be unable to make the finding
required by section 910(a)(2)(A)(i)(I) of the FD&C Act. FDA encourages
applicants to provide this information with the initial SE Report to
support an efficient review of the SE Report, although FDA acknowledges
this may be more difficult if the applicant is not the manufacturer or
owner of the predicate tobacco product. FDA requests specific public
comment on this proposed provision and any challenges it may present.
4. Amendments (Proposed Sec. 1107.20)
Proposed Sec. 1107.20(a) would permit an applicant to submit an
amendment to an SE Report. Proposed Sec. 1107.20(a) would require any
applicant who chose to submit a health information summary with its SE
Report under proposed Sec. 1107.18(j)(1) to submit with the amendment
a redacted copy of the amendment that excludes research subject
identifiers and trade secret and confidential and commercial
information as defined in Sec. Sec. 20.61 and 20.63 (21 CFR 20.61 and
20.63).
An applicant may not amend an SE Report to change the predicate
tobacco product (proposed Sec. 1107.20(b)). Because the comparison
between the new and predicate tobacco products is the crux of the
substantial equivalence determination, changing the predicate product
changes the fundamental basis of the analysis. An applicant that
determines that a predicate change is necessary should withdraw the
initial SE Report and resubmit the SE Report with the information
related to the new predicate tobacco product as described in proposed
Sec. 1107.18.
In addition, under proposed Sec. 1107.20(c), an applicant may not
amend a closed SE Report, e.g., one that FDA has refused to accept,
closed, canceled, or issued an order for under proposed Sec. 1107.44,
or one that has been withdrawn under proposed Sec. 1107.22. Proposed
Sec. 1107.20(d) also explains that FDA would review the additional
information in the next review cycle (proposed Sec. 1107.42 discusses
review cycles). As explained in proposed Sec. 1107.62, SE Reports,
including amendments, would be submitted to CTP's Document Control
Center. Phone calls and emails to FDA staff would not be considered
amendments to an SE Report.
5. Withdrawal by Applicant (Proposed Sec. 1107.22)
Proposed Sec. 1107.22 would permit an applicant to make a request
to withdraw an SE Report unless FDA has closed the SE Report through an
action in proposed Sec. 1107.44 (all FDA actions in proposed Sec.
1107.44 would close the SE
[[Page 12766]]
Report except for a request for additional information in proposed
Sec. 1107.44(b)). FDA has determined that withdrawal of an SE Report
would benefit both the Agency and the applicant by potentially saving
time and resources if the original SE Report might otherwise be
insufficient or marketing authorization is no longer desired. The
withdrawal request would state: (1) If the withdrawal is due to a
health or safety concern related to the tobacco product; (2) the STN;
and (3) the name of the new tobacco product that is the subject of the
SE Report. This information would assist FDA in correctly identifying
the SE Report to be withdrawn and also help inform FDA as to whether
there were any concerns under section 909 of the FD&C Act (e.g.,
relating to serious unexpected adverse experiences). Under proposed
Sec. 1107.22(b), an SE Report would be considered withdrawn when FDA
issues a notice stating the SE Report has been withdrawn (see also
proposed Sec. 1107.40(e)).
The SE Report is an Agency record even if withdrawn. Thus, under
proposed Sec. 1107.22(c), FDA would retain the withdrawn SE Report
consistent with Agency record retention schedules and policies and,
under the Agency's public information regulations in part 20, would
provide a copy to the applicant upon request subject to Sec. 20.45. If
the withdrawal request is made at the final review stage and FDA has
identified unresolved deficiencies in the SE Report, FDA may provide a
list of deficiencies in the communication that the Agency sends to the
applicant acknowledging withdrawal. Under proposed Sec. 1107.40(e), an
SE Report would be considered withdrawn when FDA issues a notice
stating that it is withdrawn.
6. Change in Ownership of an SE Report (Proposed Sec. 1107.24)
Proposed Sec. 1107.24 would reflect that transfers in ownership of
SE Reports occur. This proposed section is intended to facilitate
transfers of ownership and help ensure that FDA has current information
regarding the ownership of an SE Report. Proposed Sec. 1107.24 applies
to both pending SE Reports and SE Reports that are the subject of an SE
order. Under proposed Sec. 1107.24, at the time of the transfer, the
new and former applicants (or owners) of the SE Report would be
required to submit certain information to the Agency. First, the former
applicant would be required to submit a notice to FDA identifying the
new applicant and stating that all of the former applicant's rights and
responsibilities relating to the SE Report have been transferred to the
new applicant. Second, the new applicant would be required to submit a
signed notice to FDA containing the following information:
To the extent applicable, the new applicant's commitment
to agreements, promises, and conditions made by the former applicant
and contained in the SE Report (e.g., this could be an agreement by the
new applicant to conduct studies the former applicant had agreed to
conduct in support of a request for an extension of time to respond to
a deficiency);
The date that the change in ownership is effective;
Either a statement that the new applicant has a complete
copy of the SE Report that FDA determined was substantially equivalent
(including any amendments, or any records required to be kept under
proposed Sec. 1107.58); or a statement of intent to request a copy of
the SE Report under the Freedom of Information Act (FDA's implementing
regulations are in part 20); and
A certification that no modifications have been made to
the new tobacco product since the SE Report was submitted to FDA.
Although FDA expects that the new applicant would have a copy of
the SE Report from the former applicant, if the new applicant requests
a copy of the SE Report from FDA, FDA would provide a copy to the new
applicant, subject to the Freedom of Information Act requirements as
implemented by FDA at part 20 and under the fee schedule in Sec.
20.45.
The new applicant also would be required to make available all
required records upon inspection by FDA (proposed Sec. 1107.58 would
impose a recordkeeping requirement). The information required to be
made available for inspection would include raw data and other
information necessary to substantiate the SE Report.
C. FDA Review (Proposed Subpart D)
1. Communications Between FDA and Applicants (Proposed Sec. 1107.40)
Proposed Sec. 1107.40 would establish general principles and
provide clarity regarding communications between FDA and applicants
during review of an SE Report. Proposed Sec. 1107.40(a) explains that,
during the course of FDA's review of an SE Report, FDA may seek to
communicate with applicants about relevant matters, including
scientific and procedural issues that arise during the review process.
Communications regarding medical issues may arise if adverse events
reports exist for the tobacco product. FDA may use a variety of methods
to communicate with applicants, such as telephone conversations,
letters, or emails, depending on the circumstances and issues. FDA
would document any communications regarding an SE Report in accordance
with 21 CFR 10.65.
Proposed Sec. 1107.40(b) would provide that applicants and
representatives of the Agency may have meetings to discuss scientific
and other issues. Applicants interested in requesting meetings would
direct their requests to the Office of Science through the Document
Control Center. For further information, applicants may review the
guidance entitled ``Meetings with Industry and Investigators on the
Research and Development of Tobacco Products'' (May 25, 2012, 77 FR
31368; revised guidance issued July 2016). As discussed in this
guidance, FDA does not intend to grant meetings in most circumstances
to discuss an applicant's questions related to a pending SE Report
because the timing is frequently inappropriate (e.g., premature or
late, depending on stage of review) and such meetings are generally an
inefficient or duplicative use of resources. For example, the applicant
may be seeking substantive information while FDA's review is underway
but before FDA has issued a deficiency letter or other response. Please
note that each SE Report has a specific CTP contact to whom an
applicant may ask clarifying questions, which helps ensure faster and
more direct responses. FDA specifically requests public comment on the
proposed decision to not grant meetings to discuss an applicant's
questions related to a pending SE Report. Specifically, FDA seeks to
understand if there are reasons why such meetings may be necessary for
an applicant to respond to a deficiency letter or if the absence of
such meetings present obstacles to the applicant in responding to
deficiency letters.
Proposed Sec. 1107.40(c) would provide that, upon receipt of an SE
Report under proposed Sec. 1107.18, FDA would either refuse to accept
the SE Report or issue an acknowledgement letter. FDA requests comment
on what a reasonable period of time would be within which such refusal
to accept or acknowledgement of receipt letters should be issued.
Proposed Sec. 1107.40(d) addresses FDA's notification of
deficiencies in an SE Report submitted under proposed Sec. 1107.18.
FDA reviewers would make reasonable efforts to communicate to
applicants the procedural, administrative, or scientific deficiencies
found in an SE Report and, if appropriate, the data needed to enable
[[Page 12767]]
the Agency's review. For example, a reviewer might inform the applicant
that a signature is needed for a certification, that provided test
results have last values cutoff or appear to have a typographical
error, or that the SE Report is missing a reference for support. This
communication is intended to give applicants an opportunity to correct
deficiencies in the SE Report and to submit an amendment if needed.
Proposed Sec. 1107.40(e) explains that an SE Report would be
considered withdrawn when FDA issues a notice stating that it is
withdrawn, which would ensure that FDA has received the withdrawal
notification and that both FDA and the applicant now consider the SE
Report as withdrawn.
FDA invites public comments on the following topics related to
reasonable time periods to respond to a deficiency letter:
Appropriate timelines for responding to a deficiency
letter identifying missing information that is described in the final
rule;
Appropriate timelines for responding to a deficiency
letter identifying missing information that requests additional
information not described in the final rule;
When requests for extensions of time to respond to a
deficiency letter should be granted, and
Whether or not deadlines to respond to deficiency letters
should be tailored to the relative burden of the request.
2. Review Cycles (Proposed Sec. 1107.42)
Proposed Sec. 1107.42(a) would set forth the timeframe for FDA's
initial review cycle. The ``initial review cycle'' would consist of the
90 calendar days following: (1) FDA's receipt of the SE Report and
determination that a predicate product is grandfathered (for SE Reports
that claim the predicate product was commercially marketed in the
United States as of February 15, 2007, and FDA has not already
determined the tobacco product is grandfathered) or (2) FDA's receipt
of an SE Report (for SE Reports that contain a predicate product that
was previously found substantially equivalent or for which FDA has
previously determined that the predicate product is grandfathered). As
described in more detail in proposed Sec. 1107.44, FDA intends to
review the SE Report and communicate with the applicant or take an
action on an SE Report during this time period. At any time before FDA
issues an order on the SE Report, the applicant would be allowed to
withdraw it under proposed Sec. 1107.22.
Proposed Sec. 1107.42(b) would provide for the use of additional
review cycles to complete FDA's review of an SE Report. If FDA issues a
deficiency letter for an SE Report under proposed Sec. 1107.40(d), FDA
would stop reviewing the SE Report until it received a response to the
notification of deficiencies (or deficiency letter) or the timeframe
specified in the letter has elapsed. If the applicant fails to provide
a response within the time period provided, FDA would issue an order
denying marketing authorization for the new tobacco product under the
criteria set forth in Sec. 1107.48. If the applicant provides a
response within the allotted timeframe, but FDA identifies the need for
additional information as a result of this response, FDA could issue an
additional deficiency notification. Each response would begin a new 90
calendar day review cycle for FDA to review the response.
FDA's intent is to complete review of an SE Report submitted under
proposed Sec. 1107.18 within a maximum of 270 review days (i.e., three
90-day review cycles). Based on FDA's review experience, an SE Report
should be resolved within three review cycles. If fewer review cycles
are needed, FDA intends to decide in a shorter time period. Section
1107.40 would not obligate FDA to notify applicants of deficiencies in
all circumstances before taking an action on an SE Report per proposed
Sec. 1107.44 or proposed Sec. 1107.48. In any case where the SE
Report has significant deficiencies, FDA might issue an order denying
marketing authorization without providing additional opportunities to
provide the missing information. Examples of significant deficiencies
include when an SE Report provides no scientific evidence to
substantiate a statement from the applicant that the new tobacco
product does not raise different questions of public health or when an
SE Report has multiple deficiencies but the applicant does not provide
responses to all of the deficiencies. FDA requests public comment on
whether FDA should provide specific timeframes within which applicants
would need to respond to deficiency letters, along with an explanation
as to why the proposed timeframes may be suitable for addressing the
concerns commonly cited in the letters and why.
Proposed Sec. 1107.42(c) states that, in the event that an
applicant's response to FDA's deficiency notification(s) does not
provide adequate information or the applicant provides information but
the SE Report remains deficient, FDA intends to issue an order denying
market authorization under the criteria set forth in proposed Sec.
1107.48. The applicant also could make a written request to withdraw
the SE Report under proposed Sec. 1107.22 at any time before FDA
issues an order regarding the SE Report.
3. FDA Action on an SE Report (Proposed Sec. 1107.44)
Proposed Sec. 1107.44 lists six actions FDA may take after
completing review of an SE Report:
First, FDA could refuse to accept the SE Report and not
begin substantive scientific review if the SE Report does not comply
with the requirements of proposed Sec. 1107.18 (this action would stop
the review clock and end the review cycle). For example, FDA could
refuse to accept an SE Report that was not written in English as
required under Sec. 1107.18(b), or did not provide the information on
product composition as required under Sec. 1107.19(c)(1). Or, FDA
could advise the applicant that the SE Report is not appropriate under
chapter IX of the FD&C Act because the product does not meet the
definition of a tobacco product under section 201(rr) of the FD&C Act.
Second, FDA could request additional information as
provided in proposed Sec. 1107.40(d).
Third, FDA could issue a letter closing the SE Report if
it not possible to make a determination on an SE Report (sometimes
referred to as an administrative closure, for example, which we might
do when there is no way to determine if a new product is SE or NSE and
additional information is unavailable);
Fourth, FDA could issue a letter canceling the SE Report
if FDA finds it mistakenly acknowledged the SE Report, e.g., the SE
Report does not pertain to a new tobacco product;
Fifth, FDA could issue an order finding the new tobacco
product to be substantially equivalent and in compliance with the
requirements of the FD&C Act under proposed Sec. 1107.46.
Sixth, FDA could issue an order denying marketing
authorization under proposed Sec. 1107.48 (NSE order) because:
[cir] The applicant has failed to provide the information needed
for FDA to find that the new tobacco product is substantially
equivalent to a tobacco product that was commercially marketed in the
United States on February 15, 2007;
[cir] The new tobacco product is not substantially equivalent to a
tobacco product that was commercially marketed in the United States on
February 15, 2007; or
[[Page 12768]]
[cir] The new tobacco product is not in compliance with the
requirements of the FD&C Act. For example, a new tobacco product is not
in compliance with the requirements of the FD&C Act if the manufacturer
of such product is in arrears with respect to its user fees; therefore,
FDA would issue an NSE order.
4. Issuance of an Order Finding a New Tobacco Product Substantially
Equivalent (Proposed Sec. 1107.46)
Proposed Sec. 1107.46 would explain that if, after review, FDA
determines that the new tobacco product is substantially equivalent to
a predicate tobacco product that was commercially marketed in the
United States on February 15, 2007, and in compliance with the FD&C
Act, the Agency would send the applicant an order authorizing the
marketing of the product. The marketing authorization would be
effective on the date the order is issued, which would typically be
noted on the first page of the order.
5. Issuance of an Order Denying Marketing Authorization (Proposed Sec.
1107.48)
Proposed Sec. 1107.48(a) would provide that, in general, if FDA:
(1) Is unable to determine that the new tobacco product is
substantially equivalent to a predicate tobacco product that was
commercially marketed in the United States on February 15, 2007, or (2)
determines that the new tobacco product is not in compliance with the
FD&C Act, the Agency would issue an NSE order indicating that the
manufacturer cannot market the new tobacco product. FDA would
communicate this decision to the applicant in writing. Proposed Sec.
1107.48(b) provides that the NSE order would describe the basis for
denying marketing authorization. FDA intends to describe any
deficiencies that FDA has identified in an SE Report.
6. Rescission of Order (Proposed Sec. 1107.50)
Proposed Sec. 1107.50 would provide the procedural mechanism for
FDA to rescind an SE order and describes the grounds for when an SE
order may be rescinded. FDA intends to exercise this authority in a
judicious and timely way in specific circumstances. FDA is proposing
this provision based on our authority to issue an order only when it
can make the findings provided in section 910(a)(2)(A)(i) of the FD&C
Act and our authority to promulgate regulations for the efficient
enforcement of the FD&C Act (section 701 of the FD&C Act). FDA's
inherent authority to timely revisit and reconsider prior decisions is
also supported by case law, with the inherent authority for timely
administrative reconsideration premised on the notion that the ``
`power to reconsider is inherent in the power to decide.' '' See Ivy
Sports Med. LLC, v. Burwell, 767 F.3d 81, 86 (D.C. Cir. 2014) (quoting
Albertson v. FCC, 182 F.2d 397, 399 (D.C. Cir. 1950)). Where, as here,
nothing in the Tobacco Control Act suggests that Congress intended to
displace this inherent authority in the context of SE determinations,
FDA may rescind an SE order based on its inherent authority. If, after
issuing an SE order, FDA later determines, for example, that the order
was based on false information or there was an error in information
upon which the SE order is based, FDA would rescind the SE order. This
proposed section would provide that--
First, FDA may rescind an SE order if, after an order has
issued, FDA becomes aware that the tobacco product for which the order
has been issued:
[cir] Does not have the same characteristics as the predicate
tobacco product or
[cir] has different characteristics and there is insufficient
information demonstrating that it was not appropriate to require a
premarket tobacco product application under section 910(b) of the FD&C
Act because the product does not raise different questions of public
health.
Second, FDA may rescind an SE order if, after an order has
issued, FDA becomes aware that the SE Report (including any submitted
amendments) contains an untrue statement of material fact.
Third, FDA may rescind an SE order if the SE Report
compared the new tobacco product to a tobacco product that FDA
previously found substantially equivalent, and the predicate tobacco
product relied on in the SE Report has been found ineligible because
its SE Report (including any submitted amendments) contains an untrue
statement of material fact, and/or a predicate product on which any of
the previous substantial equivalence determinations was based, going
back to the original grandfathered product, has been found ineligible
because its SE Report (including any amendments) contained an untrue
statement of material fact.
Fourth, FDA may rescind an SE order if FDA or the
applicant has removed from the market due to a health or safety concern
related to the tobacco product:
[cir] The predicate product on which the substantial equivalence
determination is based and/or
[cir] a predicate product on which any of the previous substantial
equivalence determinations is based, going back to the original
grandfathered product, if the SE Report compared the new tobacco
product to a tobacco product that FDA previously found substantially
equivalent. FDA may rescind in this scenario because the new tobacco
product is SE to, or is in the same generational line as a predicate
tobacco product with safety issues, and, therefore, may present similar
safety concerns.
Proposed Sec. 1107.50(b) states that, generally, FDA would rescind
an SE order only after it has provided notice to the applicant and an
opportunity for a hearing under part 16. FDA is proposing to amend
Sec. 16.1 to add a reference Sec. 1107.50. FDA encourages applicants
to bring errors to the Agency's attention that may necessitate
rescission, and FDA intends to work with applicants in such scenarios.
In addition, FDA may need to rescind an order without providing
notice and a prior opportunity for a hearing if FDA finds that the
continued marketing of the tobacco product presents a serious risk to
public health, e.g., if the applicant represented that the new tobacco
product conformed to a tobacco product standard, but FDA later
determined that the new tobacco product did not conform to a tobacco
product standard in a way that presents a serious risk to public
health. Another example would be if FDA identifies data integrity
issues during an inspection that would lead FDA to believe that the
tobacco product presents a serious risk to public health. In these
cases, FDA would provide the applicant an opportunity for a hearing as
soon as possible after the rescission.
D. Miscellaneous (Proposed Subpart E)
Subpart E describes other procedures and requirements related to SE
Reports, including record retention, electronic submission
requirements, foreign data, and confidentiality considerations.
1. Record Retention (Proposed Sec. 1107.58)
Consistent with the authority to require recordkeeping under
section 909 of the FD&C Act, proposed Sec. 1107.58, would require
applicants receiving an order under proposed Sec. 1107.46 authorizing
the marketing of a new tobacco product to maintain all records
supporting that SE Report for at least 4 years from the date of the
order even if such product is discontinued. FDA has selected 4 years as
a means to help ensure that the records would be available for at least
one biennial FDA
[[Page 12769]]
inspection under section 704 and 905(g) of the FD&C Act. The records
would be required to be legible, written in English or an English
translation provided, and available for inspection and copying by
officers or employees designated by the Secretary of Health and Human
Services. Applicants that have stopped marketing a tobacco product may
want to retain the records for a longer period, if the product might be
reintroduced in order to avoid the time and expense of having to
generate the information again.
2. Confidentiality (Proposed Sec. 1107.60)
Proposed Sec. 1107.60(a) states that FDA would determine the
public availability of any part of any SE Report and other content
related to an SE Report as provided under this proposed section and
part 20 (Public Information). The Freedom of Information Act (FOIA) (5
U.S.C. 552), as well as certain provisions of the FD&C Act, e.g.,
section 301(j) (21 U.S.C. 331(j)) and section 906(c) (21 U.S.C.
387f(c)), govern the disclosure of the existence of a pending SE Report
and the information contained in such an SE Report. Under FOIA, the
public has broad access to government documents. However, FOIA provides
certain exemptions from mandatory public disclosure. One such
provision, 5 U.S.C. 552(b)(4), exempts records that are ``trade secrets
and commercial or financial information obtained from a person and
privileged or confidential'' from the requirement of mandatory
disclosure. Part 20 of FDA's regulations sets forth FDA's general
regulations concerning public availability of FDA records.
Like with drugs and devices, the intent to market a tobacco product
is often considered confidential commercial information, as premature
disclosure could result in a competitive advantage to competitors.
Therefore, FDA is proposing Sec. 1107.60(b)(1), which would address
the confidentiality of an SE Report prior to the issuance of an order
under either proposed Sec. 1107.46 or proposed Sec. 1107.48. Under
the proposed regulation and consistent with part 20, FDA would not
publicly disclose the existence of an SE Report unless the applicant
has publicly disclosed or acknowledged the existence (as such
disclosure is defined in Sec. 20.81), or has authorized FDA in writing
to publicly disclose or acknowledge, that the applicant has submitted
the SE Report to FDA.
Proposed Sec. 1107.60(b)(2) provides that FDA would not disclose
the existence or contents of an FDA communication with an applicant
regarding its SE Report except to the extent that the applicant has
publicly disclosed or acknowledged, or authorized FDA in writing to
publicly disclose or acknowledge, the existence of or contents of that
particular FDA communication. Proposed Sec. 1107.60(b)(3) provides
that FDA would not disclose information contained in an SE Report
unless the applicant has publicly disclosed or acknowledged, or
authorized FDA in writing to publicly disclose or acknowledge, that
particular information. If the applicant has publicly disclosed or
acknowledged, or authorized FDA in writing to publicly disclose or
acknowledge, that particular information contained in an SE Report, FDA
may disclose that particular information.
Proposed Sec. 1107.60(c) would address the disclosure of data and
information after an order is issued under proposed Sec. 1107.46. This
proposed section would provide that, after an order under Sec. 1107.46
(finding a new tobacco product substantially equivalent), FDA would
make the following information related to the SE Report and order
available for public disclosure upon request or at FDA's own
initiative, including information from amendments to the SE Report and
FDA's reviews of the SE Report: (1) All data previously disclosed to
the public, as such disclosure is defined in Sec. 20.81; (2) any
protocol for a test or study, except to the extent it is shown to fall
within the exemption established for trade secrets and confidential
commercial information in Sec. 20.61; (3) information and data
submitted to demonstrate that the new tobacco product does not raise
different questions of public health, except to the extent it is shown
to fall within the exemptions established in Sec. 20.61 for trade
secrets and confidential commercial information, or in Sec. 20.63 for
personal privacy; (4) correspondence between FDA and the applicant,
including any requests FDA made for additional information and
responses to such requests, and all written summaries of oral
discussions between FDA and the applicant, except to the extent it is
shown to fall within the exemptions in Sec. 20.61 for trade secrets
and confidential commercial information, or in Sec. 20.63 for personal
privacy; and (5) the environmental assessment or, if applicable, the
claim of categorical exclusion from the requirement to submit an
environmental assessment under part 25 of this chapter.
Even after issuance of an order under Sec. 1107.48 (Denying
marketing authorization), the applicant's intent to market may still
constitute confidential commercial information, as the applicant may
still be planning to market the new tobacco product that is the subject
of the SE Report (e.g., by submitting a new SE Report, a PMTA, or a
request for exemption from substantial equivalence, or by seeking
further review of the denial). Therefore, proposed Sec. 1107.60(d)
addresses the disclosure of data and information after FDA issues an
order under Sec. 1107.48 (Denying marketing authorization). Under this
proposed subsection, FDA may make certain information related to the SE
Report and the order available for public disclosure upon request or at
FDA's own initiative except to the extent the information is otherwise
exempt from disclosure under part 20. Information FDA may disclose
includes the tobacco product category (e.g., cigarette), tobacco
product subcategory (e.g., filtered), package size, and the basis for
the order denying marketing authorization.
Proposed Sec. 1107.60(e) addresses disclosure of the health
information summary or statement and would provide that health
information required by section 910(a)(4) of the FD&C Act, if submitted
as part of the SE Report (which includes any amendments), would be
disclosed within 30 calendar days of issuing a substantially equivalent
order. If the applicant has instead submitted a 910(a)(4) statement as
provided in Sec. 1107.18(j)(2), FDA would make publicly available on
FDA's website the responsible official to whom a request for health
information may be made. FDA intends to include this information on our
website to ensure that the information is easily accessible to
requestors.
3. Electronic Submission (Proposed Sec. 1107.62)
Based on our authority in section 905 of the FD&C Act to prescribe
the format of SE Reports, proposed Sec. 1107.62(a) and (b) would
require the applicant to submit the SE Report and supporting and other
related documents in an electronic format that FDA can process, read,
review, and archive unless a waiver from this requirement is requested
by the applicant and FDA grants the waiver. Reasons that an applicant
might request a waiver would include that the applicant has no access
to email or a computer. Under proposed Sec. 1107.62(c), an applicant
that has a waiver would submit a paper submission to the address that
FDA provides in the letter granting the waiver. FDA is proposing Sec.
1107.62 based on FDA's general experiences with electronic submission,
which FDA
[[Page 12770]]
has found helps facilitate premarket reviews because electronic
submission typically has enabled FDA to receive, open, and read a
submission more quickly than a submission submitted on paper through
postal mail. If this rule is finalized, FDA intends to provide
information on submitting information in an electronic format that FDA
can process, read, review and archive (e.g., method of transmission,
media, file formats, preparation, organization of files, accompanying
metadata) (https://www.fda.gov/TobaccoProducts/default.htm). FDA
intends to update this information as needed (e.g., to accommodate
changes in technology).
IV. Other Issues for Consideration
In addition to comments and information on the proposed
requirements described in section III, FDA is also seeking comments and
information on whether some modifications to tobacco products that
result in a new tobacco product, beyond those eligible for an exemption
from substantial equivalence, might be handled through a
``categorical'' approach to substantial equivalence. Under such an
approach, FDA would establish categories of modifications, and if a
modification is within a category, the applicant could then submit a
streamlined SE Report that identifies the modification and demonstrates
substantial equivalence. FDA is soliciting concerns or benefits of this
type of approach, along with information on the types of modifications
or categories that might be handled in this way, or should not be
handled this way.
V. Paperwork Reduction Act of 1995
This proposed rule contains information collection provisions that
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). A
description of these provisions is given in the Description section of
this document with an estimate of the annual reporting and
recordkeeping. Included in the estimate is the time for reviewing
instructions, searching existing data sources, gathering and
maintaining the data needed, and completing and reviewing each
collection of information.
FDA invites comments on these topics: (1) Whether the proposed
collection of information is necessary for the proper performance of
FDA's functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Title: Substantial Equivalence Reports for Tobacco Products.
Description: Tobacco Products, Substantial Equivalence Reports,
Requirements for Submitting Information Needed to Determine Substantial
Equivalence and Maintaining Records to Support a Substantial
Equivalence Report.
This proposed rule would establish requirements for the content and
format of substantial equivalence (SE) Reports (proposed Sec. Sec.
1107.18 and 1107.19). Most of the proposed requirements would mirror
current practices and recommendations related to the submission of SE
Reports, including information related to part 25 (environmental
considerations), but the rule would provide both applicants and FDA
more certainty regarding the content and format the SE Reports. A
health information summary or statement would continue to be required
(section 910(a)(4) of the FD&C Act) and the health summary or response
to a request would be required to be in the format of a redacted SE
Report, along with any additional health information about the new
tobacco product, including any information, research, or data about
adverse health effects, that the applicant has or knows about and that
is not contained in the SE Report.
As is currently the practice, the proposed rule would continue to
permit amendments for SE Reports submitted under proposed Sec.
1107.18, e.g., to address deficiencies (proposed Sec. 1107.20). Also
in accordance with current practice, the proposed rule would continue
to permit withdrawals (proposed Sec. 1107.22) of pending SE Reports.
The proposed rule would also propose requirements for when the
ownership of an SE Report changes to ensure that FDA has information
related to the current applicant (proposed Sec. 1107.24).
The proposed rule would establish a recordkeeping requirement,
under which applicants would be required to maintain records supporting
the SE Report for an authorized new tobacco product for 4 years from
the date of an order finding substantial equivalence, even if such
product is discontinued (proposed Sec. 1107.58).
The proposed rule would require that respondents submit an SE
Report in an electronic format, unless a waiver from this requirement
is requested by the applicant and granted by FDA (proposed Sec.
1107.62). FDA created two new forms for submission; Form FDA 3964,
Tobacco Amendment and General Correspondence; and Form FDA 3965,
Tobacco Substantial Equivalence Report Submission.
Description of Respondents: Manufacturers of tobacco products who
submit SE Reports.
Existing Burden OMB Control Number 0910-0673
Table 9--Estimated Annual Reporting Burden 1 2
----------------------------------------------------------------------------------------------------------------
Number of Average
Activity Number of responses per Total annual burden per Total hours
respondents respondent responses response
----------------------------------------------------------------------------------------------------------------
Full SE 905(j)(1)(A)(i) and 410 1 410 300 123,000
910(a).........................
Full SE 905(j)(1)(A)(i) and 250 1 250 90 22,500
910(a) Bundled.................
Product Quantity Change SE 264 1 264 87 22,968
Report.........................
Product Quantity Change Bundled 55 1 55 62 3,410
SE Report......................
-------------------------------------------------------------------------------
Totals...................... .............. .............. .............. .............. 171,878
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
\2\ This chart represents the currently OMB approved burden for the SE program.
Reporting Burden Updated Estimates
[[Page 12771]]
Table 10--Estimated Annual Reporting Burden 1 2
----------------------------------------------------------------------------------------------------------------
Number of Average
Activity Number of responses per Total annual burden per Total hours
respondents respondent responses response
----------------------------------------------------------------------------------------------------------------
Full SE 905(j)(1)(A)(i) and 683 1 683 300 204,900
910(a).........................
Full SE 905(j)(1)(A)(i) and 456 1 456 90 41,040
910(a) Bundled.................
Product Quantity Change SE 239 1 239 87 20,793
Report.........................
Product Quantity Change Bundled 192 1 192 62 11,904
SE Report......................
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 278,637
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
\2\ Draft burden not yet OMB approved.
In the Federal Register of September 6, 2018 (83 FR 45251), FDA
published a notice soliciting comments on the extension of the current
SE program. The numbers above in table 10 represent the tentative
revisions which have not yet been approved by OMB. These estimates
revise the number of reports under OMB control number 0910-0673 and
take into account updated registration and listing data. The previous
estimate for reports was 979 and total burden hours were 171,878. This
chart accounts for the tentative increase in burden due to the expected
rise in submissions other than any increases in burden due to the
proposed rule, if finalized.
New Reporting Per Rule
Table 11--Estimated Annual Reporting Burden 1 2
----------------------------------------------------------------------------------------------------------------
Number of
21 CFR part Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
----------------------------------------------------------------------------------------------------------------
FDA 3965 Tobacco Substantial 1,570 1 1,570 .5 785
Equivalence Report Submission..
FDA 3964 Tobacco Amendment and 628 1 628 .083 52
General Correspondence.........
Waiver from Electronic 240 1 240 .25 60
submission 1107.62(b)..........
-------------------------------------------------------------------------------
Totals...................... .............. .............. .............. .............. 897
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
\2\ Draft burden not yet OMB approved.
Final Combined Reporting Burden (Tables 10 +11)
Table 12--Estimated Annual Reporting Burden 1 2
----------------------------------------------------------------------------------------------------------------
Number of Average
21 CFR part Number of responses per Total annual burden per Total hours
respondents respondent responses response
----------------------------------------------------------------------------------------------------------------
SE Report 1107.18............... 683 1 683 300 204,900
Bundled SE 1107.18.............. 456 1 456 90 41,040
SE Report where applicant 239 1 239 87 20,793
provides certification for
identical characteristics
1107.18(g) and 1107.18(1)(2)...
SE Report where applicant 192 1 192 62 11,904
provides certification for some
identical characteristics
(bundled) 1107.18(g) and
1107.18(1)(2)..................
FDA 3965 Tobacco Substantial 1,570 1 1,570 .5 785
Equivalence Report Submission..
FDA 3964 Tobacco Amendment and 628 1 628 .083 52
General Correspondence Report..
Waiver from Electronic 240 1 240 .25 60
submission 1107.62(b)..........
rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr
Totals...................... .............. .............. .............. .............. 279,534
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
\2\ Draft burden not yet OMB approved.
New Final Recordkeeping Burden
[[Page 12772]]
Table 13--Estimated Annual Recordkeeping Burden 1 2
----------------------------------------------------------------------------------------------------------------
Number of
21 CFR part Number of records per Total annual Average burden Total hours
recordkeepers recordkeeper records per recordkeeping
----------------------------------------------------------------------------------------------------------------
Recordkeeping SE Report 471 1 471 2.5 1,178
under 1107.18 1107.58......
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
\2\ Draft burden not yet OMB approved.
FDA's estimates are based on experience with SE Reports,
registration and listing data, interactions with the industry, and
information related to other regulated products. As explained above,
taking into account the updated registration and listing data for
deemed tobacco products, the estimated annual number of SE Reports is
expected to be 1,570. That estimate is not expected to change as a
result of the proposed rule, if finalized.
When groups of full SE Reports or SE Reports that each contain a
certification that some characteristics are identical have identical
content, they may be bundled; when a group of similar reports are
bundled, the subsequent bundled reports are expected to take less time
to prepare than the initial report.
FDA has based these estimates on information it now has available
from interactions with the industry, information related to other
regulated products, and FDA expectations regarding the tobacco
industry's use of the substantial equivalence pathway to market their
products. Table 9 describes the annual reporting burden for compliance
with the requirements to demonstrate substantial equivalence under the
FD&C Act. We do not expect a large burden increase for this program,
as, without the proposed rule, manufacturers would routinely submit SE
Reports for new tobacco products, and the Agency believes most
respondents are currently practicing most of the proposed requirements.
FDA will revise this collection with the new burden. FDA requests
public comments on the estimated burden associated with the
requirements associated with this rule and whether there is any
evidence, information, or data to support alternate burden estimates.
Table 11 describes the annual reporting burden as a result of the
requirements proposed in Sec. Sec. 1107.18 and 1107.19, implementing
the substantial equivalence requirements of section 905(j)(1)(A)(i) and
910(a) of the FD&C Act. This proposed rule would require manufacturers
to submit SE Reports electronically (proposed Sec. 1107.62). We
estimate that it would initially take about 30 minutes per product to
fill out the Form FDA 3965. However, for amendments we estimate that
filling out the Form FDA 3964 will take 5 minutes as applicants can
copy and paste from the first submission. Proposed 1107.62(b) also
allows for waivers from the electronic format requirement. FDA
estimates that 240 respondents or 15 percent of SE Reports (1,570) will
submit a waiver.
Based on updated information, FDA estimates that it will receive
683 full initial SE Reports for a new tobacco product each year under
proposed Sec. 1107.18 that take a manufacturer approximately 300 hours
to prepare. Additionally, manufacturers may bundle groups of SE Reports
for their new products in the same product category and subcategory
where the proposed modifications are the same; when a group of similar
SE Reports are bundled, the reporting burden for the initial SE Report
is expected to take the same amount of time as a stand-alone SE Report.
However, the reporting burden for subsequent bundled SE Reports is
expected to be lower than the initial SE Report. We expect to receive
456 bundled SE Reports under proposed Sec. 1107.18 (other than the
initial SE Report in the bundle) at approximately 90 hours per response
for a total of 41,040 hours.
In the absence of more specific information concerning SE Reports
where applicants provide a certification for some identical
characteristics under proposed Sec. 1107.18(g) and 1107.18(l)(2), FDA
estimates receiving 239 such SE Reports at 87 hours per response for a
total of 20,973 hours. We also estimate receiving 192 bundled SE
Reports where applicants provide a certification for some identical
characteristics under proposed Sec. Sec. 1107.18(g) and 1107.18(l)(2)
(other than the initial SE Report in the bundle) at 62 hours per
response for a total of 11,904 hours. Although we believe that the
number of SE Reports that include a certification will increase because
the proposed rule clarifies when applicants may certify that certain
characteristics are identical in the new tobacco product and the
predicate tobacco product, in the absence of specific information on
how many more applicants might choose to certify, we are maintaining
our previous estimates at this time. We request comment on these
estimates.
FDA has based these estimates on the full analysis of economic
impacts and experience with the recently-revised existing information
collection that applies to tobacco products. In addition, anyone
submitting an SE Report is required to submit an environmental
assessment prepared in accordance with Sec. 25.40 under proposed Sec.
1107.18(k). The burden for environmental reports has been included in
the burden per response for each type of SE Report.
Based on FDA's experience with EAs for currently regulated tobacco
products, we expect industry to spend 80 hours preparing an
environmental assessment for a full SE Report under proposed Sec.
1107.18.
Generally, an applicant may withdraw its SE Report after submission
(proposed Sec. 1107.22), change the ownership of its SE Report
(proposed Sec. 1107.24), and amend its SE Report (proposed Sec.
1107.20). The information required to grant these requests is already
being collected, so we do not expect a change in burden.
FDA estimates that 30 percent of SE Reports or 471 respondents will
maintain required records related to their SE Reports at 2.5 hours per
record for a total of 1,178 recordkeeping hours.
FDA estimates that the burden for new requirements will increase
this collection by 108,834 (107,656 + 1,178 recordkeeping). The burden
for the submission of substantial equivalence information is estimated
to total 280,712 hours (279,534 reporting and 1,178 recordkeeping).
This proposed rule also refers to previously approved collections of
information found in FDA regulations. Proposed Sec. 1107.40 references
meetings that may be held with applicants who want to meet with FDA to
discuss scientific and other issues. Additional information about how
to request meetings with FDA's CTP can be found in FDA's guidance
entitled ``Meetings with Industry and Investigators on the Research and
Development of Tobacco Products.'' The collections of information in
the guidance referenced have been approved under OMB control number
[[Page 12773]]
0910-0731. In addition to the premarket application under section
910(b) and a report under 905(j)(1)(A)(i), certain new tobacco products
may use the exemption premarket pathway, see 21 CFR 1107.1. The
collections of information found in 21 CFR 1107.1 have been approved
under OMB control number 0910-0684.
To ensure that comments on information collection are received, OMB
recommends that written comments be faxed to the Office of Information
and Regulatory Affairs, OMB (see ADDRESSES). All comments should be
identified with the title of the information collection.
In compliance with the Paperwork Reduction Act of 1995 (44 U.S.C.
3407(d)), the Agency has submitted the information collection
provisions of this proposed rule to OMB for review. These requirements
will not be effective until FDA obtains OMB approval. FDA will publish
a notice concerning OMB approval of these requirements in the Federal
Register.
VI. Executive Order 13132: Federalism
We have analyzed this proposed rule in accordance with the
principles set forth in Executive Order 13132. Section 4(a) of the
Executive Order requires Agencies to ``construe . . . a Federal statute
to preempt State law only where the statute contains an express
preemption provision or there is some other clear evidence that the
Congress intended preemption of State law, or where the exercise of
State authority conflicts with the exercise of Federal authority under
the Federal statute.''
Section 916(a)(2) of the FD&C Act (21 U.S.C. 387p) is an express
preemption provision. Section 916(a)(2) provides that ``no State or
political subdivision of a State may establish or continue in effect
with respect to a tobacco product any requirement which is different
from, or in addition to, any requirement under the provisions of this
chapter relating to . . . premarket review.'' Thus, if this proposed
rule is made final, the final rule would create requirements that fall
within the scope of section 916(a)(2) of the FD&C Act.
VII. Consultation and Coordination With Indian Tribal Governments
We have analyzed this proposed rule in accordance with the
principles set forth in Executive Order 13175. We have tentatively
determined that the rule does not contain policies that would have a
substantial direct effect on one or more Indian Tribes, on the
relationship between the Federal Government and Indian Tribes, or on
the distribution of power and responsibilities between the Federal
Government and Indian Tribes. The Agency solicits comments from tribal
officials on any potential impact on Indian Tribes from this proposed
action.
VIII. Analysis of Environmental Impact
The Agency has determined under 21 CFR 25.30(h) that this action is
of a type that does not individually or cumulatively have a significant
effect on the human environment. No extraordinary circumstances exist
to indicate that the specific proposed action may significantly affect
the quality of the human environment. Therefore, neither an
environmental assessment nor an environmental impact statement is
required.
IX. Economic Analysis of Impacts
We have examined the impacts of the proposed rule under Executive
Order 12866, Executive Order 13563, Executive Order 13771, the
Regulatory Flexibility Act (5 U.S.C. 601-612), and the Unfunded
Mandates Reform Act of 1995 (Pub. L. 104-4). Executive Orders 12866 and
13563 direct us to assess all costs and benefits of available
regulatory alternatives and, when regulation is necessary, to select
regulatory approaches that maximize net benefits (including potential
economic, environmental, public health and safety, and other
advantages; distributive impacts; and equity). We believe that this
proposed rule is not an economically significant regulatory action as
defined by Executive Order 12866.
The Regulatory Flexibility Act requires us to analyze regulatory
options that would minimize any significant impact of a rule on small
entities. Because we have determined that the compliance costs are less
than 0.1 percent of revenues, we propose to certify that the rule would
not have a significant economic impact on a substantial number of small
entities.
The Unfunded Mandates Reform Act of 1995 (section 202(a)) requires
us to prepare a written statement, which includes an assessment of
anticipated costs and benefits, before proposing ``any rule that
includes any Federal mandate that may result in the expenditure by
State, local, and tribal governments, in the aggregate, or by the
private sector, of $100,000,000 or more (adjusted annually for
inflation) in any one year.'' The current threshold after adjustment
for inflation is $150 million, using the most current (2017) Implicit
Price Deflator for the Gross Domestic Product. This proposed rule would
not result in an expenditure in any year that meets or exceeds this
amount.
This proposed rule would impose compliance costs on affected
entities to read and understand the rule, establish or revise internal
procedures, and fill out a form for SE Reports. We estimate that the
present value of industry compliance costs ranges from $0.60 million to
$2.64 million, with a primary estimate of $1.61 million at a 3 percent
discount rate, and from $0.56 million to $2.32 million, with a primary
estimate of $1.43 million at a 7 percent discount rate over 10 years.
Annualized industry compliance costs over 10 years range from $0.07
million to $0.31 million, with a primary estimate of $0.19 million at a
3 percent discount rate and from $0.08 million to $0.33 million, with a
primary estimate of $0.20 million at a 7 percent discount rate.
The benefits of this proposed rule are potential time-savings to
industry and cost-savings to government. This proposed rule clarifies
when applicants may certify that certain characteristics are identical
in the new tobacco product and the predicate tobacco product.
Certifying may save applicants time in preparing their SE Reports. In
this proposed rule, we intend to shorten review times for SE Reports.
In addition, based on our experience with prior SE Reports, we believe
this proposed rule would lead to better SE Reports, saving us time in
review and requiring fewer staff to review SE Reports, which would
result in cost-savings. We estimate that the present value of
government cost-savings ranges from $15 million to $198 million at a 3
percent discount rate, and from $12 million to $163 million at a 7
percent discount rate over 10 years. Annualized government cost-savings
over 10 years range from $1.7 million to $23.2 million at both 3 and 7
percent discount rates.
The qualitative benefits of this proposed rule include additional
clarity to industry about the requirements for the content and format
of SE Reports. The proposed rule would also establish the general
procedures we intend to follow in reviewing and communicating with
applicants. In addition, this proposed rule would make the SE pathway
more predictable.
The proposed rule's costs and benefits are summarized in Table 14
entitled ``Economic Data: Costs and Benefits Statement.''
[[Page 12774]]
Table 14--Economic Data: Costs and Benefits Statement
--------------------------------------------------------------------------------------------------------------------------------------------------------
Units
------------------------------------
Category Low Primary High Period Notes
estimate estimate estimate Year Discount covered
dollars rate (%) (years)
--------------------------------------------------------------------------------------------------------------------------------------------------------
Benefits:
Annualized Monetized $millions/year....... 1.7 7.2 23.2 2016 7 10 Cost-savings to government.
1.7 7.2 23.2 2016 3 10 Cost-savings to government.
Annualized................................ .......... .......... .......... 2016 7 10 ................................
Quantified................................ .......... .......... .......... 2016 3 10 ................................
Qualitative............................... .......... .......... .......... .......... .......... .......... Greater certainty for SE
applicants.
Costs:
Annualized Monetized $millions/year....... 0.08 0.20 0.33 2016 7 10 ................................
0.07 0.19 0.31 2016 3 10
Annualized................................ .......... .......... .......... 2016 7 10 ................................
Quantified................................ .......... .......... .......... 2016 3 10 ................................
Qualitative. .......... .......... .......... .......... .......... .......... ................................
Transfers:
Federal Annualized Monetized $millions/ .......... .......... .......... 2016 7 10 ................................
year. 2016 3 10
------------------------------------------------------------------------
From:
To: ..........
------------------------------------------------------------------------
Other Annualized Monetized $millions/year. .......... .......... .......... 2016 7 10 ................................
2016 3 10
------------------------------------------------------------------------
From:
To: ..........
---------------------------------------------------------------------------------------------------------
Effects:
State, Local or Tribal Government: No effect
Small Business: No effect
Wages: No effect
Growth: No effect
--------------------------------------------------------------------------------------------------------------------------------------------------------
In line with Executive Order 13771, in Table 15 we estimate present
and annualized values of costs and cost-savings over an infinite time
horizon. Our primary estimate of the present value over an infinite
time horizon of net costs due to this proposed rule is -$101.4 million
at a 7 percent discount rate, and -$237.7 million at a 3 percent
discount rate. Our primary estimate of the annualized net costs is -
$7.1 million at a 7 percent discount rate and -$7.1 million at a 3
percent discount rate. Table 15 summarizes the costs, cost-savings and
net costs of this proposed rule. Based on these cost-savings this
proposed rule, if finalized, would be considered a deregulatory action
under E.O. 13771.
Table 15--E.O. 13771 Summary Table
[In $ Millions 2016 dollars, over infinite time horizon]
--------------------------------------------------------------------------------------------------------------------------------------------------------
Lower bound Upper bound Lower bound Upper bound
Primary (7%) (7%) (7%) Primary (3%) (3%) (3%)
--------------------------------------------------------------------------------------------------------------------------------------------------------
Present Value of Costs.................................. $2.05 $0.57 $3.56 $3.75 $0.69 $6.92
Present Value of Cost Savings........................... 103.49 24.84 331.18 241.48 57.96 772.75
Present Value of Net Costs.............................. (101.4) (24.3) (327.6) (237.7) (57.3) (765.8)
Annualized Costs........................................ 0.14 0.04 0.25 0.11 0.02 0.21
Annualized Cost Savings................................. 7.24 1.74 23.18 7.24 1.74 23.18
Annualized Net Costs.................................... (7.1) (1.7) (22.9) (7.1) (1.7) (23.0)
--------------------------------------------------------------------------------------------------------------------------------------------------------
Note: Values in parentheses denote net negative costs (i.e., cost-savings).
We have developed a comprehensive Economic Analysis of Impacts that
assesses the impacts of the proposed rule. The full analysis of
economic impacts is available in the docket for this proposed rule
(Ref. 54) and at https://www.fda.gov/AboutFDA/ReportsManualsForms/Reports/EconomicAnalyses/default.htm.
X. References
The following references are on display in the Dockets Management
Staff (see ADDRESSES) and are available for viewing by interested
persons between 9 a.m. and 4 p.m., Monday through Friday; they are also
available electronically at https://www.regulations.gov. FDA has
verified the website addresses, as of the date this document publishes
in the Federal Register, but websites are subject to change over time.
1. Wayne, G. F. and G. N. Connolly, ``Application, Function, and
Effects of Menthol in Cigarettes: A Survey of Tobacco Industry
Documents,'' Nicotine & Tobacco Research, 6(Suppl. 1):S43-S54, 2004.
2. Brunnemann, K. D., J. C. Scott, and D. Hoffmann, ``N-
Nitrosomorpholine and
[[Page 12775]]
Other Volatile N-nitrosamines in Snuff Tobacco,'' Carcinogenesis,
3(6):693-696, 1982.
3. Draft Form FDA 3965 (Substantial Equivalence Submission).
4. Draft Form FDA 3964 (Amendment).
5. Agaku, I. T., C. I. Vardavas, and G. N. Connolly, ``Cigarette Rod
Length and Its Impact on Serum Cotinine and Urinary Total NNAL
Levels, NHANES 2007-2010,'' Nicotine & Tobacco Research, 16(1):100-
107, 2014.
6. Eaker, D. W., ``Dynamic Behavior and Filtration of Mainstream
Smoke in the Tobacco Column and Filter,'' Recent Advances in Tobacco
Science, 16:103-187, 1990.
7. Connolly, G. N., H. R. Alpert, G. F. Wayne, et al., ``Trends in
Nicotine Yield in Smoke and its Relationship with Design
Characteristics Among Popular US Cigarette Brands, 1997-2005,''
Tobacco Control, 16(5):e5, 2007, doi: 10.1136/tc.2006.019695.
8. American Tobacco, ``Cigarette Pressure Drop,'' Bates Numbers
991508327-991508331, 1990.
9. U.S. Department of Health and Human Services, ``The Health
Consequences of Smoking: The Changing Cigarette,'' A Report of the
Surgeon General; 1981.
10. Torikaiu, K., Y. Uwano, T. Nakamore, et al., ``Study on Tobacco
Components Involved in Pyrolytic Generation of Selected Smoke
Constituents,'' Food and Chemical Toxicology, 43: 559-568, 2005.
11. Spears, A. W., ``Effect of Manufacturing Variables on Cigarette
Smoke Composition,'' CORESTA Information Bulletin, Special Issue:
65-78, 1974.
12. Geiss, O. and D. Kotzias, ``Tobacco, Cigarettes and Cigarette
Smoke: An Overview,'' Institute for Health and Consumer Protection,
European Commission, Directorate-General, Joint Research Centre,
2007, available at https://publications.jrc.ec.europa.eu/repository/bitstream/111111111/8885/1/7472%20-%20EUR22783EN_Geiss_Kotzias.pdf.
13. DeBardeleben, M. Z., W. E. Claflin, and W. F. Gannon, ``Role of
Cigarette Physical Characteristics on Smoke Composition,'' Recent
Advances in Tobacco Science, 4:85-111, 1978.
14. Bourlas, M. C., D. F. Magin, R. A., Kornfeld, et al., ``The
Generation of Water in the Tobacco Oven Volatile Test, Beitr[auml]ge
zur Tabakfoschung International, 10(3), 149-154, 1980.
15. Coleman, W. M., ``Tobacco Volatiles: Gas Chromatography,'' R. J.
Reynolds Tobacco Company, 4380-4388, Academic Press, 2000.
16. Owens, W. F., ``Effect of Cigarette Paper on Smoke Yield and
Composition,'' Recent Advances in Tobacco Science, 4:3-24, 1978.
17. British American Tobacco, Research & Development, ``Lower
Ignition Propensity.''
18. Adam, T., J. McAughey, C. Mocker, et al., ``Influence of Filter
Ventilation on the Chemical Composition of Cigarette Mainstream
Smoke,'' Analytica Chimica Acta, 657(1): 36-44, 2010.
19. Hammond, D., N. Collishaw, and C. Callard, ``Secret Science:
Tobacco Industry Research on Smoking Behaviour and Cigarette
Toxicity,'' The Lancet, 367 (9512) 781-787, 2006.
20. Browne, C. L., The Design of Cigarettes. Charlotte, NC: Hoechst
Celanese, 1990.
21. World Health Organization, ``The Scientific Basis of Tobacco
Product Regulation,'' Second Report of a WHO Study Group, WHO
Technical Report Series 951, 2008.
22. Taylor, M. J., Scientific Services Manager, Filtrona Technology
Centre, ``The Role of Filter Technology in Reduced Yield
Cigarettes,'' Text of Presentation for World Tobacco Symposium
Kunming, Nov. 17, 2004.
23. Podraza K., Director, Product Integrity, Philip Morris USA,
``Basic Principles of Cigarette Design and Function,'' Presentation
to LSRO, Oct. 29-30, 2001 (Slides 40 & 46).
24. O'Connor, R. J., D. Hammond, A. McNeill, et al., ``How Do
Different Cigarette Design Features Influence the Standard Tar
Yields of Popular Cigarette Brands Sold in Different Countries?,''
Tobacco Control, 17(Suppl. 1):i1-i5, 2008, doi:10.1136/
tc.2006.019166.
25. Dash, S., P. N. Murthy, L. Nath, et al., ``Kinetic Modeling on
Drug Release from Controlled Drug Delivery Systems,'' Acta Poloniae
Pharmaceutica--Drug Research, 67(3):217-223, 2010.
26. Gale, N., G. Errington, and K. McAdam, Group Research &
Development, British American Tobacco, ``Effects of Product Format
on Nicotine and TSNA Extraction from Snus Pouches,'' Presentation at
the 67th Tobacco Science Research Conference, Williamsburg, VA,
September 15-18, 2013.
27. Stepanov, I., J. Jensen, L. Biener, et al., ``Increased Pouch
Sizes and Resulting Changes in the Amounts of Nicotine and Tobacco-
Specific N-Nitrosamines in Single Pouches of Camel Snus and Marlboro
Snus,'' Nicotine & Tobacco Research, 14(10):1241-1245, 2012.
28. Zhang, H., J. Zhang, and J. B. Streisand, ``Oral Mucosal Drug
Delivery: Clinical Pharmacokinetics and Therapeutic Applications,''
Drug Delivery Systems, 41(9):661-680, 2002.
29. Lewis, S., G. Subramanian, S. Pandey, et al., ``Design,
Evaluation and Pharmacokinetic Study of Mucoadhesive Buccal Tablets
of Nicotine for Smoking Cessation,'' Indian Journal of
Pharmaceutical Sciences, 68:829-831, 2006.
30. Hoffmann, D. and I. Hoffmann, ``The Changing Cigarette: Chemical
Studies and Bioassays,'' Chapter 5 in Risks Associated with Smoking
Cigarettes with Low Machine-Measured Yields of Tar and Nicotine,
Smoking and Tobacco Control Monograph No. 13:159-191, Bethesda, MD:
U.S. Department of Health and Human Services, National Institutes of
Health, National Cancer Institute, 2001, available at https://cancercontrol.cancer.gov/brp/tcrb/Monographs/13/m13_5.pdf.
31. Hammond, D., G. T. Fong, K. M. Cummings, et al., ``Cigarette
Yields and Human Exposure: A Comparison of Alternative Testing
Regimens,'' Cancer Epidemiology, Biomarkers & Prevention,
15(8):1495-1501, 2006.
32. Rees, V. W., G. F. Wayne, B. F. Thomas, et al., ``Physical
Design Analysis and Mainstream Smoke Constituent Yields of the New
Potential Reduced Exposure Product, Marlboro UltraSmooth,'' Nicotine
& Tobacco Research, 9(11):1197-1206, 2007.
33. Ding, Y. S., J. S. Trommel, X. J. Yan, et al., ``Determination
of 14 Polycyclic Aromatic Hydrocarbons in Mainstream Smoke from
Domestic Cigarettes, Environmental Science & Technology, 39(2):471-
478, 2005.
34. Ding, Y. S., L. Zhang, R. B. Jain, et al., ``Levels of Tobacco-
Specific Nitrosamines and Polycyclic Aromatic Hydrocarbons in
Mainstream Smoke from Different Tobacco Varieties,'' Cancer
Epidemiology, Biomarkers & Prevention, 17(12):3366-3371, 2008.
35. Baker, R. R., ``The Generation of Formaldehyde in Cigarettes--
Overview and Recent Experiments,'' Food and Chemical Toxicology,
44:1799-1822, 2006.
36. U.S. Department of Health and Human Services, ``Preventing
Tobacco Use Among Young People,'' A Report of the Surgeon General;
1994.
37. U.S. Department of Health and Human Services, ``How Tobacco
Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-
Attributable Disease,'' A Report of the Surgeon General; 2010,
available at https://www.ncbi.nlm.nih.gov/books/NBK53017.
38. National Cancer Institute, Centers for Disease Control and
Prevention, U.S. Department of Health and Human Services,
``Smokeless Tobacco and Public Health: A Global Perspective, 91-106,
2014, available at https://cancercontrol.cancer.gov/brp/tcrb/global-perspective/SmokelessTobaccoAndPublicHealth.pdf.
39. German Cancer Research Center (DKFZ), ``Additives in Tobacco
Products. Contribution of Carob Bean Extract, Cellulose Fibre, Guar
Gum, Liquorice, Menthol, Prune Juice Concentrate and Vanillin to
Attractiveness, Addictiveness and Toxicity of Tobacco Smoking,''
Report, 2012.
40. Naworal, J. D., ``Pyrolysis GC/MS analysis of Guar Gum and
Hydroxypropyl Guar at 300 Degrees C and 600 Degrees C,'' Philip
Morris, Inter-Office Correspondence, Mar. 26, 1990, available at
https://industrydocuments.library.ucsf.edu/tobacco/docs/ptnn0108.
41. Baker, R. R. and L. J. Bishop, ``The Pyrolysis of Non-Volatile
Tobacco Ingredients Using a System that Simulates Cigarette
Combustion Conditions,'' Journal of Analytical and Applied
Pyrolysis, 74:145-170, 2005.
42. Smith, T. E., ``A Literature Review of Aging and Fermentation of
Tobacco,'' Brown and Williamson Tobacco Corporation, 1964.
43. Cornell, A., W. F. Cartwright, and T. A. Bertinuson, ``Influence
of
[[Page 12776]]
Microorganisms (Fermentation) on the Chemistry of Tobacco,'' Recent
Advances in Tobacco Science, 5:27-62, 1979.
44. Schulthess, D., Philip Morris International, ``Project Clover,
Marlboro-Roll Your Own, Report on the Microbial Analysis,'' January
26, 1984.
45. Geiss, V. L., Brown and Williamson Tobacco Corporation,
``Control and Use of Microbes in Tobacco Product Manufacturing,''
1989.
46. Andersen, R. A., P. D. Fleming, T. R. Hamilton-Kemp, et al.,
``pH Changes in Smokeless Tobaccos Undergoing Nitrosation During
Prolonged Storage: Effects of Moisture, Temperature, and Duration,''
Journal of Agricultural and Food Chemistry, 41:968-972, 1993.
47. Mutasa, E. S., K. J. Seal, and N. Magan, ``The Water Content/
Water Activity Relationship of Cured Tobacco and Water Relations of
Associated Spoilage Fungi,'' International Biodeterioration, 26:
381-896, 1990.
48. St. Charles, F. K., ``Reduction of the Water Activity of Wet
Snuff/259,'' Brown and Williamson Tobacco Corporation, Research &
Development, File Note, December 20, 1989.
49. Andersen, R. A., H. R. Burton, P. D. Fleming, et al., ``Effect
of Storage Conditions on Nitrosated, Acylated, and Oxidized Pyridine
Alkaloid Derivatives in Smokeless Tobacco Products,'' Cancer
Research, 49:5895-5900, 1989.
50. Rutqvist, L.E., M. Curvall, T. Hassler, et al., ``Swedish Snus
and the GothiaTek[supreg] Standard,'' Harm Reduction Journal, 8:11,
2011.
51. Brunnemann, K. D., B. Prokopczyk, M. V. Djordjevic, et al.,
``Formation and Analysis of Tobacco-Specific N-Nitrosamines,''
Critical Reviews in Toxicology 26(2):121-137, 1996.
52. Fisher, M. T., C. B. Bennett, A. Hayes, et al., ``Sources of and
Technical Approaches for the Abatement of Tobacco Specific
Nitrosamine Formation in Moist Smokeless Tobacco Products,'' Food
and Chemical Toxicology, 50:942-948, 2012.
53. Djordjevic, M. V., J. Fan, L. P. Bush, et al., ``Effects of
Storage Conditions on Levels of Tobacco-Specific N-Nitrosamines and
N-Nitrosamino Acids in U.S. Moist Snuff,'' Journal of Agricultural
and Food Chemistry, 41:1790-1794, 1993.
54. Preliminary Regulatory Impact Analysis; Initial Regulatory
Flexibility Analysis; Unfunded Mandates Reform Act Analysis, Content
and Format of Substantial Equivalence Reports; Proposed Rule.
XI. Effective Date
FDA proposes that any final rule that issues based on this proposal
become effective 30 days after the final rule publishes in the Federal
Register.
List of Subjects
21 CFR Part 16
Administrative practice and procedure.
21 CFR Part 1107
Administrative practice and procedure, Smoke, Smoking, Tobacco,
Tobacco products.
Therefore, under the Federal Food, Drug, and Cosmetic Act, and
under authority delegated to the Commissioner of Food and Drugs, it is
proposed that chapter I of title 21 of the Code of Federal Regulations
be amended as follows:
PART 16--REGULATORY HEARING BEFORE THE FOOD AND DRUG ADMINISTRATION
0
1. The authority citation for part 16 continues to read as follows:
Authority: 15 U.S.C. 1451-1461; 21 U.S.C. 141-149, 321-394,
467f, 679, 821, 1034; 28 U.S.C. 2112; 42 U.S.C. 201-262, 263b, 364.
0
2. In Sec. 16.1(b)(2) add in numerical sequence an entry for ``Sec.
1107.50'' to read as follows:
Sec. 16.1 Scope.
* * * * *
(b) * * *
(2) * * *
Sec. 1107.50, relating to rescission of an order finding a tobacco
product substantially equivalent.
* * * * *
PART 1107--EXEMPTIONS AND SUBSTANTIAL EQUIVALENCE REPORTS
0
3. The authority citation for part 1107 is revised to read as follows:
Authority: 21 U.S.C. 371, 374, 387b, 387c, 387e(j), 387i, and
387j.
0
4. The heading of part 1107 is revised to read as set forth above.
0
5. Add subparts B through E to read as follows:
Subpart B--General
Sec.
1107.10 Scope.
1107.12 Definitions.
Subpart C--Substantial Equivalence Reports
1107.16 Submission of a substantial equivalence report.
1107.18 Required content and format of a report.
1107.19 Comparison information.
1107.20 Amendments.
1107.22 Withdrawal by applicant.
1107.24 Change in ownership of an SE report.
Subpart D--FDA Review
1107.40 Communications between FDA and applicants.
1107.42 Review cycles.
1107.44 FDA action on an SE report.
1107.46 Issuance of an order finding a new tobacco product
substantially equivalent.
1107.48 Issuance of an order denying marketing authorization.
1107.50 Rescission of order.
Subpart E--Miscellaneous
1107.58 Record retention.
1107.60 Confidentiality.
1107.62 Electronic submission.
Subpart B--General
Sec. 1107.10 Scope.
(a) Subparts B through E of this part apply to a substantial
equivalence report (or SE Report) for a new tobacco product that has:
(1) Characteristics different from a predicate tobacco product and
for which information is submitted to demonstrate it is not appropriate
to regulate the product under section 910(b) and (c) of the Federal
Food, Drug, and Cosmetic Act because the new tobacco product does not
raise different questions of public health; or
(2) The same characteristics as a predicate tobacco product.
(b) These subparts set forth procedures and requirements for the
submission to FDA of an SE Report under sections 905 and 910 of the
Federal, Food, Drug, and Cosmetic Act; the basic criteria for
establishing substantial equivalence; and the general procedures FDA
will follow when evaluating submissions.
Sec. 1107.12 Definitions.
For purposes of this part:
Accessory means any product that is intended or reasonably expected
to be used with or for the human consumption of a tobacco product; does
not contain tobacco and is not made or derived from tobacco; and meets
either of the following:
(1) Is not intended or reasonably expected to affect or alter the
performance, composition, constituents, or characteristics of a tobacco
product; or
(2) Is intended or reasonably expected to affect or maintain the
performance, composition, constituents, or characteristics of a tobacco
product; but
(i) Solely controls moisture and/or temperature of a stored
product; or
(ii) Solely provides an external heat source to initiate but not
maintain combustion of a tobacco product.
Additive means any substance the intended use of which results or
may reasonably be expected to result, directly or indirectly, in its
becoming a component or otherwise affecting the characteristic of any
tobacco product (including any substances intended for use as a
flavoring or coloring or in producing, manufacturing, packing,
processing, preparing, treating,
[[Page 12777]]
packaging, transporting, or holding), except that the term does not
include tobacco or a pesticide chemical residue in or on raw tobacco,
or a pesticide chemical.
Applicant means any manufacturer of tobacco products who is subject
to chapter IX of the Federal Food, Drug, and Cosmetic Act that submits
a premarket application to receive marketing authorization for a new
tobacco product.
Brand means a variety of tobacco product distinguished by the
tobacco used, tar content, nicotine content, flavoring used, size,
filtration, packaging, logo, registered trademark, brand name,
identifiable pattern of colors, or any combination of such attributes.
Characteristic means the materials, ingredients, design,
composition, heating source, or other features of a tobacco product.
Commercial distribution means any distribution of a tobacco product
to consumers or to another person through sale or otherwise, but does
not include interplant transfers of a tobacco product between
registered establishments within the same parent, subsidiary, and/or
affiliate company, nor does it include providing a tobacco product for
product testing where such product is not made available for
consumption or resale. ``Commercial distribution'' does not include the
handing or transfer of a tobacco product from one consumer to another
for personal consumption. For foreign establishments, the term
``commercial distribution'' has the same meaning, except that it does
not include distribution of a tobacco product that is neither imported
nor offered for import into the United States.
Component or part means any software or assembly of materials
intended or reasonably expected:
(1) To alter or affect the tobacco product's performance,
composition, constituents, or characteristics; or
(2) To be used with or for the human consumption of a tobacco
product. Component or part excludes anything that is an accessory of a
tobacco product.
Composition means the materials in a tobacco product, including
ingredients, additives, and biological organisms. The term includes the
manner in which the materials, for example, ingredients, additives, and
biological organisms, are arranged and integrated to produce a tobacco
product.
Constituent means any chemical or chemical compound in a tobacco
product that is or potentially is inhaled, ingested, or absorbed into
the body, any chemical or chemical compound in an emission from a
tobacco product, or any chemical or chemical compound in mainstream or
sidestream tobacco smoke that either transfers from any component of
the tobacco product to the smoke or that is formed by the combustion or
heating of tobacco, additives, or other component of the tobacco
product.
Container closure system means any packaging materials that are a
component or part of a tobacco product.
Design means the form and structure concerning, and the manner in
which, components or parts, ingredients, software, and materials are
integrated to produce a tobacco product.
Distributor means any person who furthers the distribution of a
tobacco product, whether domestic or imported, at any point from the
original place of manufacture to the person who sells or distributes
the product to individuals for personal consumption. Common carriers
are not considered distributors for the purposes of this part.
Finished tobacco product means a tobacco product, including all
components and parts, sealed in final packaging (e.g., filters or
filter tubes sold separately to consumers or as part of kits).
Grandfathered tobacco product means a tobacco product that was
commercially marketed in the United States as of February 15, 2007, and
does not include a tobacco product exclusively in test markets as of
that date. A grandfathered tobacco product is not subject to the
premarket requirements of section 910 of the Federal Food, Drug, and
Cosmetic Act.
Harmful or potentially harmful constituent (HPHC) means any
chemical or chemical compound in a tobacco product or tobacco smoke or
emission that:
(1) Is or potentially is inhaled, ingested, or absorbed into the
body; and
(2) Causes or has the potential to cause direct or indirect harm to
users or nonusers of tobacco products.
Health information statement means a statement, made under section
910(a)(4) of the Federal Food, Drug, and Cosmetic Act, that the health
information related to a new tobacco product will be made available
upon request by any person.
Health information summary means a summary, submitted under section
910(a)(4) of the Federal Food, Drug, and Cosmetic Act, of any health
information related to a new tobacco product.
Heating source means the source of energy used to burn or heat a
tobacco product.
Ingredient means tobacco, substances, compounds, or additives
contained within or added to the tobacco, paper, filter, or any other
component or part of a tobacco product, including substances and
compounds reasonably expected to be formed through a chemical reaction
during tobacco product manufacturing.
Material means an assembly of ingredients. Materials are assembled
to form a tobacco product or components or parts of tobacco products.
New tobacco product means:
(1) Any tobacco product (including those products in test markets)
that was not commercially marketed in the United States as of February
15, 2007; or
(2) Any modification (including a change in design, any component,
any part, or any constituent, including a smoke constituent, or in the
content, delivery or form of nicotine, or any other additive or
ingredient) of a tobacco product where the modified product was
commercially marketed in the United States after February 15, 2007.
Other features means any distinguishing qualities of a tobacco
product similar to those specifically enumerated in section
910(a)(3)(B) of the Federal Food, Drug, and Cosmetic Act. Such other
features include harmful and potentially harmful constituents and any
other product characteristics that relate to the chemical, biological,
and physical properties of the tobacco product and are necessary for
review.
Package or packaging means a pack, box, carton, or container of any
kind or, if no other container, any wrapping (including cellophane), in
which a tobacco product is offered for sale, sold, or otherwise
distributed to consumers.
Predicate tobacco product means a tobacco product that is a
grandfathered tobacco product or a tobacco product that FDA has
previously found substantially equivalent under section 910(a)(2)(A)(i)
of the Federal Food, Drug, and Cosmetic Act.
Submission tracking number or STN means the number that FDA assigns
to submissions that are received from a manufacturer of tobacco
products, such as SE Reports and requests for grandfather
determinations.
Substantial equivalence or substantially equivalent means, with
respect to a new tobacco product being compared to a predicate tobacco
product, that FDA by order has found that the new tobacco product:
(1) Has the same characteristics as the predicate tobacco product;
or
(2) Has different characteristics and the information submitted
contains information, including clinical data if deemed necessary by
FDA, that demonstrates that it is not appropriate
[[Page 12778]]
to require premarket review under section 910(b) and (c) of the Federal
Food, Drug, and Cosmetic Act because the new tobacco product does not
raise different questions of public health.
Substantial equivalence report or SE Report means a submission
under section 905(j)(1)(A)(i) of the Federal Food, Drug, and Cosmetic
Act that includes the basis for the applicant's determination that a
new tobacco product is substantially equivalent to a predicate tobacco
product. This term includes the initial substantial equivalence report
and all subsequent amendments.
Tobacco product means any product made or derived from tobacco that
is intended for human consumption, including any component, part, or
accessory of a tobacco product (except for raw materials other than
tobacco used in manufacturing a component, part, or accessory of a
tobacco product). The term ``tobacco product'' does not mean an article
that under the Federal Food, Drug, and Cosmetic Act is a drug (section
201(g)(1)), a device (section 201(h)), or a combination product
(section 503(g)).
Tobacco product manufacturer means any person, including a repacker
or relabeler, who:
(1) Manufactures, fabricates, assembles, processes, or labels a
tobacco product, or
(2) Imports a finished tobacco product for sale or distribution in
the United States.
Subpart C--Substantial Equivalence Reports
Sec. 1107.16 Submission of a substantial equivalence report.
An applicant may submit a SE Report intended to demonstrate that a
new tobacco product is substantially equivalent to a predicate tobacco
product. The applicant must submit the SE Report at least 90 calendar
days prior to the date the applicant intends to introduce or deliver
for introduction a new tobacco product into interstate commerce for
commercial distribution. The applicant cannot begin commercial
distribution of the new tobacco product until FDA has provided the
applicant an order stating that the Agency has determined that the new
tobacco product is substantially equivalent to a predicate tobacco
product, unless the new tobacco product has received authorization to
be marketed through another premarket pathway.
Sec. 1107.18 Required content and format of a SE report.
(a) Overview. The SE Report must provide information uniquely
identifying the new tobacco product and the predicate tobacco product,
and compare the new tobacco product to either a grandfathered tobacco
product or a tobacco product that FDA previously found to be
substantially equivalent. The SE Report must provide sufficient
information as described in this section to enable FDA to determine
whether the new tobacco product is substantially equivalent to a
tobacco product that was commercially marketed in the United States as
of February 15, 2007. If FDA cites deficiencies and requests
information to support a statement in the SE Report, the applicant must
provide that information for review to continue, or FDA may issue an
order under Sec. 1107.48. FDA will refuse to accept an SE Report if it
does not comply with this section. The SE Report must contain the
following information:
(1) General information (as described in paragraph (c) of this
section);
(2) Summary (as described in paragraph (d) of this section);
(3) New tobacco product description (as described in paragraph (e)
of this section);
(4) Predicate tobacco product description (as described in
paragraph (f) of this section), including a statement that the
predicate tobacco product has not been removed from the market at the
initiative of FDA and has not been determined by judicial order to be
adulterated or misbranded, and the submission tracking number of the SE
order finding the predicate product SE, or the submission tracking
number of, or information to support, a grandfathered determination of
the predicate tobacco product;
(5) Comparison information (as described in paragraph (g) of this
section);
(6) Comparative testing information (as described in paragraph (h)
of this section);
(7) Statement of compliance with applicable tobacco product
standards (as described in paragraph (i) of this section);
(8) Health information summary or statement that such information
will be made available upon request (as described in paragraph (j) of
this section);
(9) Compliance with 21 CFR part 25 (as described in paragraph (k)
of this section); and
(10) Certification statement (as described in paragraph (l) of this
section).
(b) Format. The applicant must submit the SE Report using the
form(s) that FDA provides. The SE Report must contain a comprehensive
index and table of contents, be well-organized and legible, and be
written in English. As described in Sec. 1107.62, the applicant must
submit the SE Report and all information supporting the SE Report in an
electronic format that FDA can process, read, review, and archive,
unless FDA has provided a waiver.
(c) General information. The SE Report must include the following
information, using the form FDA provides:
(1) The date the SE Report is submitted;
(2) Type of submission (e.g., the SE Report or amendment to a
report);
(3) FDA STN if previously assigned;
(4) Any other relevant FDA STN, such as a request for grandfathered
determination or SE Report previously found substantially equivalent
(if applicable), and cross-references to meetings with FDA regarding
the new tobacco product;
(5) Applicant name, address, and contact information;
(6) Authorized representative or U.S. agent (for a foreign
applicant), including the name, address, and contact information;
(7) For both the new and predicate tobacco products, the following
information to uniquely identify the products:
(i) Manufacturer;
(ii) Product name, including the brand and sub brand (or other
commercial name used in commercial distribution); and
(iii) Product category, product subcategory, and product properties
(if the product does not have a listed product property, e.g.,
ventilation or characterizing flavor, the report must state ``none''
for that property) as provided in the following table:
------------------------------------------------------------------------
Tobacco product
Tobacco product category: subcategory: Product properties:
------------------------------------------------------------------------
(A)Cigarettes................. (1) Combusted, --Package type (e.g.,
Filtered. hard pack, soft
pack, clam shell).
--Product quantity
(e.g., 20
cigarettes, 25
cigarettes).
--Length (e.g., 89
millimeters (mm),
100 mm).
--Diameter (e.g., 6
mm, 8.1 mm).
[[Page 12779]]
--Ventilation (e.g.,
none, 10%, 25%).
--Characterizing
Flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(2) Combusted, --Package type (e.g.,
Non-filtered. hard pack, soft
pack, clam shell).
--Product quantity
(e.g., 20
cigarettes, 25
cigarettes).
--Length (e.g., 89
mm, 100 mm).
--Diameter (e.g., 6
mm, 8.1 mm).
--Characterizing
Flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(3) Combusted, --Package type (e.g.,
Other. hard pack, soft
pack, clam shell).
--Product quantity
(e.g., 20
cigarettes, 25
cigarettes).
--Length (e.g., 89
mm, 100 mm).
--Diameter (e.g., 6
mm, 8.1 mm).
--Ventilation (e.g.,
none, 10%, 25%).
--Characterizing
Flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(4) Non-Combusted --Package type (e.g.,
(e.g., a hard pack, soft
cigarette where pack, clam shell).
the tobacco is --Product quantity
heated not (e.g., 20
burned). cigarettes, 25
cigarettes).
--Length (e.g., 89
mm, 100 mm).
--Diameter (e.g., 6
mm, 8.1 mm).
--Ventilation (e.g.,
none, 10%, 25%).
--Characterizing
Flavor(s) (e.g.,
none, menthol).
--Source of energy
(e.g., charcoal,
electrical heater).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(5) Cigarette, Co- For a new co-packaged
Package. tobacco product
composed of multiple
cigarette tobacco
products, include,
as applicable, all
properties for each
individual tobacco
product, as
identified in this
section.
(B) Roll-Your-Own Tobacco (1) Roll-Your-Own --Package type (e.g.,
Products. Tobacco Filler. bag, pouch).
--Product quantity
(e.g., 20 g, 40 g).
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(2) Rolling Paper --Package type (e.g.,
bag, box, booklet).
--Product quantity
(e.g., 50 sheets,
200 papers).
--Length (e.g., 79
mm, 100 mm, 110 mm).
--Width (e.g., 28 mm,
33 mm, 45 mm).
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(3) Filtered --Package type (e.g.,
Cigarette Tube. bag, box).
--Product quantity
(e.g., 100 tubes,
200 tubes).
--Length (e.g., 89
mm, 100 mm).
--Diameter (e.g., 6
mm, 8.1 mm).
--Ventilation (e.g.,
none, 10%, 25%).
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(4) Non-Filtered --Package type (e.g.,
Cigarette Tube. bag, box).
--Product quantity
(e.g., 100 tubes,
200 tubes).
--Length (e.g., 89
mm, 100 mm).
--Diameter (e.g., 6
mm, 8.1 mm).
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(5) Filter....... --Package type (e.g.,
bag, box).
--Product quantity
(e.g., 100 filters,
200 filters).
--Length (e.g., 8 mm,
12 mm).
--Diameter (e.g., 6
mm, 8.1 mm).
--Ventilation (e.g.,
none, 10%, 25%).
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(6) Paper Tip.... --Package type (e.g.,
bag, box).
--Product quantity
(e.g., 200 tips, 275
tips).
--Length (e.g., 12
mm, 15 mm).
--Width (e.g., 27
mm).
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
[[Page 12780]]
(7) Roll-Your-Own --For a new co-
Co-Package. packaged tobacco
product composed of
multiple RYO tobacco
products, include,
as applicable, all
properties for each
individual tobacco
product (e.g., roll-
your own tobacco,
rolling paper,
filtered cigarette
tube, non-filtered
cigarette tube,
filter, paper tip)
as identified in
this section.
(8) Other........ --Package type (e.g.,
bag, box).
--Product quantity.
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product.
(C) Smokeless Tobacco Products (1) Loose Moist --Package type (e.g.,
Snuff. plastic can with
metal lid, plastic
can with plastic
lid).
--Product quantity
(e.g., 20 grams (g),
2 ounces).
--Tobacco cut size
(e.g., 5 mm, 7 mm).
--Characterizing
flavor(s) (e.g.,
none, menthol,
cherry,
wintergreen).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(2) Portioned --Package type (e.g.,
Moist. plastic can with
(3) Snuff........ metal lid, plastic
can with plastic
lid).
--Product quantity
(e.g., 22.5 g, 20
g).
--Portion count
(e.g., 15 pouches,
20 pieces).
--Portion mass (e.g.,
1.5 g/pouch, 2 g/
piece).
--Portion length
(e.g., 15 mm, 20
mm).
--Portion width
(e.g., 10 mm, 15
mm).
--Portion thickness
(e.g., 5 mm, 7 mm).
--Tobacco cut size
(e.g., 5 mm, 7 mm).
--Characterizing
flavor(s) (e.g.,
none, menthol,
cherry,
wintergreen).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(4) Loose Snuff.. --Package type (e.g.,
plastic can with
metal lid, plastic
can with plastic
lid).
--Product quantity
(e.g., 20 g, 2
ounces).
--Tobacco cut size
(e.g., 5 mm, 7 mm).
--Characterizing
flavor(s) (e.g.,
none, menthol,
cherry,
wintergreen).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(5) Portioned --Package type (e.g.,
Snuff. plastic can with
metal lid, plastic
can with plastic
lid).
--Product quantity
(e.g., 22.5 g, 20
g).
--Portion count
(e.g., 15 pouches,
20 pieces).
--Portion mass (e.g.,
1.5 g/pouch, 2 g/
piece).
--Portion length
(e.g., 15 mm, 20
mm).
--Portion width
(e.g., 10 mm, 15
mm).
--Portion thickness
(e.g., 5 mm, 7 mm).
--Tobacco cut size
(e.g., 5 mm, 7 mm).
--Characterizing
flavor(s) (e.g.,
none, menthol,
cherry,
wintergreen).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(6) Loose Dry --Package type (e.g.,
Snuff. plastic can with
metal lid, plastic
can with plastic
lid).
--Product quantity
(e.g., 20 g, 2
ounces).
--Tobacco cut size
(e.g., 0.05 mm, 0.07
mm).
--Characterizing
flavor(s) (e.g.,
none, menthol,
cherry,
wintergreen).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(7) Dissolvable.. --Package type (e.g.,
plastic can with
metal lid, plastic
can with plastic
lid).
--Product quantity
(e.g., 22.5 g, 20
g).
--Portion count
(e.g., 15 sticks, 20
tablets).
--Portion mass (e.g.,
1.5 g/strip, 1 g/
piece).
--Portion length
(e.g., 10 mm, 15
mm).
--Portion width
(e.g., 5 mm, 8 mm).
--Portion thickness
(e.g., 3 mm, 4 mm).
--Tobacco cut size
(e.g., 0.05 mm, 0.07
mm).
--Characterizing
flavor(s) (e.g.,
none, menthol,
cherry,
wintergreen).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(8) Loose Chewing --Package type (e.g.,
Tobacco. bag, pouch,
wrapped).
--Product quantity
(e.g., 20 g, 3
ounces).
--Tobacco cut size
(e.g., 0.05 mm, 0.07
mm).
--Characterizing
flavor(s) (e.g.,
none, menthol,
cherry,
wintergreen).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
[[Page 12781]]
(9) Portioned --Package type (e.g.,
Chewing Tobacco. plastic can with
metal lid, plastic
can with plastic
lid).
--Product quantity
(e.g., 20 g).
--Portion count
(e.g., 10 bits).
--Portion mass (e.g.,
2 g/bit).
--Portion length
(e.g., 8 mm, 10 mm).
--Portion width
(e.g., 6 mm, 8 mm).
--Portion thickness
(e.g., 5 mm, 7 mm).
--Characterizing
flavor(s) (e.g.,
none, menthol,
cherry,
wintergreen).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(10) Smokeless Co- --For a new co-
Package. packaged tobacco
product composed of
multiple smokeless
tobacco products,
include, as
applicable, all
properties for each
individual tobacco
product as
identified in this
section.
(11) Other....... --Package type (e.g.,
bag, box).
--Product quantity.
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol).
--Additional
properties needed to
uniquely identify
the tobacco product.
(D) ENDS (Electronic Nicotine (1) Open E-Liquid --Package type (e.g.,
Delivery System). bottle, box).
--Product quantity
(e.g., 1 bottle, 5
bottles).
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol, cherry,
wintergreen).
--E-liquid volume
(e.g., 10
milliliters (ml)).
--Nicotine
concentration (e.g.,
0, 0.2 mg/ml).
--PG/VG ratio (e.g.,
N/A, 0/100, 50/50).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(2) Closed E- --Package type (e.g.,
Liquid. cartridge).
--Product quantity
(e.g., 1 cartridge,
5 cartridges).
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol, cherry,
wintergreen).
--E-liquid volume
(e.g., 10 ml).
--Nicotine
concentration (e.g.,
0, 0.2 mg/ml).
--PG/VG ratio (e.g.,
N/A, 0/100, 50/50).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(3) Closed E- --Package type (e.g.,
Cigarette. box, none, plastic
clamshell).
--Product quantity
(e.g., 1 e-
cigarette, 5 e-
cigarettes).
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol, cherry,
wintergreen).
--Length (e.g., 100
mm, 120 mm).
--Diameter (e.g., 6
mm, 8 mm).
--E-liquid volume
(e.g., 2 ml, 5 ml).
--Nicotine
concentration (e.g.,
0, 0.2 mg/ml).
--PG/VG ratio (e.g.,
N/A, 0/100, 50/50).
--Wattage (e.g., 100
W, 200 W).
--Battery capacity
(e.g., 100 mAh, 200
mAh).
--Additional
properties needed to
uniquely identify
the tobacco product.
(4) Open E- --Package type (e.g.,
Cigarette. box, none, plastic
clamshell).
--Product quantity
(e.g., 1 e-
cigarette, 5 e-
cigarettes).
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol, cherry,
wintergreen).
--Length (e.g., 100
mm, 120 mm).
--Diameter (e.g., 8
mm, 14 mm).
--E-liquid volume
(e.g., 2 ml, 5 ml).
--Wattage (e.g., 100
Watts (W), 200 W).
--Battery capacity
(e.g., 100 mAh, 200
mAh).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(5) ENDS --Package type (e.g.,
Component. box, none, plastic
clamshell).
--Product quantity
(e.g., 1 e-
cigarette, 5 e-
cigarettes).
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol, cherry,
wintergreen).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(6) ENDS Co- --For a new co-
Package. packaged tobacco
product composed of
multiple ENDS
tobacco products,
include, as
applicable, all
properties for each
individual tobacco
product as
identified in this
section.
(7) ENDS Other... --Package type (e.g.,
bag, box).
--Product quantity.
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol, cherry).
[[Page 12782]]
--Additional
properties needed to
uniquely identify
the tobacco product.
(E) Cigars.................... (1) Filtered, --Package type (e.g.,
Sheet-Wrapped hard pack, soft
Cigar. pack, clam shell).
--Product quantity
(e.g., 20 filtered
cigars, 25 filtered
cigars).
--Characterizing
flavor (e.g., none,
menthol).
--Length (e.g., 89
mm, 100 mm).
--Diameter (e.g., 6
mm, 8.1 mm).
--Ventilation (e.g.,
none, 10%, 25%).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(2) Unfiltered, --Package type (e.g.,
Sheet-Wrapped box, film sleeve).
Cigar. --Product quantity
(e.g., 1 cigar, 5
cigarillos).
--Characterizing
flavor (e.g., none,
menthol).
--Length (e.g., 100
mm, 140 mm).
--Diameter (e.g., 8
mm, 10 mm).
--Tip (e.g., none,
wood tips, plastic
tips).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(3) Leaf-Wrapped --Package type (e.g.,
Cigar. box, film, sleeve,
none).
--Product quantity
(e.g., 1 cigar, 5
cigars).
--Characterizing
flavor (e.g., none,
whiskey).
--Length (e.g., 150
mm, 200 mm).
--Diameter (e.g., 8
mm, 10 mm).
--Wrapper material
(e.g., burley
tobacco leaf,
Connecticut shade
grown tobacco leaf).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(4) Cigar --Package type (e.g.,
Component. box, booklet).
--Product quantity
(e.g., 10 wrappers,
20 leaves).
--Characterizing
flavor (e.g., none,
menthol, cherry).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(5) Cigar Tobacco --Package type (e.g.,
Filler. bag, pouch).
--Product quantity
(e.g., 20 g, 16
ounces).
--Characterizing
flavor (e.g., none,
tobacco, menthol,
cherry).
--Tobacco cut size
(e.g., 5 mm, 10 mm).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(6) Cigar Co- --For a new co-
Package. packaged tobacco
product composed of
multiple cigar
tobacco products,
include, as
applicable, all
properties for each
individual tobacco
product as
identified
previously.
(7) Other........ --Package type (e.g.,
bag, box).
--Product quantity.
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol).
--Additional
properties needed to
uniquely identify
the tobacco product.
(F) Pipe Tobacco Products..... (1) Pipe......... --Package type (e.g.,
box, none).
--Product quantity
(e.g., 1 pipe).
--Length (e.g., 200
mm, 300 mm).
--Diameter (e.g., 25
mm).
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(2) Pipe Tobacco --Package type (e.g.,
Filler. bag, pouch).
--Product quantity
(e.g., 20 g, 16
ounces).
--Characterizing
flavor(s) (e.g.,
none, menthol,
cavendish, cherry).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(3) Pipe --Package type (e.g.,
Component. bowl, shank, stem,
screen, filter).
--Product quantity
(e.g., 1 bowl, 1
stem, 100 filters).
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(4) Pipe Co- --For a new co-
Package. packaged tobacco
product composed of
multiple pipe
tobacco products,
include, as
applicable, all
properties for each
individual tobacco
product as
identified
previously.
(5) Other........ --Package type (e.g.,
bag, box).
--Product quantity.
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol).
--Additional
properties needed to
uniquely identify
the tobacco product.
(G) Waterpipe Tobacco Products (1) Waterpipe.... --Package type (e.g.,
box, none).
--Product quantity
(e.g., 1 waterpipe).
--Length (e.g., 200
mm, 500 mm).
[[Page 12783]]
--Width (e.g., 100
mm, 300 mm).
--Number of hoses
(e.g., 1, 2, 4).
--Characterizing
flavor(s) (e.g.,
none, menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(2) Waterpipe --Package type (e.g.,
Tobacco Filler. bag, pouch).
--Product quantity
(e.g., 20 g, 16
ounces).
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol, apple).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(3) Waterpipe --Package type (e.g.,
Heat Source. box, film sleeve,
bag, none).
--Product quantity
(e.g., 150 g, 680
g).
--Characterizing
flavor(s) (e.g.,
none, menthol,
apple).
--Portion count(e.g.,
20 fingers, 10
discs, 1 base).
--Portion mass (e.g.,
15 g/finger).
--Portion length
(e.g., 40 mm, 100
mm).
--Portion width
(e.g., 10 mm, 40
mm).
--Portion thickness
(e.g., 10 mm, 40
mm).
--Source of energy
(e.g., charcoal,
battery,
electrical).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(4) Waterpipe --Package type (e.g.,
Component. bag, box, none).
--Product quantity
(e.g., 1 base, 1
bowl, 1 hose, 10
mouthpieces).
--Characterizing
flavor(s) (e.g.,
none, menthol,
apple).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
(5) Waterpipe Co- --For a new co-
Package. packaged tobacco
product composed of
multiple waterpipe
tobacco products,
include, as
applicable, all
properties for each
individual tobacco
product as
identified in this
section.
(6) Waterpipe --Package type (e.g.,
Other. bag, box).
--Product quantity.
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
Other......................... Other............ --Package type (e.g.,
bag, box).
--Product quantity.
--Characterizing
flavor(s) (e.g.,
none, tobacco,
menthol).
--Additional
properties needed to
uniquely identify
the tobacco product
(if applicable).
------------------------------------------------------------------------
(8) Address and the FDA Establishment Identifier (FEI) number(s) of
the establishments involved in the manufacture and/or importation of
the new and predicate tobacco products.
(d) Summary. The SE Report must include a summary at the beginning
of the SE Report that includes the following:
(1) A concise description of the characteristics of the new tobacco
product;
(2) A statement as to whether the applicant believes the new
tobacco product has the same characteristics as the predicate tobacco
product or has different characteristics but does not raise different
questions of public health; and
(3) A concise description of the similarities and differences
between the new tobacco product and the predicate tobacco product with
respect to their characteristics (materials, ingredients, design,
composition, heating source, or other features).
(e) New tobacco product description. The applicant must identify
one new tobacco product in the SE Report for comparison to one
predicate tobacco product. The SE Report must describe the new tobacco
product in sufficient detail to enable FDA to evaluate its
characteristics. This part of the SE Report must include:
(1) A narrative description of the new tobacco product and detailed
drawings or schematics of the new tobacco product, including its
container closure system, illustrating all components or parts of the
product. For a portioned tobacco product, the SE Report must also
include a diagram illustrating all components or parts of the
individual unit of use;
(2) A description and the function of each component or part of the
new tobacco product, and an explanation of how each component or part
is integrated into the design of the new tobacco product; and
(3) A concise overview of the process used to manufacture the new
tobacco product, including the fermentation process, where applicable,
with information on the type and quantity of the microbial inoculum
and/or fermentation solutions. If the manufacturing process for the new
tobacco product does not affect the characteristics of the new tobacco
product beyond what is described elsewhere in the SE Report, an
applicant must state that to satisfy this provision.
(f) Description of predicate tobacco product. (1) The applicant
must identify a predicate tobacco product that is either a
grandfathered tobacco product or a tobacco product that FDA previously
found to be substantially equivalent.
(2) A tobacco product to which a new tobacco product is compared
must:
(i) Be in the same category and subcategory of product as the new
tobacco product;
(ii) Have been either:
(A) Commercially marketed (not exclusively in a test market) in the
United States as of February 15, 2007, as shown by either specific
information sufficient to support this in the SE Report, including a
statement that ``I, (name of responsible official), confirm that the
predicate tobacco product, (insert name of predicate tobacco product),
was commercially marketed
[[Page 12784]]
other than for test marketing as of February 15, 2007'', or reference
to an STN for a previous determination by FDA that the predicate
product is grandfathered; or
(B) Previously determined to be substantially equivalent by FDA;
(iii) Be an individual product and not a composite of multiple
products;
(iv) Not be the subject of a rescission order by FDA, as described
in Sec. 1107.50; and
(v) Not have been removed from the market at the initiative of FDA
and not have been determined by judicial order to be adulterated or
misbranded.
(g) Comparison information. The SE Report must include a comparison
of the characteristics of the new tobacco product and the predicate
tobacco product, as described in Sec. 1107.19. If the new tobacco
product has limited changes to a characteristic(s) when compared to the
predicate tobacco product, and all other characteristics are identical
(e.g., a change to product quantity), the applicant must provide
comparison information related to such characteristic(s), but may
certify that the other characteristics identical under paragraph (1)(2)
of this section. The applicant must maintain records supporting the
certification consistent with Sec. 1107.58.
(h) Comparative testing information. Other than for characteristics
that are identical, and for which the applicant has certified that the
characteristics are identical under paragraph (1)(2) of this section,
the SE Report must provide comparative testing information on the
characteristics of the new and predicate tobacco products, as described
in Sec. 1107.19, except where the applicant adequately justifies that
such comparative testing information is not necessary to demonstrate
that the new product has the same characteristics as the predicate or
does not raise different questions of public health. The testing
information must:
(1) Include the test protocols, quantitative acceptance criteria,
and test results (including means and variances, data sets, and a
summary of the results);
(2) Be conducted on a sufficient sample size and on test samples
that reflect the finished tobacco product composition and design;
(3) State whether the same test methods were used for the new
tobacco product and the predicate product, and if the methods differed,
an explanation as to how the results of the different test methods can
be compared; and
(4) Identify national and international standards used to test the
new and predicate tobacco products and explain any deviations from the
standard, or state that no standards were used for the testing.
(i) Statement of compliance with applicable tobacco product
standards. The SE Report must either:
(1) List and describe the action(s) taken by the applicant to
comply with applicable requirements under section 907 of the Federal
Food, Drug, and Cosmetic Act; or
(2) State there are no applicable requirements under section 907 of
the Federal Food, Drug, and Cosmetic Act.
(j) Health information summary or statement regarding availability
of such information. The SE Report must include either a health
information summary or a statement that such information will be made
available upon request, as provided in section 910(a)(4) of the Federal
Food, Drug, and Cosmetic Act, in accord with the following:
(1) Health information summary. If including a health information
summary with the SE Report, the applicant must provide a copy of the
full SE Report that excludes research subject identifiers and trade
secret and confidential commercial information as defined in Sec. Sec.
20.61 and 20.63 of this chapter (21 CFR 20.61 and 20.63); and either
(i) Provide accurate, complete, and not false or misleading,
additional health information, including information, research, or data
about adverse health effects, that the applicant has or knows about
concerning the new tobacco product that is not contained in the SE
Report; or
(ii) Provide the following statement, if true, about the new
tobacco product: ``Applicant does not have or know of any additional
health information, including information, research or data regarding
adverse health effects, about the new tobacco product that is the
subject of this SE Report.''
(2) Statement regarding availability of health information. If the
applicant chooses to make the health information available upon
request, the SE Report must include the following statement, with the
appropriate applicant information inserted as indicated by
parenthetical text, signed by an authorized representative of the
applicant, made on a separate page of the SE Report, and clearly
identified as ``910(a)(4) health information statement''. ``I certify
that, in my capacity as (the position held in company by person
required to submit the SE Report, preferably the responsible official
of the applicant) of (company name), I will make available, upon
request, the information identified in 21 CFR 1107.18(j)(3) within 30
calendar days of a request.''
(3) Content of health information. The health information the
applicant agrees to make available in paragraph (j)(2) of this section
must be a copy of the full SE Report, excluding all research subject
identifiers, trade secrets, and confidential commercial information, as
defined in 21 CFR 20.61 and 21 CFR 20.63; and either.
(i) Accurate, complete, and not false or misleading, additional
health information, including information, research, or data about
adverse health effects, that the applicant has or knows about
concerning the new tobacco product and that is not contained in the SE
Report; or
(ii) The following statement, if true, about the new tobacco
product. ``(Company name) does not have or know of any additional
health information, including information, research or data regarding
adverse health effects about the new tobacco product that is the
subject of the provided SE Report.''
(4) Requests for information. All requests for information under
paragraph (j)(2) of this section must be made in writing to the
authorized representative of the applicant, whose contact information
will be posted on the FDA website listing substantial equivalence
determinations. The applicant must provide FDA any updated information
if the contact information changes.
(5) No modified risk violations. To the extent information is
included in the health information summary or health information
provided upon request under paragraphs (j)(1) and (2) of this section
that is not required by section 910(a)(4) of the Federal Food, Drug,
and Cosmetic Act or paragraph (j) of this section, that information
must not contain a statement that would cause the tobacco product to be
in violation of section 911 of the Federal Food, Drug, and Cosmetic Act
upon the introduction or delivery for introduction of the proposed new
product into interstate commerce.
(k) Compliance with 21 CFR part 25. (1) The SE Report must include
an environmental assessment prepared in accordance with Sec. 25.40 of
this chapter, or a valid claim of categorical exclusion. If the
applicant believes that the action qualifies for an available
categorical exclusion, the applicant must state under Sec. 25.15(a)
and (d) of this chapter that the action requested qualifies for a
categorical exclusion, citing the particular exclusion that is claimed,
and that to the applicant's knowledge, no extraordinary circumstances
exist under Sec. 25.21.
[[Page 12785]]
(2) The environmental assessment must include a statement
explaining whether the new tobacco product is intended to replace the
predicate tobacco product once the new tobacco product receives market
authorization, is intended to be a line extension of the predicate
tobacco product, is intended to be introduced as an additional product
by the same manufacturer, or if the new tobacco product will be
introduced as an additional product but by a different manufacturer.
(l) Certification Statement. (1) The SE Report must contain the
following certification, with the appropriate information inserted (as
indicated by parenthetical text), and be signed by an authorized
representative of the applicant. ``I (name of responsible official) on
behalf of (applicant), hereby certify that (applicant) will maintain
all records to substantiate the accuracy of this SE Report for the
period of time required in Sec. 1107.58 and ensure that such records
remain readily available to the FDA upon request. I certify that this
information and the accompanying submission are true and correct, that
no material fact has been omitted, and that I am authorized to submit
this on the applicant's behalf. I understand that under section 1001 of
title 18 of the United States Code anyone who knowingly and willfully
makes a materially false, fictitious, or fraudulent statement or
representation in any matter within the jurisdiction of the executive,
legislative, or judicial branch of the Government of the United States
is subject to criminal penalties.''
(2) The SE Report must include the following certification if an
applicant chooses to certify that certain characteristics are identical
in lieu of providing data for each characteristic of the new and
predicate tobacco products. This certification must include the
appropriate information inserted (as indicated by parenthetical text)
and be signed by an authorized representative of the applicant. ``I,
(name of responsible official), on behalf of (name of company), certify
that (new tobacco product name) has the following modification(s) as
compared to (name of predicate tobacco product): (describe
modification(s), e.g., change in product quantity or change in
container closure system). Aside from these modifications, the
characteristics of (new tobacco product name) and (name of predicate
tobacco product) are identical. I certify that (name of company)
understands this means there is no other modification to the materials,
ingredients, design features, heating source, or any other feature. I
also certify that (name of company) will maintain records to support
the comparison information in 21 CFR 1107.19 that substantiate the
accuracy of this statement for the period of time required in 21 CFR
1107.58, and ensure that such records remain readily available to FDA
upon request.''
Sec. 1107.19 Comparison information.
The SE Report must include a comparison of the characteristics of
the new tobacco product to the predicate tobacco product. The
comparison section of the SE Report must be organized in the following
manner:
(a) Comparison of product design. The SE Report must include
descriptions of the product designs of the new and predicate tobacco
products and identify any differences. The SE Report must include, in a
tabular format, a side-by-side comparison of each design parameter of
the new and predicate tobacco products. For each design parameter, the
target value and range of acceptable values, actual measured value
(where applicable), and range of measured values (where applicable)
with units of measure must be provided. In addition, for each
applicable design parameter, test data must be provided.
(1) Cigarettes. For cigarettes, the required design parameter
information to be provided for each predicate and new tobacco product
is as follows:
Table 1 to Sec. 1107.19(a)(1)
------------------------------------------------------------------------
Provide test data (include
test protocols, quantitative
Provide target specification with upper acceptance criteria, data
and lower range limits for: sets, and a summary of the
results) for:
------------------------------------------------------------------------
--Cigarette length (mm) --Puff count
--Cigarette circumference (mm) --Cigarette draw resistance
(mm H2O)
--Cigarette draw resistance (mm H2O) --Tobacco filler mass (mg)
--Tobacco filler mass (mg) --Tobacco moisture (%)
--Tobacco rod density (g/cubic centimeter --Filter ventilation (%)
(cm3))
--Tobacco moisture (%) --Cigarette paper base paper
basis weight (g/m2))
--Filter ventilation (%) --Cigarette paper base paper
porosity (CU)
--Tipping paper length (mm) --Filter efficiency (%) (If
no filter efficiency data
is available for the
products, include
information sufficient to
show that the cigarette
filter is unchanged (e.g.,
denier per filament, total
denier, and filter
density))
--Cigarette paper base paper basis weight --Filter pressure drop (mm
(g/m2) H2O)
--Cigarette paper base paper porosity (CU)
--Cigarette paper band width (mm)
--Cigarette paper band space (mm)
--Filter efficiency (%) (If no filter
efficiency data is available for the
products, include information sufficient
to show that the cigarette filter is
unchanged (e.g., denier per filament,
total denier, and filter density))
--Filter length (mm)
--Filter pressure drop (mm H2O)
------------------------------------------------------------------------
(2) Smokeless tobacco. For portioned and non-portioned smokeless
tobacco products, the required design parameter information to be
provided for each predicate and new tobacco product is as follows:
[[Page 12786]]
Table 2 to Sec. 1107.19(a)(2)
------------------------------------------------------------------------
Provide test data (include
test protocols, quantitative
Provide target specification with upper acceptance criteria, data
and lower range limits for: sets, and a summary of the
results) for:
------------------------------------------------------------------------
Portioned Smokeless Tobacco Products
------------------------------------------------------------------------
--Tobacco cut size (mm) --Tobacco cut size (mm).
--Tobacco moisture (%) --Tobacco moisture (%).
--Portion length (mm) (if applicable) --Portion mass (mg) (if
applicable).
--Portion width (mm) (if applicable) --Pouch paper porosity (CU).
--Portion mass (mg) (if applicable) --Pouch paper basis weight
(g/m2).
Portion thickness (mm) (if applicable)
Pouch paper wicking
Pouch paper porosity (CU)
Pouch paper basis weight (g/m2)
------------------------------------------------------------------------
Nonportioned Smokeless Tobacco Products
------------------------------------------------------------------------
--Tobacco cut size (mm) --Tobacco cut size (mm).
--Tobacco moisture (%) --Tobacco moisture (%).
------------------------------------------------------------------------
(3) Roll-your-own tobacco, rolling papers. For roll-your-own
tobacco rolling papers, the required design parameter information to be
provided for each predicate and new tobacco product is as follows:
Table 3 to Sec. 1107.19(a)(3)
------------------------------------------------------------------------
Provide test data
(include test protocols,
Provide target specification with upper and quantitative acceptance
lower range limits for: criteria, data sets, and
a summary of the results)
for:
------------------------------------------------------------------------
--Paper length(mm) --Mass per paper (mg).
--Paper width (mm) --Cigarette paper base
--Mass per paper (mg) paper basis weight (g/
--Cigarette paper base paper basis weight (g/ m2).
m2) --Cigarette paper base
paper porosity (CU).
--Cigarette paper band
porosity (CU) (if
applicable).
--Cigarette paper base paper porosity (CU)
--Cigarette paper band porosity (CU) (if
applicable)
--Cigarette paper band width (mm) (if
applicable)
--Cigarette paper band space (mm)
(applicable)
------------------------------------------------------------------------
(4) Roll-your-own tobacco, tubes. For roll-your-own tobacco tubes,
the required design parameter information to be provided for each
predicate and new tobacco product is as follows:
Table 4 to Sec. 1107.19(a)(4)
------------------------------------------------------------------------
Provide test data (include
test protocols, quantitative
Provide target specification with upper acceptance criteria, data
and lower range limits for: sets, and a summary of the
results) for:
------------------------------------------------------------------------
--Tube length (mm) --Total mass (mg).
--Tube circumference (mm) --Cigarette paper base paper
--Total mass (mg) basis weight (g/m2).
--Cigarette paper base paper basis weight --Cigarette paper base paper
(g/m2) porosity (CU).
--Cigarette paper band
porosity (CU).
--Cigarette paper base paper porosity (CU)
--Cigarette paper band porosity (CU)
--Cigarette paper band width (mm)
--Cigarette paper band space (mm)
------------------------------------------------------------------------
(5) Roll-your-own tobacco, filtered tubes. For roll-your-own
tobacco filtered tubes, the required design parameter information to be
provided for each new predicate and new tobacco product is as follows:
Table 5 to Sec. 1107.19(a)(5)
------------------------------------------------------------------------
Provide test data (include
test protocols, quantitative
Provide target specification with upper acceptance criteria, data
and lower range limits for: sets, and a summary of the
results) for:
------------------------------------------------------------------------
--Tube length (mm) --Total mass (mg).
--Tube circumference (mm) --Filter ventilation (%).
--Total mass (mg) --Cigarette paper base paper
--Tipping paper length (mm) basis weight (g/m2).
--Cigarette paper base paper
porosity (CU).
[[Page 12787]]
--Filter ventilation (%) --Cigarette paper band
--Cigarette paper base paper basis weight porosity (CU).
(g/m2) --Filter denier per filament
--Cigarette paper base paper porosity (CU) (DPF).
--Cigarette paper band porosity (CU) --Filter total denier (g/
9000m).
--Filter density (g/cm3).
--Cigarette paper band width (mm) --Filter pressure drop (mm
H2O).
--Cigarette paper band space (mm)
--Filter length (mm)
--Filter denier per filament (DPF)
--Filter total denier (g/9000m)
--Filter density (g/cm3)
--Filter pressure drop (mm H2O)
------------------------------------------------------------------------
(6) Roll-your-own tobacco. For roll-your-own tobacco, the required
design parameter information to be provided for each predicate and new
tobacco product is as follows:
Table 6 to Sec. 1107.19(a)(6)
------------------------------------------------------------------------
Provide test data (include
test protocols, quantitative
Provide target specification with upper acceptance criteria, data
and lower range limits for: sets, and a summary of the
results) for:
------------------------------------------------------------------------
--Tobacco filler mass (mg) --Tobacco filler mass (mg).
--Tobacco size (mm) --Tobacco size (mm).
--Tobacco moisture (%) --Tobacco moisture (%).
------------------------------------------------------------------------
(b) Comparison of heating sources. The SE Report must include a
description of the heating source for the new and predicate tobacco
products and identify any differences, or state that there is no
heating source.
(c) Comparison of product composition. The SE Report must include
descriptions of the product composition of the new and predicate
tobacco products and identify any differences. The SE Report must
include, in a tabular format, a side-by-side comparison of the
materials and ingredients for each component or part of the new and
predicate tobacco products. For each material and ingredient quantity,
the target value and range of acceptable values, actual measured value
(where applicable), and range of measured values (where applicable)
reported as mass per component or part, must be provided.
(1) Materials. For each material in the products include:
(i) The material name and common name(s), if applicable;
(ii) The component or part of the tobacco product where the
material is located;
(iii) The subcomponent or subpart where the material is located, if
applicable;
(iv) The function of the material;
(v) The quantities (including ranges or means, acceptance limits)
of the material(s) in each new tobacco product and predicate tobacco
product (with any specification variation, if applicable);
(vi) The specification(s) (including quality/grades, suppliers)
used for the new tobacco product and predicate tobacco product (with
any specification variations, if applicable); and
(vii) Any other material properties necessary to characterize the
new and predicate tobacco products.
(2) Ingredients other than tobacco. For ingredients other than
tobacco in each material and/or component or part of the product
include:
(i) The International Union of Pure and Applied Chemistry (IUPAC)
chemical name and common name, if applicable;
(ii) The Chemical Abstracts Service (CAS) number(s) or FDA Unique
Ingredient Identifier (UNII);
(iii) The function of the ingredient;
(iv) The quantity with the unit of measure (including ranges or
means, acceptance limits) of the material(s) in the new tobacco product
and predicate tobacco product reported as mass per gram of tobacco for
non-portioned tobacco products and as mass per portion for portioned
tobacco products (with any specification variation, if applicable);
(v) The specification(s) (including purity or grade and supplier);
(vi) For complex purchased ingredients, each single chemical
substance reported separately; and
(vii) Any other ingredient information necessary to characterize
the new and predicate tobacco products.
(3) Tobacco ingredients. For tobacco include:
(i) The type, including grade and variety;
(ii) The quantity with the unit of measure (including ranges or
means, acceptance limits) of tobacco in the new tobacco product and
predicate tobacco product reported as mass per gram of tobacco for non-
portioned tobacco products and as mass per portion for portioned
tobacco products (with any specification variation, if applicable);
(iii) The specification of tobacco used for the new tobacco product
and the predicate tobacco product (with any specification variation, if
applicable);
(iv) A description of any genetic engineering of the tobacco; and
(v) Any other information necessary to characterize the new and
predicate tobacco products.
(vi) If the new tobacco product does not contain tobacco, then
include a statement that the new tobacco product does not contain
tobacco.
(4) Container closure system. A description of the container
closure system for the new and predicate tobacco products, including a
side-by-side quantitative comparison of the components and materials
and annotated illustrations.
(d) Comparison of other features. The SE Report must include
descriptions of any other features of the new and
[[Page 12788]]
predicate tobacco products, such as those described in this section,
and identify any differences. If a specific feature specified in this
section is not applicable to the product design, this must be stated
clearly. If FDA requests a scientific justification explaining why a
feature is not applicable, the applicant must provide the justification
to FDA. The comparison of other features must include information on:
(1) Constituents. HPHCs and other constituents, as appropriate, to
demonstrate that:
(i) The new tobacco product has the same characteristics as the
predicate tobacco product, or
(ii) Any differences in characteristics between the new and
predicate product do not cause the new tobacco product to raise
different questions of public health, including:
(A) The constituent names in alphabetical order;
(B) The common name(s);
(C) The Chemical Abstract Services number(s);
(D) The mean quantity and variance with unit of measure;
(E) The number of samples and measurement replicates for each
sample;
(F) The analytical methods used and associated reference(s);
(G) The testing laboratory or laboratories and documentation
showing that the laboratory or laboratories is (or are) accredited by a
nationally or internationally recognized external accreditation
organization;
(H) Length of time between dates of manufacture and date(s) of
testing;
(I) Storage conditions of the tobacco product before it was tested;
and
(J) Full test data (including test protocols, any deviation(s) from
the test protocols, quantitative acceptance (pass/fail) criteria and
complete data sets) for all testing performed.
(2) Any other features. A description and comparison of any other
features of the new tobacco product and the predicate tobacco product.
(e) Stability information. For smokeless tobacco products and
tobacco products that contain fermented tobacco, the SE Report must
contain information on the stability of the new and predicate tobacco
products, including the following information:
(1) A description of how the stability is indicated on the tobacco
product, and an explanation as to whether the stability testing is
identical for the predicate and the new tobacco product;
(2) Any known or expected impacts of the differences between the
new and predicate products on the product stability. If no impact is
known or expected, state that. For those products that contain
fermented tobacco, the SE Report must provide information on the
fermentation processing steps, including the composition of the
inoculum, with species name(s) and concentration(s); pH; temperature;
moisture content; water activity; duration; and added ingredients;
(3) Detailed stability testing, including test protocols,
quantitative acceptance criteria, data sets, and a summary of the
results for all stability testing performed. Stability testing must be
performed at the beginning (zero time), middle, and end of the expected
storage time for the chemical and microbial endpoints as follows:
Microbial content data including total aerobic microbial count and
total yeast and mold count along with identification of detected
microbiological organisms by genus and species names (if applicable);
pH; moisture content; water activity; tobacco-specific nitrosamines
(total, N-nitrosonornicotine (NNN), 4-methylnitrosamino)-1-(3-
pydridyl)-1-butanone) (NNK)); nitrate and nitrite levels; preservatives
and microbial metabolic inhibitors (if any); and method of heat
treatment or pasteurization used to reduce microbial loads;
(4) Testing information, including the storage conditions for
samples retained for testing; identification of the test methods used;
a statement that the testing was performed on a tobacco product in the
same container closure system in which the tobacco product is intended
to be marketed; and support for the expiration date (e.g., by showing
that an adequate number of batches was tested);
(5) Stability testing laboratory or laboratories used and
documentation showing that the laboratory or laboratories is (or are)
accredited by a nationally or internationally recognized external
accreditation organization; and
(6) Identification of microbiological organisms by genus and
species names, where applicable, and culture collection number either
used during the manufacturing process and/or detected through stability
testing.
(f) Applicant's basis for substantial equivalence determination.
The applicant must state that the new tobacco product has either:
(1) The same characteristics as the predicate tobacco product and
the basis for this determination, or
(2) Different characteristics than the predicate tobacco product.
Where an applicant states that its new tobacco product has different
characteristics than the predicate tobacco product, the applicant must
also include an explanation as to why a difference in any of the
following characteristics do not cause the new product to raise
different questions of public health: Product design (Sec.
1107.19(a)); heating source (Sec. 1107.19(b)); materials and
ingredients (Sec. 1107.19(c)); and other features (Sec. 1107.19(d)).
In addition, to demonstrate that a new tobacco product with different
characteristics is substantially equivalent, an applicant must also
explain why any differences in the manufacturing process between the
new tobacco product and the predicate tobacco product does not raise
different questions of public health (Sec. 1107.18(e)). Similarly, for
smokeless tobacco products, an applicant must explain why any
difference in stability between the new tobacco product and the
predicate tobacco product does not raise different questions of public
health (Sec. 1107.19(e)).
(g) Comparison to grandfathered product. If the applicant is
comparing the new tobacco product to a predicate tobacco product that
FDA has previously found to be substantially equivalent, FDA may
request that the applicant include information related to the original
grandfathered tobacco product for that predicate, even if the
grandfathered tobacco product is back several predicate tobacco
products. FDA will request this information when necessary to ensure
that any order the Agency may issue finding the new tobacco product
substantially equivalent complies with section 910(a)(2)(A)(i)(I) of
the Federal Food, Drug, and Cosmetic Act. FDA may need to review the
first SE Report that received a finding of substantial equivalence
using the grandfathered product as a predicate tobacco product in order
to make this finding.
Sec. 1107.20 Amendments.
(a) Except as provided in paragraphs (b) and (c) of this section,
the applicant may submit an amendment to an SE Report in accordance
with subpart C of this part. If an applicant chose to submit a health
information summary with its SE Report under Sec. 1107.18(j)(1), the
applicant must submit with the amendment a redacted copy of the
amendment that excludes research subject identifiers and trade secret
and confidential commercial information as defined in 21 CFR 20.61 and
20.63.
(b) An applicant may not amend an SE Report to change the predicate
tobacco product.
(c) An applicant may not amend an SE Report after FDA has closed
the SE Report under Sec. 1107.44 or it has been withdrawn under Sec.
1107.22.
[[Page 12789]]
(d) In general, amendments will be reviewed in the next review
cycle as described in Sec. 1107.42.
Sec. 1107.22 Withdrawal by applicant.
(a) An applicant may at any time make a written request to withdraw
an SE Report for which FDA has not issued an order. The withdrawal
request must state:
(1) Whether the withdrawal is due to a health or safety concern
related to the tobacco product;
(2) The submission tracking number; and
(3) The name of the new tobacco product that is the subject of the
SE Report.
(b) An SE Report will be considered withdrawn when FDA issues a
notice stating the SE Report has been withdrawn.
(c) The SE Report is an agency record, even if withdrawn. FDA will
retain the withdrawn SE Report under Federal Agency records schedules.
The availability of the withdrawn SE Report will be subject to FDA's
public information regulations in Sec. 20.45 of this chapter.
Sec. 1107.24 Change in ownership of an SE Report.
An applicant may transfer ownership of its SE Report. On or before
the time of transfer, the new and former applicants are required to
submit information to FDA as follows:
(a) The former applicant must sign and submit a notice to FDA that
states that all of the former applicant's rights and responsibilities
relating to the SE Report have been transferred to the new applicant.
This notice must identify the name and address of the new applicant and
the SE Report transferred.
(b) The new applicant must sign and submit a notice to FDA
containing the following:
(1) The new applicant's commitment to agreements, promises, and
conditions made by the former applicant and contained in the SE Report;
(2) The date that the change in ownership is effective;
(3) Either a statement that the new applicant has a complete copy
of the SE Report and order (if applicable), including amendments and
records that are required to be kept under Sec. 1107.58, or a request
for a copy of the SE Report from FDA's files by submitting a request in
accordance with 21 CFR part 20. In accordance with the Freedom of
Information Act, FDA will provide a copy of the SE Report to the new
applicant under the fee schedule in FDA's public information
regulations in Sec. 20.45 of this chapter; and
(4) A certification that no modifications have been made to the new
tobacco product since the SE Report was submitted to FDA.
Subpart D--FDA Review
Sec. 1107.40 Communications between FDA and applicants.
(a) General principles. During the course of reviewing an SE
Report, FDA may communicate with applicants about relevant matters,
including scientific, medical, and procedural issues that arise during
the review process. These communications may take the form of telephone
conversations, letters, or emails, and will be documented in the SE
Report in accordance with Sec. 10.65 of this chapter.
(b) Meeting. Meetings between FDA and applicants may be held to
discuss scientific and other issues. Requests for meetings will be
directed to the Office of Science, and FDA will make every attempt to
grant requests for meetings that involve important issues.
(c) Acknowledgement of an SE Report. After receiving an SE Report
under Sec. 1107.18, FDA will either refuse to accept the SE Report or
issue an acknowledgement letter.
(d) Notification of deficiencies in a SE Report submitted under
Sec. 1107.18. FDA will make reasonable efforts to communicate to
applicants the procedural, administrative, or scientific deficiencies
found in an SE Report and any additional information and data needed
for the Agency's review. The applicant must also provide additional
comparison information under Sec. 1107.19 if requested by FDA.
(e) Withdrawal of SE Report. An SE Report will be considered
withdrawn when FDA issues a notice stating that the SE Report has been
withdrawn.
Sec. 1107.42 Review cycles.
(a) Initial review cycle. FDA intends to review the SE Report and
either communicate with the applicant as described in Sec. 1107.40 or
take an action under Sec. 1107.44 within 90 calendar days of FDA's
receipt of the SE Report, or within 90 days of determining that the
predicate was found to be commercially marketed in the United States as
of February 15, 2007 (if applicable), whichever is later. This 90-day
period is called the ``initial review cycle.''
(b) Additional review cycles. If FDA issues a deficiency
notification under Sec. 1107.40(d) during the initial review cycle,
FDA will stop reviewing the SE Report until it receives a response from
the applicant or the timeframe specified in the notification of
deficiencies for response has elapsed. If the applicant fails to
respond within the time period provided in the notification of
deficiency, FDA will issue an order denying marketing authorization
under the criteria set forth in Sec. 1107.48. If the applicant's
response to the notification of deficiencies provides the information
FDA requested, but FDA identifies additional deficiencies, FDA may
issue an additional deficiency notification. Each response will begin a
new 90-day review cycle.
(c) Inadequate response. If the applicant's response to FDA's
deficiency notification(s) does not provide the information FDA
requested, or the applicant provides information but the SE Report is
still deficient, FDA will issue an order denying market authorization
under the criteria set forth in Sec. 1107.48. At any time before FDA
issues an order, an applicant may make a written request to withdraw a
SE Report under Sec. 1107.22.
Sec. 1107.44 FDA action on an SE Report.
After receipt of an SE Report, FDA will:
(a) Refuse to accept the SE Report if it does not comply with Sec.
1107.18;
(b) Request additional information as provided in Sec. 1107.40(d);
(c) Issue a letter administratively closing the SE Report if it is
not possible to make a determination on an SE Report;
(d) Issue a letter canceling the SE Report if FDA finds the SE
Report was created in error;
(e) Issue an order as described in Sec. 1107.46 finding the new
tobacco product to be substantially equivalent and in compliance with
the requirements of the Federal Food, Drug, and Cosmetic Act; or
(f) Issue an order as described in Sec. 1107.48 denying marketing
authorization because the new tobacco product is:
(1) Not substantially equivalent to a tobacco product commercially
marketed in the United States on February 15, 2007, or
(2) Not in compliance with the requirements of the Federal Food,
Drug, and Cosmetic Act.
Sec. 1107.46 Issuance of an order finding a new tobacco product
substantially equivalent.
If FDA finds that the information submitted in the SE Report
establishes that the new tobacco product is substantially equivalent to
a predicate tobacco product that was commercially marketed in the
United States on February 15, 2007, and finds that the new tobacco
product is in compliance with the requirements of the Federal
[[Page 12790]]
Food, Drug, and Cosmetic Act, FDA will send the applicant an order
authorizing marketing of the product. A marketing authorization order
becomes effective on the date the order is issued.
Sec. 1107.48 Issuance of an order denying marketing authorization.
(a) General. FDA will issue an order that the new tobacco product
cannot be marketed if FDA finds that:
(1) The information submitted in the SE Report does not establish
that the new tobacco product is substantially equivalent to a predicate
tobacco product that was commercially marketed in the United States on
February 15, 2007; or
(2) The new tobacco product is not in compliance with the Federal
Food, Drug, and Cosmetic Act.
(b) Basis for order. The order will describe the basis for denying
marketing authorization.
Sec. 1107.50 Rescission of order.
(a) Grounds for rescinding a substantially equivalent order. FDA
may rescind a substantial equivalence order allowing a new tobacco
product to be marketed if FDA determines that:
(1) The tobacco product for which the order has been issued:
(i) Does not have the same characteristics as the predicate tobacco
product; or
(ii) Has different characteristics and there is insufficient
information demonstrating that it is not appropriate to require a
premarket tobacco product application under section 910(b) of the
Federal Food, Drug, and Cosmetic Act because the product does not raise
different questions of public health; or
(2) The SE Report (including any submitted amendments) contains an
untrue statement of material fact; or
(3) Concerning a SE Report that compared the new tobacco product to
a tobacco product that FDA previously found substantially equivalent:
(i) The predicate tobacco product relied on in the SE Report has
been found ineligible because its substantial equivalence SE Report
(including any amendments) contains an untrue statement of material
fact; or
(ii) A predicate tobacco product on which any of the previous
substantial equivalence determinations was based, going back to the
original grandfathered product, has been found ineligible because its
substantial equivalence SE Report (including any amendments) contains
an untrue statement of material fact; or
(4) FDA or the applicant has removed from the market, due to a
health or safety concern related to the tobacco product:
(i) The predicate tobacco product on which the substantial
equivalence determination is based; or
(ii) A predicate tobacco product on which any of the previous
substantial equivalence determinations is based, going back to the
original grandfathered product, if the substantial equivalence SE
Report compared the new tobacco product to a tobacco product that FDA
previously found substantially equivalent.
(b) Opportunity for a hearing. In general, FDA will rescind an
order only after notice and opportunity for a hearing under part 16 of
this chapter. However, FDA may rescind a substantially equivalent order
prior to notice and opportunity for a hearing under part 16 of this
chapter if it finds that there is a reasonable probability that
continued marketing of the tobacco product presents a serious risk to
public health. In that case, FDA will provide the manufacturer an
opportunity for a hearing as soon as possible after the rescission.
Subpart E--Miscellaneous
Sec. 1107.58 Record retention.
Each applicant that receives an order under Sec. 1107.46
authorizing the marketing of a new tobacco product must maintain all
records required by this subpart and that support the SE Report for a
substantial equivalence order. These records must be legible, in the
English language, and available for inspection and copying by officers
or employees duly designated by the Secretary. All records must be
retained for a period of not less than 4 years from the date of the
order even if such product is discontinued.
Sec. 1107.60 Confidentiality.
(a) General. FDA will determine the public availability of any part
of an SE Report and other content related to such an SE Report under
this section and part 20 of this chapter.
(b) Confidentiality of data and information prior to an order.
Prior to issuing an order under this section:
(1) FDA will not publicly disclose the existence of an SE Report
unless:
(i) The tobacco product has been introduced or delivered for
introduction into interstate commerce for commercial distribution; or
(ii) The applicant has publicly disclosed or acknowledged the
existence of the SE Report (as such disclosure is defined in Sec.
20.81 of this chapter), or has authorized FDA in writing to publicly
disclose or acknowledge, that the applicant has submitted the SE Report
to FDA;
(2) FDA will not disclose the existence of or contents of an FDA
communication with an applicant regarding its SE Report except to the
extent that the applicant has publicly disclosed or acknowledged, or
authorized FDA in writing to publicly disclose or acknowledge, the
existence of or contents of that particular FDA communication.
(3) FDA will not disclose information contained in an SE Report
unless the applicant has publicly disclosed or acknowledged, or
authorized FDA in writing to publicly disclose or acknowledge, that
particular information. If the applicant has publicly disclosed or
acknowledged, or authorized FDA in writing to publicly disclose or
acknowledge, that particular information contained in an SE Report, FDA
may disclose that particular information.
(c) Disclosure of data and information after an order under Sec.
1107.46. After FDA issues an order under Sec. 1107.46 finding a new
tobacco product substantially equivalent, it will make the following
information related to the SE Report and order available for public
disclosure upon request or at FDA's own initiative, including
information from amendments to the SE Report and FDA's reviews of the
SE Report:
(1) All data previously disclosed to the public, as such disclosure
is defined in Sec. 20.81 of this chapter;
(2) Any protocol for a test or study, except to the extent it is
shown to fall within the exemption established for trade secrets and
confidential commercial information in Sec. 20.61 of this chapter;
(3) Information and data submitted to demonstrate that the new
tobacco product does not raise different questions of public health,
except to the extent it is shown to fall within the exemptions
established in Sec. 20.61 of this chapter for trade secrets and
confidential commercial information, or in Sec. 20.63 of this chapter
for personal privacy;
(4) Correspondence between FDA and the applicant, including any
requests FDA made for additional information and responses to such
requests, and all written summaries of oral discussions between FDA and
the applicant, except to the extent it is shown to fall within the
exemptions in Sec. 20.61 of this chapter for trade secrets and
confidential commercial information, or in Sec. 20.63 of this chapter
for personal privacy; and
(5) In accordance with Sec. 25.51 of the chapter (21 CFR 25.51),
the environmental assessment or, if applicable, the claim of
categorical exclusion from the requirement to
[[Page 12791]]
submit an environmental assessment under part 25 of this chapter.
(d) Disclosure of data and information after an order under Sec.
1107.48. After FDA issues an order under Sec. 1107.48 (denying
marketing authorization), FDA may make certain information related to
the SE Report and the order available for public disclosure upon
request or at FDA's own initiative except to the extent the information
is otherwise exempt from disclosure under part 20 of this chapter.
Information FDA may disclose includes the tobacco product category
(e.g., cigarette), tobacco product subcategory (e.g., filtered),
package size, and the basis for the order denying marketing
authorization.
(e) Health information summary or statement. Health information
required by section 910(a)(4) of the Federal Food, Drug, and Cosmetic
Act, if submitted as part of the SE Report (which includes any
amendments), will be disclosed within 30 calendar days of issuing a
substantially equivalent order. If the applicant has instead submitted
a 910(a)(4) statement as provided in Sec. 1107.18(j)(2), FDA will make
publicly available on FDA's website the responsible official to whom a
request for health information may be made.
Sec. 1107.62 Electronic submission.
(a) Electronic format requirement. Applicants submitting any
documents to the Agency under this part must provide all required
information to FDA using the Agency's electronic system, except as
provided in paragraph (b) of this section. The SE Report and all
supporting information must be in an electronic format that FDA can
process, read, review, and archive.
(b) Waivers from electronic format requirement. An applicant may
submit a written request that is legible and written in English, to the
Center for Tobacco Products asking that FDA waive the requirement for
electronic format and content. Waivers will be granted if use of
electronic means is not reasonable for the person requesting the
waiver. To request a waiver, applicants can send the written request to
the address included on our website (www.fda.gov/tobaccoproducts). The
request must include the following information:
(1) The name and address of the applicant, list of individuals
authorized for the applicant to serve as the contact person, and
contact information. If the applicant has submitted a SE Report
previously, the regulatory correspondence must also include any
identifying information for the previous submission; and
(2) A statement that creation and/or submission of information in
electronic format is not reasonable for the person requesting the
waiver, and an explanation of why creation and/or submission in
electronic format is not reasonable. This statement must be signed by
the applicant or by an employee of the applicant who is authorized to
make the declaration on behalf of the applicant.
(c) Paper submission. An applicant who has obtained a waiver from
filing electronically must send a written SE Report through the
Document Control Center to the address provided in the FDA
documentation granting the waiver.
Dated: March 21, 2019.
Scott Gottlieb,
Commissioner of Food and Drugs.
[FR Doc. 2019-05787 Filed 3-28-19; 11:15 am]
BILLING CODE 4164-01-P